An investigation of the relationship between the inflammatory response and outcome in patients with gastro-oesophageal cancer by Crumley, Andrew B.C.








Crumley, Andrew B.C. (2011) An investigation of the relationship 
between the inflammatory response and outcome in patients with gastro-







Copyright and moral rights for this thesis are retained by the Author 
 
A copy can be downloaded for personal non-commercial research or 
study, without prior permission or charge 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the 
author, title, awarding institution and date of the thesis must be given 
 
AN INVESTIGATION OF THE RELATIONSHIP BETWEEN THE 





ANDREW B.C CRUMLEY 
MB.ChB, M.R.C.S (Glas) 
 
SUBMITTED IN FULFILMENT OF THE REQUIREMENTS  
FOR THE DEGREE OF DOCTOR OF MEDICINE 
 
to 
THE UNIVERSITY OF GLASGOW 
 
from RESEARCH CONDUCTED IN THE UNIVERSITY DEPARTMENT OF 
SURGERY, 















I dedicate this thesis to my wife Jennifer, for her continual encouragement and support.  
To my son James, whose infectious sense of fun was always a welcome distraction and 






I owe a large debt to the following people, for their help, advice and encouragement: 
 
Professor Donald C McMillan, University Department of Surgery, Royal Infirmary, 
Glasgow 
 
Mr Robert C Stuart, University Department of Surgery, Royal Infirmary, Glasgow 
 
Dr James J Going, University Department of Pathology, Royal Infirmary, Glasgow 
 
Dr Joanne Edwards, University Department of Surgery, Royal Infirmary, Glasgow 
4 
 
CONTENTS                   PAGE 
DECLARATION         10 
LIST OF TABLES         11 
LIST OF FIGURES         14 
PUBLICATIONS         17 
SUMMARY OF THESIS        19 
 
CHAPTER1:  INTRODUCTION      22 
1.1 Incidence and mortality of gastro-oesophageal cancer   22 
1.1.1 Age          22 
1.1.2 Gender         23 
1.1.3 Geography         24 
1.1.4 Ethnic groups         24 
1.1.5 Trends          25 
1.1.6 Deprivation         27 
1.1.7 Mortality of gastro-oesophageal cancer     27 
1.1.7.1 Trends in mortality        27 
1.2 Aetiology of gastro-oesophageal cancer     28 
1.2.1 Inheritance         28 
1.2.2 Predisposing conditions       29 
1.2.3 Gastro-oesophageal reflux       29 
1.2.4 Helicobacter Pylori        30 
1.2.5 Lifestyle factors        32 




          PAGE 
1.4 Diagnosis of gastro-oesophageal cancer     35 
1.4.1 Upper GI Endoscopy        35 
1.4.2 Barium swallow/meal        36 
1.5 Staging of gastro-oesophageal cancer     36 
1.5.1 Computerised Tomography        40 
1.5.2 Endoscopic Ultrasound       40 
1.5.3 Laparoscopy         40 
1.5.4 Pathological stage        41 
1.6 Treatment of gastro-oesophageal cancer     42 
1.6.1 Treatment of operable gastro-oesophageal cancer    42 
1.6.2 Treatment of inoperable gastro-oesophageal cancer    44 
1.6.2.1 Chemo-radiotherapy        44 
1.6.2.2 Endoscopic palliation        45 
1.7 Pathological determinants of survival in patients with gastro  46 
oesophageal cancer 
1.7.1 Established tumour associated determinants of survival   46 
1.7.2 Tumour proliferation        47 
1.8 Host determinants of survival in patients with gastro   48 
oesophageal cancer 
1.8.1 Host immune response       49 
1.8.2 Local inflammatory response in patients with gastro-oesophageal  51  
cancer 




                    PAGE 
1.8.3 Systemic inflammatory response      53 
1.8.4 Acute phase proteins        54 
1.8.4.1 C-reactive protein        57 
1.8.4.2 Albumin         57 
1.8.5 Systemic inflammatory response and survival    58 
1.8.5.1 Systemic inflammatory response and survival in patients with  59  
inoperable gastro-oesophageal cancer 
1.8.5.2 Systemic inflammatory response and survival in patients with  60  
operable gastro-oesophageal cancer 
1.9 Aims          62 
CHAPTER 2:  AN ELEVATED C-REACTIVE PROTEIN   63 
CONCENTRATION, PRIOR TO SURGERY, PREDICTS POOR 
CANCER SPECIFIC SURVIVAL IN PATIENTS UNDERGOING 
 RESECTION FOR GASTRO-OESOPHAGEAL CANCER 
  
2.1 Introduction         63 
2.2 Patients and methods       64 
2.2.1 Patients         64 
2.2.2 Methods         65 
2.2.3 Statistics         66 
2.3 Results         66 
2.4 Discussion         68 
 
CHAPTER 3:  THE RELATIONSHIP BETWEEN THE SYSTEMIC  76 
INFLAMMATORY RESPONSE, TUMOUR PROLIFERATIVE 
ACTIVITY, LEUCOCYTE AND MACROPHAGE INFILTRATION 
AND SURVIVAL IN PATIENTS SELECTED FOR POTENTIALLY  





                    PAGE 
3.1 Introduction         76 
3.2 Patients and methods       78 
3.2.1 Patients         78 
3.2.2 Methods         79 
3.2.2.1 Immunohistochemistry       79 
3.2.2.2 Morphometry         79 
3.2.2.3 Assessment of inflammatory infiltrate     80 
3.2.3 Statistics         81 
3.3 Results         82 
3.4 Discussion         83 
 
CHAPTER 4:   EVALUATION OF AN INFLAMMATION   95 
BASED PROGNOSTIC SCORE (GPS) IN PATIENTS WITH  
INOPERABLE GASTRO-OESOPHAGEAL CANCER. 
 
4.1 Introduction         95 
4.2 Patients and methods       96 
4.2.1 Patients         96 
4.2.2 Methods         98 
4.2.3 Statistics         98 
4.3 Results         99 




                    PAGE 
CHAPTER 5:  COMPARISON OF AN INFLAMMATION BASED  110 
PROGNOSTIC SCORE (GPS) WITH PERFORMANCESTATUS 
(ECOG-PS), IN PATIENTS RECEIVING PALLIATIVE  
CHEMOTHERAPY FOR GASTRO-OESOPHAGEAL CANCER.   
 
5.1 Introduction         110 
5.2 Patients and methods       111 
5.2.1 Patients         111 
5.2.2 Methods         112 
5.2.3 Statistics         113 
5.3 Results         114 
5.4  Discussion         115 
  
CHAPTER 6:  IS HYPOALBUMINAEMIA, AN  INDEPENDENT  125 
PROGNOSTIC FACTOR IN PATIENTS WITH GASTRIC CANCER? 
 
6.1 Introduction         125 
6.2 Patients and methods       126 
6.2.1 Patients         126 
6.2.2 Methods         127 
6.2.3 Statistics         128 
6.3 Results         128 
6.4 Discussion         130 
 
CHAPTER 7:  COMPARISON OF PRE-TREATMENT CLINICAL  138 
PROGNOSTIC FACTORS IN PATIENTS WITH GASTRO  
OESOPHAGEAL CANCER AND PROPOSAL OF A NEWSTAGING 
SYSTEM. 
 




                    PAGE 
7.2 Patients and methods       139 
7.2.1 Patients         139 
7.2.2 Methods         140 
7.2.3 Statistics         141 
7.3 Results         141 
7.4 Discussion         143 
 
CHAPTER 8:    DISCUSSION AND FUTURE WORK  154 
REFERENCES         158 
APPENDIX 1:  DATABASE FOR CHAPTER 2   181 
APPENDIX 2:  DATABASE FOR CHAPTER 3   197 
APPENDIX 3:  DATABASE FOR CHAPTER 4   210 
APPENDIX 4:  DATABASE FOR CHAPTER 5   229 
APPENDIX 5:  DATABASE FOR CHAPTER 6   239 






I declare that the work presented in this thesis was carried out solely by myself, as a 
clinical research fellow in the University Dept of Surgery, Royal Infirmary, Glasgow, 
except where indicated below: 
 
Measurement of biochemical and haematological data was performed by the hospital 
laboratory service. 
 
The selection of appropriate tissue-tumour sections was carried out with the assistance 
of Dr James J. Going, University Dept of Pathology, Royal Infirmary, Glasgow. 
 
The immune-histochemical tissue staining was carried out with the assistance of Dr 
Joanne Edwards, University Dept of Surgery, Royal Infirmary, Glasgow. 
 
The inter-observer reproducibility assessment of the immuno-histochemical staining 
was performed with the assistance of Dr James J Going, Mr Sumanta Dutta and Mr 
Mustafa Hilmy, University Departments of Pathology and Surgery, Royal Infirmary, 
Glasgow. 
 
Statistical analysis was performed with the assistance of Prof Donald C McMillan, 





LIST OF TABLES                  PAGE 
Table 1.1  TNM staging in oesophageal cancer     38 
Table 1.2  TNM staging in gastric cancer      39 
Table 1.3 Systemic changes associated with the acute phase response  54 
Table 1.4 The major acute-phase proteins      55 
Table 2.1.  Characteristics of patients selected for potentially curative  72 
resection for gastro-oesophageal cancer:  Univariate survival analysis 
Table 2.2.  The relationship between the presence of a pre-operative  73  
systemic inflammatory response and tumour characteristics of  
gastro-oesophageal cancer.  
Table 3.1.  Clinico-pathological characteristics in patients selected for  87 
potentially curative resection for gastro-oesophageal cancer. 
Table 3.2.  Interrelationships between pathological and biochemical 88 
 criteria in patients selected for potentially curative resection for 
gastro-oesophageal cancer 
Table 3.3.  The relationship between clinico-pathological factors and  89 
survival, in patients selected for potentially curative resection for 
gastro-oesophageal cancer. 
Table 4.1  Clinical characteristics and cancer specific survival in patients  103  





                    PAGE 
Table 4.2 Clinical characteristics and cancer specific survival in patients  104  
with inoperable gastro-oesophageal cancer:  Multivariate survival analysis  
Table 4.3  Clinical characteristics and cancer specific survival in patients  105  
with inoperable gastro-oesophageal cancer receiving active treatment: 
Multivariate survival analysis 
Table 4.4  Clinical characteristics and cancer specific survival in patients  106  
with inoperable gastro-oesophageal cancer receiving supportive treatment:  
Multivariate survival analysis 
Table 4.5 The relationship between stage, the GPS and the 12 month cancer 107 
 specific survival rate in patients with inoperable gastro-oesophageal cancer 
 receiving active treatment  
Table 5.1.  Number of patients in each chemotherapy/ radiotherapy regime  119 
Table 5.2.  Baseline clinicopathological characteristics in patients with  120  
advanced gastro-oesophageal cancer, receiving platinum based treatment. 
Table 5.3.  Relationship between the GPS and baseline clinicopathological  121 
characteristics, in patients with gastro-oesophageal cancer, receiving platinum  
based treatment. 
Table 5.4.  Clinical characteristics and cancer specific survival in patients  122  
with gastro-oesophageal cancer, receiving platinum based treatment: 




                    PAGE 
Table 5.5.  Clinical characteristics and cancer specific survival in patients with 123  
gastro-oesophageal adeno-carcinoma, receiving platinum based treatment:   
Univariate survival analysis. 
Table 5.6.  The relationship between the GPS and response to palliative  124 
chemotherapy in patients with gastro-oesophageal cancer.  
Table 6.1.  The relationship between hypoalbuminaemia, clinicopathological 134  
characteristics, systemic inflammatory response and survival in patients with  
gastric cancer 
Table 6.2  Clinicopathological characteristics and cancer specific survival in 135  
patients with gastric cancer: Survival analysis 
Table 7.1.  Prognostic scoring systems in patients with gastro-oesophageal  148  
cancer. 
Table 7.2.  Pre-treatment clinical characteristics and cancer specific survival 149 
rates of patients with gastro-oesophageal cancer:  Univariate survival analysis 
Table 7.3.  Pre-treatment clinical characteristics and cancer specific survival of 150  
patients with gastro-oesophageal cancer:  Multivariate survival analysis 
Table 7.4.  Relationship between clinical characteristics and the mGPS  151 
14 
 
LIST OF FIGURES                  PAGE 
Figure 1.1  Numbers of new cases and age-specific incidence rates by sex,  23 
cancer of the oesophagus, UK 2002 
Figure 1.2  Innate and adaptive immunity (Abbas, 2005)    50 
Figure 1.3  Humoral and cell-mediated immunity (Abbas, 2005)   51 
Figure 1.4: Characteristic patterns of change in plasma concentrations of some 56 
acute phase proteins after a moderate inflammatory stimulus  
Figure 2.1.  The relationship between the positive to total lymph node ratio    74  
(0/ <0.2/ >0.2 from top to bottom) and cancer specific survival in patients 
undergoing resection for gastro-oesophageal cancer. 
Figure 2.2.  The relationship between the systemic inflammatory response  75  
(<10/ >10mg/l from top to bottom) and cancer specific survival in patients  
undergoing resection for gastro-oesophageal cancer. 
Figure 3.1.  Ki67 immunohistochemical staining (high power)   90 
Figure 3.2. CD 68+ immunohistochemical staining (high power)   90 
Figure 3.3.  Example of  “low grade” local tumor inflammatory infiltrate  91 
(low power and high power view). 
Figure 3.4.  Example of  “high grade”  local tumor inflammatory infiltrate  91  
(low power and high power view). 
Figure 3.5.  The relationship between tumour differentiation   92 
(well-moderate/ poor, from top to bottom) and cancer specific survival in  




                    PAGE 
Figure 3.6.  The relationship between tumour inflammatory infiltrate 93  
(high grade/ low grade, from top to bottom) and cancer specific survival in  
patients undergoing resection for gastro-oesophageal cancer. 
Figure 3.7.  The relationship between tumour proliferation    94 
(Ki67 tertiles 1/ 2/ 3 from bottom to top) and survival in patients selected for 
potentially curative resection for gastro-oesophageal cancer. 
Figure 4.1  The relationship between an inflammation based prognostic score 108  
(GPS, 0, 1, 2 from top to bottom) and survival in patients with inoperable gastro-
oesophageal cancer. 
Figure 4.2  The relationship between an inflammation based prognostic score 109  
(GPS, 0, 1, 2 from top to bottom) and survival in patients with inoperable gastro-
oesophageal cancer receiving active treatment. 
Figure 6.1.  The relationship between C-reactive protein and albumin in patients 136 
with operable (top line) and inoperable (bottom line) gastric cancer. 
Figure 6.2.  The relationship between the systemic inflammatory response  137 
(C-reactive protein <10mg/l, >10mg/l from top to bottom) and cancer specific  
survival (p<0.0001) in patients with gastric cancer and a normal albumin  
concentration (>35g/l). 
Figure 6.3.  The relationship between the systemic inflammatory response  138  
(C-reactive protein <10mg/l, >10mg/l from top to bottom) and cancer specific  
survival (p=0.0023) in patients with gastric cancer and hypoalbuminaemia (<35g/l) 
Figure 7.1.  The relationship between the mGPS (0/ 1/ 2 from top to bottom)  152  




                    PAGE 
Figure 7.2.  The relationship between the cTNM stage (I/ II/ III/ IV   153 
from top to bottom) and survival in patients with gastro-oesophageal cancer  
and a mGPS score 0  
Figure 7.3.  The relationship between the cTNM stage (I/ II/ III/ IV   154 
from top to bottom) and survival in patients with gastro-oesophageal cancer  





The work presented in this thesis has resulted in the following publications: 
1: Crumley AB, McMillan DC, McKernan M, Going JJ, Shearer CJ, Stuart RC 
(2006) An elevated C-reactive protein concentration, prior to surgery, predicts poor 
cancer-specific survival in patients undergoing resection for gastro-oesophageal cancer. 
Br J Cancer 94: 1568-1571 
2: Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC (2006) 
Evaluation of an inflammation-based prognostic score in patients with inoperable 
gastro-oesophageal cancer. Br J Cancer 94: 637-641 
3: Crumley AB, Stuart RC, McKernan M, McDonald AC, McMillan DC (2008) 
Comparison of an inflammation-based prognostic score (GPS) with performance status 
(ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer. J 
Gastroenterol Hepatol 23: e325-e329 
4: Crumley AB, Stuart RC, McKernan M, Going JJ, Shearer CJ, McMillan DC 
(2010) Comparison of Pre-treatment Clinical Prognostic Factors in Patients with 
Gastro-Oesophageal Cancer and Proposal of a New Staging System. J Gastrointest Surg 
14(5):781-7 
5: Crumley AB, Stuart RC, McKernan M, McMillan DC (2010) 
Is hypoalbuminaemia an independent prognostic factor in patients with gastro-
oesophageal cancer?  World J Surg. 34(10):2393-8.  
18 
 
6: Crumley AB, Going JJ, Hilmy M, Dutta S, Tannahill C, McKernan M, 
Edwards J, Stuart RC, McMillan DC    
Interrelationships between tumour proliferative activity, leucocyte and macrophage 
infiltration, systemic inflammatory response, and survival, in patients selected for 
potentially curative resection for Gastro-oesophageal cancer. 
Annals of Surgical Oncology.  16 March 2011 (Epub ahead of print) 
19 
 
SUMMARY OF THESIS 
 Gastro-oesophageal cancer is the third commonest cause of cancer death in the 
UK.  Each year, there are approximately 16,500 new cases and over 13,000 deaths 
attributable to the disease.  Overall survival is poor with the majority of patients 
presenting with advanced, inoperable disease and less than 15% surviving 5 years.  
Even in those who undergo potentially curative resection, fewer than 30% survive 5 
years.  It is increasingly recognised that it is not only the intrinsic properties of tumour 
cells which determine tumour spread but also the host inflammatory response.  Indeed, 
the systemic inflammatory response, as evidenced by elevated circulating 
concentrations of C-reactive protein, prior to surgery, has previously been shown to 
have independent prognostic value in patients with resectable oesophageal cancer. In 
addition, in patients with advanced/ inoperable cancer (including patients with advanced 
gastric cancer) there is evidence that an elevated systemic inflammatory response is 
associated with poorer survival. 
 The overall aim of the thesis was to examine the inter-relationships between 
local and systemic inflammatory responses and cancer specific survival, in patients with 
gastro-oesophageal cancer. 
 
Chapter 2 examines the relationship between the systemic inflammatory 
response (as measured by an elevated C-reactive protein concentration) and survival in 
120 patients, selected for potentially curative surgery, for gastro-oesophageal cancer.  
This chapter demonstrated that an elevated C-reactive protein concentration (>10mg/l) 
was associated with poor survival, independent of tumour stage.  This suggests that 
patients deemed suitable for curative surgery but who have an elevated C-reactive 
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protein concentration may not benefit from potentially curative surgery, as their 3 year 
survival is only 7%. 
Chapter 3 examines the inter-relationships between tumour proliferation, local 
host inflammatory response to tumour, macrophage infiltration, the systemic 
inflammatory response and survival in 100 patients selected for potentially curative 
surgery for gastro-oesophageal cancer.  This chapter shows that low tumour 
proliferation rate, poor local inflammatory infiltrate and an elevated systemic 
inflammatory response ((Glasgow Prognostic Score (GPS)) independently predict poor 
survival.  Both low tumour proliferation rate and poor local inflammatory infiltrate are 
associated with an increased nodal burden but not directly associated with each other.  
There was no direct relationship between the systemic inflammatory response and the 
local inflammatory response.  This would suggest that the mechanisms underlying the 
relationship between local and systemic inflammatory responses and cancer-specific 
survival are likely to be complex.   
 Chapter 4 examines the relationship between an inflammation based prognostic 
score (GPS) and survival, in an unselected cohort of 258 patients with inoperable 
gastro-oesophageal cancer.  This chapter demonstrated that the presence of an elevated 
systemic inflammatory response (as measured by the GPS) was associated with poor 
cancer specific survival, independent of tumour stage and of treatment received.   
Chapter 5 compares the value of the GPS and performance status (ECOG-ps) in 
evaluating the response to palliative platinum based chemotherapy and survival, in 65 
patients with advanced gastro-oesophageal cancer.  This chapter demonstrated that an 
elevated GPS predicted poor survival, poorer clinical response to treatment and an 
increased need for chemotherapy dose reduction.  Performance status however (a tool 
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commonly used to select patients for chemotherapy), did not predict survival in this 
cohort. 
Chapter 6 examines the relationship between albumin concentration and survival 
in an unselected cohort of 217 patients with gastric cancer.  This chapter demonstrates 
that although a low albumin concentration (<35 g/l) is associated with poor survival on 
univariate analysis, its concentration is closely related to that of C-reactive protein.  The 
prognostic value of hypoalbuminaemia is therefore degraded with the inclusion of C-
reactive protein and on multivariate survival analysis, albumin is no longer associated 
with survival.  This would suggest that the prognostic power of albumin is secondary to 
its relationship to an elevated systemic inflammatory response, as measured by an 
elevated C-reactive protein concentration. 
Chapter 7 compares the prognostic value of a number of pre-treatment clinical 
factors including tumour stage, performance status, weight loss, C-reactive protein 
concentration and albumin concentration, in 217 patients undergoing staging for gastro-
oesophageal cancer.  It demonstrated, that only the GPS and clinical tumour stage were 
independently associated with cancer specific survival.   
The results of the chapters taken together demonstrate, that an elevated systemic 
inflammatory response (as evidenced by the GPS) predicts poorer survival, independent 
of tumour stage and treatment received in patients with operable and inoperable gastro-
oesophageal cancer.  This would suggest that measurement of the GPS should be 
performed routinely as part of clinical staging, to improve stratification of patients and 
therefore enable a more appropriate allocation of treatment, most likely to benefit. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Incidence and mortality of gastro-oesophageal cancer 
 
The incidence of gastro-oesophageal cancer varies significantly between 
country, sex and age.  It has been estimated that in 1990, 316,000 new cases of 
oesophageal cancer were diagnosed globally and 286,000 deaths were attributable to the 
disease.  In the same year, it was estimated that 798,000 new cases of gastric cancer 
were diagnosed worldwide, with 628,000 deaths attributable to the disease.  Together, 




Gastric and oesophageal cancers are predominantly diseases of the elderly.  In 
the United States between 1994-1998, the incidence rate in the 40-44 age-group was 4 
per 100,000 rising to 88 per 100,000 in the 80-84 age group [SEER, 2004].   
This predominance of tumours with increasing age is mirrored in the UK as a 
whole, with <5% of tumours diagnosed in people under the age of 40 [Cancer Research 
UK Information Resource Centre, 2004].  Figure 1.1 
In Scotland during 1999, there were 1008 new gastric cancers and 790 
oesophageal cancers, of which only 9 and 2 respectively were diagnosed in people 




Figure 1.1  Numbers of new cases and age-specific incidence rates by sex, cancer of 




1.1.2 Gender  
 
The majority of gastric and oesophageal cancer is seen in males.  World-wide 
the incidence of gastric and oesophageal cancer in men is more than twice that seen in 
women (24.5 and 10.2 per 100,000 men, compared with 11.6 and 4.2 women) [Parkin et 
al., 1999a].  Regionally, the incidence in females is never higher than in males.  In 
North America the incidence of gastric cancer is 8.4 and 5.2 per 100,000, compared 
with 4.0 and 1.4 in oesophageal cancer, in males and females respectively [Parkin et al., 
1999a].  In the UK in 2002, there was a similar distribution between sexes with the 
incidence of gastric cancer being 16.9 and 6.8 per 100,000, compared with 14.1 and 5.7 
in oesophageal cancer, in males and females respectively [Cancer Research UK 



















































































































 gastric cancer was 18.6 and 8.1 per 100,000, compared with 18.0 and 7.3 in 




There is wide variation in the incidence of gastric and oesophageal cancer 
between countries.  For gastric cancer the highest rates are seen in the far East and in 
particular Japan, where there are 78 new cases per 100,000 men and 33 new cases per 
100,000 women [Parkin et al., 1999b].  The global distribution of oesophageal cancer is 
similar, with high incidence in China and Japan (22 and 10 new cases per 100,000 men 
respectively).  The highest incidence is, however Southern Africa, with 33 new cases 
per 100,000 men and 12 new cases per 100,000 women [Parkin et al., 1999b].   In 
Western Europe the incidence of gastric cancer is less than a quarter of that seen in 
Japan and in North America, the incidence is approximately a tenth of the incidence in 
Japan [Parkin et al., 1999b].  In North America, the incidence of oesophageal cancer is 
6 per 100,000 men and 1 per 100,000 women [Parkin et al., 1999b].   
In Scotland there were 20 and 10 new cases of gastric cancer per 100,000 men 
and women respectively in 1999 [ISD, 2004].  Scotland, also has one of the world’s 
highest incidence of oesophageal cancer, with 19 and 8 new cases per 100,000 men and 
women respectively in 1999 [ISD, 2004]. 
 
1.1.4 Ethnic groups 
 
Not only are there ethnic variations in the incidence of oesophageal and gastric 
cancer but there are also variations within histological sub-types.  For example in the 
United States, the most recent figures (1992-98), show that the overall incidence rates 
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for oesophageal  cancer varies three fold among different American ethnic groups.  
African Americans have the highest age adjusted rates (8 cases per 100,000), followed 
by Whites (4 per 100,000) and Hispanics, native American Indians and Pacific islanders 
(2.5 per 100,000).  In oesophageal squamous cancer, the rate in white American men is 
1/6 of that of African Americans (2 and 13 per 100,000 respectively), whereas in 
oesophageal adeno-carcinoma, the rate in white American men is almost 4 times that 
seen in African American men (1.5 and 0.4 per 100,000 respectively) [SEER, 2004]. 
Similar magnitudes of variation in incidence between ethnic groups is seen in 
gastric cancer.  In the USA, the incidence of gastric cancer in African Americans is 
twice that of white Americans (14 and 7 per 100,000 respectively).  The rate in 
Hispanics is 13 per 100,000 but the highest incidence is found in people from the 




Overall the rates of oesophageal cancer globally have increased in the last 35 
years.  This is due largely to the increase in rates of oesophageal adenocarcinoma [Pera 
et al., 1993;Blot et al., 1993;Jankowski et al., 2000].   In African American females the 
rate increased by 13.8% per year between 1973 and 1995 but the largest increase was 
seen in Icelandic females; 18.6% per year.  The corresponding change in men during the 
same period was 4.1% and 7.7% per year.  In the USA the incidence of oesophageal 
tumours and tumours of the cardia have risen dramatically since the 1970’s [Devesa et 
al., 1998;Pera et al., 1993].  The incidence in North American white men and African 
American men increased by 8.6% and 4.1% per year respectively.  Squamous cell 
carcinoma is still the most common type globally and the ratio of the two histological 
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types varies from equal in South Australian men to 34:1 in African American males 
[Vizcaino et al., 2002].  In the USA there was a trend towards decreasing rates of 
oesophageal squamous cancer between 1973 and 1995.  The incidence in North 
American white men decreased by 1.5% per year and the incidence in African American 
men decreased marginally at 0.6% per year.  In the corresponding women, the rate has 
essentially remained the same (0.1% per year increase and 0.3% per year decrease).   
With regards to gastric cancer, most countries in the world have seen a constant 
declining trend in incidence over the last 30 years [Inoue and Tsugane, 2005;Ajiki et al., 
2004;Parkin et al., 1999a].  The cause for this decline is not fully understood but may be 
due to dietary modification.   
The marginal decrease in rates of oesophageal squamous cancer in males was 
also evident in European countries.  In females, however the incidence in several 
European countries has increased.  This is most marked in Switzerland where the 
incidence has increased by 8.5% per year.   The global increase in the rate of 
oesophageal adenocarcinoma is mirrored in Europe and the incidence appears to be 
continuing to rise [Bollschweiler et al., 2001].  Locally, in Scotland, the incidence in 
males and females has increased at a similar rate (3.1% per year and 4.8% per year 
respectively) [ISD, 2004].  In Scotland, however there was an increase in the incidence 
of oesophageal squamous cancer in both males and females (0.7% per year and 2.8% 
per year respectively) [Vizcaino et al., 2002].   In Scotland the incidence of gastric 




1.1.6 Deprivation  
 
Increasing deprivation has been shown to be linked with a higher incidence of 
oesophageal squamous cancer and for gastric cancer in the UK [Brewster et al., 
2000;ISD Scotland, 2005] .  In contrast, an increasing incidence of oesophageal adeno-
carcinomas has been linked to the most affluent socio-economic groups [Dutta et al., 
2005]. 
 
1.1.7 Mortality of gastro-oesophageal cancer 
 
Globally gastro-oesophageal cancer represents the second most common cause 
of cancer death behind lung cancer, with 914,000 and 921,000 deaths respectively 
[Parkin et al., 1999b].  In Scotland in 2004, gastro-oesophageal cancer was responsible 
for 1416 deaths (9.4% of cancer deaths), making it the third commonest cause of cancer 
death in Scotland [ISD, 2004].   
 
1.1.7.1 Trends in mortality 
 
Gastric and oesophageal cancer have demonstrated opposite trends in mortality 
over the last 30 years.  Mortality rates from gastric cancer have decreased rapidly in the 
USA between 1975 and 2002; 8.5 per 100,000 to 4.2 deaths per 100,000 [SEER, 2004].  
Oesophageal cancer mortality rates have, conversely risen.  In the USA the rates have 
increased steadily from 3.7 to 4.4 per 100,000 [SEER, 2004].   
In the UK, similar trends have been demonstrated. The mortality rates for gastric 
cancer have also halved over a similar period of time and increased mortality in patients 
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with oesophageal cancer has been found [Cancer Research UK Information Resource 
Centre, 2004].     
In Scotland, between 1980 and 2004, the mortality rates for gastric cancer in 
decreased from 23.8 to 14.6 per 100,000 men and the mortality rate for oesophageal 
cancer rose from 10.6 to 20.9 per 100,000 men [ISD, 2004]. 
In Scotland, despite the fact that incidence rates are higher in the most affluent 
group, mortality rates are comparable across the deprivation quintiles [ISD, 2004].  
 




Mutations in the E-cadherin (CDH1) gene have been found in families with 
hereditary diffuse gastric cancer.  This is characterised by a highly penetrant 
susceptibility to diffuse gastric cancer in young people, with an autosomal dominant 
pattern of inheritance [Caldas et al., 1999;Huntsman et al., 2001].  In addition, there 
have been reports of inherited gastric cancer [Jones E.G., 1964;Shafiuddin et al., 1995].  
However, the vast majority of gastro-oesophageal cancers are sporadic and hereditary 
genetic mutations make only a small contribution to the overall occurrence of gastric 
and oesophageal cancer [Hemminki and Jiang, 2002;Lagergren et al., 2000b;Caldas et 




1.2.2 Predisposing conditions 
 
There are a number of conditions that confer an increased risk of gastro-
oesophageal cancer.  Tylosis, an autosomal dominant inherited condition associated 
with palmoplantar keratosis has been associated with increased risk of oesophageal 
squamous cancer [Ellis et al., 1994;Stevens et al., 1996].  Surgery for benign peptic 
ulcers has been shown to increase risk for oesophageal cancer [Lundegardh et al., 1994] 
and gastric cancer [Macintyre and O'Brien, 1994].  Pernicious anaemia is also known to 
predispose patients to gastric cancer, carcinoids and squamous oesophageal cancer [Ye 
and Nyren, 2003].  It is not clear however, if pernicious anaemia predisposes to 
oesophageal adenocarcinoma [Mellemkjaer et al., 1996].   Despite an increased risk of 
gastric cancer in patients with pernicious anaemia, endoscopic surveillance is not 
recommended [Bresky et al., 2003].  Achalasia has been shown to increase risk of 
squamous oesophageal cancer in large population based studies [Sandler et al., 
1995;Brucher et al., 2001].  However, a large number of surveillance endoscopies 
would have to be performed to identify the relatively small number of tumours and it is 
not clear as to whether or not this would reduce mortality.  Oesophageal 
adenocarcinoma has been reported in patients with achalasia but overall the incidence is 
low [Ellis, Jr. et al., 1997].   
 
1.2.3 Gastro-oesophageal reflux 
 
The direct relationship between gastro-oesophageal reflux disease and 
oesophageal cancer is well recognised [Lagergren et al., 1999a;Chow et al., 1995;Wu et 
al., 2003], as is the relationship between Barrett’s oesophagus and reflux disease 
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[Spechler and Goyal, 1986;Winters, Jr. et al., 1987].    In the UK, patients with Barrett’s 
oesophagus have a 1% per annum risk of developing oesophageal adenocarcinoma 
[Jankowski et al., 2002].  The relative risk of developing adenocarcinoma of the 
oesophagus in patients with Barrett’s is greater than 30 times that of the population in 
general [Van der Veen et al., 1989;Spechler and Goyal, 1986].  It has been suggested 
that the risk of cancer in patients with Barrett’s oesophagus is significantly greater than 
in patients with longstanding heartburn in the absence of Barrett’s [Solaymani-Dodaran 
et al., 2004].  It is not clear however, whether or not the development of Barrett’s 
oesophagus provides the link between reflux and neoplasia.  A systematic review of the 
literature has shown that around 5% of patients with oesophageal adenocarcinoma had 
pre-operative Barrett’s oesophagus [Dulai et al., 2002].  Furthermore, in Scotland, only 
14% of oesophageal adenocarcinomas occur in patients previously known to have 
Barrett’s oesophagus [ISD Scotland, 2005].  An association between reflux disease and 
cancers of the gastro-oesophageal junction has also been demonstrated but with lesser 
magnitude [Velanovich et al., 2002;Lagergren et al., 1999a].   
 
1.2.4 Helicobacter pylori 
 
The generally accepted model of carcinogenesis in gastric cancer is thought to 
result from a continuum of changes from chronic non-atrophic gastritis, multi-focal 
atrophy, intestinal metaplasia, dysplasia and neoplasia [Correa et al., 1975].  A number 
of studies have shown there to be a relationship between Helicobacter pylori (H-pylori) 
and an increased risk of developing gastric cancer and in addition, the World Health 
Organisation and the International Agency for Research on Cancer has stated that there 
is now sufficient evidence to classify H pylori as a class I carcinogen [Forman et al., 
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1991;Parsonnet et al., 1991;Huang et al., 1998].  Indeed in a study following over 1500 
patients who underwent endoscopy and testing for H-pylori, 36 patients in the H-pylori 
group developed gastric cancer compared with none in the H-pylori negative group 
[Uemura et al., 2001].  Eslick and co-workers performed a meta-analysis of 8 cohort 
and 34 case-control studies and concluded that H-pylori conveyed a doubling of the risk 
of gastric cancer [Eslick et al., 1999].  Similarly, Danesh and colleagues and Xue and 
co-workers, demonstrated a 2-3 times increased risk of gastric cancer associated with H-
pylori [Danesh, 1999;Xue et al., 2001].   In Western populations, gastric cancer is 
mainly  associated with infection by cytotoxin-associated gene A (cagA) strains of the 
organism [Ekstrom et al., 2001].  Huang and co-workers performed a meta-analysis of 
case-controlled studies (2284 cases and 2770 controls) investigating the relationship 
between H-pylori (in particular the cag A strain) and the risk of gastric cancer.  In 
concordance with the above studies, they calculated that infection with H-pylori 
increased the risk of gastric cancer between 2 and 3 fold.   
Although H-pylori infection is strongly associated with gastric cancer, the exact 
mechanism by which it facilitates malignant transformation is not clear.  It is felt to be 
multi-factorial, with the combination of infection, a permissive environment and genetic 
host susceptibility required [Egan et al., 2007;Amieva and El Omar, 2008].  With 
regards to host susceptibility, polymorphisms in the interleukin 1 gene (a pro-
inflammatory cytokine), appear to be pivotal in enhancing the host inflammatory 
response to infection with H-pylori [Noach et al., 1994] and furthermore, certain 
interleukin 1 alleles are associated with an increased risk of gastric cancer [El Omar et 
al., 2000;El Omar et al., 2003;Machado et al., 2003]. 
The association between H-Pylori infection and junctional carcinomas however 
is not clear.  The above studies demonstrated either no link or insufficient data to 
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analyse [Huang et al., 2003;Eslick et al., 1999;Danesh, 1999].  It has been shown 
however, that there is a reduced risk of oesophageal adenocarcinoma among individuals 
with Helicobacter pylori infection in the stomach but an increased level of oesophageal 
squamous cancer [Ye et al., 2004;Chow et al., 1998a].   
 
1.2.5 Lifestyle factors and risk of gastro-oesophageal cancer 
 
It has long been recognised that tobacco smoking is a risk factor for oro-
pharyngeal and oesophageal squamous cancers, with a direct relationship between tar 
yield and risk of developing cancer having been demonstrated [Brown et al., 
2001;Gallus et al., 2003].  The risk of developing a gastro-oesophageal junction tumour 
or a gastric adeno-carcinoma, is also increased with smoking, albeit to a lesser extent 
[Engel et al., 2003].  However, whether there is a causal relationship between  smoking 
and oesophageal adenocarcinoma is not clear [Lagergren et al., 2000a;Engel et al., 
2003]. 
Similar to smoking, oesophageal squamous cancer is strongly associated with 
heavy alcohol consumption [Bagnardi et al., 2001].  Indeed in a large case-control study 
of American men, the combination of smoking and heavy alcohol intake, along with 
lower social class and poor intake of fruit and vegetables, accounted for almost all 
(98%) of oesophageal squamous tumours [Brown et al., 2001].  In contrast however, 
alcohol consumption does not appear to be a risk factor for adenocarcinoma of the 
oesophagus or gastro-oesophageal junction [Gammon et al., 1997;Lagergren et al., 
2000a;Engel et al., 2003]. 
The exact nature of the relationship between dietary intake and gastro-
oesophageal cancer is not clear.  A large population-based survey showed that, diets 
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with a high plant-based content are associated with lower risk than diets with a high 
intake of animal-based food [Mayne et al., 2001].  A  high fibre diet  has been shown to 
decrease the risk of oesophageal squamous cancers [Mayne et al., 2001].  The link 
however, appears to be stronger in oesophageal adenocarcinoma and adenocarcinoma of 
the gastric cardia.  Zhang and colleagues performed a hospital based case-control study, 
over a two year period in patients with cancers of the gastric cardia and oesophageal 
adenocarcinomas.  They found that the risk of cancer was significantly associated with 
an increased intake of dietary calories and fat and a decreased risk of cancer was 
associated increased dietary intake of fibre [Zhang et al., 1997].  Similarly, Terry and 
co-workers performed a large population based case-control study and found that a high 
intake of cereal fibre was associated with a significantly reduced the risk of 
adenocarcinoma of the gastric cardia and (to a lesser extent) oesophageal carcinoma 
[Terry et al., 2001].  People with diets rich in vitamin C, vitamin E and beta carotene are 
associated with reduced risk of oesophageal and gastric cancers [Ekstrom et al., 
2000;Terry et al., 2000;Serafini et al., 2002].  Diets with poor fruit and vegetable intake 
have been associated with oesophageal cancer in the USA [Engel et al., 2003] and 
gastric cancer in Brazil [Nishimoto et al., 2002]. 
The ingestion of nitrates and an increased risk of gastro-oesophageal cancer has 
also been reported.  Nitrates are ingested via drinking water, processed foods, cured 
meats and smoking, are transformed by gastric acid into nitric oxide and in chronic 
inflammatory conditions, nitrosating agents are overproduced [Bartsch and 
Spiegelhalder, 1996;Tricker, 1997].  Overall however, the relationship between nitrates 
and gastro-oesophageal cancer is not clear, with an association with the development of 




Increasing body mass index (BMI) is associated with an enhanced risk of 
oesophageal adenocarcinoma and carcinoma of the oesophago-gastric junction.  Chow 
and colleagues performed a population based case-control study in the USA.  They 
demonstrated that the risk of adenocarcinoma of the oesophagus or gastro-oesophageal 
junction was associated with a increasing BMI [Chow et al., 1998b].  They found no 
correlation, however between increasing BMI and oesophageal squamous cancers or 
distal gastric cancers.  Lagergren and colleagues similarly found a direct relationship 
between increasing BMI and the risk of developing oesophageal and gastric cardia 
adenocarcinoma, in a Swedish population based study [Lagergren et al., 1999b].  Again 
they found no association of high BMI with gastric cancer or with squamous cancer of 
the oesophagus. 
More recently the link between obesity and the risk of cancer death was studied 
in a cohort of over 900,000 patients in the USA [Calle et al., 2003].  They found that 
increasing BMI was associated with an increased risk of gastric and oesophageal cancer.  
It is known that adipocytes are important in the production of pro-inflammatory 
cytokines.  It may be therefore, that obesity provides a direct link between chronic 
systemic inflammation and the development of cancer. 
 
1.3 Presentation of gastro-oesophageal cancer 
 
Clinical diagnosis of patients with gastro-oesophageal cancer is recognised to be 
difficult, with correlation of symptoms with endoscopic findings known to be poor  
[Adang et al., 1996].  In an American study of almost 4,000 patients undergoing 
endoscopy for dyspepsia, they found that age and symptoms were not effective 
predictors of endoscopic findings [Wallace et al., 2001].  However, there are several 
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“alarm symptoms”, that have been associated with the diagnosis of gastro-oesophageal 
cancer; dysphagia, weight loss and age >55 [Kapoor et al., 2005].  These alarm 
symptoms can help to differentiate between patients with significant organic pathology 
and those without [Numans et al., 2001].  Indeed, in the study by Kapoor and 
colleagues, if alarm symptoms were used to identify those patients most likely to have 
cancer, 92% of patients with underlying cancers would have been appropriately 
identified [Kapoor et al., 2005].   
In contrast,  patients presenting with uncomplicated dyspeptic symptoms have 
been shown to be at low risk of underlying malignancy [Gillen and McColl, 1999].  In a 
UK study of patients with gastric cancer from a single geographical area over a seven 
year period, only one patient out of 319 diagnosed with cancer, presented with 
uncomplicated dyspepsia, under the age of 55 [Christie et al., 1997]. 
 
1.4 Diagnosis of gastro-oesophageal cancer 
 
1.4.1 Upper GI Endoscopy 
 
The most commonly used diagnostic tool in gastro-oesophageal cancer, is 
endoscopy [ISD Scotland, 2005].  Oesophago-Gastro-Duodenoscopy (OGD) is safe and 
has the advantage over a Barium swallow or meal, that it can provide a histological 
diagnosis, accurate tumour mapping and avoids ionising radiation [Graham et al., 




1.4.2 Barium Swallow/Meal 
 
Barium radiology is also sensitive for the diagnosis of gastro-oesophageal 
cancer.  Its advantages are, that it avoids an invasive procedure and the use of sedation, 
with its associated (although albeit rare) morbidity and mortality [ISD Scotland, 
2005;Abbas et al., 2004].  However, pre-malignant and early cancers, identifiable on 
endoscopy, may not be identified on barium x-rays and endoscopy is therefore the 
investigation of choice in patients with suspected gastro-oesophageal cancer [Dooley et 
al., 1984]. 
 
1.5 Staging of gastro-oesophageal cancer 
 
Accurate staging of disease is important for a number of reasons: 
• It aids in the selection and planning of appropriate treatment. 
• It provides an indication of prognosis. 
• It permits standardised evaluation of results and treatment. 
• Facilitates exchange of information between centres. 
 
The staging system used most commonly in the Western World is the UICC  
Tumour, Nodes Metastasis (TNM) classification, [Sobin and Wittekind C, 1997]. 
 Tables 1.1 and 1.2   
It is important to differentiate between clinical and pathological staging.  
Clinical TNM staging (cTNM) is made on pre-treatment findings and is therefore based 
on the assessment of CT, laparoscopy and Endoscopic Ultrasound (EUS) findings.  
37 
 
Pathological staging (pTNM) is based on the objective assessment of the resected 
specimen.  This information is therefore only available following surgery. 
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Table 1.1  TNM staging in oesophageal cancer 
 
Primary tumour (T) 
   
T1 Invades lamina propria or submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades adventitia 
T4 Tumour invades adjacent structures 
 
Regional  lymph nodes (N) 
 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
 
Distant metastasis (M) 
 
M0 No distant metastasis 
M1a  
M1b Distant metastasis 
 
For tumours in the lower thoracic oesophagus: For tumours in the upper thoracic 
oesophagus: 
 
M1a Metastasis in ceoliac lymph nodes  M1a  Metastasis in cervical  
       lymph nodes 
M1b  Other distant metastasis   M1b  Other distant metastasis 
 
For tumours in the mid thoracic oesophagus: 
 
M1a N/A 




     Stage grouping 
 
I T1  N0  M0 
 
IIa T2  N0  M0 
IIa T3  N0  M0 
IIb T1  N1  M0 
IIb T2  N1  M0 
 
III T3  N1  M0 
III T4  Any N  M0 
 
IV Any T  Any N  M1 
IVa Any T  Any N  M1a 
IVb Any T  Any N  M1b 
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Table 1.2  TNM staging in gastric cancer 
 
Primary tumour (T) 
   
T1 Invades lamina propria or submucosa 
T2 Tumour invades muscularis propria or sub-serosa 
T3 Tumour penetrates serosa without invasion of adjacent structures 
T4 Tumour invades adjacent structures 
 
Regional  lymph nodes (N) 
 
N0 No regional lymph node metastasis 
N1 Metastasis in 1 to 6 regional lymph nodes 
N2 Metastasis in 7 to 15 regional lymph nodes  
N3 Metastasis in more than 15 regional lymph nodes 
 
Distant metastasis (M) 
 
M0 No distant metastasis  
M1 Distant metastasis 
 
 
Note: Involvement of retro-pancreatic, mesenteric and para-aortic lymph nodes, are 




     Stage grouping 
 
Ia T1  N0  M0 
Ib T1  N1  M0 
Ib T2  N0  M0 
 
II T1  N2  M0 
II T2  N1  M0 
II T3  N0  M0 
 
IIIa T2  N2  M0 
IIIa T3  N1  M0 
IIIa T4  N0  M0 
IIIb T3  N2  M0 
 
IV T4  N1,2,3  M0 
IV T1,2,3  N3  M0 




There are a number of modalities currently used to stage patients with gastro-
oesophageal cancer and are usually used in combination. 
 
1.5.1 Computerised Tomography (CT) 
 
CT is the most commonly used staging investigation in patients with gastro-
oesophageal cancer [ISD Scotland, 2005].  It is accurate in detecting distant metastasis 
but has been shown to be relatively poor in assessing the T and N components of 
disease stage [Blackshaw et al., 2003].  In a study of 108 consecutive patients 
undergoing gastrectomy for gastric cancer, pathological T and N stage was compared 
with CT assessed stage.  CT correctly assessed T and N stage in 43% and 51% of 
patients respectively  [Ziegler et al., 1993]. 
 
1.5.2 Endoscopic Ultrasound (EUS) 
 
EUS has been demonstrated to increase the accuracy of T and N staging over CT 
scanning [Kelly et al., 2001].  In addition, the combination of EUS and fine needle 
aspiration (FNA) cytology of distant nodes has been shown to improve staging accuracy 
compared to CT and EUS alone [Vazquez-Sequeiros et al., 2003].  In the recent Scottish 
Audit of Gastro-Oesophageal Cancer (SAGOC)  however, EUS was performed in 3% of 
patients overall [ISD Scotland, 2005]. 
 
1.5.3 Laparoscopy 
CT scanning is not sensitive in the diagnosis of peritoneal metastasis and the use 
of laparoscopy has therefore been shown to improve clinical staging, demonstrate 
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inoperable disease and subsequently reduce the incidence of attempted resection, in 
patients with inoperable gastric cancers or cancers of the oesophago-gastric junction 
[Clements et al., 2004;Blackshaw et al., 2003].  In a study of 244 patients with tumours 
of the stomach or oesophagus, laparoscopy demonstrated inoperable disease in 93 
[Molloy et al., 1995].  Blackshaw and co-workers examined the accuracy of 
laparoscopy in 258 consecutive patients with gastric cancer.  They found evidence of 
metastatic disease in 21 patients at laparoscopy, in whom CT scanning had shown no 
evidence of widespread disease [Blackshaw et al., 2003].   
The importance prognostically of free peritoneal tumour cells using cytology of 
lavage fluid, is however more controversial.  Bryan and co-workers demonstrated a 
statistically significant difference in survival between the cytology +ve and –ve patients, 
with a median survival of 122 and 378 days  respectively [Bryan et al., 2001].  In 
addition, in a study of 371 patients undergoing resection for gastric cancer, cytology 
+ve washings were found to be independently associated with a poorer survival; median 
survival 14.8 vs 98.5 months [Bentrem et al., 2005].   
A separate study by Wilkiemeyer and colleagues however in a smaller cohort, 
found that no additional prognostic information was conferred by the addition of 
cytology and no clinically stage III patients were upstaged by cytology [Wilkiemeyer et 
al., 2004]. 
 
1.5.4 Pathological Stage 
 
Pathological tumour stage (pTNM) has been consistently found to be the most 
important predictor of survival following resection for gastro-oesophageal cancer [Lerut 
et al., 2004;Barchielli et al., 2001].  Although the pathological T category has been 
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shown to be independently associated with survival, within the TNM system, the 
presence of metastatic tumour in lymph nodes has been shown to be of primary 
importance [Karpeh et al., 2000].  In particular, the ratio of involved nodes, to resected 
nodes has been demonstrated to better predict survival than positivity of nodes alone 
[Roder et al., 1994;Siewert et al., 1998]. 
 
1.6 Treatment of gastro-oesophageal cancer 
 
The treatment strategy for patients with gastro-oesophageal cancer is dependent on 
TNM stage, the presence of co-morbid disease and patient wishes.  Patients can be 
classified using the above criteria into operable and inoperable groups. 
 
1.6.1 Treatment of operable gastro-oesophageal cancer 
 
Surgery confers the greatest chance of long-term cure and has the aim of 
achieving the complete removal of macroscopic and microscopic tumour (R0 resection).  
It is however associated with significant morbidity and in the UK, mortality rates for 
oesophago-gastric resections are approximately 10% [Pye et al., 2001;McCulloch et al., 
2003;ISD Scotland, 2005].  Mortality and the extent or radicality of the surgery 
involved is therefore a subject of debate.   
In gastric cancer, it has been suggested, that a radical (D2) resection may be 
associated with increased morbidity and mortality, with no benefit in long-term survival 
[McCulloch et al., 2004].  However there is some evidence that radical 
lymphadenectomy is associated with improved long-term survival [Marubini et al., 
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2002].  In a randomised trial in the UK, D2 gastrectomy was shown to increase 5 year 
survival compared to D1 gastrectomy, on multivariate analysis [Edwards et al., 2004]. 
In oesophageal cancer, extensive lymphadenectomy is felt to improve survival, 
with the ratio of involved to resected nodes an independent prognostic factor  
[Tachibana et al., 2000;Roder et al., 1994].  However there are no randomised, control 
trials comparing limited to radical lymphadenectomy and survival. 
The use of neoadjuvant chemotherapy/ chemo-radiotherapy in patients with 
gastro-oesophageal cancer is controversial.  The MRC OE 02 study demonstrated a 
median survival benefit of 3 months (16 months compared to 13 months) in patients 
with oesophageal cancer treated with pre-operative cisplatin and 5- Fluorouracil (5FU), 
compared with surgery alone [MRC Oesophageal cancer working group, 2002].  A 
further randomised- controlled trial of patients with squamous and adenocarcinomas of 
the oesophagus however, found no survival benefit with adjuvant chemotherapy [Kelsen 
et al., 1998].   
A meta-analysis of studies investigating the use of neo-adjuvent chemo-
radiotherapy compared with surgery alone in patients with oesophageal cancer, found 
that 3 year survival was superior in the group receiving neo-adjuvent chemo-
radiotherapy [Urschel and Vasan, 2003].  However, only one trial in the meta-analysis 
demonstrated a statistically significant difference in survival and there was significant 
morbidity associated with neo-adjuvent treatment. 
The use of adjuvant or post-operative chemotherapy in patients with 
oesophageal cancer, has been shown not to confer any survival benefit [Lehnert, 1999].  
In addition, it is associated with increased mortality. 
In patients with gastric cancer, a meta-analysis has demonstrated no survival 
benefit comparing surgery alone, with neo-adjuvent chemotherapy [Janunger et al., 
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2002].  However, the use of chemotherapy as adjuvant or post operative treatment in 
patients with gastric cancer, may confer a survival advantage, particularly in node 
positive patients [Janunger et al., 2002]. 
 
1.6.2 Treatment of inoperable gastro-oesophageal cancer 
 
The majority of patients presenting with gastro-oesophageal cancer, have 
advanced, inoperable disease and are therefore treated with palliative intent [ISD 




Combined chemo-radiotherapy and radiotherapy alone, can be used as curative 
treatment for oesophageal adenocarcinomas and squamous cancers but more commonly 
they are used with palliative intent [Okawa et al., 1989;Allum et al., 2002].  Combined 
chemo-radiotherapy has been shown to be superior to radiotherapy alone in overall 
survival but this is, however not without the risk of significant side effects.  In a 
randomised controlled trial, the five year survival in the group treated with radiotherapy 
and concomitant chemotherapy was 14%, compared with 0% in the radiotherapy group.  
However, the incidence of severe toxicity and side effects were significantly higher in 
the combined group, with life-threatening toxicity in 10% and 2% of patients in the 
combined chemo-radiotherapy and radiotherapy alone groups respectively [Cooper et 
al., 1999].   Radiation treatment alone is associated with low morbidity and mortality 
and can provide symptomatic relief from dysphagia,  however, systemic disease 
recurrence is not uncommon [Ask et al., 2003].  
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A recent meta-analysis of palliative chemotherapy in gastric cancer has 
demonstrated a survival benefit of between 3 to 9 months [Janunger et al., 2002] .  
Whilst such palliative treatment may confer a small survival advantage over best 
supportive care, it’s primary aim is the relief of symptoms [Pyrhonen et al., 1995;Murad 
et al., 1993;Enzinger et al., 1999].   
 
1.6.2.2 Endoscopic Palliation 
 
Insertion of stents for control of malignant dysphagia is a common method of 
endoscopic palliation.  Partially covered metal stents, compared with uncovered stents,  
provide the best symptom control and lowest complication rate [Vakil et al., 2001].  
Ablative therapy with laser is an alternative mode of endoscopic palliation.  In a 
randomised controlled trial of stenting versus laser therapy in patients with oesophageal 
cancer or cancers of the gastro-oesophageal junction, laser therapy was associated with 
improved survival compared with stenting and may slow the decline in quality of life 
[Dallal et al., 2001]. 
A randomised control trial comparing Photodynamic Therapy (PDT) and laser in 
218 patients, has shown PDT to be as efficacious as laser therapy in symptomatic 
control of dysphagia [Lightdale et al., 1995].  The incidence of minor complications due 
to photosensitivity in PDT, is significantly greater than the incidence of complications 
with laser therapy.  However perforation due to laser is associated with mortality. 
46 
 
1.7 Pathological determinants of survival in patients with gastro-oesophageal 
cancer 
 
Although there is a wide geographical variation, overall survival in patients with 
gastro-oesophageal cancer is comparatively poor.   For oesophageal cancer in Europe, 
overall five year survival is 10% [Sant et al., 2003] and in America similar survival was 
found, with 15.6% of  patients living 5 years [SEER, 2004].  Locally, in Scotland the 5 
year survival is similarly poor with only 10% of men and 13% of women surviving 5 
years [ISD, 2004].   
In gastric cancer, overall survival was greater than for oesophageal cancer.  In 
Europe and in America similar survival was found, with 23.9% of  patients living 5 
years [Sant et al., 2003;SEER, 2004].  Locally in Scotland, survival is poorer with only 
13% of men and 18% of women surviving five years [ISD, 2004].   
 
1.7.1 Established tumour associated determinants of survival 
 
As discussed in chapter 1.7.4, a number of criteria based on the resected 
specimen predict long-term survival in patients undergoing potentially curative surgery.  
Increasing pTNM stage, the presence of lymph node metastasis (in particular the ratio of 
involved nodes to the total number of nodes removed and identified), positive resection 
margins (R1 resection) and poorly differentiated tumours are associated with poorer 
survival [Siewert et al., 1998;Roder et al., 1994;Shiu et al., 1989;Robey-Cafferty et al., 
1991;Khan et al., 2004].  However, some patients with favourable, conventional 
prognostic markers unfortunately still have a poor outcome and the identification of 
alternative prognostic markers would therefore be of considerable benefit.   
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1.7.2 Tumour proliferation 
 
Ki67 is a large protein, which undergoes phosphorylation and dephosphorylation 
during mitosis.  It is known to be important in cell proliferation but its exact function is 
unclear [Duchrow et al., 2003;Schluter et al., 1993;MacCallum and Hall, 2000].  
Despite the lack of clarity over its function, Ki67 has been shown to have prognostic 
value in a variety of tumours.  In breast cancer in particular, there have been a number 
of studies which have demonstrated a link between high proliferative activity (as 
measured by Ki67) and poor survival [Locker et al., 1992;Beck et al., 1995;Chang et al., 
1999].  Ki67 has also been shown to be of prognostic value in lung tumours and brain 
tumours [Pence et al., 1993;Harpole, Jr. et al., 1995;Wakimoto et al., 1996;Ellison et al., 
1995].  However, in colorectal cancer the relationship between ki67 and survival is 
inconsistent, with some studies indicating that high Ki67 expression is associated with 
poor prognosis and other studies suggesting the converse is true [Palmqvist et al., 
1999;Saleh et al., 1999;Kimura et al., 2000].   
In patients with oesophageal cancer, high Ki67 expression has been associated 
with the progression from dysplasia to neoplasia [Polkowski et al., 1995;Xu et al., 
2002;Kerkhof et al., 2008].  In addition, in a study of 56 patients with either squamous 
or adenocarcinoma of the oesophagus undergoing chemo-radiotherapy, increased 
expression of Ki67 was associated with greater tumour response [Ressiot et al., 2008].  
This is in keeping with studies in patients with colorectal cancer, where tumours with a 
high proliferative activity are more likely to respond to chemotherapy [Allegra et al., 
2002;Allegra et al., 2003;Garrity et al., 2004]    
The data regarding tumour proliferation and survival in patients with gastric 
cancer is sparse.  In a study of 122 Arab patients with gastric cancer, high tumour 
48 
 
proliferation (as measured by Ki67) was associated with p53 over-expression [Al 
Moundhri et al., 2005].  Ki67 however, was not an independent prognostic factor. 
In a separate study analysing cell proliferation and apoptosis in patients with gastric 
cancer and intestinal metaplasia, increased proliferation rate was found in patients with 
cancer, compared to metaplasia [Forones et al., 2005].  This was a study however, with 
22 patients in each group. 
Tenderenda et al, analysed tissue from 58 patients who had undergone radical 
gastrectomy for adenocarcinoma [Tenderenda et al., 2001].  They investigated the 
relationship between micro-vessel density and tumour proliferation (as measured by 
Ki67), p53 expression and tumour stage, type and grade.  There was however, no 
significant relationship between Ki67 and the other variables.  
 
1.8 Host determinants of survival 
 
It has long been recognized that disease progression in cancer patients is not 
solely determined by intrinsic properties of tumour cells but also by the host response.   
At present however, decision making regarding the allocation of treatment in patients 
with gastro-oesophageal cancer is predominately based on tumour factors along with, 
patient selection based on co-morbidity and performance status.  Poor performance 
status has been shown to predict a poor outcome in patients with advanced gastric and 
oesophageal disease  [Polee et al., 2003;Yoshida et al., 2004;Chau et al., 2004].  The 
assessment of performance status is however subjective.  For example, significant 
differences in the assessment of performance status have been reported between 
oncologists, nurses and patients, oncologists being the most optimistic in their 
assessment and patients the least [Ando M, 2001].  As a result there is continuing 
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interest in the development of objective and reproducible prognostic scores, which 
better reflect clinical outcome in patients with advanced cancer. [Bennett and Ryall, 
2000;Sloan et al., 2001]. 
 
1.8.1 Host Immune response 
 
The purpose of the host immune response is to prevent infection or tissue 
destruction.  The way this is achieved is subdivided broadly into two categories; innate 
and adaptive immunity.  The innate immune system or native immunity is non-specific 
defence against microbes and is present before an infection takes place.  Adaptive 
immunity or specific immunity, in contrast, is stimulated by microbes or antigens and 
takes time to become effective.  The tumour-host immune interaction is complex and 
not fully understood. 
The main components of the innate immune system are phagocytic cells, such as 
neutrophils, natural killer cells and macrophages and the complement proteins.  
Infection by a microbe stimulates the acute inflammatory response, with mobilisation of 
initially neutrophils, and subsequently macrophages, to engulf and destroy the microbes. 
  
 Figure 1.2 
Innate and adaptive immunity (Abbas, 2005).
 
 
The adaptive immune system itself,
mediated immunity and humoral immunity.  Cell mediated immunity is responsible for 
defence against intracellular microbes and is controlled by T lymphocytes from the 
Thymus.  Humoral immunity, in contrast, is respo




 can be divided into two categories; cell 




 Figure 1.3 
Humoral and cell
    
 
1.8.2 Local inflammatory response in patients with gastro
 
Since Virchow first observed leucocyte infiltration of tumours, it has been 
recognised that the local inflammatory response is key to the development of a variety 
of tumours [O'Byrne and Dalgleish, 2001]
able to recognise tumour antigens and local infiltration of tumours by leucocytes may be 
associated with improved survival 
In gastric cancer, it has been shown that, pronounced leucocy
tumour, on haematoxylin and eosin staining of sections, is associated with improved 
51 
-mediated immunity (Abbas, 2005). 
-oesophageal cancer
.  It is known now, that the immune system is 
[Brigati et al., 2002]  
 
 
te infiltration of the 
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survival [Ma et al., 1994].  The specific inflammatory cell subtype involved however, is 
not clear.  Schumacher and colleagues examined a consecutive series of 70 resected 
oesophageal squamous and adenocarcinomas for CD8 infiltration.  They found that 
increased local infiltration of tumour with CD8 lymphocytes was associated with 




The relationship between tumour associated macrophages (TAM) and survival is 
not clear and this in part, may be due to the fact that macrophages have both pro-
angiogenic and anti-angiogenic properties [Mantovani et al., 1992;Brigati et al., 2002].  
The angiogenic properties of macrophages are secondary to their ability to stimulate 
production of proangiogenic cytokines, such as vascular endothelial growth factor 
(VEGF), IL-8 and tumour necrosis factor (TNF), which are known to be crucial in 
cancer angiogenesis [Carmeliet and Jain, 2000].  Increased infiltration of cancers by 
TAM has therefore been shown to be associated with poor cancer specific survival in a 
number of tumour types, including breast, cervical and malignant melanoma [Leek et 
al., 1996;Torisu et al., 2000;Salvesen and Akslen, 1999]. 
In contrast, increased macrophage infiltration of tumour has also been associated 
with improved survival [Shimura et al., 2000;Pupa et al., 1996].  This may be as a result 
of increased stimulation of production of angiostatic cytokines by macrophages, such as 
IL-12 and IL-18 [Tsung et al., 2002;Belardelli and Ferrantini, 2002;Coughlin et al., 
1998].   
There are no reported studies analysing the relationship between macrophage 
infiltration of oesophageal cancer and survival.  Increased infiltration of tumour 
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associated macrophages (CD68) to cancer nest cells has been shown to be associated 
with improved survival however in gastric cancer [Ohno et al., 2003].  Ohno and 
colleagues examined the relationship between tumour associated macrophages and 
survival, in 84 patients who had undergone resection for T2 and T3 adenocarcinoma.  
They found, that increased TAM in the cancer nest cells was associated with improved 
survival on multi-variate analysis. 
 
1.8.3 Systemic Inflammatory response 
 
Inflammation is the generic, physiological response to cell injury or damage.  It 
can be activated by a number of stimuli, including infection, trauma, malignancy or 
hypersensitivity reactions.  Its role is not fully understood but is thought to be to restore 
tissue function.  Changes distant from the local stimulus to inflammation, often 
accompany the local inflammatory reaction and are felt to be mediated by cytokines and 
in particular, interleukin-6 [Heinrich et al., 1990].  These changes include neuro-
endocrine, haemopoietic, metabolic and hepatic phenomenon and this cascade of 
changes is referred to as the “acute phase response” Table 1.3.  The concentration of a 
number of plasma proteins rise or fall significantly as part of the acute phase response 
and they are accordingly named “acute-phase proteins” [Gabay and Kushner, 1999].  
However, it has been shown that a persistent response is seen in many patients, 
including those with malignant disease.  It has therefore been suggested that the term 
“systemic inflammatory response” is used to reflect the sometimes chronic nature of the 






 Fever, somnolence, and anorexia 
 Increased secretion of corticotropin-releasing hormone, 
 Decreased production of insulin-like growth factor I 
 Increased adrenal secretion of catecholamines 
 
Hematopoietic changes 





 Loss of muscle and negative nitrogen balance 
 Decreased gluconeogenesis 
 Increased hepatic lipogenesis 
 Increased lipolysis in adipose tissue 




 Increased metallothionein, inducible nitric oxide synthase, 
 tissue inhibitor of metalloproteinase-1 
 decreased phosphopyruvate carboxykinase activity 
   hypozincemia, hypoferremia, and hypercupremia 
 increased plasma retinol and glutathione concentrations 
 
Table 1.3 Systemic changes associated with the acute phase response. 
 
1.8.4 The acute phase proteins 
 
To be described as an acute-phase protein, the serum concentration must either 
decrease or increase by at least 25% during inflammatory disorders [Morley and 
Kushner, 1982].  A number of acute phase proteins have been identified (Table 1.4).  
The magnitude and timing of their response however, varies greatly (figure 1.4).  C-
reactive protein and amyloid A for example, exhibit a fast and significant response 
compared to the slower and more sustained response of haptoglobin.  The acute phase 
proteins C-reactive protein and albumin are the two most commonly measured, due to 




Table 1.4  The major acute-phase proteins 
 
Protein Types Increased Decreased 
Proteinase inhibitors α-antitrypsin  





Complement Proteins C1-5 
C56 
Properdin 
Miscellaneous C-reactive protein 









Figure 1.4: Characteristic patterns of change in plasma concentrations of some acute 








1.8.4.1 C-reactive protein. 
 
C-reactive protein is a non-specific, acute phase protein, was first described in 
1930 and was named due to its ability to bind to the C-polysaccharide in the 
pneumococcal cell wall.   It has been shown to activate the complement cascade, act as 
an opsonin and bind to monocytes, stimulating cytokine production [Ballou and 
Lozanski, 1992;Du Clos, 2000].  It is synthesised by hepatocytes in response to pro-
inflammatory cytokines, such as, interleukin-1 (IL-1), interleukin-6 (IL-6) and tumour 
necrosis factor alpha (TNF-α) [Du Clos, 2000].  The production of CRP increases 
rapidly (approx 6h) following a single inflammatory stimulus, reaching peak 
concentrations at 48h, with a doubling rate of 8h [Kushner et al., 1978].  Concentrations 
greater than 200 mg/l can be measured within 24h of an acute stimulus and can fall to 
near normal within 2-3 days of cessation [Kolb-Bachofen, 1991].  The sensitivity and 
rapid response of CRP to inflammation has lead to it becoming a useful tool in the 




Albumin is the most abundant protein in plasma, accounting for around half of 
the hepatic protein production.  Unlike C-reactive protein, albumin has a long plasma 
half-life of around twenty days, compared with 19 hours for C-reactive protein.  
Albumin concentration is the standard, objective, biochemical factor used routinely in 
clinical practice to assess nutritional status.   Following stimulation of the systemic 
inflammatory response, serum albumin concentrations fall.  The mechanism of this fall 
in patients with cancer however is complex, with low albumin concentrations found 
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secondary to a combination of poor nutritional intake and increased catabolism [Al 
Shaiba et al., 2004;McMillan et al., 2001b].  
Hypo-albuminaemia has been identified as an independent predictor of survival in 
resectable colon and rectal cancer  [Heys et al., 1998b], resectable and advanced breast 
cancer [Heys et al., 1998a;Lis et al., 2003].   
Lien et al investigated the relationship between pre-operative serum albumin 
concentration and survival in more than 300 patients undergoing resection for gastric 
cancer.  They found that an albumin concentration of < 35 g/dl was associated with 
poorer survival independent of TNM stage and whether or not patients underwent 
curative resection [Lien et al., 2004].  C-reactive protein concentration was however, 
not measured in any of the above studies. 
 
1.8.5 Systemic inflammatory response and survival 
 
Survival, in patients with cancer is determined by a complex interaction of 
tumour biology and the host response.  Production of pro-inflammatory cytokines, 
whether by the tumour or the host, stimulates the release of acute phase proteins, 
including C-reactive protein [Tisdale, 1999;Barber et al., 2000].  This increased 
production of acute phase proteins, leads to the consumption of amino acids and the 
breakdown of host muscle is therefore required to continue this supply of amino acids 
[McMillan et al., 1998;Preston et al., 1998].  Chronically increased production of acute 
phase proteins may therefore contribute to the irreversible wasting and decline in 
patients with advanced cancer.  In addition to the catabolic effect of pro-inflammatory 
cytokines, they may also influence survival by promoting the growth of the tumour 
[Abramovitch et al., 1999;Balkwill and Mantovani, 2001].   
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An elevated systemic inflammatory response (as evidenced by an increased C-
reactive protein concentration) has been found to be associated with a poor survival in 
patients with a variety of cancers including those with either operable or inoperable/ 
advanced disease.  The bulk of this evidence is in patients with colorectal cancer, where 
increased C-reactive protein concentration is associated with more advanced tumour 
stage and decreased survival [McMillan et al., 1995;Nozoe et al., 1998;1995;Wigmore 
et al., 2001;Nielsen et al., 2000;Wigmore et al., 2001;McMillan et al., 2003;Miki et al., 
2004].  However there is now evidence that an elevated systemic inflammatory response 
predicts poor survival in most solid tumour types [Mahmoud and Rivera, 2002].  In both 
operable and inoperable primary hepatico-pancreatico-biliary tumours, an elevated C-
reactive protein concentration predicts poor survival [Jamieson et al., 2005;Hashimoto 
et al., 2005].  Similarly, In ovarian cancer [Kodama et al., 1999], renal cancer [Masuda 
et al., 1998], bronchial cancer [Scott et al., 2002] and breast cancer [Albuquerque et al., 
1995], increased C-reactive protein concentrations predicted poorer survival.  In 
addition, it has been shown that an elevated C-reactive protein and hypoalbuminaemia 
may be combined to form a score, the Glasgow Prognostic score (GPS), which has 
prognostic value, independent of stage and performance status, in patients with 
inoperable non-small cell lung cancer [Forrest et al., 2004;Forrest et al., 2003]. 
 
1.8.5.1 Systemic inflammatory response and survival in patients with inoperable gastro-
oesophageal cancer. 
 
There is little evidence in patients with inoperable gastric or oesophageal cancer, 
regarding the relationship between an elevated systemic inflammatory response and 
survival.  An increased C-reactive protein concentration and hypo-albuminaemia, either 
alone or in combination, have however been shown to predict decreased survival in a 
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heterogeneous group of patients with advanced cancer, including gastric cancer 
[McMillan et al., 2001a;O'Gorman et al., 2000].  In a further study of 165 patients with 
advanced cancer (66 with gastric cancer) median survival in the gastric cancer group 
was 6.1, 3.1 and 1.6 months in patients with a GPS of 0, 1 and 2 respectively [Elahi et 
al., 2004].  The relationship between an elevated systemic inflammatory response and 
survival, has not to date been examined specifically in patients with inoperable gastro-
oesophageal cancer.    
 
1.8.5.2 Systemic inflammatory response and survival in patients with operable gastro-
oesophageal cancer. 
 
The relationship between the presence of an elevated systemic inflammatory 
response and poor outcome in patients with gastro-oesophageal cancer, has been 
previously confirmed.  Specifically, an elevated serum C-reactive protein concentration, 
prior to surgery, has previously been shown to have independent prognostic value in 
patients with resectable oesophageal cancer [Nozoe et al., 2001;Ikeda et al., 
2003;Shimada et al., 2003].   
Nozoe and colleagues [Nozoe et al., 2001] analysed 262 patients with 
oesophageal carcinoma (245 squamous cell carcinomas and 17 adenocarcinomas) 
treated with surgery over a 7 year period.  Their cohort included patients receiving neo-
adjuvent therapy and also patients with T4 disease.  Eighty four patients had an elevated 
C-reactive protein concentration (>5mg/l) and this was associated with poorer survival 
on multivariate analysis. 
Ikeda et al [Ikeda et al., 2003], analysed 356 patients with oesophageal 
squamous carcinoma, over a 9 year period.  All patients underwent oesophagectomy, 
with neo-adjuvent and adjuvant chemo/ radiotherapy given to a subset of patients  One 
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hundred and forty nine patients had an elevated C-reactive protein concentration 
(>5mg/l) and again this was associated with poor cancer specific survival.  This study 
also included patients with advanced disease. 
Shimada and colleagues [Shimada et al., 2003] investigated the relationship 
between an elevated C-reactive protein concentration and survival in 150 patients 
undergoing oesophagectomy.  In this study all patients had squamous cell tumours, 
received no pre-operative therapy and the cut-off for an elevated C-reactive protein 
concentration was >10mg/l.  Thirty five patients had an elevated C-reactive protein 
concentration and on multivariate analysis, this was again associated with poor survival. 
Only one paper investigating the relationship between pre-operative C-reactive 
protein and survival in gastric cancer could be identified from the literature, published 
in 1983.  De Mello et al looked at 100 patients with gastric cancer and found that an 
elevated C-reactive protein concentration > 20mg/l, was associated with more advanced 
TNM stage and an increased likelihood of inoperability [de Mello et al., 1983].  
However C-reactive concentration protein, did not independently predict survival on 
multivariate analysis.  The relevance of this study however, in the context of current 





 The overall aim of the thesis was to examine the inter-relationships between 
local and systemic inflammatory responses and cancer specific survival, in patients with 
gastro-oesophageal cancer.   
More specifically:  
To determine how markers of the systemic inflammatory response might be used to 
predict outcome, independent of tumour stage and other patient related factors, in 
patients undergoing treatment for operable and inoperable gastro-oesophageal cancer. 
To examine the relationship between local and systemic inflammatory responses and 
outcome in patients undergoing potentially curative resection. 
To examine how such information might be used in the pre-treatment clinical staging of 
patients with gastro-oesophageal cancer 
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CHAPTER 2:  AN ELEVATED C-REACTIVE PROTEIN 
CONCENTRATION, PRIOR TO SURGERY, PREDICTS POOR CANCER 





 In patients with gastro-oesophageal cancer, surgery confers the greatest chance 
of long-term cure but is associated with appreciable morbidity and mortality.  As a 
consequence, potentially curative surgery is carried out relatively infrequently.  The 
prognosis for patients who undergo potentially curative resection, is influenced by 
various pathologic characteristics of the resected tumour specimen.  In particular, 
residual tumour (R), lymph node status and the ratio of positive to total lymph nodes 
sampled have been shown to have independent prognostic value [Roder et al., 
1994;Siewert et al., 1998].   
It is increasingly recognised that it is not only the intrinsic properties of tumour 
cells which determine tumour spread but also the host inflammatory response [Balkwill 
and Mantovani, 2001;Coussens and Werb, 2002].  Indeed, the systemic inflammatory 
response, as evidenced by elevated circulating concentrations of C-reactive protein, has 
been shown to be a disease independent prognostic factor in a variety of tumours, when 
resections are carried out with curative intent [McMillan et al., 2003;Jamieson et al., 
2005;Hilmy et al., 2005]. 
An elevated serum C-reactive protein concentration, prior to surgery, has 
previously been shown to have independent prognostic value in patients with resectable 
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oesophageal cancer [Nozoe et al., 2001;Ikeda et al., 2003;Shimada et al., 2003].  
However, some of these studies included patients with metastatic disease at the time of 
surgery and used variable C-reactive protein thresholds.  To date, the prognostic value 
of C-reactive protein has not been examined in patients undergoing potentially curative 
resection for gastric cancer. 
The aim of the present study was to examine the relationship between clinico-
pathologic status, C-reactive protein concentration measured prior to surgery and cancer 
specific survival, in patients selected for potentially curative resection of gastro-
oesophageal cancer. 
 
2.2 Patients and methods 
 
2.2.1 Patients 
Patients selected for potentially curative resection of gastro-oesophageal cancer 
(between January 1996 and December 2004) and who had a pre-operative measurement 
of C-reactive protein were included in the study.  For gastric cancers, TNM stage I to III 
tumours were considered to be amenable to curative surgical resection.  For 
oesophageal cancers, TNM stage I to III tumours, excluding T4, were considered to be 
amenable to curative surgical resection.  Measurements of haemoglobin, white cell, 
lymphocyte and platelet counts, albumin and C-reactive protein were carried out prior to 
staging laparoscopy or surgery.  All patients underwent en-bloc resection with 
lymphadenectomy (median 20, range 3-55 nodes resected).  All patients were treated in 
the upper GI surgical unit at Glasgow Royal Infirmary and survived at least 30 days 




Data for 1996–1998 (n= 16) were collected retrospectively and that for 1999–2004 (n= 
104) prospectively.  






The extent of tumour spread was recorded using the TNM stage.  Tumours of 
the gastro-oesophageal junction were further classified according to site, using the 
Siewert system [Siewert and Stein, 1998]; type 1 and 2 lesions of the gastro-
oesophageal junction were designated as cancers of the oesophagus.  Type 3 tumours of 
the cardia were designated gastric cancers.  
Routine pre-operative laboratory measurements of albumin and C-reactive 
protein were carried out. The coefficient of variation for this method, over the range of 
measurement, was less than 5% as established by routine quality control procedures.  
The limit of detection of the assay is a C-reactive protein concentration of less than 
5mg/l with the upper limit of normal values being <10mg/l.  Based on previous work 
[O'Gorman et al., 2000;McMillan et al., 2001a] a C-reactive protein concentration of 







Data are presented as median and range. Comparisons between groups of 
patients were carried out using contingency table analysis (X2) as appropriate.  
Grouping of the laboratory variables haemoglobin, white cell, lymphocyte and platelet 
counts, albumin and C-reactive protein, protein was carried out using standard 
thresholds [O'Gorman et al., 2000;McMillan et al., 2001a;Ikeda et al., 2002;Maltoni et 
al., 2005;Shen et al., 2005].  Survival (cancer-specific) analysis of the group variables 
was performed using the Cox proportional hazard model.  Deaths up to the end of 
February 2006 have been included in the analysis.  Multivariate survival analysis, 
including all covariates that were significant on univariate analysis, was performed 
using a stepwise backward procedure to derive a final model of the variables that had a 
significant independent relationship with survival. To remove a variable from the 
model, the corresponding P-value had to be greater than 0.10.  Analysis was performed 




Baseline clinicopathological characteristics of the patients (n= 120) studied are 
shown in Table 2.1.  The majority of patients were male, under 65 years and had 
adenocarcinoma.  The majority of patients had localised disease with clear resection 
margins and therefore underwent potentially curative surgery (n= 99).  Of the remaining 
21 patients, 3 patients were found to have metastasis at the time of surgery; 1 patient 
with a small bowel deposit, 1 patient with a single liver deposit and 1 patient with 
metastatic disease affecting the terminal ileum/ascending colon.  The remaining 18 
patients had positive circumferential resection margins of the oesophagus (tumour 
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<1mm from resection margin).  No patients had positive longitudinal margin 
involvement.   
The majority of patients had laboratory based measures including haemoglobin, 
white cell, lymphocyte and platelet counts, albumin and C-reactive protein 
concentrations in the normal range.  Fifteen patients (13%) had an elevated circulating 
C-reactive protein concentration (>10mg/l) prior to surgery.   
During the follow-up period 60 (50%) patients died; 58 of their disease.  The 
median follow-up of the survivors was 55 months.  On univariate analysis, pTNM stage 
(p<0.01), lymph node status (p<0.01), positive to total lymph node ratio (p<0.001) and 
pre-operative C-reactive protein (p<0.001) were significantly associated with survival 
(Table 2.1).  On multivariate analysis of these significant variables, positive to total 
lymph node ratio (HR 2.02, 95%CI 1.44-2.84, p<0.001, Figure 2.1) and pre-operative 
C-reactive protein (HR 3.53, 95%CI 1.88-6.64, p<0.001, Figure 2.2) retained 
independent significance.   
The pre-operative values of C-reactive protein at the thresholds of >5mg/l and 
>10mg/l were compared in multivariate survival analysis.  In this analysis, the 
prognostic significance of the threshold of >10mg/l (p=0.013) was greater than >5mg/l 
(p= 0.559).  
The relationship between the presence of an elevated pre-operative C-reactive 
protein concentration and clinicopathological characteristics are shown in Table 2.2.  
There was no significant difference in age, sex, tumour site, tumour type, pTNM stage, 
presence of positive resection margins, lymph node status, positive to total lymph node 
ratio, haemoglobin, white cell, lymphocyte and platelet counts and albumin groupings 
between the inflammatory and non-inflammatory groups.  In contrast, a greater 
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proportion of patients had a lower haemoglobin (p<0.05) and percentage lymphocyte 
counts (p<0.001) in the elevated systemic inflammatory response group. 
The patient group with no evidence of a pre-operative systemic inflammatory 
response (C-reactive protein <10mg/l) had a median survival of 79 months compared 
with 19 months in the elevated systemic inflammatory response group (p<0.001).  The 1 
and 2 year survival rates in the patient group with no evidence of a pre-operative 
systemic inflammatory response were 83% and 72% respectively compared with 67% 
and 33% respectively in the elevated systemic inflammatory response group. 
 
2.4 Discussion 
Surgical resection remains the best prospect for long term survival in patients 
with gastro-oesophageal cancer.  Currently, in patients undergoing surgery, prognostic 
factors are based on the pathological findings from the resected tumour.  However, this 
means that the assessment of prognosis occurs after a major operation with significant 
morbidity and mortality.  Therefore, it is of interest that in the present study an elevated 
circulating concentration of C-reactive protein (>10mg/l) measured pre-operatively, was 
associated with poor survival, independent of the pathological positive to total lymph 
node ratio or pTNM stage.  In contrast, neither anaemia, leukocytosis, 
lymphocytopaenia or thrombocytosis predicted survival in this group of patients 
undergoing resection for gastro-oesophageal cancer. 
There have been 3 previous studies from Japan that have shown the prognostic 
value of an elevated C-reactive protein concentration in patients undergoing resection 
for oesophageal cancer.  However, in contrast with the present study, they included 
patients with primarily (>90%) squamous tumours [Nozoe et al., 2001;Ikeda et al., 
2003;Shimada et al., 2003], patients receiving neo-adjuvant treatment [Nozoe et al., 
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2001;Ikeda et al., 2003], patients who had advanced disease prior to surgery [Nozoe et 
al., 2001;Ikeda et al., 2003], they used a threshold for C-reactive protein of >5mg/l 
[Nozoe et al., 2001;Ikeda et al., 2003] and the positive to total lymph node ratio was not 
assessed [Nozoe et al., 2001;Ikeda et al., 2003;Shimada et al., 2003]. 
In contrast to the above studies the majority of patients in the present study had 
adenocarcinoma, reflecting the prevailing type in the Western World.  Also, only those 
patients who underwent potentially curative resection and did not receive neo-adjuvant 
treatment were included in the present study.  In these patients the positive to total 
lymph node ratio was prognostic independent of an elevated C-reactive protein 
concentration, prior to surgery.  
Therefore, the results of the present study are consistent with C-reactive protein, 
measured prior to surgery, having prognostic value independent of established 
pathological criteria in patients with resectable oesophageal cancer [Nozoe et al., 
2001;Ikeda et al., 2003;Shimada et al., 2003].  Moreover, we have shown that an 
elevated C-reactive protein concentration, prior to surgery, is associated with poor 
cancer specific survival in patients undergoing potentially curative resection for gastro-
oesophageal adenocarcinoma.  
It was of interest that the threshold for C-reactive protein (>10mg/l) which we 
established in previous studies in patients with gastro-intestinal cancer [O'Gorman et al., 
2000;McMillan et al., 2001a;McMillan et al., 2003] was superior to that (>5mg/l) used 
in previous prognostic studies in oesophageal cancer [Nozoe et al., 2001;Ikeda et al., 
2003].  Moreover, compared with patients undergoing potentially curative resection for 
colorectal cancer in the same institution [McMillan et al., 2003], the proportion of 
patients who had an elevated circulating concentration of C-reactive protein (>10mg/l) 
pre-operatively was lower in the present study (13% vs 28%).  This probably reflects, 
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given the increased morbidity and mortality associated with gastro-oesophageal surgery, 
a more selective approach than that in colorectal cancer.  The use of an elevated C-
reactive protein concentration as a poor prognostic factor, in this highly selected cohort, 
is therefore only relevant in 13% of cases.  
Nevertheless, taken together these results show the utility of C-reactive protein 
in the pre-operative assessment of patients undergoing potentially curative surgery for 
gastrointestinal cancer.  Indeed, the combination of pathological stage and C-reactive 
protein has recently been used to improve the prediction of outcome in patients who 
underwent potentially curative resection for colorectal cancer [Canna et al., 2004]. 
The basis of the independent relationship between an elevated C-reactive protein 
concentration and poor survival in gastro-oesophageal cancer is not clear.  There are a 
number of possible explanations.  Firstly, that an elevated C-reactive protein identifies 
those patients with an impaired T-lymphocytic response, since poor infiltration of 
gastrointestinal tumours appears to be associated with poor outcome [Schumacher et al., 
2001;Ali et al., 2004] and an elevated C-reactive protein concentration has recently been 
shown to be inversely associated with T-lymphocyte subset infiltration [Canna et al., 
2005].  Indeed, in the present study an elevated C-reactive protein concentration was 
associated with greater proportion of patients having lymphocytopenia. 
An alternative explanation is that an elevated C-reactive protein concentration 
may identify those patients with a pro-angiogenic environment, since angiogenesis is 
associated with poor outcome in patients with gastrointestinal tumours [Tanigawa et al., 
1997;Fondevila et al., 2004] and circulating concentrations of vascular endothelial 
growth factor are directly associated with C-reactive protein [Xavier et al., 2006].  
Clearly, both these mechanisms may be related and promote unrestrained tumour 
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growth and the dissemination required for the greater malignant potential associated 
with an elevated C-reactive protein concentration. 
This is a relatively small study in a single centre and requires verification in 
large cohorts in other centres.  If an elevated C-reactive protein concentration is 
confirmed to predict a poorer prognosis, it may be the case that patients staged to have 
potentially resectable gastro-oesophageal cancer, yet a high inflammatory profile pre-
operatively, should not undergo surgery as a sole treatment.  It may be that future trials 
of neoadjuvant or adjuvant chemo-radiotherapy, could utilise measurement of C-
reactive protein concentration as a selection criteria.  Alternatively, modulation of the 
systemic inflammatory response may be a useful approach in these patients in the peri-
operative period.   
In summary, the results of the present study indicate that, in patients, selected to 
undergo potentially curative resection for gastro-oesophageal cancer, the presence of an 
elevated C-reactive protein concentration pre-operatively (>10mg/l) is an independent 




Table 2.1.  Characteristics of patients selected for potentially curative resection for 






Age (<65/ 65-74/ >75 years) 60/ 47/ 13 1.34 (0.92-1.95) 0.132 

















pTNM Stage (I/ II/ III/ IV) 32/ 35 /49/ 4 1.59 (1.15-2.21) 0.006 
Resection margin R0/ R1 99/ 19 1.49 (0.79-2.83) 0.218 
Lymph node status (-/ +) 44/ 74 2.84 (1.49-5.41) 0.002 
Positive to total lymph 
node ratio (0/ <0.2/ >0.2) 
 













White cell count 
(<8.5/ 8.5-11.0/ >11.0 109/l) 
 






(20-40/ 12-19.9/ 0-11.9%) 
 





Platelets (<400/ >400 109/l) 110/ 7 0.69 (0.22-2.23) 0.541 
Albumin (>35/ <35g/l) 117/ 2 0.96 (0.13-7.00) 0.970 
C-reactive protein (<10/ >10mg/l) 105/ 15 3.51 (1.89-6.53) <0.001 
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Table 2.2.  The relationship between the presence of a pre-operative systemic 
inflammatory response and tumour characteristics of gastro-oesophageal cancer.  
 C-reactive protein 
< 10mg/l (n= 105) 
C-reactive protein 
> 10mg/l (n= 15) 
(p-value) 
Age (<65/ 65-74/ >75 years) 54/ 39/ 12 6/ 8/ 1 0.721 

















pTNM Stage (I/ II/ III/ IV) 31/ 29/ 41/ 4 1/ 6/ 8/ 0 0.223 
Resection margin R0/ R1 88/ 15 11/ 4 0.235 
Lymph node status (-/ +) 39/ 64 5/ 10 0.736 
Positive to total lymph 
node ratio (0/ <0.2/ >0.2) 
 
39/ 35/ 29 
 











White cell count 
(<8.5/ 8.5-11.0/ >11.0 109/l) 
 
71/ 25/ 7 
 




(20-40/ 12-19.9/ 0-11.9%) 
 
90/ 11/ 2 
 
7/ 6/ 2 
 
<0.001 
Platelets (<400/ >400 109/l) 96/ 6 14/ 1 0.905 
Albumin (>35/ <35g/l) 102/ 2 15/ 0 0.590 
































Figure 2.1.  The relationship between the positive to total lymph node ratio       (0/ 
<0.2/ >0.2 from top to bottom) and cancer specific survival in patients undergoing 
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Figure 4.2.  The relationship between the systemic inflammatory response     (<10/ 
>10mg/l from top to bottom) and cancer specific survival in patients undergoing 

















Figure 2.2.  The relationship between the systemic inflammatory response     (<10/ 
>10mg/l from top to bottom) and cancer specific survival in patients undergoing 
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CHAPTER 3:  THE RELATIONSHIP BETWEEN THE SYSTEMIC 
INFLAMMATORY RESPONSE, TUMOUR PROLIFERATIVE ACTIVITY, 
LEUCOCYTE AND MACROPHAGE INFILTRATION AND SURVIVAL IN 





A number of criteria based on the resected specimen predict long-term survival 
in patients undergoing potentially curative surgery for gastro-oesophageal cancer.  
These include pTNM stage, lymph node metastasis (in particular the ratio of involved 
nodes to the total number of nodes removed and identified), clear resection margins (R0 
resection) and tumour differentiation [Siewert et al., 1998;Roder et al., 1994;Shiu et al., 
1989;Robey-Cafferty et al., 1991;Khan et al., 2004]. 
High tumour proliferative activity has also been linked with aggressive 
malignancy [Rosenwald, 2004] and Ki-67, a nuclear protein associated with cell 
division, expression has been associated with poorer survival in a number of tumours 
[Brown and Gatter, 2002].  Few studies have examined the relationship between Ki-67 
expression and survival in patients with gastro-oesophageal cancer.  Solcia and co-
workers [Solcia et al., 2009] reported that, in 294 patients undergoing resection for 
gastric cancer, increased Ki-67 expression was associated with poorer survival.  Also, in 
a study of patients with squamous and adenocarcinoma of the oesophagus undergoing 
chemo-radiotherapy, increased expression of Ki-67 was associated with greater tumour 
response [Ressiot et al., 2008]. 
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It is becoming increasingly clear that tumour associated inflammatory responses, 
both local and systemic, are important independent factors in tumour progression and 
metastases [McMillan, 2009;Colotta et al., 2009;Roxburgh and McMillan, 2010].  There 
is evidence that in patients with gastro-oesophageal cancer, pronounced leucocyte 
infiltration of the tumour, on haematoxylin and eosin staining of sections, is associated 
with improved survival [Ma et al., 1994].  Furthermore, the type, density, and location 
of immune cells in gastro-oesophageal tumours may provide prognostic information, 
independent of tumour staging [Lee et al., 2008;Hyakudomi et al., 2008;Ohno et al., 
2003;Cho et al., 2003;Schumacher et al., 2001]]. 
Recently, Klintrup and coworkers simplified the subjective assessment of the 
tumour inflammatory infiltrate by including all white blood cell types and classifying 
the inflammatory infiltrate as either low or high grade [Klintrup et al., 2005].  They 
showed that a high-grade inflammatory infiltrate was associated with improved survival 
in patients undergoing potentially curative resection of colorectal cancer.  This approach 
has been validated in a separate cohort of patients undergoing curative resection for 
colorectal cancer [Roxburgh et al., 2009b;Roxburgh et al., 2009a].  To date, the 
prognostic value of this simple scoring system has not been examined in patients 
undergoing potentially curative resection for gastro-oesophageal cancer. 
In terms of systemic inflammation, there is now good evidence that a systemic 
inflammatory response, as evidenced by elevated circulating concentrations of C-
reactive protein and hypoalbuminaemia and combined in a simple objective score 
(Glasgow prognostic score, mGPS), is independently associated with poor cancer 
specific survival in patients with operable gastro-oesophageal cancer [Nozoe et al., 
2001;Shimada et al., 2003;Ikeda et al., 2003;Gockel et al., 2006;Kobayashi et al., 2008]. 
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The aim of the present study was to examine the relationship between the 
systemic inflammatory response, tumour proliferative activity, leucocyte and 
macrophage infiltration and survival in patients undergoing potentially curative 
resection for gastro-oesophageal cancer.  
 




One hundred patients selected for potentially curative resection of gastro-
oesophageal cancer (between January 1996 and December 2004) in the upper GI 
surgical unit at Glasgow Royal Infirmary were studied.  The patients studied were the 
same as in Chapter 2.  However, the availability of appropriate blocks to make blank 
sections for immune-staining limited the number of patients to 100.  Patients who died 
within 30 days of surgery and patients receiving neo-adjuvant chemotherapy were 
excluded. 
For gastric cancers, TNM stage I to III tumours were considered amenable to 
curative surgical resection.  For oesophageal cancers, TNM stage I to III tumours, 
excluding T4, were considered amenable to curative surgical resection.  Tumours of the 
gastro-oesophageal junction were further classified according to site, using the Siewert 
system; type 1 and 2 lesions of the gastro-oesophageal junction were regarded as 
cancers of the oesophagus.  Type 3 tumours of the cardia were designated gastric 
cancers [Siewert et al., 1998].  







Sections from a representative tumour block were cut (4µm) and mounted on 
slides coated with aminopropyltriethoxysilane.  Sections were dewaxed and rehydrated 
for immunohistochemistry of Ki67 (tumour proliferative index) and CD 68+ (tumour 




Appropriate positive controls were included in each run.  Negative controls were 
omission of the primary antibody.  Sections were immunostained using the peroxidise 
based Envision technique (Dako, Cambridgeshire, UK) The primary antibody for Ki-67 
was mouse monoclonal antibody (Dako) at a dilution of 1:500.  The primary antibody 





The percentages of Ki-67-reactive tumour cells were evaluated with a light 
microscope at x 400 magnification (Figure 3.1).  A 10 x 10 square grid eyepiece 
graticule was used and the percentage of Ki67 reactive cells counted over ten fields as 
previously described [Going, 1994].  Only fields containing tumour were counted and 





Quantitive analysis of the tumour associated macrophages (CD68) was 
performed using a point counting method, with a random sampling technique (Figure 
3.2).  With this method the volume occupied by any given component (volume density) 
is expressed as a percentage of the total volume of the tissue.  A 100 point ocular grid 
was used at x 400 magnification and 30 fields were counted per case.  Only fields 
containing tumour were counted and any normal tissue on the slide was excluded from 
the analysis.   
 
3.2.2.3 Assessment of inflammatory infiltrate 
 
Haematoxylin and eosin slides from the resected specimens were retrieved and 
scored as described by Klintrup and colleagues [Klintrup et al., 2005].  Briefly, tumours 
were scored according to a four-point score.  Scores were based on the appearances of 
tumour invasion at the deepest area.  A score of 0 indicated that there was no increase in 
the inflammatory cells at the deepest point of the tumours invasive margin; score 1 
denoted a mild and patchy increase in the inflammatory cells; score 2 denoted a 
prominent inflammatory reaction forming a continuous band at the invasive margin with 
some evidence of destruction of cancer cell islands and score 3 denoted a florid ‘cup-
like’ inflammatory infiltrate at the invasive edge with frequent destruction of cancer cell 
islands. These scores were then subsequently classified as low grade (scores 0 and 1) or 
high grade (scores 2 and 3) figures 3.3 and 3.4 respectively.  
All cases were counted by the author (AC) and these were used in the data 
analysis.  For the purpose of assessing inter-observer reproducibility, as second observer 
(MH, SD and JG) independently scored the slides for Ki67, CD 68+ and Klintrup local 
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inflammatory infiltrate respectively.  The inter-observer intraclass correlation 
coefficient values were 0.77 for Ki67, 0.71 for CD68+ and 0.77 for Klintrup local 
inflammatory infiltrate (inter-observer intraclass correlation coefficient values >0.7 
were considered acceptable). The observers were blinded to the clinical outcome of the 
patients.   
The mGPS was calculated as previously described [McMillan, 2008] .  Briefly, 
patients with an elevated C-reactive protein concentration (>10 mg/L) and a decreased 
albumin concentration (<35 g/L) score 2.  Those patients with an elevated C-reactive 
protein concentration (>10mg/L) score 1 and patients with a C-reactive protein 




Data are presented as median (range).  Grouping of the variables was carried out 
using standard thresholds.  Interrelationships between variables were assessed using 
contingency table analysis with the X2 test for trend as appropriate.  Univariate and 
multivariate survival analysis and calculation of hazard ratios (HR) were performed 
using a Cox proportional- hazards model.  A stepwise backward procedure was used to 
derive a final model of the variables with a significant independent relationship with 
survival.  To remove a variable from the model, the corresponding P value had to be 
greater than 0.05.  Deaths up to the end of August 2009 have been included in the 






One hundred patients undergoing potentially curative resection for gastro-
oesophageal cancer were studied (Table 3.1).  The majority of patients were older than 
65 years (51%), male (63%), had oesophageal cancer (52%) and had adenocarcinomas 
(81%).  The majority of patients had pathological TNM stage (pTNM) I-II disease 
(59%), clear resection margins (85%), positive lymph node ratio <0.2 (71%) and well-
moderate differentiated tumours (57%).  Thirteen patients had an elevated mGPS 
(13%), 19 patients had high grade local inflammatory infiltrate according to Klintrup 
criteria (19%) and the median values for CD68+ and Ki-67 were 5% and 2.7% 
respectively.  Patients with an R1 resection were due to positive circumferential margin 
involvement (<1mm).  No patient had positive longitudinal margin involvement. 
The inter-relationship between the clinic-pathological characteristics are shown 
in Table 3.2.  Increased age was associated with a greater proportion of females and 
gastric cancers (both p<0.05).   Oesophageal cancer was associated with a greater 
proportion of squamous carcinomas (p<0.001) and positive resection margins (p<0.05).  
Higher pTNM stage was associated with positive resection margins (R1) and an 
increased lymph node ratio (both p<0.001).  Positive resection margins (R1) were 
associated with a greater lymph node ratio (p<0.01).   An increased lymph node ratio 
was associated with poor tumour differentiation (p<0.05), low grade Klintrup criteria 
(p<0.005) and low tumour proliferative activity (p<0.05).  An increased white cell count 
was associated with an increased neutrophil count (p<0.001).   
During the follow-up period 55 patients died; 51 of their disease.  The minimum 
follow-up was 59 months and the median follow-up of survivors was 100 months.  On 
univariate survival analysis, pTNM stage (p<0.001), lymph node ratio (p<0.001), 
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tumour differentiation (p<0.01 figure 3.5), mGPS (p<0.001), Klintrup score (p<0.05 
figure 3.6) and Ki-67 (p<0.01 Figure 3.7) were significantly associated with cancer 
specific survival (Table 3.3).  On multivariate survival analysis, lymph node ratio (HR 
1.63, 95% CI 1.11-2.40, p<0.05), tumour differentiation (HR 2.63, 95% CI 1.45-4.77, 
p=0.001), mGPS (HR 3.91, 95% CI 1.96-8.11, p<0.001), Klintrup score (HR 3.47, 95% 
CI 1.14-10.55, p<0.05) and Ki-67 (HR 0.67, 95% CI 0.47-0.96, p<0.05) remained 




The present study, to our knowledge, shows for the first time the 
interrelationships between tumour proliferative activity, local peritumoral inflammatory 
response (Klintrup criteria), the systemic inflammatory response (GPS criteria) and 
cancer-specific survival, in patients undergoing potentially curative resection for gastro-
oesophageal cancer.  These results indicate that, low tumour proliferative activity, a 
local low grade inflammatory infiltrate and an elevated systemic inflammatory response 
are all associated with, independent of tumour staging, poorer cancer specific survival.   
Although the results of the present study show that Ki-67 labelling index was 
independently associated with cancer specific survival in patients with gastro-
oesophageal cancer, paradoxically an elevated Ki-67 labelling index was associated 
with better cancer specific survival in these patients.  Furthermore, low tumour cell 
proliferation was associated with a greater ratio of positive to resected nodes.  These 
results appear contrary to the results of Solcia and colleagues [Solcia et al., 2009] who 
reported that, in 294 patients undergoing resection for gastric cancer, increased Ki-67 
expression was associated with poorer survival.  However, in a study of patients with 
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squamous and adenocarcinoma of the oesophagus undergoing chemo-radiotherapy, 
increased expression of Ki-67 was associated with greater tumour response [Ressiot et 
al., 2008].   
It is of particular interest that the present paradoxical relationship between the 
Ki67 proliferation index and cancer specific survival has recently been reported by Lee 
and colleagues in 245 patients with gastric cancer [Lee et al., 2010].  Moreover, a low 
Ki67 proliferation index was also significantly associated with the presence of lymph 
node metastases.  Similarly, Lee and colleagues suggested that a high proliferation rate 
may be associated with a better response to chemotherapy. 
Irrespectively, to further examine the basis of the relationship between elevated 
Ki-67 labelling index and better cancer specific survival in gastro-oesophageal, cancer it 
will be important to carry out further observations and detailed survival analysis in 
gastric and oesophageal cancers, adeno and squamous carcinomas and in node positive 
and node negative disease.  The relatively small numbers of observations in the present 
study precludes such detailed analysis. 
In the present study it was of interest that a local low grade inflammatory 
infiltrate was associated with, independent of tumour staging, poorer cancer specific 
survival in patients with gastro-oesophageal cancer.  Also, low grade Klintrup criteria, 
was also associated with a greater nodal burden.  These results are consistent with those 
previously observed in relatively large studies of patients undergoing potentially 
curative resection for colorectal cancer (Klintrup et al., 2005; Roxburgh et al., 2009a; 
Roxburgh et al., 2009c).  Therefore, it was of interest that Klintrup criteria and Ki-67 
labelling index were not associated.  This might suggest that the local immune response 
is not stimulated directly by increased tumour proliferation and may be a more passive 
response to production of local, pro-inflammatory cytokines.  Alternatively, as 
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suggested above, that there may be unknown confounding factors associated with the 
present analysis of Ki-67 labelling index in gastro-oesophageal cancer. 
Nevertheless, the results of the present study would suggest that a high-grade 
local immune response represents an effective host cellular immune response preventing 
further tumour dissemination and progression.  Furthermore, the results of the present 
study are consistent with the concept that the density and location of a variety of 
immune cells, and not an individual immune cell type, are important independent 
determinants of cancer-specific survival in patients with gastro-oesophageal cancer.  In 
this context it was of interest to note that a specific subset of the local inflammatory 
response (tumour associated macrophages, CD 68+ cells) were not associated with 
cancer specific survival, in the present study.  This would suggest that other immune 
cell-types are important in determining tumour progression and cancer specific survival 
in patients with gastro-oesophageal cancer. 
The systemic inflammatory response is now an established indicator of poor 
prognosis in a variety of human cancers [McMillan, 2008;McMillan, 2009].  However, 
it remains to be determined which components of the systemic inflammatory response 
play pivotal roles.  Of these, the value of C-reactive protein is most recognized as being 
associated with cancer cachexia [Morley et al., 2006;Fearon et al., 2006], compromised 
cell-mediated immunity [Du Clos and Mold, 2004] and upregulation of growth factors 
and angiogenesis [Krzystek-Korpacka et al., 2008].  Nevertheless, the mechanisms 
underlying the relationship between local and systemic inflammatory responses and 
cancer-specific survival are likely to be complex.  These include extrinsic pathways 
such as nutritional and functional decline, immune dysfunction and tumour 
angiogenesis, growth, and dissemination.  Recently, it has been proposed that there are 
also intrinsic pathways involved in cancer-related inflammation, such as the induction 
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of genetic instability by inflammatory mediators, leading to the accumulation of genetic 
alterations in cancer cells and progressive tumour growth and dissemination.  Indeed, a 
recent review proposes that cancer-related inflammation is the seventh ‘hallmark’ of 
cancer [Colotta et al., 2009]. 
With reference to tumour proliferation, Klintrup scoring and the mGPS, such 
routinely available measures offer a new approach to staging the biologic phenotype of 
the tumour and, together with TNM tumour staging, offer a more sophisticated and 
accurate approach to outcome prediction in patients with primary operable gastro-
oesophageal cancers. 
In summary, the results of the present study show that tumour proliferation rate 
and local and systemic inflammatory responses are important independent predictors of 
cancer specific survival in patients undergoing potentially curative surgery for gastro-
oesophageal cancer.  These scores may be combined with tumour based factors to 
improve prediction of outcome in these patients.  
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Table 3.1.  Clinico-pathological characteristics in patients selected for potentially 
curative resection for gastro-oesophageal cancer. 
 Patients (n= 100) 
Age  (<65/ 65-74/ >75 years) 49/ 41/ 10 
Sex  (m/ f) 63/ 37 
Tumour site  (oesophageal/ gastric) 52/ 48 
Tumour type  (adenocarcinoma/ squamous) 81/ 19 
pTNM Stage  (I/ II/ III/ IV) 28/ 31/ 38/ 3 
Resection margin  (R0/ R1) 85/ 15 
Positive to total lymph node ratio  (0/ <0.2/ >0.2) 41/ 30/ 29 
Tumour differentiation  (Well-moderate/ poor) 57/ 43 
mGPS  (0/ 1) 87/ 13 
  
Klintrup score (High / low grade) 19/ 81 
CD68  Tertiles  1* 1.5 (0.2- 2.3) 
                          2* 5.0 (2.4- 6.4) 
                          3* 9.5 (6.5- 21.3) 
Ki67  Tertiles  1* 0.3 (0- 1.4) 
                        2* 2.7 (1.5- 4.5) 
                        3* 10.9 (4.7- 48.1) 
  
Alive 
Cancer related death 







Table 3.2.  Interrelationships between pathological and biochemical criteria in patients selected for potentially curative resection for gastro-oesophageal cancer  
 


























Age  in years 
(<65/ 65-74/ >75 years ) 
0.045 0.043 0.321 0.364 0.950 0.902 0.880 0.632 0.444 0.099 0.066 0.821 0.666 0.088 
Sex (m/ f) 
 
 0.921 0.119 0.228 0.403 0.392 0.200 0.180 0.106 0.126 0.402 0.987 0.131 0.229 
Tumour site 
(Oesophageal/ gastric) 
  <0.001 0.942 0.019 0.366 0.813 0.297 0.854 0.159 1.00 0.113 0.813 0.224 
Tumour type 
(adenocarcinoma/ squamous) 
   0.375 0.915 0.255 0.702 0.689 0.766 0.615 0.294 0.369 0.655 0.846 
pTNM Stage  
(I/ II/ III/ IV) 
    <0.001 <0.001 0.123 0.320 0.106 0.270 0.640 0.078 0.922 0.145 
Resection margin (R0/ R1) 
 
     0.009 0.772 0.967 0.798 0.429 1.00 0.189 0.916 0.918 
Positive to total LNR 
(0/ <0.2/ >0.2) 
      0.032 0.875 0.538 0.378 0.622 0.003 0.737 0.042 
Tumour differentiation 
Well-moderate/ poor 
       0.419 0.298 0.691 1.00 0.371 0.580 0.544 
mGPS (0/ 1/ 2) 
 
        0.497 0.947 0.231 0.689 0.393 0.121 
White cell count 
(<8.5/ 8.5-11/ >11 109/l) 
         <0.001 0.192 0.382 0.928 0.799 
Neutrophil count 
(<7.5/ >7.5 109/l) 
          1.00 0.609 0.346 0.733 
Lymphocyte count 
(<1/ 1-3/ >3 109/l) 
           0.304 0.995 0.318 
Klintrup score (High / low grade)             0.148 0.258 
CD68 (tertiles 1, 2, 3)              0.650 
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Table 3.3.  The relationship between clinico-pathological factors and survival, in 






HR (95% CI) 
P value 
Age  (<65/ 65-74/ >75yrs) 49/ 41/ 10 1.09 (0.70-1.60) 0.789 
Sex  (m/ f) 63/ 37 1.17 (0.66- 2.07) 0.589 
Tumour site  (Oesophageal/ gastric) 52/ 48 1.33 (0.77-2.31) 0.307 
Tumour type  (adenocarcinoma/ squamous) 81/ 19 1.27 (0.69-2.47) 0.490 
pTNM Stage  (I/ II/ III/ IV) 28/ 31/ 38/ 3 1.80 (1.27-2.55) 0.001 
Resection margin  (R0/ R1) 85/ 15 1.23 (0.60-2.52) 0.581 
Positive to total lymph node ratio  (0/ <0.2/ >0.2) 41/ 30/ 29 2.06 (1.45-2.91) <0.001 
Tumour differentiation  (Well-moderate/ poor) 57/ 43 2.40 (1.35-4.18) 0.003 
mGPS  (0/ 1) 87/ 13 3.41 (1.74-6.64) <0.001 
    
Klintrup score (High / low grade) 19/ 81 3.74 (1.34-10.41) 0.012 
CD68 (tertiles 1, 2, 3) 30/ 32/ 32 0.84 (0.59-1.21) 0.351 















Figure 3.3.  Example of  “low grade” local tumor inflammatory infiltrate (low 





Figure 3.4.  Example of  “high grade”  local tumor inflammatory infiltrate (low 








Figure 3.5.  The relationship between tumour differentiation (well-moderate/ poor, 
from top to bottom) and cancer specific survival in patients undergoing resection 































Figure 3.6.  The relationship between tumour inflammatory infiltrate (high grade/ 
low grade, from top to bottom) and cancer specific survival in patients undergoing 
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Figure 3.7.  The relationship between tumour proliferation (Ki67 tertiles 1/ 2/ 3 
from bottom to top) and survival in patients selected for potentially curative 
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CHAPTER 4: EVALUATION OF AN INFLAMMATION-BASED 





Overall survival in patients with gastro-oesophageal cancer is poor, with the 
majority of patients presenting with advanced, inoperable disease and less than 15% 
surviving 5 years [Cancer Research UK Information Resource Centre, 2004].  Despite 
an often short median and poor overall survival, there is marked heterogeneity in the 
duration of survival amongst patients.  Therefore, there is continuing interest in 
prognostic factors to permit more accurate patient stratification and which will improve 
clinical decision making, and possibly contribute to more rational study design and 
analysis [Allgayer et al., 1997].  A small proportion of patients with inoperable, but 
localized oesophageal cancers may be suitable for potentially curative non-surgical 
treatment with (chemo) radiation therapy however most frequently these modalities are 
used in palliation.  Whilst such palliative treatment may confer a small survival 
advantage over best supportive care it is primarily directed towards symptom relief 
[Pyrhonen et al., 1995].  This however may sometimes be at the expense of toxicity 
[Ross et al., 2002] and therefore the appropriate selection of patients, most likely to 
benefit is of considerable importance.  Previous studies have indicated that weight loss 
or performance status may be associated with treatment outcome and survival in 
inoperable oesophago-gastric cancer [Chau et al., 2004].  However, the use of weight 
loss as a prognostic factor remains problematical since it is often not well defined and 
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subject to bias [Morgan et al., 1980;Rowland, 1990].  Furthermore performance status is 
recognised to be subjective [Ando M, 2001]. 
There is increasing evidence that the presence of a systemic inflammatory 
response, as evidenced by elevated concentrations of C-reactive protein, is a prognostic 
factor independent of stage, performance status and weight loss in patients with 
advanced cancer [Mahmoud and Rivera, 2002;O'Gorman et al., 2000;Scott et al., 2002].  
Recently, we have shown that an elevated C-reactive protein and hypoalbuminaemia 
(using standardised assays and accepted thresholds for C-reactive protein and albumin 
concentrations), may be combined to form a score, the Glasgow Prognostic score 
(GPS), which has prognostic value, independent of stage and performance status, in 
patients with inoperable non-small cell lung cancer [Forrest et al., 2004;Forrest et al., 
2003]. 
The aim of the present study was to assess the relationship between the GPS and 
survival in patients with inoperable gastro-oesophageal cancer. 
 




Patients diagnosed with inoperable gastro-oesophageal carcinoma, attending the 
upper GI surgical unit in the Royal Infirmary, Glasgow between the 1st January 2000 
and the 31st December 2004 and who had a pre-treatment measurement of C-reactive 
protein and albumin were studied.   Patients were staged using a combination of 
endoscopy, CT scan of chest and abdomen, laparoscopy and endoscopic ultrasound, in 
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addition to clinical assessment. The specific use of these modalities was dependent upon 
the clinical tumour features and where appropriate, assessment of fitness, cardiac and 
lung function testing was also performed. 
The extent of tumour spread was recorded using the TNM stage.  Tumours 
around the gastro-oesophageal junction were further classified according to site, using 
the Siewert system [Siewert and Stein, 1998]; type 1 and 2 lesions of the gastro-
oesophageal junction were designated as cancers of the oesophagus.  Type 3 tumours of 
the cardia were designated gastric cancers.  
Patients identified as being suitable for resection or radical, non surgical 
treatment given with curative intent were excluded from this analysis, as were patients 
who had any form of chronic inflammatory disease (e.g. vasculitis, connective tissue 
disorders, rheumatological conditions) and those with cancers arising in other organs.  
Therefore, the study group comprised patients unsuitable for either surgical resection or 
radical, non-surgical treatment. 
Patients who underwent palliative chemotherapy, palliative radiotherapy or 
endoscopic laser were considered to have had “active” treatment.  Patients receiving 
palliative care (symptom control) were considered to have had “supportive” treatment.  
The “active” treatment group was further subdivided into: chemotherapy based 
(chemotherapy +/- radiotherapy +/- endoscopic treatment), radiotherapy based 
(radiotherapy +/- endoscopic treatment) and endoscopic laser (laser +/- stent).   






Routine laboratory measurements of C-reactive protein and albumin at the time 
of diagnosis were carried out.  The limit of detection of the C-reactive protein assay was 
<6mg/l.  The coefficients of variation of these methods, over the range of 
measurements, was less than 5% as established by routine quality control. 
The GPS was constructed as previously described [Forrest et al., 2004;Forrest et 
al., 2003].  Briefly, patients with both an elevated C-reactive protein (>10 mg/l) and 
hypoalbuminaemia (<35g/l) were allocated a score of 2.  Patients in whom only one of 
these biochemical abnormalities was present were allocated a score of 1.  Patients in 




Data are presented as median and 95% CI.  Grouping of the variables was 
carried out using standard thresholds.  Univariate survival analysis was performed using 
the Kaplan–Meier method with the logrank test. Multivariate survival analysis and 
calculation of hazard ratios (HR) were performed using a Cox regression model 
including all covariates that were significant on univariate analysis.  Deaths up to 30th 
June 2005 were included in the analysis. Analysis was performed using SPSS software 





The characteristics and survival analysis of patients with inoperable gastro-
oesophageal cancer (n= 258) are shown in Table 4.1  The majority were male, over the 
age of 65 years, had stage IV disease and had tumours of the oesophagus.  Patients with 
stage I and II disease were not considered suitable for surgery or radical chemo-
radiation due to co-morbidity.  The majority of patients had an abnormal GPS.  Of the 
52 patients with hypoalbuminaemia, 45 (86%) had an elevated C-reactive protein 
concentration.  One hundred and ninety five patients (76%) received active treatment 
and the remainder received supportive care only.   
The minimum follow-up was 6 months or until date of death; the median follow-
up of the survivors was 12 months.  During this period 211 (82%) patients died, 202 
patients of their cancer and 9 of intercurrent disease.  On univariate analysis, tumour site 
(p<0.05), stage (p<0.001), alkaline phosphatase (p<0.05), the GPS (p<0.001, Figure 
4.1) and treatment (p<0.001) and were significant predictors of cancer specific survival.  
On multivariate analysis, age (p<0.05), stage (p<0.001), the GPS (p<0.001) and 
treatment (p<0.001) were significant independent predictors of cancer specific survival 
(Table 4.2). 
The characteristics and survival analysis of those patients receiving active 
treatment (n= 195) are shown in Table 4.3.  On multivariate analysis, stage (p<0.001), 
the GPS (p<0.001, Figure 4.2) and treatment (p<0.01) were significant independent 
predictors of cancer specific survival.  
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The characteristics and survival analysis of those patients receiving supportive 
treatment (n= 63) are shown in Table 4.4.  On multivariate analysis, only stage (p<0.05) 
was a significant independent predictor of cancer specific survival.   
The relationship between stage, the GPS and the 12 month survival rate in those 
patients receiving active treatment is shown in Table 4.5.  Twelve month cancer specific 
survival in patients with stage I/ II disease receiving active treatment was 67% and 60% 
for a GPS of 0 and 1 respectively. For stage III/ IV disease, 12 months cancer specific 




In the present study the presence of a systemic inflammatory response, reflected 
in the GPS predicts cancer specific survival, independent of tumour stage, in patients 
with inoperable gastro-oesophageal cancer.  Moreover, we have shown how the GPS 
might be used in combination with stage to improve the prediction of survival. It may 
be this simply-derived inflammation-based score will be a useful tool in the prediction 
of survival and possible stratification, at diagnosis, of patients with inoperable gastro-
oesophageal cancer.   
It was of interest that, in the present study, only 7 (14%) patients had 
hypoalbuminaemia in the absence of an elevated C-reactive protein concentration.  This 
is consistent with the concept that the development of hypoalbuminaemia is often 
secondary to an on-going systemic inflammatory response [Al Shaiba et al., 
2004;McMillan et al., 2001b].  GPS may thus reflect both the presence of an ongoing 
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systemic inflammatory response (C-reactive protein) and the progressive nutritional 
decline (albumin) of the patient with advanced cancer.  
The mechanism by which a systemic inflammatory response might influence 
cancer survival in these patients is not clear.  However, it may be that the presence of a 
systemic inflammatory response and the associated nutritional decline [McMillan et al., 
1998;Scott et al., 2002] influences tolerance and compliance with active treatment 
[Forrest et al., 2004;Bromwich et al., 2004].  Indeed, Andreyev and coworkers (1998) 
reported that the poorer outcome of chemotherapy in advanced gastrointestinal cancer 
patients with weight loss appeared to be as a result of receiving less chemotherapy, due 
to toxicity, rather than poorer tumour response [Andreyev et al., 1998].  
When the relationship between the GPS and 12 month survival rate was examined in 
patients with stage III/ IV disease receiving active treatment there was approximately a 
5 fold decrease in the survival rate between those patients with a GPS of 0 (57%) and 
those with a GPS of 2 (12%).  This suggests, that there is a sub-group of patients who 
derive little survival benefit from active treatment.  The division of patients into 
“active” and “supportive” groups was to enable the differentiation of patients who 
(using conventional assessment tools) were felt to have poor life expectancy and were 
therefore treated symptomatically and conservatively (supportive group) to those 
patients who were felt to have greater life expectancy and were therefore treated more 
aggressively (active group).  When the active and supportive groups were included 
together the GPS was a significant independent predictor of survival.  Figure 4.1, Table 
4.2.” 
However, it is important to remember that treatment in these patients is given 
with palliative intent and survival data do not reflect endpoints of palliation.  This 
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aspect is being explored further in ongoing work, however the identification of a patient 
sub-group with limited prognosis, through the use of a simple reliable prognostic score, 
may aid the treatment decision-making process.  In particular it would seem 
inappropriate to subject such patients to potentially toxic treatments if simpler palliative 
options exist.   
In summary, the prognosis for patients diagnosed with inoperable gastro-
oesophageal cancer, even with active treatment, remains poor.  The presence of a 
systemic inflammatory response (an elevated GPS) appears to be a useful indicator of 
outcome amongst these patients, independent of stage.  Moreover, the GPS has the 
advantage of being simple to measure, routinely available and well standardised. 
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Table 4.1  Clinical characteristics and cancer specific survival in patients with 




Median (95% CI) 
P value 
Age    <65 yrs 
            65-74yrs 










Sex    Male 







Tumour type    Adenocarcinoma 







Tumour site     Oesophagus 







TNM    Stage  I 
                        II 
                        III 













Alkaline phosphatase (U/l) 
Tertile 1  (n=85) 
Tertile 2  (n=85) 













GPS    0 
           1 










    
Treatment    Active 









Table 4.2 Clinical characteristics and cancer specific survival in patients with 
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Table 4.3  Clinical characteristics and cancer specific survival in patients with 












(<65/ 65-74/ >75 yrs) 
 






























(I/ II/ III/ IV) 
 






(0/ 1/ 2) 
 





Alkaline phosphatase (U/l) 
(Tertiles 1/ 2/ 3) 
 

















Table 4.4  Clinical characteristics and cancer specific survival in patients with 
inoperable gastro-oesophageal cancer receiving supportive treatment:  
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Table 4.5 The relationship between stage, the GPS and the 12 month cancer 
specific survival rate in patients with inoperable gastro-oesophageal cancer 
receiving active treatment (n= 195). 
 
 Stage I + II Stage  III + IV  Stage I-IV 
GPS    0 
 
67%  (n=31) 57%  (n=47)  61 %  (n=78) 
GPS    1 
 
60%  (n=10) 25%  (n=79)  29%  (n=89) 
GPS    2 
 
 
0%  (n=6) 12 %  (n=22)  16%  (n=28) 




















Figure 4.1  The relationship between an inflammation based prognostic score 




























































Figure 4.2  The relationship between an inflammation based prognostic score 
(GPS, 0, 1, 2 from top to bottom) and survival in patients with inoperable gastro-





























CHAPTER 5: COMPARISON OF AN INFLAMMATION-BASED 
PROGNOSTIC SCORE (GPS) WITH PERFORMANCE STATUS (ECOG-PS) IN 
PATIENTS RECEIVING PALLIATIVE CHEMOTHERAPY FOR GASTRO-




A small proportion of patients with inoperable, but localised oesophageal 
cancers may be suitable for potentially curative non-surgical treatment with chemo-
radiation therapy.  Most frequently however, these modalities are used in palliation for 
patients with gastro-oesophageal cancer.  Whilst such palliative treatment may confer a 
small survival advantage over best supportive care, its primary aim is the relief of 
symptoms. [Pyrhonen et al., 1995;Murad et al., 1993;Enzinger et al., 1999] 
Such palliation may however be gained at the expense of toxicity.  Therefore, 
selection of patients most likely to benefit (and least vulnerable to side-effects) is of 
considerable importance. [Ross et al., 2002;Bleiberg et al., 1997]  Previous studies in 
patients undergoing chemotherapy for gastro-oesophageal cancer have indicated 
patient’s performance status to be associated with treatment outcome and survival 
[Polee et al., 2003;Yoshida et al., 2004] and this assessment is commonly used by many 
clinicians when selecting treatment options. 
The GPS has been shown to have prognostic value independent of stage and 
performance status in patients with inoperable non-small cell lung cancer. [Forrest et al., 
2004;Forrest et al., 2003]  Furthermore, the GPS was a more accurate predictor of 
survival than performance status in those patients receiving platinum based 
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chemotherapy. [Forrest et al., 2004]  Recently, we have shown that the GPS predicts 
survival, independent of stage, in an unselected cohort of patients with inoperable 
gastro-oesophageal cancer undergoing a varied number of treatments (see chapter 4). 
The aim of the present study was to compare the value of the GPS and ECOG-
ps, in evaluating the response to palliative, platinum based treatment and survival, in 
patients with advanced gastro-oesophageal cancer. 
 




Sixty five patients presenting with gastro-oesophageal carcinoma to the upper 
GI surgical unit in the Royal Infirmary, Glasgow between January 1999 and December 
2005 and who received platinum based chemotherapy or platinum based chemo-
radiotherapy with palliative intent, were studied. The specific palliative regimes of the 
study group are shown in Table 5.1.  Patients undergoing chemo-radiotherapy for 
oesophageal lesions, (stage I-III, excluding T4 lesions) with curative intent were 
excluded.  Patients treated with curative intent, typically received 50GY radiotherapy 
with concomitant cisplatin + 5FU  chemotherapy. 
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Patients were staged using a combination of endoscopy, CT scan of chest and 
abdomen, laparoscopy and / or endoscopic ultrasound, in addition to clinical 
assessment.  The specific use of these modalities was dependent upon the clinical 
features of the cancer and where appropriate, a formal assessment of fitness, (cardiac 
and lung function testing) was also performed. 
ECOG-ps, haemoglobin, white cell and lymphocyte counts, C-reactive protein 
and albumin were recorded at the time of diagnosis.  The extent of tumor spread was 
recorded using the TNM stage.   Tumors around the gastro-esophageal junction were 
further classified according to site, using the Siewert system [Siewert and Stein, 1998]; 
type 1 and 2 lesions of the gastro-esophageal junction were designated esophageal 
cancers.  Type 3 tumors of the cardia were designated gastric cancers.  
Thirty eight patients received platinum-based chemotherapy alone and 27 
patients received platinum-based chemotherapy with concomitant radiation therapy. The 
number of patients receiving each specific regime is shown in Table 5.1  Toxicity was 
recorded using the Common Toxicity Criteria (CTC) [Oken et al., 1982] and treatment 
response was assessed radiologically with CT scanning and clinically, based on control 
of symptoms.  





 Routine laboratory measurements of haemoglobin, white cell and lymphocyte 
counts, C-reactive protein and albumin were carried out at the time of diagnosis.  The 
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limit of detection of the C-reactive protein assay was <6mg/l with the upper limit of 
normal values being <10 mg/l.  The coefficients of variation of these methods, over the 
range of measurements, was less than 10% as established by routine quality control. 
 The GPS was derived as previously detailed.[Forrest et al., 2004;Forrest et al., 
2003]   Briefly, patients with both an elevated C-reactive protein (>10 mg/l) and 
hypoalbuminaemia (<35g/l) were allocated a score of 2.  Patients in whom only one of 
these biochemical abnormalities was present were allocated a score of 1.  Patients in 




Data are presented as hazard ratios (HR) and 95% CI.  Comparisons between 
groups of patients were carried out using contingency table analysis (X2) as appropriate.  
Grouping of the laboratory variables (haemoglobin, white cell and lymphocyte counts, 
C-reactive protein and albumin) was carried out using standard thresholds.[O'Gorman et 
al., 2000;McMillan et al., 2001a;Maltoni et al., 2005]  Survival (cancer-specific) 
analysis of the group variables was performed using the Cox proportional hazards 
model.  Deaths up to the end of January 2007 have been included in the analysis. 
Multivariate survival analysis, including all covariates on univariate analysis, was 
performed using a stepwise backward procedure to derive a final model of the variables 
that had significant independent relationship with survival.  To remove a variable from 
the model, the corresponding p-value had to be greater than 0.10.  Analysis was 
performed using SPSS software (SPSS Inc., Chicago, IL, USA). 
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5.3  Results 
 
The characteristics of the 65 patients who received platinum-based treatment with 
palliative intent, are shown in Table 5.2.  The majority were male, under the age of 65 
years and had metastatic disease.  Thirty-seven patients had disease arising in the 
esophagus and 28 arising from the stomach.  The majority of patients had an abnormal 
GPS (1-2, 60%) but a good ECOG-ps (0-1, 92%).  Of the 9 patients with 
hypoalbuminaemia, 8 had an elevated C-reactive protein concentration.  
Comparison of patients with either gastric or esophageal cancer showed no 
significant differences in age distribution, gender, tumor stage, ECOG-ps, haemoglobin, 
white cell and lymphocyte counts, survival or the GPS.  In contrast, the esophageal 
cancer group included patients with squamous cell disease and patients receiving 
radiotherapy.  The relationship between the GPS and clinico-pathological 
characteristics, including radiotherapy, in patients receiving platinum-based treatment is 
shown in Table 5.3.  Age, sex, tumour type and site, TNM stage, whether radiotherapy 
was given and performance status was similar between the GPS groups.  In contrast, 
haemoglobin concentrations (p<0.10) and lymphocyte percentages (p<0.01) were lower 
and white cell counts (p<0.05) were higher with an increasing GPS score.  During the 
follow-up period 59 (91%) of patients died. The majority (58 patients) died from their 
cancer, but 1 patient died of intercurrent disease.  
On univariate and multivariate analysis only the GPS (HR 1.65, 95%CI 1.10-
2.47, p<0.05) was a significant predictor of cancer specific survival (Table 5.4). It is 
recognised that squamous cell carcinomas are relatively more sensitive to chemo-
radiation therapy [Geh, 2002].  Therefore, we carried out a subset analysis of those 
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patients with adeno-carcinomas (Table 5.5).  On univariate survival analysis, 
lymphocyte percentage (p<0.05) and the GPS (p<0.01) were significant predictors of 
cancer specific survival.  On multivariate survival analysis, only the GPS (HR 1.69, 
95%CI 1.00-2.86, p=0.05) remained an independent predictor of survival. The 
relationship between the GPS and response to treatment in those patients receiving 
palliative treatment (n= 65) is shown in Table 5.6.  Only 8 patients had a GPS of 2 and 
patients with a GPS of 1 or 2 were therefore grouped.  Patients grouped according to 
their GPS were similar in terms of tumor site, ECOG-ps and CT assessed response.  
However, in comparison with patients with GPS of 0, those patients with a GPS score of 
1 or 2 required more frequent chemotherapy dose reduction (p<0.05), were less likely to 




Amongst patients with advanced inoperable malignancy, the decision whether to 
offer active treatment is based on a number of factors including an assessment of patient 
fitness, encapsulated in the performance status scoring system.  However, the 
assessment of performance status is subjective and the development of more objective 
assessment of outcome through a laboratory based scoring system thus remains 
appealing. [Maltoni et al., 2005]  This may be in part due to the subjective nature of the 
assessment of performance status and that it reflects functional status at a specific point 
in time.  In contrast, the GPS, based on the presence of ongoing systemic inflammatory 
response and hypoalbuminaemia, reflects the process which drives the progressive 
nutritional decline of the patient with advanced cancer. [McMillan et al., 
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1998;McMillan et al., 2001a;Scott et al., 2002]  This is consistent with our findings of 
an elevated C-reactive protein in 8 out of 9 patients with hypoalbuminaemia.  The 
independent prognostic value of an elevated C-reactive protein concentration and 
hypoalbuminaemia and their combination, in the form of the GPS, has been established 
in a variety of advanced solid tumours [Forrest et al., 2003;Ramsey et al., 2007;Al 
Murri et al., 2006;Glen et al., 2006].  In the present study, similar to TNM stage, we 
have not examined the independent prognostic value of the individual components of 
these prognostic systems.   
In this small study, but with mature follow-up, an inflammation-based 
prognostic score, the GPS, appeared to be superior to the clinician assessment of 
performance status in predicting both response to treatment and survival amongst 
gastro-oesophageal cancer patients receiving palliative platinum-based chemotherapy or 
chemo-radiation.  The median difference in survival, between those patients with an 
elevated GPS (1, 2) and a normal GPS (0), although significant was small, 
approximately 2 months.  In addition, there were only 8 patients with a GPS of 2 and 
therefore caution must be used in interpreting these results.  However, there were also 
significant differences in dose reduction and clinical response which are likely to have 
impacted on quality of life of these patients.  Taken together, the positive impact of 
palliative chemotherapy is likely to be substantially greater in those patients with a 
normal GPS.   
A limitation of the study is the marked heterogeneity of the tumours studied.  
The cohort includes oesophageal tumours (both adenocarcinomas and squamous 
carcinomas), gastro-oesophageal junctional tumours and gastric cancers.  Due to the 
relatively small number of patients in this study, meaningful analysis of each anatomical 
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and histological tumour subgroup is not possible and the tumour biology and 
characteristics may vary between these groups.  It is recognised however, that squamous 
cell carcinomas are relatively more sensitive to chemo-radiation therapy [Geh, 2002] 
and we therefore, we carried out a subset analysis of those patients with adeno-
carcinomas (Table 5.5). 
Previous work has shown that an increasing GPS was associated with poorer 
cancer specific survival, independent of stage in an unselected cohort of patients with 
inoperable gastro-oesophageal cancer (see chapter 4).  In the present study we confirm 
that the GPS predicts the response to platinum-based chemotherapy or chemo-
radiotherapy, independent of the stage of disease and the treatment given. 
It remains unclear why an ongoing systemic inflammatory response should 
produce decreased tolerance of cytotoxic chemotherapy.  Recent work has shown the 
activity of the enzyme cytochrome P450 3A, (involved in the biotransformation of 
several cytotoxics), to be compromised in patients with an elevated C-reactive protein 
concentration [Rivory et al., 2002;Slaviero et al., 2003;Baker et al., 2004] and activation 
of the systemic inflammatory response (as evidenced by the GPS) increases activity of 
γ-glutamyl transferase and alkaline phosphatase. [Brown et al., 2006]  However the 
relation of these events to the specific metabolism of platinum compounds or 
fluoropyrimidines is unclear.  Irrespective of the mechanisms involved, we believe the 
presence or absence of a systemic inflammatory response, as measured by the GPS, 
should be evaluated as a possible influence on outcome in future trials of chemotherapy 
in patients with advanced cancer and may be used in the stratification of patients in such 
trials.   
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In summary, the presence of a systemic inflammatory response, as evidenced by 
the GPS, appears to be superior to the subjective assessment of performance status 
(ECOG-ps) in predicting the response to platinum-based treatment in patients with 
advanced gastro-oesophageal cancer. 
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Table 5.2.  Baseline clinicopathological characteristics in patients with advanced 
gastro-oesophageal cancer, receiving platinum based treatment. 
 Gastric 




Age (<65/ 65-75/ >75 years) 18/ 9/ 1 16/ 17/ 4 0.077 









TNM Stage (III/ IV) 6/ 22 12/ 25 0.330 
Radiotherapy (Y/ N) 3/ 25 24/ 13 <0.001 
ECOG-ps (0/ 1/ 2) 14/ 12/ 2 15/ 18/ 3 0.549 
Haemoglobin 







White cell count 
(<8.5/ 8.5-11.0/ >11.0 109/l) 
 
12/ 11/ 5 
 




(20-40/ 12-19.9/ 0-11.9%) 
 
11 14/ 3 
 
16/ 13/ 7 
 
0.844 
GPS (0/ 1/ 2) 11/ 15/ 2 15/ 16/ 6 0.643 
    
Survival (months)* 11.0 (8.8-13.2) 8.8 (5.1-12.5) 0.311 




Table 5.3.  Relationship between the GPS and baseline clinicopathological 
characteristics in patients with gastro-oesophageal cancer, receiving platinum 
based treatment. 
 GPS 0 






Age (<65/ 65-75/ >75 years) 13/ 11/ 2 18/ 10/ 3 3/ 5/ 0 0.993 





















TNM Stage (III/ IV) 8/ 18 8/ 23 2/ 6 0.676 
Radiotherapy (Y/N) 9/ 17 14/ 17 4/ 4 0.354 
ECOG-ps (0/ 1/ 2) 13/ 11/ 1 13/ 14/ 4 3/ 5/ 0 0.435 
Haemoglobin 









White cell count 
(<8.5/ 8.5-11.0/ >11.0 109/l) 
 
17/ 6/ 2 
 
13/ 10/ 8 
 




(20-40/ 12-19.9/ 0-11.9%) 
 
16/ 6/ 3 
 
9/ 19/ 3 
 




ECOG-ps Eastern Co-operative Oncology Group. 
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 Table 5.4.  Clinical characteristics and cancer specific survival in patients with 
gastro-oesophageal cancer, receiving platinum based treatment:  Univariate 
survival analysis 
 Univariate 
HR (95% CI) 
p-value 
Age (<65/ 65-75/ >75) 0.68 (0.43-1.10) 0.114 













TNM Stage (III/ IV) 1.22 (0.68-2.19) 0.504 
Radiotherapy (Y/ N) 1.24 (0.73-2.09) 0.424 
ECOG-ps (0/ 1/ 2) 0.92 (0.62-1.40) 0.675 
Haemoglobin 





White cell count 











GPS (0/ 1/ 2) 1.65 (1.10-2.47) 0.015 
GPS Glasgow Prognostic score; ECOG-ps Eastern Co-operative Oncology Group. 
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Table 5.5.  Clinical characteristics and cancer specific survival in patients with 
gastro-oesophageal adeno-carcinoma, receiving platinum based treatment:  
Univariate survival analysis. 
 Univariate 
HR (95% CI) 
p-value 
Age (<65/ 65-75/ >75) 0.71 (0.42-1.19) 0.194 
Sex (male/ female) 0.97 (0.50-1.88) 0.932 






TNM Stage (III/ IV) 1.17 (0.60-2.27) 0.639 
Radiotherapy (Y/ N) 1.15 (0.63-2.11) 0.644 
ECOG-ps (0/ 1/ 2) 0.84 (0.54-1.30) 0.424 
Haemoglobin 





White cell count 











GPS (0/ 1/ 2) 1.84 (1.16-2.90) 0.009 
GPS Glasgow Prognostic score; ECOG-ps Eastern Co-operative Oncology Group. 
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Table 5.6.  The relationship between the GPS and response to palliative 
chemotherapy in patients with gastro-oesophageal cancer.  













ECOG-ps (0/ 1/ 2) 13/ 11/ 1 16/ 19/ 4 0.286 
    
Chemo dose reduction (no/ yes) 16/ 10 13/ 26 0.026 









CT response  
(improved/ static/ progressive) 
 
14/ 8/ 3 
 
13/ 11/ 3 
 
0.717 
    
Survival (months)* 11.9 (10.1-13.7) 9.5 (7.6-11.4) 0.020 
 




CHAPTER 6: IS HYPOALBUMINAEMIA, AN INDEPENDENT 
PROGNOSTIC FACTOR IN PATIENTS WITH GASTRIC CANCER? 
 
6.1  Introduction 
 
Each year in the UK, there are approximately 8,500 new cases of gastric cancer 
and over 5,500 deaths attributable to the disease [Cancer Research UK Information 
Resource Centre, 2004].  Despite this often short median and poor overall survival, 
there is marked heterogeneity in the duration of survival amongst patients.  Surgery 
confers the greatest chance of long-term cure but is associated with appreciable 
morbidity and mortality.  As a consequence, potentially curative surgery is carried out 
relatively infrequently and most patients are treated palliatively.  Whilst such palliative 
treatment may confer a small survival advantage over best supportive care, it is 
primarily directed towards symptom relief [Pyrhonen et al., 1995].  Treatment, in 
particular with chemotherapy, may sometimes be at the expense of toxicity [Ross et al., 
2002].  Therefore, the appropriate selection of patients most likely to benefit is of 
considerable importance.   
A number of recent studies have indicated that hypoalbuminaemia is 
independently associated with survival in gastric cancer, whether operable [Lien et al., 
2004;Onate-Ocana et al., 2007] or inoperable [Alici et al., 2006;Onate-Ocana et al., 
2007;Lee et al., 2007].  Onate-Ocana and coworkers (2007), in 1023 gastric cancer 
patients, showed that lower levels of albumin predicted poorer survival independent of 
TNM stage and whether or not patients underwent curative resection.  Furthermore, the 
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same group reported that hypoalbuminaemia predicted poor survival in patients with T4 
gastric cancer [Onate-Ocana et al., 2008].  
However, there is increasing evidence that the prognostic value of albumin may 
be secondary to an ongoing systemic inflammatory response, as evidenced by elevated 
concentrations of C-reactive protein, in a variety of advanced cancers [McMillan et al., 
2007;Al Murri et al., 2006;Forrest et al., 2003;Glen et al., 2006;McMillan et al., 2001b].  
If this were the case in patients with gastric cancer, then it might be expected that the 
prognostic significance of hypoalbuminaemia would be dependent on the presence of a 
systemic inflammatory response.   
The aim of the present study was to assess the relationship between 
hypoalbuminaemia, an elevated C-reactive protein and survival in patients with gastric 
cancer.  
 
6.2  Patients and methods 
 
6.2.1  Patients 
 
Patients diagnosed with gastric carcinoma, attending the upper GI surgical unit in the 
Royal Infirmary, Glasgow between April 1997 and December 2005 and who had a pre-
treatment measurement of albumin and C-reactive protein were studied.   Patients were 
staged using a combination of endoscopy, CT scan of chest, abdomen and pelvis, 
laparoscopy and endoscopic ultrasound, in addition to clinical assessment. The specific 
use of these modalities was dependent upon the clinical tumour features and where 
appropriate, assessment of fitness, cardiac and lung function testing was also performed. 
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The extent of tumour spread was recorded using the TNM stage.  Tumours 
around the gastro-oesophageal junction were further classified according to site, using 
the Siewert system [Siewert and Stein, 1998]; type 1 and 2 lesions of the gastro-
oesophageal junction were designated as cancers of the oesophagus and were therefore 
excluded.  Type 3 tumours of the cardia were designated gastric cancers.  
Patients who had any form of chronic inflammatory disease (e.g. vasculitis, 
connective tissue disorders, rheumatological conditions) and those with cancers arising 
in other organs were excluded from the analysis.  Patients with stage I - III disease with 
significant co-morbidity were not considered suitable for curative surgery. 
In the non-operable group, patients who underwent palliative chemotherapy, 
radiotherapy, endoscopic laser or palliative by-pass surgery were considered to have had 
“active” treatment.  Patients receiving palliative care (symptom control) were 
considered to have had “supportive” treatment. 
The study was approved by the Research Ethics Committee of Glasgow Royal 
Infirmary. 
 
6.2.2  Methods 
 
Routine laboratory measurements of C-reactive protein and albumin at the time 
of diagnosis were carried out.  The limit of detection of the C-reactive protein assay was 
<6mg/l.  The coefficients of variation of these methods, over the range of 




6.2.3  Statistics 
 
Comparisons between groups of patients were carried out using the Mantel-
Haenszel (X2) test for trend and Spearman rank correlation as appropriate.  Grouping of 
the laboratory variables albumin and C-reactive protein was carried out by using 
standard thresholds.[Maltoni et al., 2005]  Survival (cancer-specific) analysis of the 
group variables was performed using a Cox proportional-hazards model.  Deaths up to 
the end of April 2007 were included in the analysis.  Multivariate survival analysis, 
including all covariates that were significant on univariate analysis, was performed 
using a stepwise, backward procedure to derive a final model of the variables that had a 
significant independent relation with survival.  To remove a variable from the model, 
the corresponding P value had to be >.10.  Analyses were performed using SPSS 
software (SPSS Inc., Chicago, IL). 
 
6.3  Results 
 
The baseline characteristics of patients with gastric cancer (n= 217), grouped 
according to the albumin concentration, are shown in Table 6.1.  The majority were 
male, over the age of 65 years, had stage III/ IV disease and received palliative 
treatment.  The majority of patients had albumin and C-reactive protein concentrations 
in the normal range and on follow-up, died of their cancer.   
Patients were grouped according to the absence or presence of 
hypoalbuminaemia (Table 6.1).  Patients with hypoalbuminaemia were older (p<0.01), 
had more advanced disease (p<0.01), had higher C-reactive protein concentrations 
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(p<0.0001), more likely to receive palliative treatment (p<0.0001) and die on follow-up 
(p<0.01) compared with patients who had albumin concentrations in the normal range.  
The minimum follow-up was 15 months; the median follow-up of the survivors was 31 
months.  During this period 157 (72%) patients died of their cancer and a further 5 
patients died of intercurrent disease. 
Survival analysis is shown in Table 6.2.  On univariate analysis, age (p<0.10), 
tumour site (p<0.01), clinical stage (p<0.0001) and treatment (p<0.001) were significant 
predictors of cancer specific survival.  Also, whether treated as continuous or 
categorical variables, albumin (p<0.0001) and C-reactive protein (p<0.0001) were 
significant predictors of cancer specific survival.  On multivariate analysis, clinical 
stage (p<0.0001) and treatment (p<0.0001) remained significant independent predictors 
of cancer specific survival.  Also, whether treated as continuous or categorical variables, 
C-reactive protein (p<0.0001) remained a significant independent predictor of cancer 
specific survival.  Albumin, however, was no longer an independent predictor of 
survival (Table 6.2). 
The relationship between log10 C-reactive protein and albumin concentrations 
(rs= 0.47, p<0.001) is shown in Figure 6.1.  The relationship between C-reactive protein 
(<10mg/l, >10mg/l) and cancer specific survival (p<0.0001) in patients with gastric 
cancer and a normal albumin concentration (>35g/l) is shown in Figure 6.2.  The 
relationship between C-reactive protein (<10mg/l, >10mg/l) and cancer specific survival 




6.4  Discussion 
 
The results of the present study confirm the work of previous authors that low 
albumin concentrations, either as a continuous or categorical variable, are significantly 
associated with poorer survival in patients with gastric cancer [Lien et al., 2004;Alici et 
al., 2006;Onate-Ocana et al., 2007;Lee et al., 2007;Onate-Ocana et al., 2008].  However, 
the results of the present study show that there is a direct relationship between an 
elevated C-reactive protein concentration and hypoalbuminaemia.  Moreover, both 
hypoalbuminaemia and C-reactive protein predict survival in patients with gastric 
cancer and the prognostic value of hypoalbuminaemia is degraded by the inclusion of 
C-reactive protein.  Therefore, the current view (held by many clinicians) that 
hypoalbuminaemia reflects poor nutritional status, is likely to be an over simplification 
and the relationship between hypoalbuminaemia and poor survival in patients with 
gastric cancer is more complex.  Indeed, Ellegard and co-workers have recently 
concluded that although several biochemical markers are frequently used to monitor 
nutritional status, including subnormal serum levels of albumin, transferrin, and 
transthyretin, systemic inflammation is central to weight loss in cancer, explaining 
variations in body composition [Ellegard and Bosaeus, 2008]. Furthermore, they 
conclude that the most important biochemical index to be measured in malignant 
disease is the assessment of systemic inflammatory response.  It is of interest therefore, 
that Onate- Ocana and co-workers (2007) previously recognised that there may be a 
number of potential confounding factors responsible for the association between 
hypoalbuminaemia and poor survival in gastric cancer.  They identified the systemic 
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inflammatory response as a plausible confounding factor, consistent with the present 
results. 
In patients with gastric cancer it is recognised that there may be reduced caloric 
intake due to stenosis of the cardia or pylorus.  However the results of the present and 
these previous studies are consistent with the hypothesis that the systemic inflammatory 
response plays a major role in the progressive nutritional and functional decline in 
patients with cancer [McMillan, 2008].  Indeed, measurement of the systemic 
inflammatory response, in particular C-reactive protein, has been included in the 
definition of cancer cachexia, together with weight loss and reduced calorie intake 
[Morley et al., 2006;Fearon et al., 2006].  Therefore, taken together with the results of 
the present study, it would appear that the relationship between hypoalbuminaemia and 
poor cancer specific survival, is secondary to that of the systemic inflammatory 
response, in patients with gastric cancer. 
The basis of the systemic inflammatory response in patients with gastric cancer 
is not clear.  It may be due to the increased production of pro-inflammatory cytokines 
by the tumour or in response to bacterial infection and tissue necrosis.  Indeed there is 
some evidence of increased production of interleukin 6 (IL-6), a primary mediator of 
increased C-reactive protein concentration, from gastric tumours [Ashizawa et al., 
2005;Liao et al., 2008].  In addition, serum IL-6 levels have been shown to be closely 
correlated with C-reactive protein concentration, in patients with gastric cancer 
[Ikeguchi et al., 2009;Kim et al., 2009].  Increasing tumour size and the degree of 
tumour ulceration has also been shown be associated with poor prognosis in patients 
with gastric cancer [Xu et al., 2009].   However, it remains to be determined whether 
tumour expression of IL-6, tissue necrosis or the host response, is responsible for 
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elevated C-reactive protein concentrations and hypoalbuminaemia in patients with 
gastric cancer. 
The mechanism by which an elevated C-reactive protein concentration is related 
to poorer survival is similarly not clear.  It may be that an elevated systemic 
inflammatory response is associated with a poor host, local immune response to the 
tumour and therefore increased lymph node spread and metastases.  Alternatively, it 
may be that an elevated C-reactive protein concentration is associated with increased 
vascular invasion or angiogenesis, thus again conveying metastatic potential.  However 
the tumour/ host interaction and its relationship to the systemic inflammatory response 
and survival, is likely to be complex. 
Measurement of C-reactive protein in patients with gastric cancer may be used 
to better predict patient outcome, improving stratification of patients and therefore 
ensuring allocation of the most appropriate treatment, most likely to benefit.  Indeed, 
measurement of C-reactive protein (as part of inflammation based prognostic scores) 
has been shown to improve clinical staging in patients with gastro-oesophageal cancer 
and can be incorporated into current staging algorithms [Deans et al., 2007].  
Furthermore, measurement of C-reactive protein, systemic inflammation-based markers 
and prognostic scores not only identify patients at risk of a poor outcome, but may also 
provide well-defined therapeutic targets for clinical trials. 
In summary, the results of the present study show that the systemic 
inflammatory response is a major confounding factor in the relationship between low 
albumin concentrations and poorer cancer specific survival.  Accordingly, C-reactive 
protein should be measured in addition, to albumin to define baseline risk in patients 
with gastric cancer.  
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Table 6.1  The relationship between hypoalbuminaemia, clinicopathological 
characteristics, systemic inflammatory response and survival in patients with 




 median (range) 
 





Age (<65/ 65-74/ >75years) 71/ 50/ 50 11/ 7/ 28 0.001 
Sex (male/ female) 111/ 60 27/ 19 0.438 
Tumour site (proximal/ body/ antrum/ 
overlapping/ not defined) 
35/ 41/ 48/ 33/ 14 8/ 10/ 10/ 14/ 4 0.316 
Clinical TNM Stage (I/ II/ III/ IV) 42/ 34/ 26/ 69 6/ 4/ 6/ 30 0.004 
    
C-reactive protein (mg/l)a <6 (<6-190) 28 (<6-253) <0.001 
C-reactive protein (<10/ >10mg/l) 110/ 61 12/ 34 <0.001 
    
Treatment  (surgery/ palliative-active/ 
palliative-supportive) 
 
68/ 83/ 20 
 
3/ 30/ 13 
 
<0.001 
    
Alive 
Dead 
   Cancer 














Table 6.2  Clinicopathological characteristics and cancer specific survival in 
patients with gastric cancer (n=217): Survival analysis 
 
                                                                     Univariate survival 
                                                                     Analysis 
Multivariate survival 
analysis 




P- value Hazard ratio 
(95%) C.I) 
P- value 
Age < 65 years 
       65-74 years 


















Sex     Male 










Tumour site    proximal 
                        body 
                       antrum 
                       overlapping 






























TNM stage        I 
                          II 
                          III 























Treatment    Surgery 
                     Palliative-active 
                     Palliative-         


















Albumin (g/l) 217 0.93 (0.91-0.95) 
 
<0.001 1.00 (0.96-1.03) 
 
0.802 
C-reactive protein (mg/l)a 217 5.09 (3.59-7.22) 
 
<0.001 2.57 (1.70-3.87) 
 
<0.001 
Albumin                 > 35g/l 













C-reactive protein < 10mg/l 

































Figure 6.1  The relationship between C-reactive protein and albumin in 











































Figure 6.2  The relationship between the systemic inflammatory response (C-
reactive protein <10mg/l, >10mg/l from top to bottom) and cancer specific survival 















































Figure 6.3  The relationship between the systemic inflammatory response (C-
reactive protein <10mg/l, >10mg/l from top to bottom) and cancer specific survival 


























CRP < 10mg/l 
CRP > 10mg/l 
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CHAPTER 7: COMPARISON OF PRE-TREATMENT CLINICAL 
PROGNOSTIC FACTORS IN PATIENTS WITH GASTRO-OESOPHAGEAL 




Currently, clinical staging in patients with gastro-oesophageal cancer, is based 
on measures of the burden of disease (CT, laparoscopy and Endoscopic Ultrasound) and 
the fitness of the patient (weight loss and performance status).  However, neither weight 
loss or performance status are objectively defined [Ando M, 2001;Morley et al., 
2006;Fearon et al., 2006], and as a consequence do not accurately stratify patient 
outcomes and responses to the treatment.  Clearly, more accurate assessment of patient 
fitness will improve the allocation of treatment and therefore outcomes for all patients 
with gastro-oesophageal cancer. 
In addition, the use of neoadjuvant chemo and radiotherapy has increased the 
need for more accurate clinical staging methods.  In particular, following neoadjuvant 
therapy pathologic staging of the tumour specimen is not as informative as in untreated 
patients.  Therefore, clinical staging is of crucial importance in determining the likely 
benefit of treatment, in terms of subsequent quality of life and survival.   
Recently, the pre-treatment clinical factors; clinical stage, weight loss, 
performance status and an elevated C-reactive protein concentration, have been shown 
to independently predict survival in patients undergoing clinical staging for gastro-
oesophageal cancer [Deans et al., 2007].  However, this has not to date been 
prospectively validated. 
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Also, the selective combination of C-reactive protein and albumin (termed the 
Glasgow Prognostic score, GPS) has been shown to be a prognostic factor, independent 
of tumour stage, in a variety of gastrointestinal cancers [McMillan, 2008] including 
gastro-oesophageal cancer [Kobayashi et al., 2008]. 
The aim of the present study was to examine the relationship between pre-
treatment clinical prognostic factors and cancer specific survival in an unselected cohort 
of patients with gastro-oesophageal cancer. 
 




Two hundred and seventeen patients, undergoing staging investigations for 
gastro-oesophageal cancer (between January 2002 and December 2004) in the upper GI 
surgical unit at Glasgow Royal Infirmary, were studied.   
For gastric cancers, TNM stage I to III tumours were considered to be amenable 
to curative surgical resection.  For oesophageal cancers, TNM stage I to III tumours, 
excluding T4, were considered to be amenable to curative surgical resection.   






The extent of tumour spread was recorded using the TNM stage.  Tumours of 
the gastro-oesophageal junction were further classified according to site, using the 
Siewert system; type 1 and 2 lesions of the gastro-oesophageal junction were designated 
as cancers of the oesophagus.  Type 3 tumours of the cardia were designated gastric 
cancers [Siewert and Stein, 1998].  
Routine pre-operative laboratory measurements of albumin and C-reactive 
protein were carried out prior to staging laparoscopy.  The coefficient of variation for 
these methods, over the range of measurement, was less than 10% as established by 
routine quality control procedures.  The limit of detection of the assay was a C-reactive 
protein concentration of less than 5mg/l with the upper limit of normal values being 
<10mg/l. 
The Edinburgh Clinical Risk Score (ECRS) was constructed as previously 
described [Deans et al., 2007].  An elevated C-reactive protein concentration (>5mg/l) 
scores 20, rate of weight loss of > 2.75% per month scores 20, Karnofsky PS of <60 
scores 68, 60-70 scores 32 and 80-100 scores 0, and clinical stage IV scores 94, III 
scores 46, II scores 30 and I scores 0 (Table 7.1). 
The mGPS was calculated as previously described [McMillan, 2008].  Briefly, 
patients with an elevated C-reactive protein concentration (>10 mg/L) and a decreased 
albumin concentration (<35 g/L) score 2.  Those patients with an elevated C-reactive 
protein concentration (> 10mg/L) score 1 and patients with a C-reactive protein 





Deaths up to the end of July 2008 have been included in the analysis.  Univariate 
survival analysis and calculation of hazard ratios (HR) were performed using Cox 
proportional hazard model on age, sex, tumour site, histological tumour type, clinical 
TNM stage (cTNM), weight loss, Karnofsky performance status, C-reactive protein 
concentration, Edinburgh Clinical Risk Score mGPS and treatment.  Multivariate 
survival analysis, including all covariates that were significant on univariate analysis, 
was performed using a stepwise backward procedure to derive a final model of the 
variables that had a significant independent relationship with survival.  To remove a 
variable from the model, the corresponding P-value had to be greater than 0.10.  




The characteristics of patients, undergoing staging for gastro-oesophageal cancer 
are shown in Table 7.2.  The majority of patients were male, greater than 65 years, had 
adenocarcinomas and had clinical TNM stage (cTNM) III disease.  Thirty eight patients 
underwent surgery with curative intent, 14 patients received radical chemo-
radiotherapy, 91 patients received chemo/radiotherapy, 35 patients were treated with 
laser, 5 underwent palliative by-pass surgery and 34 patients underwent stenting or 
received palliative care only.  One hundred and ten patients had an elevated C-reactive 
protein concentration (>10mg/l).  Of the 38 patients with hypo-albuminaemia, 32 (84%) 
had an elevated C-reactive protein concentration (>10mg/l).   
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During the follow-up period 188 (87%) patients died; 178 of their disease.  The 
minimum follow-up was 46 months and the median follow-up of the survivors was 65 
months.  On univariate analysis, age (p<0.05), tumour site (P<0.01), cTNM stage 
(p<0.001), weight loss (p<0.01), C-reactive protein concentration >5mg/l (p<0.001), 
ECRS (p<0.001), mGPS (p<0.001) and treatment (p<0.001), were significantly 
associated with cancer specific survival (Table 7.2). 
On multivariate survival analysis of the significant factors, excluding treatment; 
age (HR 1.41, 95% CI 1.17-1.69, p< 0.001), tumour position (HR 1.49, 95% CI 1.10-
2.01, p= 0.010), cTNM stage (HR 1.90, 95% CI 1.59-2.28, p< 0.001) and mGPS (HR 
2.07, 95%CI 1.67-2.58, p<0.001), were independently associated with cancer specific 
survival (Table 7.3).  
When treatment was included in the multivariate analysis, only cTNM stage 
(HR 1.84, 95% CI 1.56-2.17, p< 0.001), treatment (HR 2.12, 95% CI 1.73-2.60, p< 
0.001) and mGPS (HR 1.67, 95% CI 1.35-2.07, p< 0.001) were independently 
associated with cancer specific survival (Table 7.3). 
 When those patients who underwent surgery were tested independently (n=38) 
to establish prognostic variables, on univariate analysis only C-reactive protein <5mg/l 
(p<0.01) and mGPS (p<0.01) were associated with cancer specific survival.  On 
multivariate analysis, only the mGPS was significantly associated with cancer specific 
survival HR 4.34, 95%CI 1.44-13.13, p=0.009). 
Patients with clinical stage III disease are the most challenging group in which 
to allocate the treatment, from which they are most likely to benefit.  Figure 7.1 
demonstrates how the mGPS can be used to provide additional prognostic information 
to aid decision making, along with clinical stage (HR 1.89, 95% CI 1.17-3.06, p= 0.01).  
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Figures 7.2-7.3 demonstrate the relationship between cTNM stage and survival, in 
patients with an mGPS of 0 and 1 respectively. 
The relationship between the patient clinical characteristics and the mGPS is 
shown in Table 7.4.  An elevated mGPS was associated with advanced cTNM stage (p< 
0.001), poor performance status (p<0.05), an elevated ECRS (p< 0.001) and more 




In the present study of a comparison of pre-treatment clinical prognostic factors 
in patients with gastro-oesophageal cancer, only clinical TNM stage, treatment and the 
mGPS were shown to have independent prognostic significance.  These results suggest 
that the systemic inflammatory response, as evidenced by the mGPS, is the most 
important patient related factor in determining outcome in patients with gastro-
oesophageal cancer.  Therefore, a measure of the systemic inflammatory response, in 
particular the mGPS, should be included in the pre-treatment assessment of these 
patients, and subsequent discussion at a multi-disciplinary team meeting. 
In the present study C reactive protein and albumin concentrations were 
measured at the time of diagnosis, prior to staging laparoscopy.  Serial measurements 
were not performed and it is unclear whether longitudinal measurement of the mGPS 
throughout treatment, would have added additional prognostic information.  However, 
this may be particularly relevant in patients selected for neo-adjuvant treatment. 
In the present study 18% of patients underwent resection.  This may appear low 
compared with the resection rate in other countries, however, in the UK the majority of 
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patients with gastro-oesophageal cancer present with advanced, inoperable disease.  
Moreover in recent years there has been a decrease in the resection rate for gastric and 
oesophageal cancer with the recognition that although the resection rate was 
approximately 40% only 60% of operations were considered to be curative by the 
surgeon [ISD Scotland, 2005].  With the advent of EUS and high resolution CT in more 
recent years, accurate clinical staging has improved and the percentage of patients 
selected for potentially curative surgery has therefore decreased.   
In the present study the aim was to compare pre-treatment prognostic variables 
which may useful in informing treatment decisions and therefore clinical TNM (cTNM) 
staging was used in all patients.  This reflects the situation faced by clinicians at 
multidisciplinary team meetings.  Nevertheless, it has long been recognised that the 
level of concordance between pre-operative clinical stage and post-operative 
pathological stage is sub-optimal even with enhanced imaging techniques [Ziegler et al., 
1993;Kelly et al., 2001;Blackshaw et al., 2003;Lightdale and Kulkarni, 2005].  In the 
present study the numbers of patients who underwent surgery and had pathological 
stage was small 38 (18%) and therefore it remains to be determined whether the mGPS 
improves the prediction of pathological TNM stage in patients with gastro-oesophageal 
cancer.   
Similarly, the assessment of patient fitness by the amount of weight loss or 
performance status is known to be suboptimal.  For example, there remains controversy 
about what weight loss (the amount of and over what period) significantly impacts on 
outcome [Morley et al., 2006;Fearon et al., 2006].  Also, differences in the assessment 
of performance status have been reported between oncologists, nurses and patients, 
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oncologists being the most optimistic in their assessment and patients the least [Ando 
M, 2001].   
It is of note that the 2 year survival of the group receiving endoscopic/ 
symptomatic treatment and who had a mGPS of 0, was greater than the 2 year survival 
of patients receiving palliative chemo/radiotherapy who’s mGPS was greater than 0.  
Thus, it would appear that according to survival, some patients may have received more 
aggressive treatment without necessarily benefiting them and conversely, some patients 
may have been denied more aggressive treatment, which may have prolonged their life. 
In contrast to the mGPS, the ECRS comprises 4 variables, 2 of which are 
subjective; performance status and weight loss.  These two subjective variables account 
for almost half of the possible risk score and in the present study did not retain 
independent significance when compared with the mGPS.  Although both scores have 
incorporated C-reactive protein, in the ECRS C-reactive protein can account for a score 
of 20 out of a possible 202 (10%).  In contrast, C-reactive protein can account for a 
score of 1 out of a possible 2 (50%).  In addition, in the present study the C reactive 
protein threshold of >5 mg/l did not retain independent significance when compared 
with the mGPS. 
Therefore, the mGPS offers a simple to perform, objective and well standardised 
pre-treatment assessment to guide treatment.  For example, since an elevated pre-
treatment mGPS identifies patients at high risk of dying of their disease, they should be 
offered low morbidity treatment tailored to symptomatic control.  Indeed, recent 
evidence from surgical and chemoradiotherapy studies are consistent with this approach 
[Kobayashi et al., 2008;Ikeda et al., 2003].   In the present study, it would appear that in 
those patients with evidence of an elevated systemic inflammatory response, clinical 
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stage performs less well in predicting cancer specific survival (figures 7.2-7.3) It is 
important to note however, that there are relatively few patients in this cohort with a 
mGPS of 2 and clinical stage I-III disease and therefore some caution is necessary in 
interpreting results in this sub-group of patients. 
In summary, the pre-treatment measurement of the mGPS improves clinical 
staging in patients with gastro-oesophageal cancer.  Therefore, it is likely to aid clinical 




Table 7.1.  Prognostic scoring systems in patients with gastro-oesophageal cancer. 
 
 
Edinburgh Clinical Risk Score 
(ECRS) 
Score modified Glasgow Prognostic Score 
(mGPS) 
Score 
CRP < 5mg/l 







Rate of weight loss  
<2.75 (% per month) 




































Table 7.2.  Pre-treatment clinical characteristics and cancer specific survival rates 







rate % (SE) 
3 year 
survival 
rate % (SE) 
P-value 
(log rank) 
Age    <65 years 
           65-74years 













Sex     male 









Site    oesophageal 









Type    adenocarcinoma 









Edinburgh clinical risk score     
Clinical TNM Stage      I 
                                     II 
                                     III 

















Weight loss                 No 









Karnofsky PS              80-100 
                                     60-70 
                                     <60    
203 (93) 
12  (6) 










C-reactive protein  <5mg/l 





















     












     
Treatment    
Surgery 
Chemoradiotherapy with curative intent 




38  (18) 
14  (6) 
91  (42) 


















Table 7.3.  Pre-treatment clinical characteristics and cancer specific survival of 
patients with gastro-oesophageal cancer:   
Multivariate survival analysis 
excluding treatment 
Patients 
n= 217  
Survival  
HR (95% CI) 
P-value 
 
Age  (<65/ 65-74/ >75 years) 87/ 53/ 77 1.41 (1.17- 1.69) <0.001 
Site  (oesophageal/ gastric) 121/ 96 1.49 (1.10- 2.01) 0.010 
Clinical TNM Stage  (I/ II/ III/ IV) 29/ 31/ 60/ 97 1.90 (1.59- 2.28) <0.001 
Weight loss  (no/ yes) 83/ 134 1.32(0.95- 1.82) 0.098 
C-reactive protein  (<5/ >5mg/l) 86/ 131 1.07 (0.68- 1.67) 0.777 
mGPS  (0/ 1/ 2) 107/ 78/ 32 2.07 (1.67- 2.58) <0.001 
Multivariate survival analysis 
Including treatment 
   
Age  (<65/ 65-74/ >75 years) 87/ 53/ 77 1.08 (0.89- 1.32) 0.430 
Site  (oesophageal/ gastric) 121/ 96 1.15 (0.84- 1.58) 0.387 
Clinical TNM Stage  (I/ II/ III/ IV) 29/ 31/ 60/ 97 1.84 (1.56- 2.17) <0.001 
Weight loss  (no/ yes) 83/ 134 1.21(0.87- 1.68) 0.263 
mGPS  (0/ 1/ 2) 107/ 78/ 32 1.67 (1.35- 2.07) <0.001 
Treatment 
(Surgery/ Chemoradiotherapy with curative 
intent/ Palliative chemotherapy / radiotherapy/ 















Table 7.4.  Relationship between clinical characteristics and the mGPS 
 







Age   (<65 / 65-74/ >75 years) 43/ 28/36 36/ 15/ 27 8/ 10/ 14 0.302 
Sex   (male/ female) 74/ 33 52/ 26 23/ 9 0.920 
Site   (oesophageal/ gastric) 63/ 44 45/ 33 13/ 19 0.122 
Type   (adenocarcinoma/ squamous) 83/ 24 53/ 25 24/ 8 0.430 
cTNM Stage (I/ II/ III/ IV)  22/ 22/ 35/ 28 4/ 6/21/ 47 3/3/4/ 22 <0.001 
Weight loss   (no/ yes) 49/ 58 21/ 57 13/ 19 0.158 
Karnofsky PS   (80-100/ 60-70/ <60) 103/ 3/ 1 74/ 4/ 0 26/ 5/ 1 0.018 
ECRS   (tertiles)       48/ 54/ 5 7/ 35/ 36 3/13/ 16 <0.001 
Treatment   
Surgery  
Chemoradiotherapy with curative intent 






















2 year survival rate % (SE)  
Surgery  
Chemoradiotherapy with curative intent 

























Figure 7.1.  The relationship between the mGPS (0/ 1/ 2 from top to bottom) and 
survival in patients with cTNM stage III gastro-oesophageal cancer (Kaplan Meier 






























Figure 7.2.  The relationship between the cTNM stage (I/ II/ III/ IV from top to 
bottom) and survival in patients with gastro-oesophageal cancer and a mGPS score 

































Figure 7.3.  The relationship between the cTNM stage (I/ II/ III/ IV from top to 
bottom) and survival in patients with gastro-oesophageal cancer and a mGPS score 



























CHAPTER 8:  DISCUSSION AND FUTURE WORK 
 
 The overall aim of the thesis was to examine the inter-relationships between 
local and systemic inflammatory responses and cancer specific survival, in patients with 
gastro-oesophageal cancer. 
  
 The results of the work presented in this thesis have demonstrated that, in 
particular, the presence of an elevated systemic inflammatory response predicts poor 
survival, independent of stage and treatment received, in patients with operable and 
inoperable gastro-oesophageal cancer.  The mechanisms by which the systemic 
inflammatory response impacts on cancer specific survival is, however, still unclear. 
  
 There are a number of potential mechanisms; 
It is possible that the presence of an elevated systemic inflammatory response may 
represent occult metastasis and therefore under-staging of patients.  Since work began 
on this thesis, there has been an increase in the use of PET CT, in the staging of gastro-
oesophageal cancer.  Indeed, the use of PET CT has been shown to alter clinical stage 
and subsequent management decisions in approximately 20% of patients with 
oesophageal cancer [Gilles et al 2010, Williams et al 2009].  It remains to be seen if the 
increased diagnosis of metastatic disease by this modality (in patients that previously 
would have been deemed to have local, operable disease), is associated with the 
presence of a systemic inflammatory response.  However, this theory of occult 
metastasis is unlikely to explain the ability of the systemic inflammatory response (as 
evidenced by the mGPS) to consistently and independently predict poor cancer survival 
 155
in a number of tumour types and at different stages of disease [McMillan, 
2009;Roxburgh and McMillan, 2010].  From these reports and the results of the present 
study, it is more likely that the presence of a systemic inflammatory response enhances 
the malignant potential of the tumour.   
 In chapter 3, it was of interest that a local low grade inflammatory infiltrate was 
associated with, independent of tumour staging, poorer cancer specific survival in 
patients with gastro-oesophageal cancer.  Also, that low grade Klintrup criteria was also 
associated with a greater nodal burden.  These results are consistent with those 
previously observed in relatively large studies of patients undergoing potentially 
curative resection for colorectal cancer [Klintrup et al., 2005;Roxburgh et al., 
2009b;Roxburgh et al., 2009a].  Therefore, it was of interest that Klintrup criteria and 
Ki-67 labelling index were not associated.  This might suggest that the local immune 
response is not stimulated directly by increased tumour proliferation and may be a more 
passive response to production of local, pro-inflammatory cytokines.  Alternatively, as 
suggested above, that there may be unknown confounding factors associated with the 
present analysis of Ki-67 labelling index in gastro-oesophageal cancer. 
 Nevertheless, the results of the present study are consistent with the concept that 
a high-grade local immune response represents an effective host cellular immune 
response preventing further tumour dissemination and progression.  Furthermore, the 
fact that the Klintrup score had superior prognostic value to that of tumour macrophage 
infiltrate is also consistent with the concept that the density and location of a variety of 
immune cells, and not an individual immune cell type, are important independent 
determinants of cancer-specific survival in patients with gastro-oesophageal cancer.  
Also, it would suggest that other immune cell-types are important in determining 
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tumour progression in these patients.  Further detailed analysis of mediators of the local 
and systemic inflammatory responses such as the interleukins e.g. IL-4, IL-6 and IL-10 
and chemokines e.g. MCP-1, MIP-1 and IL-8 would be warranted to explain how these 
local and systemic inflammatory responses are linked. 
 Another potential mechanism linking the systemic inflammatory response to 
malignant potential is the inflammation driven process of angiogenesis/ vascular 
invasion and its associated dissemination of the tumour at an early stage of disease.  
Examining the relationship between angiogenesis/ vascular invasion, the local and 
systemic inflammatory responses and survival would be an important area for future 
work.  In the present thesis tumour macrophage infiltration, although reported to be 
linked to angiogenesis/ vascular invasion [Murri et al., 2008] was not associated with 
local or systemic inflammatory responses and did not predict cancer specific survival 
(Chapter 3).  Further detailed analysis of the relationship between local and systemic 
inflammatory responses and angiogenesis/ vascular invasion is warranted to investigate 
this potential mechanism. 
 At the time of this thesis, the treatment algorithm for patients with operable 
disease did not routinely include neo-adjuvant chemotherapy.  However, as a result of 
the MAGIC trial, patients are now routinely treated with neoadjuvant chemotherapy 
[Cunningham et al., 2006].  Although this enabled the analysis of tumour proliferation, 
macrophage and inflammatory infiltrate and pathological factors in “native” tumours we 
were unable to examine the relationship between the systemic inflammatory response 
and response to neoadjuvant chemotherapy.  Nevertheless, it was of interest that, in 
chapter 5, the presence of an elevated GPS in patients undergoing palliative 
chemotherapy was associated with poorer survival and the need for dose reduction.  
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These results are consistent with the recent report that the GPS predicts poor survival in 
patients undergoing neoadjuvant chemo-radiotherapy for oesophageal squamous cancer 
[Kobayashi et al., 2008].  It would therefore be important for future work to assess the 
relationship between the systemic inflammatory response, tolerance and response to 
neo-adjuvant chemotherapy and survival in patients with oesophageal and gastric 
adenocarcinoma. 
 As discussed in chapter 7, we believe that the mGPS should now be 
incorporated into staging of patients and therefore treatment allocation.  The clinical 
utility of measures of the systemic inflammatory response (such as the mGPS) is an 
important area for further study.  Whether its value will be greater in the initial staging 
of patients or in guiding the use anti-inflammatory treatment, remains to be determined.  
Indeed, an area not addressed in the thesis is whether or not the systemic inflammatory 
response (as evidenced by the mGPS) can be modified.  An important area for future 
work would therefore be to assess whether treatment with anti-inflammatory agents can 
down regulate the systemic inflammatory response and whether such anti-inflammatory 
treatment can improve long term survival for patients with operable and inoperable 
gastro-oesophageal cancer. Finally, it remains to be seen whether the mGPS is of value 
in monitoring such a process. 
 In conclusion, measurement of the systemic inflammatory response (as 
evidenced by the mGPS) provides additional prognostic information in patients with 
gastro-oesophageal cancer, it can improve clinical staging and help predict patients less 
likely to benefit from high morbidity treatments.  Furthermore, it is an objective 
measure which is well standardised and easily reproducible and can be readily included 
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APPENDIX 1: DATABASE FOR CHAPTER 2:   
AN ELEVATED C-REACTIVE PROTEIN CONCENTRATION, 
PRIOR TO SURGERY, PREDICTS POOR CANCER SPECIFIC 





Patient m0f1 age agecd Dateop site positcd histolog typecd T n m tnmstcd posnodes lymphcd 
1 0.00 63 0.00 18-Apr-2001 o 0.00 squam 1.00 1 0.00 0 1.00 0.00 0.00 
2 0.00 77 2.00 01-Sep-1996 g 1.00 adeno 0.00 3 0.00 0 2.00 0.00 0.00 
3 1.00 34 0.00 16-Jul-1997 G 1.00 AD 0.00 3 1.00 0 3.00 3.00 1.00 
4 0.00 73 1.00 08-Jun-1998 o 0.00 adeno 0.00 3 0.00 0 2.00 0.00 0.00 
5 0.00 72 1.00 21-Oct-1998 g 1.00 adeno 0.00 3 0.00 0 2.00 0.00 0.00 
6 1.00 73 1.00 28-Oct-1998 o 0.00 adeno 0.00 2 0.00 0 1.00 0.00 0.00 
7 0.00 59 0.00 29-Mar-1999 g 1.00 adeno 0.00 1 0.00 0 1.00 0.00 0.00 
8 0.00 51 0.00 07-Apr-1999 o 0.00 squam 1.00 3 1.00 0 3.00 7.00 1.00 
9 0.00 66 1.00 05-Jul-1999 g 1.00 adeno 0.00 3 0.00 0 2.00 2.00 1.00 
10 1.00 58 0.00 16-Jul-1999 o 0.00 adeno 0.00 1 0.00 0 1.00 0.00 0.00 
11 0.00 49 0.00 09-Aug-1999 o 0.00 squam 1.00 2 1.00 0 2.00 4.00 1.00 
12 1.00 77 2.00 23-Aug-1999 o 0.00 squam 1.00 3 1.00 0 3.00 5.00 1.00 
13 1.00 67 1.00 28-Sep-1999 o 0.00 squam 1.00 2 1.00 0 2.00 1.00 1.00 
14 0.00 59 0.00 03-Nov-1999 o 0.00 adeno 0.00 1 0.00 0 1.00 5.00 1.00 
15 0.00 71 1.00 24-Nov-1999 o 0.00 squam 1.00 2 0.00 0 2.00 0.00 0.00 
16 0.00 48 0.00 01-Dec-1999 g 1.00 adeno 0.00 2 0.00 0 1.00 1.00 1.00 
17 0.00 74 1.00 26-Jan-2000 o 0.00 squam 1.00 1 0.00 0 1.00 0.00 0.00 
18 1.00 69 1.00 14-Feb-2000 o 0.00 squam 1.00 1 0.00 0 1.00 0.00 0.00 
19 0.00 72 1.00 16-Feb-2000 o 0.00 adeno 0.00 1 0.00 0 1.00 0.00 0.00 
20 1.00 61 0.00 01-Mar-2000 o 0.00 squam 1.00 2 1.00 0 2.00 2.00 1.00 
21 1.00 55 0.00 15-Mar-2000 o 0.00 adeno 0.00 2 0.00 0 2.00 0.00 0.00 
22 0.00 61 0.00 22-May-2000 g 1.00 adeno 0.00 1 0.00 0 1.00 0.00 0.00 
23 1.00 59 0.00 29-May-2000 g 1.00 adeno 0.00 2 0.00 0 1.00 0.00 0.00 
24 0.00 47 0.00 30-Aug-2000 o 0.00 adeno 0.00 1 0.00 0 1.00 0.00 0.00 
25 0.00 75 2.00 08-Nov-2000 G 1.00 adeno 0.00 2 0.00 0 1.00 0.00 0.00 
26 0.00 61 0.00 20-Dec-2000 g 1.00 adeno 0.00 1 0.00 0 1.00 0.00 0.00 
27 0.00 64 0.00 10-Jan-2001 g 1.00 adeno 0.00 1 0.00 0 1.00 0.00 0.00 
28 1.00 72 1.00 11-Apr-2001 G 1.00 adeno 0.00 2 0.00 0 1.00 0.00 0.00 
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Patient m0f1 age agecd dateop site positcd histolog typecd t n m tnmstcd posnodes Lymphcd 
29 0.00 71 1.00 16-May-2001 g 1.00 adeno 0.00 1 0.00 0 1.00 1.00 1.00 
30 0.00 52 0.00 11-Jul-2001 G 1.00 adeno 0.00 1 0.00 0 1.00 0.00 0.00 
31 1.00 52 0.00 29-Aug-2001 o 0.00 squam 1.00 1 0.00 0 1.00 1.00 1.00 
32 1.00 41 0.00 14-Nov-2001 g 1.00 adeno 0.00 3 0.00 0 2.00 7.00 1.00 
33 0.00 72 1.00 09-Jan-2002 g 1.00 adeno 0.00 3 0.00 0 2.00 0.00 0.00 
34 0.00 64 0.00 06-Mar-2002 o 0.00 adeno 0.00 3 0.00 0 2.00 0.00 0.00 
35 0.00 70 1.00 17-Apr-2002 g 1.00 adeno 0.00 2 0.00 0 1.00 0.00 0.00 
36 1.00 73 1.00 24-Apr-2002 o 0.00 adeno 0.00 2 0.00 0 2.00 0.00 0.00 
37 0.00 59 0.00 29-May-2002 g 1.00 adeno 0.00 2 0.00 0 1.00 0.00 0.00 
38 1.00 72 1.00 29-May-2002 g 1.00 adeno 0.00 2 0.00 0 1.00 0.00 0.00 
39 0.00 58 0.00 25-Jul-2002 o 0.00 adeno 0.00 3 0.00 0 2.00 0.00 0.00 
40 0.00 68 1.00 02-Oct-2002 o 0.00 adeno 0.00 1 0.00 0 1.00 0.00 0.00 
41 0.00 70 1.00 01-Nov-2002 g 1.00 adeno 0.00 3 0.00 0 2.00 0.00 0.00 
42 0.00 61 0.00 04-Dec-2002 o 0.00 adeno 0.00 1 0.00 0 1.00 0.00 0.00 
43 0.00 59 0.00 17-Mar-2003 o 0.00 squam 1.00 3 0.00 0 2.00 0.00 0.00 
44 1.00 65 1.00 08-May-2003 g 1.00 adeno 0.00 1 0.00 0 1.00 0.00 0.00 
45 0.00 76 2.00 11-Jun-2003 g 1.00 adeno 0.00 1 0.00 0 1.00 0.00 0.00 
46 1.00 71 1.00 25-Jun-2003 o 0.00 squam 1.00 3 1.00 0 3.00 1.00 1.00 
47 0.00 55 0.00 10-Sep-2003 o 0.00 adeno 0.00 3 1.00 0 3.00 1.00 1.00 
48 1.00 80 2.00 11-Feb-2004 o 0.00 adeno 0.00 3 0.00 0 2.00 0.00 0.00 
49 1.00 58 0.00 21-Apr-2004 o 0.00 squam 1.00 1 0.00 0 1.00 0.00 0.00 
50 0.00 58 0.00 28-Apr-2004 o 0.00 squam 1.00 2 1.00 0 2.00 1.00 1.00 
51 0.00 52 0.00 10-May-2004 g 1.00 adeno 0.00 1 0.00 0 1.00 0.00 0.00 
52 1.00 71 1.00 12-May-2004 o 0.00 squam 1.00 1 0.00 0 1.00 0.00 0.00 
53 1.00 46 0.00 17-Jun-2004 o 0.00 squam 1.00 3 1.00 0 3.00 1.00 1.00 
54 0.00 68 1.00 30-Jun-2004 g 1.00 adeno 0.00 1 0.00 0 1.00 0.00 0.00 
55 0.00 42 0.00 18-Aug-2004 g 1.00 adeno 0.00 1 0.00 0 1.00 0.00 0.00 
56 0.00 51 0.00 22-Dec-2004 o 0.00 squam 1.00 3 1.00 0 3.00 8.00 1.00 
57 0.00 56 0.00 07-Jan-1998 g 1.00 adeno 0.00 3 1.00 0 3.00 2.00 1.00 
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61 0.00 69 1.00 04-Feb-2004 o 0.00 adeno 0.00 2 1.00 0 2.00 4.00 1 
62 0.00 52 0.00 11-Feb-2002 o 0.00 adeno 0.00 3 1.00 0 3.00 5.00 1 
63 0.00 60 0.00 09-Mar-1998 o 0.00 adeno 0.00 3 1.00 0 3.00 7.00 1 
64 0.00 68 1.00 03-Mar-2003 o 0.00 adeno 0.00 2 1.00 0 2.00 5.00 1 
65 1.00 73 1.00 26-Mar-2001 G 1.00 adeno 0.00 3 2.00 1 4.00 7.00 1 
66 1.00 77 2.00 24-Mar-2003 G 1.00 adeno 0.00 3 2.00 0 3.00 16.00 1 
67 0.00 68 1.00 20-Mar-2002 g 1.00 adeno 0.00 3 1.00 0 3.00 5.00 1 
68 0.00 76 2.00 03-May-2000 g 1.00 adeno 0.00 3 1.00 0 3.00 5.00 1 
69 1.00 63 0.00 06-May-1999 g 1.00 adeno 0.00 2 1.00 0 2.00 6.00 1 
70 0.00 65 1.00 09-May-2001 o 0.00 adeno 0.00 3 1.00 0 3.00 7.00 1 
71 0.00 65 1.00 17-May-2000 o 0.00 adeno 0.00 3 1.00 0 3.00 6.00 1 
72 1.00 67 1.00 01-Jun-2000 g 1.00 adeno 0.00 3 2.00 0 3.00 9.00 1 
73 0.00 62 0.00 21-May-2003 o 0.00 adeno 0.00 4 1.00 0 4.00 1.00 1 
74 0.00 66 1.00 11-Jun-2001 G 1.00 adeno 0.00 2 1.00 0 2.00 3.00 1 
75 1.00 77 2.00 17-May-2004 g 1.00 adeno 0.00 3 2.00 0 3.00 10.00 1 
76 0.00 60 0.00 30-Jun-1997 g 1.00 adeno 0.00 3 1.00 0 3.00 2.00 1 
77 0.00 56 0.00 21-Jun-2000 g 1.00 adeno 0.00 3 2.00 0 3.00 8.00 1 
78 1.00 66 1.00 22-Jul-1996 g 1.00 adeno 0.00 3 1.00 0 3.00 5.00 1 
79 0.00 68 1.00 03-Jun-2002 o 0.00 adeno 0.00 2 2.00 0 3.00 8.00 1 
80 0.00 46 0.00 26-Jun-2003 o 0.00 adeno 0.00 2 1.00 0 2.00 1.00 1 
81 0.00 68 1.00 24-Jun-2002 g 1.00 adeno 0.00 2 1.00 0 2.00 1.00 1 
82 0.00 63 0.00 19-Aug-1996 o 0.00 adeno 0.00 3 1.00 0 3.00 5.00 1 
83 0.00 62 0.00 26-Jun-2002 o 0.00 adeno 0.00 3 1.00 0 3.00 4.00 1 
84 0.00 44 0.00 09-Aug-2000 o 0.00 adeno 0.00 3 1.00 0 3.00 0.00 0 
85 1.00 48 0.00 03-Jul-2002 G 1.00 adeno 0.00 2 1.00 0 2.00 2.00 1 
86 1.00 88 2.00 12-Aug-1999 g 1.00 adeno 0.00 2 1.00 1 4.00 3.00 1 
Patient m0f1 age agecd dateop site positcd histolog typecd t n m tnmstcd posnodes Lymphcd 
58 1.00 59 0.00 14-Jan-2004 g 1.00 adeno 0.00 2 1.00 1 4.00 6.00 1.00 
59 0.00 56 0.00 15-Jan-2003 o 0.00 adeno 0.00 3 1.00 0 3.00 4.00 1.00 
60 0.00 67 1.00 24-Jan-2001 g 1.00 adeno 0.00 2 1.00 0 2.00 4.00 1.00 
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Patient m0f1 age agecd dateop site positcd histolog typecd t n m tnmstcd posnodes Lymphcd 
87 0.00 56 0.00 16-Aug-2000 o 0.00 adeno 0.00 3 1.00 0 3.00 3.00 1 
88 0.00 41 0.00 17-Aug-2000 G 1.00 adeno 0.00 3 1.00 0 3.00 5.00 1 
89 0.00 66 1.00 04-Aug-2003 o 0.00 adeno 0.00 3 1.00 0 3.00 2.00 1 
90 0.00 75 2.00 21-Aug-2000 o 0.00 adeno 0.00 3 1.00 0 3.00 4.00 1 
91 1.00 38 0.00 13-Aug-2003 0 0.00 adeno 0.00 3 1.00 0 3.00 10.00 1 
92 0.00 70 1.00 20-Aug-2003 g 1.00 adeno 0.00 3 1.00 0 3.00 1.00 1 
93 0.00 73 1.00 01-Aug-2002 o 0.00 adeno 0.00 3 1.00 0 3.00 1.00 1 
94 0.00 59 0.00 27-Aug-2003 o 0.00 adeno 0.00 3 1.00 0 3.00 7.00 1 
95 0.00 51 0.00 16-Sep-1998 g 1.00 adeno 0.00 3 1.00 0 3.00 2.00 1 
96 1.00 73 1.00 14-Aug-2002 o 0.00 adeno 0.00 2 1.00 0 2.00 2.00 1 
97 0.00 74 1.00 10-Sep-2003 g 1.00 adeno 0.00 3 2.00 0 3.00 9.00 1 
98 0.00 73 1.00 13-Oct-1999 g 1.00 adeno 0.00 3 2.00 0 3.00 9.00 1 
99 0.00 75 2.00 03-Sep-2002 g 1.00 adeno 0.00 3 1.00 0 3.00 4.00 1 
100 1.00 59 0.00 23-Oct-2000 o 0.00 adeno 0.00 3 1.00 0 3.00 6.00 1 
101 0.00 61 0.00 10-Nov-1999 o 0.00 adeno 0.00 3 1.00 0 2.00 1.00 1 
102 0.00 59 0.00 05-Dec-2001 G 1.00 adeno 0.00 3 1.00 0 3.00 2.00 1 
103 0.00 60 0.00 06-Oct-2004 g 1.00 adeno 0.00 3 1.00 0 3.00 2.00 1 
104 1.00 68 1.00 16-Jun-1997 G 1.00 ADE 0.00 3 1.00 0 3.00 2.00 1 
105 0.00 60 0.00 14-Apr-1999 o 0.00 adeno 0.00 2 0.00 0 2.00 0.00 0 
106 1.00 65 1.00 11-Oct-1999 o 0.00 squam 1.00 3 0.00 0 2.00 0.00 0 
107 0.00 74 1.00 03-Apr-2000 o 0.00 adeno 0.00 2 0.00 0 2.00 0.00 0 
108 0.00 54 0.00 05-Sep-2000 o 0.00 squam 1.00 3 0.00 0 2.00 0.00 0 
109 0.00 60 0.00 06-Nov-2000 g 1.00 adeno 0.00 2 0.00 0 1.00 0.00 0 
110 1.00 61 0.00 28-Nov-2001 o 0.00 squam 1.00 2 1.00 0 2.00 3.00 1 
111 1.00 70 1.00 25-Mar-2003 o 0.00 adeno 0.00 3 0.00 0 2.00 0.00 0 
112 0.00 34 0.00 22-Mar-2000 G 1.00 adeno 0.00 3 2.00 0 3.00 11.00 1 
113 1.00 74 1.00 28-Apr-1997 g 1.00 adeno 0.00 3 1.00 0 3.00 1.00 1 
114 0.00 58 0.00 03-May-2001 o 0.00 adeno 0.00 3 1.00 0 3.00 1.00 1 





Patient m0f1 age agecd dateop site positcd histolog typecd t n m tnmstcd posnodes Lymphcd 
116 1.00 65 1.00 09-Oct-1996 o/g 1.00 adeno 0.00 3 1.00 0 3.00 2.00 1 
117 0.00 64 0.00 05-Sep-2002 G 1.00 adeno 0.00 2 1.00 0 2.00 2.00 1 
118 1.00 78 2.00 11-Dec-1995 g 1.00 adeno 0.00 3 2.00 0 3.00 9.00 1 
119 0.00 71 1.00 16-Nov-2000 g 1.00 adeno 0.00 2 2.00 0 3.00 29.00 1 
120 0.00 68 1.00 31-Dec-1997 g 1.00 adeno 0.00 3 1.00 0 3.00 4.00 1 
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Patient totalnod nodratio Ratiocd r a0c1n2 doffu survmths crpgre5 crpfinal cfinalcd albfinal Albfincd 
1 9.00 0.00 0.00 0.00 1.00 07-Dec-2001 7.77 0.00 5.00 0.00   
2 5.00 0.00 0.00 0.00 1.00 12-Jan-2001 53.13 0.00 5.00 0.00 41.00 0.00 
3 27.00 0.11 1.00 0.00 0.00 28-Feb-2006 104.97 0.00 5.00 0.00 43.00 0.00 
4 20.00 0.00 0.00 1.00 1.00 28-Jul-2002 50.37 0.00 5.00 0.00 36.00 0.00 
5 10.00 0.00 0.00 0.00 1.00 29-Nov-2004 74.37 0.00 5.00 0.00 46.00 0.00 
6 22.00 0.00 0.00 0.00 0.00 28-Feb-2006 89.33 0.00 5.00 0.00 43.00 0.00 
7 17.00 0.00 0.00 0.00 0.00 28-Feb-2006 84.27 0.00 5.00 0.00 45.00 0.00 
8 28.00 0.25 2.00 0.00 1.00 16-Nov-2001 31.80 0.00 5.00 0.00 41.00 0.00 
9 14.00 0.14 1.00 0.00 1.00 14-Feb-2003 44.00 0.00 5.00 0.00 42.00 0.00 
10 19.00 0.00 0.00 0.00 0.00 28-Feb-2006 80.63 0.00 5.00 0.00 43.00 0.00 
11 16.00 0.25 2.00 0.00 1.00 29-Aug-2001 25.03 0.00 5.00 0.00 42.00 0.00 
12 35.00 0.14 1.00 1.00 0.00 28-Feb-2006 79.37 0.00 5.00 0.00 43.00 0.00 
13 13.00 0.08 1.00 0.00 1.00 09-Nov-1999 1.40 0.00 5.00 0.00 42.00 0.00 
14 20.00 0.25 2.00 0.00 1.00 20-Oct-2000 11.73 0.00 5.00 0.00 44.00 0.00 
15 10.00 0.00 0.00 0.00 0.00 28-Feb-2006 76.27 1.00 5.00 0.00 42.00 0.00 
16 18.00 0.06 1.00 0.00 0.00 28-Feb-2006 76.03 0.00 5.00 0.00 41.00 0.00 
17 34.00 0.00 0.00 0.00 0.00 28-Feb-2006 74.17 0.00 5.00 0.00 37.00 0.00 
18 12.00 0.00 0.00 0.00 0.00 28-Feb-2006 73.53 1.00 7.00 0.00 45.00 0.00 
19 16.00 0.00 0.00 0.00 0.00 28-Feb-2006 73.47 0.00 5.00 0.00 44.00 0.00 
20 11.00 0.18 1.00 0.00 0.00 28-Feb-2006 73.00 0.00 5.00 0.00 44.00 0.00 
21 14.00 0.00 0.00 0.00 0.00 28-Feb-2006 72.53 1.00 10.00 0.00 36.00 0.00 
22 25.00 0.00 0.00 0.00 0.00 28-Feb-2006 70.27 0.00 5.00 0.00 43.00 0.00 
23 16.00 0.00 0.00 0.00 0.00 28-Feb-2006 70.03 0.00 5.00 0.00 42.00 0.00 
24 21.00 0.00 0.00 0.00 0.00 28-Feb-2006 66.93 0.00 5.00 0.00 43.00 0.00 
25 23.00 0.00 0.00 0.00 0.00 28-Feb-2006 64.60 0.00 5.00 0.00 44.00 0.00 
26 0.00 0.00 0.00  1.00 16-Dec-2003 36.37 1.00 9.00 0.00 40.00 0.00 
27 17.00 0.00 0.00 0.00 0.00 28-Feb-2006 62.50 1.00 7.00 0.00 42.00 0.00 
28 21.00 0.00 0.00 0.00 0.00 28-Feb-2006 59.47 1.00 8.00 0.00 44.00 0.00 
29 30.00 0.03 1.00 0.00 0.00 28-Feb-2006 58.30 0.00 5.00 0.00 37.00 0.00 
 188 
 
Patient totalnod nodratio Ratiocd r a0c1n2 doffu survmths crpgre5 crpfinal cfinalcd albfinal albfincd 
30 0.00 0.00 0.00 0.00 1.00 31-Mar-2002 8.77 0.00 5.00 0.00 42.00 0.00 
31 15.00 0.07 1.00 0.00 1.00 31-Mar-2002 7.13 0.00 5.00 0.00 43.00 0.00 
32 20.00 0.35 2.00 0.00 1.00 08-Oct-2002 10.93 0.00 5.00 0.00 43.00 0.00 
33 19.00 0.00 0.00 0.00 0.00 28-Feb-2006 50.37 0.00 5.00 0.00 41.00 0.00 
34 33.00 0.00 0.00 0.00 0.00 28-Feb-2006 48.50 0.00 5.00 0.00 39.00 0.00 
35 10.00 0.00 0.00 0.00 0.00 28-Feb-2006 47.10 0.00 5.00 0.00 43.00 0.00 
36  0.00 0.00 0.00 0.00 28-Feb-2006 46.87 0.00 5.00 0.00 43.00 0.00 
37 9.00 0.00 0.00 0.00 0.00 28-Feb-2006 45.70 0.00 5.00 0.00 42.00 0.00 
38 22.00 0.00 0.00 0.00 0.00 28-Feb-2006 45.70 0.00 5.00 0.00 44.00 0.00 
39 20.00 0.00 0.00 0.00 0.00 28-Feb-2006 43.80 0.00 5.00 0.00 47.00 0.00 
40 34.00 0.00 0.00 0.00 0.00 28-Feb-2006 41.50 0.00 5.00 0.00 42.00 0.00 
41 9.00 0.00 0.00 0.00 1.00 13-Jul-2005 32.83 0.00 5.00 0.00 39.00 0.00 
42 8.00 0.00 0.00 0.00 0.00 28-Feb-2006 39.40 1.00 7.00 0.00 46.00 0.00 
43 21.00 0.00 0.00 0.00 0.00 28-Feb-2006 35.97 0.00 5.00 0.00 45.00 0.00 
44 16.00 0.00 0.00 0.00 1.00 18-Nov-2004 18.67 0.00 5.00 0.00 42.00 0.00 
45 3.00 0.00 0.00 0.00 0.00 28-Feb-2006 33.10 0.00 5.00 0.00 41.00 0.00 
46 18.00 0.06 1.00 1.00 0.00 28-Feb-2006 32.63 0.00 5.00 0.00 40.00 0.00 
47 27.00 0.04 1.00 0.00 0.00 28-Feb-2006 30.07 0.00 5.00 0.00 37.00 0.00 
48 13.00 0.00 0.00 0.00 0.00 28-Feb-2006 24.93 0.00 5.00 0.00 42.00 0.00 
49 22.00 0.00 0.00 0.00 1.00 13-Sep-2004 4.83 0.00 5.00 0.00 42.00 0.00 
50 14.00 0.07 1.00 0.00 0.00 28-Feb-2006 22.37 0.00 5.00 0.00 39.00 0.00 
51 29.00 0.00 0.00 0.00 1.00 25-Nov-2004 6.63 0.00 5.00 0.00 42.00 0.00 
52 27.00 0.00 0.00 0.00 0.00 28-Feb-2006 21.90 0.00 5.00 0.00 44.00 0.00 
53 29.00 0.03 1.00 0.00 0.00 28-Feb-2006 20.70 1.00 8.00 0.00 36.00 0.00 
54 8.00 0.00 0.00 0.00 0.00 28-Feb-2006 20.27 0.00 5.00 0.00 45.00 0.00 
55 35.00 0.00 0.00 0.00 0.00 28-Feb-2006 18.63 0.00 5.00 0.00 46.00 0.00 
56 37.00 0.22 2.00 1.00 1.00 10-Dec-2005 11.77 0.00 5.00 0.00 49.00 0.00 
57 21.00 0.10 1.00 0.00 2.00 12-Feb-1998 1.20 0.00 5.00 0.00 38.00 0.00 
58 18.00 0.33 2.00 1.00 1.00 06-Jun-2004 4.80 1.00 7.00 0.00 37.00 0.00 
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61 32.00 0.13 1.00 0.00 1.00 10-Aug-2004 6.27 0.00 5.00 0.00 41.00 0.00 
62 24.00 0.21 2.00 1.00 0.00 28-Feb-2006 49.27 0.00 5.00 0.00 42.00 0.00 
63 40.00 0.18 1.00 1.00 1.00 24-Sep-2005 91.87 0.00 5.00 0.00 44.00 0.00 
64 17.00 0.29 2.00 0.00 0.00 28-Feb-2006 36.43 0.00 5.00 0.00 43.00 0.00 
65 16.00 0.44 2.00 1.00 1.00 26-Aug-2001 5.10 1.00 8.00 0.00 35.00 0.00 
66 43.00 0.37 2.00 0.00 1.00 01-Sep-2003 5.37 0.00 5.00 0.00 41.00 0.00 
67 15.00 0.33 2.00 0.00 1.00 22-Mar-2003 12.23 1.00 9.00 0.00 45.00 0.00 
68 16.00 0.31 2.00 0.00 1.00 30-Apr-2001 12.07 0.00 5.00 0.00 40.00 0.00 
69 17.00 0.35 2.00 0.00 0.00 28-Feb-2006 83.00 0.00 5.00 0.00 37.00 0.00 
70 28.00 0.25 2.00 1.00 0.00 28-Feb-2006 58.53 0.00 5.00 0.00 40.00 0.00 
71 39.00 0.15 1.00 1.00 1.00 16-Nov-2001 18.27 0.00 5.00 0.00 43.00 0.00 
72 25.00 0.36 2.00 0.00 1.00 08-Feb-2001 8.40 0.00 5.00 0.00 39.00 0.00 
73 34.00 0.03 1.00 1.00 0.00 28-Feb-2006 33.80 0.00 5.00 0.00 40.00 0.00 
74 22.00 0.14 1.00 0.00 1.00 18-Aug-2002 14.43 0.00 5.00 0.00 43.00 0.00 
75 39.00 0.26 2.00 0.00 0.00 28-Feb-2006 21.73 0.00 5.00 0.00 37.00 0.00 
76 17.00 0.12 1.00 0.00 0.00 28-Feb-2006 105.50 0.00 5.00 0.00 43.00 0.00 
77 37.00 0.22 2.00 0.00 1.00 01-Jan-2005 55.17 1.00 9.00 0.00 38.00 0.00 
78 23.00 0.22 2.00 0.00 0.00 28-Feb-2006 116.93 0.00 5.00 0.00 43.00 0.00 
79 15.00 0.53 2.00 0.00 1.00 13-Nov-2003 17.60 0.00 5.00 0.00 41.00 0.00 
80 16.00 0.06 1.00 0.00 0.00 28-Feb-2006 32.60 0.00 5.00 0.00 48.00 0.00 
81 27.00 0.04 1.00 0.00 0.00 28-Feb-2006 44.83 1.00 7.00 0.00 44.00 0.00 
82 24.00 0.21 2.00 1.00 1.00 20-Feb-2003 79.20 1.00 9.00 0.00 43.00 0.00 
83 13.00 0.31 2.00 0.00 1.00 10-Sep-2003 14.70 1.00 8.00 0.00 46.00 0.00 
84 32.00 0.00 0.00 0.00 0.00 28-Feb-2006 67.63 0.00 5.00 0.00 46.00 0.00 
85 14.00 0.14 1.00 0.00 0.00 28-Feb-2006 44.53 0.00 5.00 0.00 45.00 0.00 
86 11.00 0.27 2.00 1.00 1.00 05-Aug-2000 11.97 0.00 5.00 0.00 36.00 0.00 
87 35.00 0.09 1.00 0.00 0.00 28-Feb-2006 67.40 0.00 5.00 0.00 41.00 0.00 
Patient totalnod nodratio Ratiocd r a0c1n2 doffu survmths crpgre5 crpfinal cfinalcd albfinal albfincd 
59 33.00 0.12 1.00 1.00 0.00 28-Feb-2006 38.00 0.00 5.00 0.00 47.00 0.00 
60 17.00 0.24 2.00 0.00 0.00 28-Feb-2006 62.03 0.00 5.00 0.00 41.00 0.00 
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Patient totalnod nodratio Ratiocd r a0c1n2 doffu survmths crpgre5 crpfinal cfinalcd albfinal albfincd 
88 35.00 0.14 1.00 0.00 0.00 28-Feb-2006 67.37 0.00 5.00 0.00 46.00 0.00 
89 18.00 0.11 1.00 0.00 0.00 28-Feb-2006 31.30 0.00 5.00 0.00 43.00 0.00 
90 30.00 0.13 1.00 0.00 1.00 04-Feb-2002 17.73 0.00 5.00 0.00 40.00 0.00 
91 15.00 0.67 2.00 1.00 2.00 19-Jul-2005 23.53 0.00 5.00 0.00 38.00 0.00 
92 22.00 0.05 1.00 0.00 1.00 25-Mar-2004 7.27 1.00 9.00 0.00 37.00 0.00 
93 33.00 0.03 1.00 0.00 1.00 07-Jan-2005 29.67 0.00 5.00 0.00 44.00 0.00 
94 19.00 0.37 2.00 0.00 1.00 18-Apr-2005 20.00 0.00 5.00 0.00 43.00 0.00 
95 38.00 0.05 1.00 0.00 0.00 28-Feb-2006 90.73 0.00 5.00 0.00 44.00 0.00 
96 19.00 0.11 1.00 0.00 1.00 06-Nov-2003 14.97 0.00 5.00 0.00 48.00 0.00 
97 19.00 0.47 2.00 0.00 1.00 15-Dec-2005 27.57 0.00 5.00 0.00 39.00 0.00 
98 32.00 0.28 2.00 0.00 1.00 14-Dec-2003 50.77 0.00 5.00 0.00 44.00 0.00 
99 55.00 0.07 1.00 0.00 1.00 30-Jan-2004 17.13 0.00 5.00 0.00 41.00 0.00 
100 26.00 0.23 2.00 0.00 1.00 22-Jun-2001 8.07 0.00 5.00 0.00 44.00 0.00 
101 13.00 0.08 1.00 0.00 1.00 01-Aug-2002 33.17 1.00 7.00 0.00 42.00 0.00 
102 20.00 0.10 1.00 0.00 0.00 28-Feb-2006 51.53 1.00 8.00 0.00 46.00 0.00 
103 23.00 0.09 1.00 0.00 0.00 28-Feb-2006 17.00 0.00 5.00 0.00 41.00 0.00 
104 25.00 0.08 1.00 0.00 1.00 08-Dec-1999 30.17 1.00 11.00 1.00 38.00 0.00 
105 16.00 0.00 0.00 0.00 0.00 28-Feb-2006 83.73 0.00 5.00 0.00 31.00 1.00 
106 7.00 0.00 0.00 0.00 1.00 22-Jun-2002 32.83 1.00 14.00 1.00 45.00 0.00 
107 44.00 0.00 0.00 0.00 0.00 28-Feb-2006 71.90 1.00 11.00 1.00 37.00 0.00 
108 17.00 0.00 0.00 0.00 1.00 22-Jul-2001 10.67 1.00 19.00 1.00 42.00 0.00 
109 24.00 0.00 0.00 0.00 1.00 22-Sep-2001 10.67 1.00 36.00 1.00 37.00 0.00 
110 26.00 0.12 1.00 0.00 1.00 14-Jul-2003 19.77 1.00 12.00 1.00 46.00 0.00 
111 12.00 0.00 0.00 1.00 1.00 26-Oct-2004 19.37 1.00 19.00 1.00 44.00 0.00 
112 15.00 0.73 2.00 0.00 1.00 04-Aug-2001 16.67 1.00 12.00 1.00 44.00 0.00 
113 15.00 0.07 1.00 0.00 1.00 08-Oct-1999 29.77 1.00 21.00 1.00 36.00 0.00 
114 13.00 0.08 1.00 1.00 1.00 06-Mar-2002 10.23 1.00 179.00 1.00 40.00 0.00 
115 10.00 0.40 2.00 0.00 1.00 23-May-2002 11.90 0.00 5.00 0.00 34.00 1.00 
116 20.00 0.10 1.00 0.00 1.00 18-Feb-1998 16.57 1.00 22.00 1.00 43.00 0.00 
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Patient totalnod nodratio Ratiocd r a0c1n2 doffu survmths crpgre5 crpfinal cfinalcd albfinal albfincd 
117 19.00 0.11 1.00 0.00 1.00 18-Jun-2003 9.53 1.00 19.00 1.00 35.00 0.00 
118 10.00 0.90 2.00 1.00 1.00 15-Aug-1997 20.43 1.00 14.00 1.00 38.00 0.00 
119 34.00 0.85 2.00 0.00 1.00 27-Oct-2001 11.50 1.00 17.00 1.00 38.00 0.00 





Patient wcc wcccd hb hbcd plts pltscd neut lymph lymper lympercd nlr nlrcd 
1 5.80 0.00 13.20 0.00 229.00 0.00 3.50 1.80 31.03 0.00 1.94 0.00 
2 6.70 0.00 13.50 0.00 165.00 0.00 3.90 2.20 32.84 0.00 1.77 0.00 
3 8.60 1.00 13.30 0.00 416.00 1.00 6.00 2.00 23.26 0.00 3.00 0.00 
4 8.70 1.00 15.70 0.00 332.00 0.00 6.00 2.10 24.14 0.00 2.86 0.00 
5 13.40 2.00 13.80 0.00 302.00 0.00 10.50 1.90 14.18 1.00 5.53 1.00 
6 5.30 0.00 13.50 0.00 204.00 0.00 3.40 1.30 24.53 0.00 2.62 0.00 
7 6.20 0.00 16.30 0.00 188.00 0.00 3.90 1.60 25.81 0.00 2.44 0.00 
8 9.00 1.00 15.70 0.00 291.00 0.00 5.20 2.90 32.22 0.00 1.79 0.00 
9 6.60 0.00 13.30 0.00 254.00 0.00 4.50 1.30 19.70 1.00 3.46 0.00 
10 5.90 0.00 12.80 0.00 279.00 0.00 2.40 2.80 47.46 0.00 0.86 0.00 
11 7.80 0.00 17.50 0.00 230.00 0.00 5.90 1.50 19.23 1.00 3.93 0.00 
12 5.30 0.00 12.10 0.00 290.00 0.00 3.40 1.50 28.30 0.00 2.27 0.00 
13 5.70 0.00 13.60 0.00 272.00 0.00 3.50 1.60 28.07 0.00 2.19 0.00 
14             
15 9.80 1.00 16.00 0.00 351.00 0.00 6.90 2.20 22.45 0.00 3.14 0.00 
16 6.10 0.00 15.60 0.00 232.00 0.00 3.60 2.00 32.79 0.00 1.80 0.00 
17 10.30 1.00 14.50 0.00   7.90 1.50 14.56 1.00 5.27 1.00 
18 8.40 0.00 13.00 0.00 300.00 0.00 5.80 2.00 23.81 0.00 2.90 0.00 
19 7.50 0.00 12.80 0.00 195.00 0.00 4.30 2.30 30.67 0.00 1.87 0.00 
20 5.90 0.00 13.30 0.00 410.00 1.00 3.50 1.80 30.51 0.00 1.94 0.00 
21 6.00 0.00 11.50 1.00 338.00 0.00 3.90 1.70 28.33 0.00 2.29 0.00 
22 5.50 0.00 15.40 0.00 218.00 0.00 3.40 1.40 25.45 0.00 2.43 0.00 
23 6.10 0.00 11.80 1.00 251.00 0.00 3.40 2.30 37.70 0.00 1.48 0.00 
24 8.20 0.00 15.90 0.00 224.00 0.00 5.00 2.20 26.83 0.00 2.27 0.00 
25 5.70 0.00 15.40 0.00 162.00 0.00 3.60 1.60 28.07 0.00 2.25 0.00 
26 11.40 2.00 11.10 1.00 515.00 1.00 5.50 4.20 36.84 0.00 1.31 0.00 
27 7.60 0.00 14.30 0.00 182.00 0.00 3.80 2.90 38.16 0.00 1.31 0.00 
28 9.00 1.00 7.20 1.00 467.00 1.00 5.80 2.40 26.67 0.00 2.42 0.00 
29 7.80 0.00 15.20 0.00 227.00 0.00 5.10 1.80 23.08 0.00 2.83 0.00 
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Patient wcc wcccd hb hbcd plts pltscd neut lymph lymper lympercd nlr nlrcd 
30 7.80 0.00 14.30 0.00 319.00 0.00 3.90 2.80 35.90 0.00 1.39 0.00 
31 7.10 0.00 13.70 0.00 227.00 0.00 4.80 1.80 25.35 0.00 2.67 0.00 
32 7.20 0.00 15.10 0.00 151.00 0.00 4.30 2.30 31.94 0.00 1.87 0.00 
33 5.20 0.00 14.30 0.00 281.00 0.00 2.90 1.50 28.85 0.00 1.93 0.00 
34 9.40 1.00 15.40 0.00 343.00 0.00 5.60 2.30 24.47 0.00 2.43 0.00 
35 9.30 1.00 11.10 1.00 344.00 0.00 6.20 2.00 21.51 0.00 3.10 0.00 
36 7.10 0.00 13.10 0.00 234.00 0.00 4.80 1.80 25.35 0.00 2.67 0.00 
37 6.50 0.00 13.80 0.00 239.00 0.00 4.30 1.40 21.54 0.00 3.07 0.00 
38 10.30 1.00 13.00 0.00 301.00 0.00 6.80 2.50 24.27 0.00 2.72 0.00 
39 6.80 0.00 14.00 0.00 318.00 0.00 3.20 2.90 42.65 0.00 1.10 0.00 
40 10.00 1.00 14.10 0.00 244.00 0.00 6.70 2.60 26.00 0.00 2.58 0.00 
41 8.90 1.00 11.00 1.00 357.00 0.00 5.70 2.00 22.47 0.00 2.85 0.00 
42 7.60 0.00 15.00 0.00 352.00 0.00 5.20 1.60 21.05 0.00 3.25 0.00 
43             
44 5.40 0.00 14.40 0.00 306.00 0.00 2.50 2.20 40.74 0.00 1.14 0.00 
45 9.50 1.00 15.70 0.00 110.00 0.00 5.10 3.30 34.74 0.00 1.55 0.00 
46 5.10 0.00 12.60 0.00 359.00 0.00 3.50 1.20 23.53 0.00 2.92 0.00 
47 11.60 2.00 10.00 1.00 343.00 0.00 9.80 0.70 6.03 2.00 14.00 1.00 
48 8.80 1.00 13.80 0.00 299.00 0.00 5.80 2.40 27.27 0.00 2.42 0.00 
49 5.30 0.00 12.20 0.00 274.00 0.00 3.30 1.30 24.53 0.00 2.54 0.00 
50 6.20 0.00 14.40 0.00 244.00 0.00 4.10 1.50 24.19 0.00 2.73 0.00 
51 7.90 0.00 4.10 1.00 319.00 0.00 4.90 2.30 29.11 0.00 2.13 0.00 
52 6.70 0.00 12.10 0.00 374.00 0.00 4.40 1.80 26.87 0.00 2.44 0.00 
53 5.60 0.00 9.90 1.00 184.00 0.00 4.70 0.40 7.14 2.00 11.75 1.00 
54 5.40 0.00 15.80 0.00 190.00 0.00 3.70 1.10 20.37 0.00 3.36 0.00 
55 9.30 1.00 15.30 0.00 224.00 0.00 6.30 2.40 25.81 0.00 2.63 0.00 
56 9.30 1.00 13.50 0.00 316.00 0.00 5.70 2.70 29.03 0.00 2.11 0.00 
57 7.90 0.00 14.00 0.00 170.00 0.00 4.70 2.40 30.38 0.00 1.96 0.00 
58 6.00 0.00 8.60 1.00 488.00 1.00 4.00 1.50 25.00 0.00 2.67 0.00 
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Patient wcc wcccd hb hbcd plts pltscd neut lymph lymper lympercd nlr nlrcd 
59 8.50 1.00 15.40 0.00 229.00 0.00 6.60 1.10 12.94 1.00 6.00 1.00 
60 7.20 0.00 16.90 0.00 211.00 0.00 5.40 1.40 19.44 1.00 3.86 0.00 
61 6.30 0.00 9.00 1.00 241.00 0.00 3.60 1.90 30.16 0.00 1.89 0.00 
62 12.00 2.00 14.30 0.00 451.00 1.00 9.20 2.30 19.17 1.00 4.00 0.00 
63 4.90 0.00 13.00 0.00 196.00 0.00 2.40 2.00 40.82 0.00 1.20 0.00 
64 7.00 0.00 14.40 0.00 184.00 0.00 4.80 1.60 22.86 0.00 3.00 0.00 
65 7.50 0.00 14.10 0.00 208.00 0.00 5.00 1.60 21.33 0.00 3.13 0.00 
66 5.70 0.00 13.80 0.00 220.00 0.00 3.50 1.40 24.56 0.00 2.50 0.00 
67 5.40 0.00 15.00 0.00 214.00 0.00 3.60 1.20 22.22 0.00 3.00 0.00 
68 7.10 0.00 14.90 0.00 232.00 0.00 4.30 1.90 26.76 0.00 2.26 0.00 
69 4.90 0.00 10.20 1.00 370.00 0.00 2.60 1.80 36.73 0.00 1.44 0.00 
70 6.30 0.00 14.20 0.00 321.00 0.00 4.10 1.30 20.63 0.00 3.15 0.00 
71 6.20 0.00 10.80 1.00 279.00 0.00 3.40 2.20 35.48 0.00 1.55 0.00 
72 8.40 0.00 14.40 0.00 217.00 0.00 5.00 2.30 27.38 0.00 2.17 0.00 
73 7.60 0.00 14.60 0.00 306.00 0.00 5.10 1.40 18.42 1.00 3.64 0.00 
74 5.50 0.00 15.60 0.00 174.00 0.00 3.40 1.40 25.45 0.00 2.43 0.00 
75 7.60 0.00 11.30 1.00 373.00 0.00 4.90 1.70 22.37 0.00 2.88 0.00 
76 5.60 0.00 14.60 0.00 199.00 0.00 3.60 1.30 23.21 0.00 2.77 0.00 
77 11.40 2.00 13.10 0.00 370.00 0.00 7.80 2.30 20.18 0.00 3.39 0.00 
78 9.90 1.00 13.80 0.00 391.00 0.00 5.90 2.80 28.28 0.00 2.11 0.00 
79 6.00 0.00 14.70 0.00 318.00 0.00 4.30 1.00 16.67 1.00 4.30 0.00 
80 4.10 0.00 8.30 1.00 284.00 0.00 2.50 1.00 24.39 0.00 2.50 0.00 
81 8.70 1.00 14.40 0.00 292.00 0.00 6.10 1.60 18.39 1.00 3.81 0.00 
82 14.90 2.00 15.10 0.00 361.00 0.00 12.10 2.10 14.09 1.00 5.76 1.00 
83 6.90 0.00 14.90 0.00 201.00 0.00 4.50 1.50 21.74 0.00 3.00 0.00 
84 7.20 0.00 15.40 0.00 257.00 0.00 4.70 1.90 26.39 0.00 2.47 0.00 
85 8.70 1.00 12.90 0.00 343.00 0.00 5.30 2.80 32.18 0.00 1.89 0.00 
86 8.20 0.00 16.50 0.00 284.00 0.00 5.20 2.10 25.61 0.00 2.48 0.00 
87 6.90 0.00 14.30 0.00 231.00 0.00 4.20 2.00 28.99 0.00 2.10 0.00 
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Patient wcc wcccd hb hbcd plts pltscd neut lymph lymper lympercd nlr nlrcd 
88 6.20 0.00 13.60 0.00 347.00 0.00 4.10 1.50 24.19 0.00 2.73 0.00 
89 8.90 1.00 13.90 0.00 260.00 0.00 5.70 1.80 20.22 0.00 3.17 0.00 
90 7.00 0.00 14.70 0.00 288.00 0.00 4.70 1.60 22.86 0.00 2.94 0.00 
91 5.20 0.00 13.60 0.00 156.00 0.00 2.70 2.10 40.38 0.00 1.29 0.00 
92 5.10 0.00 13.90 0.00 257.00 0.00 2.80 1.80 35.29 0.00 1.56 0.00 
93 5.70 0.00 16.00 0.00 212.00 0.00 3.00 2.00 35.09 0.00 1.50 0.00 
94 7.00 0.00 15.20 0.00 282.00 0.00 4.20 1.80 25.71 0.00 2.33 0.00 
95 9.00 1.00 15.90 0.00 231.00 0.00 4.80 2.80 31.11 0.00 1.71 0.00 
96 10.80 1.00 11.00 1.00 233.00 0.00 7.00 3.20 29.63 0.00 2.19 0.00 
97 6.80 0.00 9.80 1.00 389.00 0.00 4.10 1.80 26.47 0.00 2.28 0.00 
98 9.40 1.00 15.30 0.00 308.00 0.00 6.60 1.90 20.21 0.00 3.47 0.00 
99 8.70 1.00 12.70 0.00 398.00 0.00 5.90 2.00 22.99 0.00 2.95 0.00 
100 12.30 2.00 14.10 0.00 326.00 0.00 8.30 3.10 25.20 0.00 2.68 0.00 
101 6.60 0.00 12.60 0.00 334.00 0.00 3.40 2.40 36.36 0.00 1.42 0.00 
102 9.00 1.00 15.90 0.00 338.00 0.00 6.30 1.90 21.11 0.00 3.32 0.00 
103 7.80 0.00 14.80 0.00 333.00 0.00 5.40 1.60 20.51 0.00 3.38 0.00 
104 9.70 1.00 10.90 1.00 441.00 1.00 6.70 2.10 21.65 0.00 3.19 0.00 
105 7.00 0.00 12.70 0.00 311.00 0.00 4.50 2.00 28.57 0.00 2.25 0.00 
106 7.40 0.00 12.40 0.00 246.00 0.00 4.60 2.00 27.03 0.00 2.30 0.00 
107 8.00 0.00 10.70 1.00 273.00 0.00 4.70 2.20 27.50 0.00 2.14 0.00 
108 12.50 2.00 12.40 0.00 236.00 0.00 9.90 1.80 14.40 1.00 5.50 1.00 
109 6.70 0.00 10.80 1.00 268.00 0.00 5.20 0.70 10.45 2.00 7.43 1.00 
110 9.00 1.00 14.30 0.00 299.00 0.00 7.20 1.20 13.33 1.00 6.00 1.00 
111 8.00 0.00 11.90 1.00 216.00 0.00 6.00 1.40 17.50 1.00 4.29 0.00 
112 8.00 0.00 15.80 0.00 262.00 0.00 5.20 2.00 25.00 0.00 2.60 0.00 
113 7.10 0.00 10.70 1.00 288.00 0.00 5.50 1.10 15.49 1.00 5.00 1.00 
114 19.60 2.00 14.40 0.00 252.00 0.00 17.80 0.70 3.57 2.00 25.43 1.00 
115 5.00 0.00 12.20 0.00 364.00 0.00 3.20 1.30 26.00 0.00 2.46 0.00 
116 10.20 1.00 13.90 0.00 294.00 0.00 7.20 2.20 21.57 0.00 3.27 0.00 
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Patient wcc wcccd hb hbcd plts pltscd neut lymph lymper lympercd nlr nlrcd 
117 9.90 1.00 9.20 1.00 284.00 0.00 7.20 2.00 20.20 0.00 3.60 0.00 
118 8.30 0.00 13.50 0.00 327.00 0.00 6.30 1.50 18.07 1.00 4.20 0.00 
119 9.70 1.00 14.70 0.00 299.00 0.00 7.20 1.40 14.43 1.00 5.14 1.00 




APPENDIX 2: DATABASE FOR CHAPTER 3: 
THE RELATIONSHIP BETWEEN THE SYSTEMIC 
INFLAMMATORY RESPONSE, TUMOUR PROLIFERATIVE 
ACTIVITY, LEUCOCYTE AND MACROPHAGE INFILTRATION 
AND SURVIVAL IN PATIENTS SELECTED FOR POTENTIALLY 





Patient m0f1 ki67ac ki67cd Ki67mh klinjjg klinac klincd cd68 cd68ter cd68suma age agecd dateop posi positcd histolog typecd 
1 1.00 0.00 0.00 1.00 1.00 1.00 59 0.00 14-Jan-2004 g 1.00 Adeno 0.00 
2 1.00 0.30 0.00 1.00 1.00 1.00 65 1.00 08-May-2003 g 1.00 Adeno 0.00 
3 0.00 2.80 1.00 1.00 1.00 1.00 52 0.00 10-May-2004 g 1.00 Adeno 0.00 
4 0.00 4.50 1.00 1.00 1.00 1.00 61 0.00 22-May-2000 g 1.00 Adeno 0.00 
5 1.00 4.80 2.00 1.00 1.00 1.00 61 0.00 28-Nov-2001 o 0.00 squam 1.00 
6 1.00 0.00 0.00 1.00 1.00 1.00 0.20 0.00 59 0.00 23-Oct-2000 o 0.00 Adeno 0.00 
7 1.00 1.40 0.00 1.00 1.00 1.00 0.20 0.00 74 1.00 28-Apr-1997 g 1.00 Adeno 0.00 
8 1.00 3.00 1.00 1.00 1.00 1.00 0.30 0.00 73 1.00 26-Mar-2001 G 1.00 Adeno 0.00 
9 1.00 1.30 0.00 1.00 1.00 1.00 0.40 0.00 65 1.00 09-Oct-1996 o/g 1.00 Adeno 0.00 
10 0.00 0.00 0.00 2.00 3.00 0.00 0.60 0.00 73 1.00 01-Aug-2002 o 0.00 Adeno 0.00 
11 0.00 0.40 0.00 1.00 1.00 1.00 0.70 0.00 71 1.00 16-Nov-2000 g 1.00 Adeno 0.00 
12 0.00 15.00 2.00 1.00 1.00 1.00 0.70 0.00 4.00 70 1.00 20-Aug-2003 g 1.00 Adeno 0.00 
13 0.00 2.40 1.00 1.00 1.00 1.00 1.00 0.00 2.60 77 2.00 01-Sep-1996 g 1.00 Adeno 0.00 
14 1.00 5.10 2.00 1.00 1.00 1.00 1.10 0.00 77 2.00 24-Mar-2003 G 1.00 Adeno 0.00 
15 1.00 0.00 0.00 1.00 0.00 1.00 1.20 0.00 66 1.00 22-Jul-1996 g 1.00 Adeno 0.00 
16 1.00 2.70 1.00 1.00 1.00 1.00 1.20 0.00 77 2.00 17-May-2004 g 1.00 Adeno 0.00 
17 0.00 14.30 2.00 1.00 1.00 1.00 1.20 0.00 49 0.00 09-Aug-1999 o 0.00 squam 1.00 
18 0.00 33.70 2.00 1.00 1.00 1.00 1.20 0.00 4.50 54 0.00 05-Sep-2000 o 0.00 squam 1.00 
19 1.00 3.30 1.00 1.00 1.00 1.00 1.30 0.00 38 0.00 13-Aug-2003 0 0.00 Adeno 0.00 
20 1.00 3.50 1.00 1.00 1.00 1.00 1.50 0.00 3.50 73 1.00 28-Oct-1998 o 0.00 Adeno 0.00 
21 0.00 39.00 2.00 1.00 1.00 1.00 1.50 0.00 52 0.00 11-Feb-2002 o 0.00 Adeno 0.00 
22 0.00 0.60 0.00 1.00 1.00 1.00 1.60 0.00 70 1.00 01-Nov-2002 g 1.00 Adeno 0.00 
23 1.00 4.80 2.00 1.00 1.00 1.00 1.60 0.00 58 0.00 16-Jul-1999 o 0.00 Adeno 0.00 
24 0.00 4.50 1.00 2.00 1.00 1.00 1.70 0.00 72 1.00 21-Oct-1998 g 1.00 Adeno 0.00 
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Patient m0f1 ki67ac ki67cd Ki67mh klinjjg klinac klincd cd68 cd68ter cd68suma age agecd dateop posi positcd histolog typecd 
25 0.00 6.90 2.00 13.50 1.00 1.00 1.00 1.70 0.00 70 1.00 17-Apr-2002 g 1.00 Adeno 0.00 
26 0.00 1.30 0.00 2.00 2.00 0.00 1.80 0.00 71 1.00 24-Nov-1999 o 0.00 squam 1.00 
27 0.00 0.00 0.00 1.00 1.00 1.00 1.90 0.00 75 2.00 08-Nov-2000 G 1.00 Adeno 0.00 
28 1.00 0.00 0.00 1.00 1.00 1.00 1.90 0.00 4.00 67 1.00 01-Jun-2000 g 1.00 Adeno 0.00 
29 0.00 5.30 2.00 1.00 2.00 0.00 2.00 0.00 68 1.00 02-Oct-2002 o 0.00 Adeno 0.00 
30 1.00 8.20 2.00 1.00 1.00 1.00 2.00 0.00 4.00 71 1.00 12-May-2004 o 0.00 squam 1.00 
31 0.00 12.30 2.00 1.00 1.00 1.00 2.10 0.00 47 0.00 30-Aug-2000 o 0.00 Adeno 0.00 
32 1.00 2.20 1.00 1.00 1.00 1.00 2.20 0.00 41 0.00 14-Nov-2001 g 1.00 Adeno 0.00 
33 0.00 0.00 0.00 1.00 1.00 1.00 2.30 0.00 7.60 48 0.00 01-Dec-1999 g 1.00 Adeno 0.00 
34 1.00 0.00 0.00 2.00 2.00 0.00 2.30 0.00 65 1.00 11-Oct-1999 o 0.00 squam 1.00 
35 1.00 3.00 1.00 1.00 1.00 1.00 2.30 0.00 4.00 34 0.00 16-Jul-1997 G 1.00 AD 0.00 
36 0.00 0.10 0.00 1.00 1.00 1.00 2.40 1.00 46 0.00 26-Jun-2003 o 0.00 Adeno 0.00 
37 1.00 1.80 1.00 1.00 1.00 1.00 2.40 1.00 67 1.00 28-Sep-1999 o 0.00 squam 1.00 
38 0.00 4.90 2.00 10.90 1.00 1.00 1.00 2.40 1.00 59 0.00 29-May-2002 g 1.00 Adeno 0.00 
39 1.00 23.90 2.00 29.60 1.00 1.00 1.00 2.40 1.00 72 1.00 11-Apr-2001 G 1.00 Adeno 0.00 
40 0.00 18.70 2.00 15.40 1.00 1.00 1.00 2.50 1.00 64 0.00 06-Mar-2002 o 0.00 Adeno 0.00 
41 0.00 3.40 1.00 1.00 1.00 1.00 2.60 1.00 60 0.00 09-Mar-1998 o 0.00 Adeno 0.00 
42 0.00 4.90 2.00 7.80 2.00 2.00 0.00 2.60 1.00 60 0.00 14-Apr-1999 o 0.00 Adeno 0.00 
43 0.00 1.20 0.00 1.00 1.00 1.00 3.10 1.00 58 0.00 28-Apr-2004 o 0.00 squam 1.00 
44 0.00 5.40 2.00 1.00 1.00 1.00 3.10 1.00 62 0.00 21-May-2003 o 0.00 Adeno 0.00 
45 0.00 5.60 2.00 1.00 1.00 1.00 3.10 1.00 34 0.00 22-Mar-2000 G 1.00 Adeno 0.00 
46 0.00 17.30 2.00 1.00 1.00 1.00 3.20 1.00 14.00 51 0.00 22-Dec-2004 o 0.00 squam 1.00 
47 1.00 25.50 2.00 1.00 1.00 1.00 3.20 1.00 69 1.00 14-Feb-2000 o 0.00 squam 1.00 
48 1.00 0.20 0.00 1.00 1.00 1.00 4.00 1.00 4.00 63 0.00 06-May-1999 g 1.00 Adeno 0.00 
49 0.00 0.30 0.00 1.00 1.00 1.00 4.50 1.00 66 1.00 04-Aug-2003 o 0.00 Adeno 0.00 
50 1.00 8.60 2.00 1.00 1.00 1.00 4.70 1.00 80 2.00 11-Feb-2004 o 0.00 Adeno 0.00 
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Patient m0f1 ki67ac ki67cd Ki67mh klinjjg klinac klincd cd68 cd68ter cd68suma age agecd dateop posi positcd histolog typecd 
51 1.00 0.50 0.00 1.00 1.00 1.00 5.00 1.00 6.00 46 0.00 17-Jun-2004 o 0.00 squam 1.00 
52 0.00 4.70 2.00 1.00 1.00 1.00 5.00 1.00 52 0.00 11-Jul-2001 G 1.00 Adeno 0.00 
53 0.00 5.70 2.00 1.00 1.00 1.00 5.00 1.00 5.00 56 0.00 15-Jan-2003 o 0.00 Adeno 0.00 
54 0.00 0.60 0.00 4.30 2.00 2.00 0.00 5.00 1.00 22.00 60 0.00 06-Nov-2000 g 1.00 Adeno 0.00 
55 0.00 1.50 1.00 3.00 2.00 0.00 5.20 1.00 13.00 74 1.00 26-Jan-2000 o 0.00 squam 1.00 
56 0.00 0.00 0.00 1.00 1.00 1.00 5.30 1.00 63 0.00 19-Aug-1996 o 0.00 Adeno 0.00 
57 0.00 2.90 1.00 2.00 2.00 0.00 5.40 1.00 14.00 61 0.00 04-Dec-2002 o 0.00 Adeno 0.00 
58 0.00 9.90 2.00 3.00 3.00 0.00 5.40 1.00 10.00 59 0.00 29-Mar-1999 g 1.00 Adeno 0.00 
59 0.00 4.40 1.00 1.00 1.00 1.00 5.50 1.00 62 0.00 26-Jun-2002 o 0.00 Adeno 0.00 
60 0.00 2.70 1.00 2.00 2.00 0.00 5.60 1.00 69 1.00 04-Feb-2004 o 0.00 Adeno 0.00 
61 0.00 1.50 1.00 1.00 1.00 1.00 5.70 1.00 7.00 63 0.00 18-Apr-2001 o 0.00 squam 1.00 
62 0.00 1.60 1.00 6.00 1.00 1.00 1.00 5.80 1.00 71 1.00 16-May-2001 g 1.00 Adeno 0.00 
63 1.00 0.90 0.00 1.00 1.00 1.00 5.90 1.00 5.00 70 1.00 25-Mar-2003 o 0.00 Adeno 0.00 
64 1.00 3.20 1.00 1.00 1.00 1.00 5.90 1.00 58 0.00 21-Apr-2004 o 0.00 squam 1.00 
65 0.00 4.30 1.00 3.80 1.00 1.00 1.00 5.90 1.00 9.00 59 0.00 17-Mar-2003 o 0.00 squam 1.00 
66 0.00 2.50 1.00 1.00 1.00 1.00 6.10 1.00 4.00 60 0.00 06-Oct-2004 g 1.00 Adeno 0.00 
67 0.00 5.10 2.00 8.60 1.00 1.00 1.00 6.10 1.00 65 1.00 09-May-2001 o 0.00 Adeno 0.00 
68 1.00 0.70 0.00 1.00 1.00 1.00 6.40 1.00 15.10 78 2.00 11-Dec-1995 g 1.00 Adeno 0.00 
69 0.00 2.20 1.00 1.00 1.00 1.00 6.50 2.00 42 0.00 18-Aug-2004 g 1.00 Adeno 0.00 
70 1.00 11.80 2.00 1.00 1.00 1.00 6.80 2.00 75 2.00 31-May-2001 g 1.00 Adeno 0.00 
71 0.00 3.00 1.00 1.00 1.00 1.00 7.10 2.00 72 1.00 16-Feb-2000 o 0.00 Adeno 0.00 
72 0.00 22.10 2.00 13.00 1.00 1.00 1.00 7.10 2.00 6.00 55 0.00 10-Sep-2003 o 0.00 Adeno 0.00 
73 0.00 48.10 2.00 1.00 1.00 1.00 7.30 2.00 59 0.00 27-Aug-2003 o 0.00 Adeno 0.00 
74 1.00 2.00 1.00 4.40 2.00 2.00 0.00 7.30 2.00 61 0.00 01-Mar-2000 o 0.00 squam 1.00 
75 0.00 1.30 0.00 1.00 1.00 1.00 7.60 2.00 9.00 51 0.00 07-Apr-1999 o 0.00 squam 1.00 
76 0.00 18.20 2.00 1.00 1.00 1.00 7.60 2.00 72 1.00 09-Jan-2002 g 1.00 Adeno 0.00 
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Patient m0f1 ki67ac ki67cd Ki67mh klinjjg klinac klincd cd68 cd68ter cd68suma age agecd dateop posi positcd histolog typecd 
77 1.00 0.00 0.00 1.00 1.00 1.00 7.80 2.00 73 1.00 14-Aug-2002 o 0.00 Adeno 0.00 
78 0.00 2.20 1.00 1.00 1.00 1.00 7.80 2.00 68 1.00 03-Mar-2003 o 0.00 Adeno 0.00 
79 0.00 2.90 1.00 1.00 1.00 1.00 7.90 2.00 74 1.00 10-Sep-2003 g 1.00 Adeno 0.00 
80 1.00 14.40 2.00 19.00 2.00 2.00 0.00 8.20 2.00 73 1.00 24-Apr-2002 o 0.00 Adeno 0.00 
81 1.00 36.50 2.00 3.00 2.00 0.00 8.70 2.00 19.00 55 0.00 15-Mar-2000 o 0.00 Adeno 0.00 
82 0.00 0.00 0.00 1.00 1.00 1.00 8.80 2.00 76 2.00 11-Jun-2003 g 1.00 Adeno 0.00 
83 0.00 0.00 0.00 1.00 1.00 1.00 9.30 2.00 68 1.00 03-Jun-2002 o 0.00 Adeno 0.00 
84 1.00 0.50 0.00 1.00 1.00 1.00 9.40 2.00 68 1.00 16-Jun-1997 G 1.00 ADE 0.00 
85 0.00 1.00 0.00 4.60 1.00 1.00 1.00 9.50 2.00 11.00 59 0.00 03-Nov-1999 o 0.00 Adeno 0.00 
86 0.00 1.30 0.00 1.00 1.00 1.00 9.80 2.00 18.00 75 2.00 03-Sep-2002 g 1.00 Adeno 0.00 
87 0.00 1.50 1.00 1.00 1.00 1.00 10.10 2.00 12.00 73 1.00 13-Oct-1999 g 1.00 Adeno 0.00 
88 0.00 1.90 1.00 1.00 1.00 1.00 10.20 2.00 66 1.00 05-Jul-1999 g 1.00 Adeno 0.00 
89 0.00 3.40 1.00 7.50 1.00 1.00 1.00 10.20 2.00 56 0.00 21-Jun-2000 g 1.00 Adeno 0.00 
90 1.00 2.40 1.00 1.00 1.00 1.00 10.90 2.00 71 1.00 25-Jun-2003 o 0.00 squam 1.00 
91 0.00 2.30 1.00 1.00 1.00 1.00 11.00 2.00 64 0.00 05-Sep-2002 G 1.00 Adeno 0.00 
92 0.00 40.10 2.00 3.00 3.00 0.00 11.00 2.00 68 1.00 24-Jun-2002 g 1.00 Adeno 0.00 
93 0.00 7.30 2.00 9.40 1.00 1.00 1.00 13.50 2.00 64 0.00 10-Jan-2001 g 1.00 Adeno 0.00 
94 0.00 6.60 2.00 8.40 2.00 2.00 0.00 13.70 2.00 59 0.00 05-Dec-2001 G 1.00 Adeno 0.00 
95 0.00 0.50 0.00 1.00 1.00 1.00 13.90 2.00 68 1.00 20-Mar-2002 g 1.00 Adeno 0.00 
96 1.00 2.40 1.00 4.30 1.00 2.00 0.00 13.90 2.00 59 0.00 29-May-2000 g 1.00 Adeno 0.00 
97 0.00 0.10 0.00 0.00 0.00 1.00 14.60 2.00 73 1.00 08-Jun-1998 o 0.00 Adeno 0.00 
98 0.00 32.20 2.00 17.14 2.00 3.00 0.00 14.80 2.00 17.00 74 1.00 03-Apr-2000 o 0.00 Adeno 0.00 
99 1.00 3.60 1.00 3.15 3.00 3.00 0.00 17.70 2.00 19.50 77 2.00 23-Aug-1999 o 0.00 squam 1.00 
100 1.00 2.00 1.00 2.00 3.00 0.00 21.30 2.00 33.00 48 0.00 03-Jul-2002 G 1.00 Adeno 0.00 




Patient t n m tnmstcd diffcd tdiff posnodes lymphcd totalnod nodratio ratiocd r a0c1n2 doffu Survmths 
1 2 1.00 1 4.00 1.00 0.00 6.00 1.00 18.00 0.33 2.00 1.00 1.00 06-Jun-2004 4.80 
2 1 0.00 0 1.00 1.00 0.00 0.00 0.00 16.00 0.00 0.00 0.00 1.00 18-Nov-2004 18.67 
3 1 0.00 0 1.00 0.00 2.00 0.00 0.00 29.00 0.00 0.00 0.00 1.00 25-Nov-2004 6.63 
4 1 0.00 0 1.00 1.00 0.00 0.00 0.00 25.00 0.00 0.00 0.00 0.00 31-Aug-2009 112.93 
5 2 1.00 0 2.00 1.00 0.00 3.00 1.00 26.00 0.12 1.00 0.00 1.00 14-Jul-2003 19.77 
6 3 1.00 0 3.00 1.00 0.00 6.00 1.00 26.00 0.23 2.00 0.00 1.00 22-Jun-2001 8.07 
7 3 1.00 0 3.00 0.00 2.00 1.00 1.00 15.00 0.07 1.00 0.00 1.00 08-Oct-1999 29.77 
8 3 2.00 1 4.00 1.00 0.00 7.00 1.00 16.00 0.44 2.00 1.00 1.00 26-Aug-2001 5.10 
9 3 1.00 0 3.00 0.00 1.00 2.00 1.00 20.00 0.10 1.00 0.00 1.00 18-Feb-1998 16.57 
10 3 1.00 0 3.00 1.00 0.00 1.00 1.00 33.00 0.03 1.00 0.00 1.00 07-Jan-2005 29.67 
11 2 2.00 0 3.00 1.00 0.00 29.00 1.00 34.00 0.85 2.00 0.00 1.00 27-Oct-2001 11.50 
12 3 1.00 0 3.00 1.00 0.00 1.00 1.00 22.00 0.05 1.00 0.00 1.00 25-Mar-2004 7.27 
13 3 0.00 0 2.00 1.00 0.00 0.00 0.00 5.00 0.00 0.00 0.00 1.00 12-Jan-2001 53.13 
14 3 2.00 0 3.00 0.00 1.00 16.00 1.00 43.00 0.37 2.00 0.00 1.00 01-Sep-2003 5.37 
15 3 1.00 0 3.00 0.00 1.00 5.00 1.00 23.00 0.22 2.00 0.00 0.00 31-Aug-2009 159.60 
16 3 2.00 0 3.00 0.00 1.00 10.00 1.00 39.00 0.26 2.00 0.00 0.00 31-Aug-2009 64.40 
17 2 1.00 0 2.00 1.00 0.00 4.00 1.00 16.00 0.25 2.00 0.00 1.00 29-Aug-2001 25.03 
18 3 0.00 0 2.00 1.00 0.00 0.00 0.00 17.00 0.00 0.00 0.00 1.00 22-Jul-2001 10.67 
19 3 1.00 0 3.00 0.00 1.00 10.00 1.00 15.00 0.67 2.00 1.00 2.00 19-Jul-2005 23.53 
20 2 0.00 0 1.00 1.00 0.00 0.00 0.00 22.00 0.00 0.00 0.00 0.00 31-Aug-2009 132.00 
21 3 1.00 0 3.00 0.00 1.00 5.00 1.00 24.00 0.21 2.00 1.00 1.00 28-Dec-2006 59.37 
22 3 0.00 0 2.00 1.00 0.00 0.00 0.00 9.00 0.00 0.00 0.00 1.00 13-Jul-2005 32.83 
23 1 0.00 0 1.00 0.00 2.00 0.00 0.00 19.00 0.00 0.00 0.00 0.00 31-Aug-2009 123.30 
24 3 0.00 0 2.00 0.00 1.00 0.00 0.00 10.00 0.00 0.00 0.00 1.00 29-Nov-2004 74.37 
25 2 0.00 0 1.00 0.00 1.00 0.00 0.00 10.00 0.00 0.00 0.00 0.00 31-Aug-2009 89.77 
26 2 0.00 0 2.00 0.00 1.00 0.00 0.00 10.00 0.00 0.00 0.00 0.00 31-Aug-2009 118.93 
27 2 0.00 0 1.00 0.00 1.00 0.00 0.00 23.00 0.00 0.00 0.00 0.00 31-Aug-2009 107.27 
28 3 2.00 0 3.00 1.00 0.00 9.00 1.00 25.00 0.36 2.00 0.00 1.00 08-Feb-2001 8.40 
29 1 0.00 0 1.00 0.00 2.00 0.00 0.00 34.00 0.00 0.00 0.00 0.00 31-Aug-2009 84.17 
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Patient t n m tnmstcd diffcd tdiff posnodes lymphcd totalnod nodratio ratiocd r a0c1n2 doffu Survmths 
30 1 0.00 0 1.00 0.00 1.00 0.00 0.00 27.00 0.00 0.00 0.00 0.00 31-Aug-2009 64.57 
31 1 0.00 0 1.00 0.00 2.00 0.00 0.00 21.00 0.00 0.00 0.00 0.00 31-Aug-2009 109.60 
32 3 0.00 0 2.00 0.00 1.00 7.00 1.00 20.00 0.35 2.00 0.00 1.00 08-Oct-2002 10.93 
33 2 0.00 0 1.00 1.00 0.00 1.00 1.00 18.00 0.06 1.00 0.00 0.00 31-Aug-2009 118.70 
34 3 0.00 0 2.00 1.00 0.00 0.00 0.00 7.00 0.00 0.00 0.00 1.00 22-Jun-2002 32.83 
35 3 1.00 0 3.00 0.00 2.00 3.00 1.00 27.00 0.11 1.00 0.00 0.00 31-Aug-2009 147.63 
36 2 1.00 0 2.00 0.00 1.00 1.00 1.00 16.00 0.06 1.00 0.00 0.00 31-Aug-2009 75.27 
37 2 1.00 0 2.00 0.00 1.00 1.00 1.00 13.00 0.08 1.00 0.00 1.00 09-Nov-1999 1.40 
38 2 0.00 0 1.00 0.00 2.00 0.00 0.00 9.00 0.00 0.00 0.00 0.00 31-Aug-2009 88.37 
39 2 0.00 0 1.00 0.00 1.00 0.00 0.00 21.00 0.00 0.00 0.00 0.00 31-Aug-2009 102.13 
40 3 0.00 0 2.00 0.00 1.00 0.00 0.00 33.00 0.00 0.00 0.00 0.00 31-Aug-2009 91.17 
41 3 1.00 0 3.00 0.00 1.00 7.00 1.00 40.00 0.18 1.00 1.00 1.00 24-Sep-2005 91.87 
42 2 0.00 0 2.00 0.00 2.00 0.00 0.00 16.00 0.00 0.00 0.00 0.00 31-Aug-2009 126.40 
43 2 1.00 0 2.00 0.00 2.00 1.00 1.00 14.00 0.07 1.00 0.00 1.00 16-Oct-2007 42.20 
44 4 1.00 0 4.00 1.00 0.00 1.00 1.00 34.00 0.03 1.00 1.00 2.00 26-Nov-2007 55.00 
45 3 2.00 0 3.00 1.00 0.00 11.00 1.00 15.00 0.73 2.00 0.00 1.00 04-Aug-2001 16.67 
46 3 1.00 0 3.00 0.00 1.00 8.00 1.00 37.00 0.22 2.00 1.00 1.00 10-Dec-2005 11.77 
47 1 0.00 0 1.00 1.00 0.00 0.00 0.00 12.00 0.00 0.00 0.00 0.00 31-Aug-2009 116.20 
48 2 1.00 0 2.00 0.00 1.00 6.00 1.00 17.00 0.35 2.00 0.00 0.00 31-Aug-2009 125.67 
49 3 1.00 0 3.00 0.00 1.00 2.00 1.00 18.00 0.11 1.00 0.00 0.00 31-Aug-2009 73.97 
50 3 0.00 0 2.00 0.00 1.00 0.00 0.00 13.00 0.00 0.00 0.00 2.00 30-Jul-2006 30.00 
51 3 1.00 0 3.00 0.00 1.00 1.00 1.00 29.00 0.03 1.00 0.00 1.00 11-Jun-2008 48.50 
52 1 0.00 0 1.00   0.00 0.00 0.00 0.00 0.00 0.00 1.00 31-Mar-2002 8.77 
53 3 1.00 0 3.00 1.00 0.00 4.00 1.00 33.00 0.12 1.00 1.00 0.00 31-Aug-2009 80.67 
54 2 0.00 0 1.00 1.00 0.00 0.00 0.00 24.00 0.00 0.00 0.00 1.00 22-Sep-2001 10.67 
55 1 0.00 0 1.00 1.00 0.00 0.00 0.00 34.00 0.00 0.00 0.00 0.00 31-Aug-2009 116.83 
56 3 1.00 0 3.00 1.00 0.00 5.00 1.00 24.00 0.21 2.00 1.00 1.00 20-Feb-2003 79.20 
57 1 0.00 0 1.00 0.00 1.00 0.00 0.00 8.00 0.00 0.00 0.00 0.00 31-Aug-2009 82.07 
58 1 0.00 0 1.00 0.00 2.00 0.00 0.00 17.00 0.00 0.00 0.00 0.00 31-Aug-2009 126.93 
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Patient t n m tnmstcd diffcd tdiff posnodes lymphcd totalnod nodratio ratiocd r a0c1n2 doffu Survmths 
59 3 1.00 0 3.00 1.00 0.00 4.00 1.00 13.00 0.31 2.00 0.00 1.00 10-Sep-2003 14.70 
60 2 1.00 0 2.00 1.00 0.00 4.00 1.00 32.00 0.13 1.00 0.00 1.00 10-Aug-2004 6.27 
61 1 0.00 0 1.00 1.00 0.00 0.00 0.00 9.00 0.00 0.00 0.00 1.00 07-Dec-2001 7.77 
62 1 0.00 0 1.00 0.00 2.00 1.00 1.00 30.00 0.03 1.00 0.00 0.00 31-Aug-2009 100.97 
63 3 0.00 0 2.00 0.00 2.00 0.00 0.00 12.00 0.00 0.00 1.00 1.00 26-Oct-2004 19.37 
64 1 0.00 0 1.00 0.00 2.00 0.00 0.00 22.00 0.00 0.00 0.00 1.00 13-Sep-2004 4.83 
65 3 0.00 0 2.00 0.00 1.00 0.00 0.00 21.00 0.00 0.00 0.00 0.00 31-Aug-2009 78.63 
66 3 1.00 0 3.00 0.00 1.00 2.00 1.00 23.00 0.09 1.00 0.00 0.00 31-Aug-2009 59.67 
67 3 1.00 0 3.00 0.00 2.00 7.00 1.00 28.00 0.25 2.00 1.00 0.00 31-Aug-2009 101.20 
68 3 2.00 0 3.00 0.00 1.00 9.00 1.00 10.00 0.90 2.00 1.00 1.00 15-Aug-1997 20.43 
69 1 0.00 0 1.00 0.00 2.00 0.00 0.00 35.00 0.00 0.00 0.00 0.00 31-Aug-2009 61.30 
70 3 1.00 0 3.00 1.00 0.00 4.00 1.00 10.00 0.40 2.00 0.00 1.00 23-May-2002 11.90 
71 1 0.00 0 1.00 0.00 2.00 0.00 0.00 16.00 0.00 0.00 0.00 0.00 31-Aug-2009 116.13 
72 3 1.00 0 3.00 0.00 1.00 1.00 1.00 27.00 0.04 1.00 0.00 0.00 31-Aug-2009 72.73 
73 3 1.00 0 3.00 1.00 0.00 7.00 1.00 19.00 0.37 2.00 0.00 1.00 18-Apr-2005 20.00 
74 2 1.00 0 2.00 0.00 1.00 2.00 1.00 11.00 0.18 1.00 0.00 0.00 31-Aug-2009 115.67 
75 3 1.00 0 3.00 1.00 0.00 7.00 1.00 28.00 0.25 2.00 0.00 1.00 16-Nov-2001 31.80 
76 3 0.00 0 2.00 1.00 0.00 0.00 0.00 19.00 0.00 0.00 0.00 0.00 31-Aug-2009 93.03 
77 2 1.00 0 2.00 0.00 1.00 2.00 1.00 19.00 0.11 1.00 0.00 1.00 06-Nov-2003 14.97 
78 2 1.00 0 2.00 1.00 0.00 5.00 1.00 17.00 0.29 2.00 0.00 2.00 26-Mar-2006 37.30 
79 3 2.00 0 3.00 1.00 0.00 9.00 1.00 19.00 0.47 2.00 0.00 1.00 15-Dec-2005 27.57 
80 2 0.00 0 2.00 0.00 2.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 31-Aug-2009 89.53 
81 2 0.00 0 2.00 0.00 1.00 0.00 0.00 14.00 0.00 0.00 0.00 0.00 31-Aug-2009 115.20 
82 1 0.00 0 1.00 0.00 2.00 0.00 0.00 3.00 0.00 0.00 0.00 0.00 31-Aug-2009 75.77 
83 2 2.00 0 3.00 1.00 0.00 8.00 1.00 15.00 0.53 2.00 0.00 1.00 13-Nov-2003 17.60 
84 3 1.00 0 3.00 0.00 2.00 2.00 1.00 25.00 0.08 1.00 0.00 1.00 08-Dec-1999 30.17 
85 1 0.00 0 1.00 1.00 0.00 5.00 1.00 20.00 0.25 2.00 0.00 1.00 20-Oct-2000 11.73 
86 3 1.00 0 3.00 0.00 1.00 4.00 1.00 55.00 0.07 1.00 0.00 1.00 30-Jan-2004 17.13 
87 3 2.00 0 3.00 1.00 0.00 9.00 1.00 32.00 0.28 2.00 0.00 1.00 14-Dec-2003 50.77 
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Patient t n m tnmstcd diffcd tdiff posnodes lymphcd totalnod nodratio ratiocd r a0c1n2 doffu Survmths 
88 3 0.00 0 2.00 1.00 0.00 2.00 1.00 14.00 0.14 1.00 0.00 1.00 14-Feb-2003 44.00 
89 3 2.00 0 3.00 0.00 2.00 8.00 1.00 37.00 0.22 2.00 0.00 1.00 01-Jan-2005 55.17 
90 3 1.00 0 3.00 0.00 2.00 1.00 1.00 18.00 0.06 1.00 1.00 0.00 31-Aug-2009 75.30 
91 2 1.00 0 2.00 0.00 2.00 2.00 1.00 19.00 0.11 1.00 0.00 1.00 18-Jun-2003 9.53 
92 2 1.00 0 2.00 0.00 1.00 1.00 1.00 27.00 0.04 1.00 0.00 0.00 31-Aug-2009 87.50 
93 1 0.00 0 1.00 0.00 2.00 0.00 0.00 17.00 0.00 0.00 0.00 0.00 31-Aug-2009 105.17 
94 3 1.00 0 3.00 1.00 0.00 2.00 1.00 20.00 0.10 1.00 0.00 0.00 31-Aug-2009 94.20 
95 3 1.00 0 3.00 1.00 0.00 5.00 1.00 15.00 0.33 2.00 0.00 1.00 22-Mar-2003 12.23 
96 2 0.00 0 1.00 1.00 0.00 0.00 0.00 16.00 0.00 0.00 0.00 0.00 31-Aug-2009 112.70 
97 3 0.00 0 2.00 0.00 1.00 0.00 0.00 20.00 0.00 0.00 1.00 1.00 28-Jul-2002 50.37 
98 2 0.00 0 2.00 1.00 0.00 0.00 0.00 44.00 0.00 0.00 0.00 0.00 31-Aug-2009 114.57 
99 3 1.00 0 3.00 1.00 0.00 5.00 1.00 35.00 0.14 1.00 1.00 0.00 31-Aug-2009 122.03 





Patient crpg5 crpfinal cfinalcd alb albcd gpsfin wcc wcccd hb hbcd plts pltscd neut neutcd lymph lympho lymper lympcd nlr nlrcd 
1 1.00 7.00 0.00 37.00 0.00 0.00 6.00 0.00 8.60 1.00 488.00 1.00 4.00 0.00 1.50 1.00 25.00 0.00 2.67 0.00 
2 0.00 5.00 0.00 42.00 0.00 0.00 5.40 0.00 14.40 0.00 306.00 0.00 2.50 0.00 2.20 1.00 40.74 0.00 1.14 0.00 
3 0.00 5.00 0.00 42.00 0.00 0.00 7.90 0.00 4.10 1.00 319.00 0.00 4.90 0.00 2.30 1.00 29.11 0.00 2.13 0.00 
4 0.00 5.00 0.00 43.00 0.00 0.00 5.50 0.00 15.40 0.00 218.00 0.00 3.40 0.00 1.40 1.00 25.45 0.00 2.43 0.00 
5 1.00 12.00 1.00 46.00 0.00 1.00 9.00 1.00 14.30 0.00 299.00 0.00 7.20 0.00 1.20 1.00 13.33 1.00 6.00 1.00 
6 0.00 5.00 0.00 44.00 0.00 0.00 12.30 2.00 14.10 0.00 326.00 0.00 8.30 1.00 3.10 2.00 25.20 0.00 2.68 0.00 
7 1.00 21.00 1.00 36.00 0.00 1.00 7.10 0.00 10.70 1.00 288.00 0.00 5.50 0.00 1.10 1.00 15.49 1.00 5.00 1.00 
8 1.00 8.00 0.00 35.00 0.00 0.00 7.50 0.00 14.10 0.00 208.00 0.00 5.00 0.00 1.60 1.00 21.33 0.00 3.13 0.00 
9 1.00 22.00 1.00 43.00 0.00 1.00 10.20 1.00 13.90 0.00 294.00 0.00 7.20 0.00 2.20 1.00 21.57 0.00 3.27 0.00 
10 0.00 5.00 0.00 44.00 0.00 0.00 5.70 0.00 16.00 0.00 212.00 0.00 3.00 0.00 2.00 1.00 35.09 0.00 1.50 0.00 
11 1.00 17.00 1.00 38.00 0.00 1.00 9.70 1.00 14.70 0.00 299.00 0.00 7.20 0.00 1.40 1.00 14.43 1.00 5.14 1.00 
12 1.00 9.00 0.00 37.00 0.00 0.00 5.10 0.00 13.90 0.00 257.00 0.00 2.80 0.00 1.80 1.00 35.29 0.00 1.56 0.00 
13 0.00 5.00 0.00 41.00 0.00 0.00 6.70 0.00 13.50 0.00 165.00 0.00 3.90 0.00 2.20 1.00 32.84 0.00 1.77 0.00 
14 0.00 5.00 0.00 41.00 0.00 0.00 5.70 0.00 13.80 0.00 220.00 0.00 3.50 0.00 1.40 1.00 24.56 0.00 2.50 0.00 
15 0.00 5.00 0.00 43.00 0.00 0.00 9.90 1.00 13.80 0.00 391.00 0.00 5.90 0.00 2.80 1.00 28.28 0.00 2.11 0.00 
16 0.00 5.00 0.00 37.00 0.00 0.00 7.60 0.00 11.30 1.00 373.00 0.00 4.90 0.00 1.70 1.00 22.37 0.00 2.88 0.00 
17 0.00 5.00 0.00 42.00 0.00 0.00 7.80 0.00 17.50 0.00 230.00 0.00 5.90 0.00 1.50 1.00 19.23 1.00 3.93 0.00 
18 1.00 19.00 1.00 42.00 0.00 1.00 12.50 2.00 12.40 0.00 236.00 0.00 9.90 1.00 1.80 1.00 14.40 1.00 5.50 1.00 
19 0.00 5.00 0.00 38.00 0.00 0.00 5.20 0.00 13.60 0.00 156.00 0.00 2.70 0.00 2.10 1.00 40.38 0.00 1.29 0.00 
20 0.00 5.00 0.00 43.00 0.00 0.00 5.30 0.00 13.50 0.00 204.00 0.00 3.40 0.00 1.30 1.00 24.53 0.00 2.62 0.00 
21 0.00 5.00 0.00 42.00 0.00 0.00 12.00 2.00 14.30 0.00 451.00 1.00 9.20 1.00 2.30 1.00 19.17 1.00 4.00 0.00 
22 0.00 5.00 0.00 39.00 0.00 0.00 8.90 1.00 11.00 1.00 357.00 0.00 5.70 0.00 2.00 1.00 22.47 0.00 2.85 0.00 
23 0.00 5.00 0.00 43.00 0.00 0.00 5.90 0.00 12.80 0.00 279.00 0.00 2.40 0.00 2.80 1.00 47.46 0.00 0.86 0.00 
24 0.00 5.00 0.00 46.00 0.00 0.00 13.40 2.00 13.80 0.00 302.00 0.00 10.50 1.00 1.90 1.00 14.18 1.00 5.53 1.00 
25 0.00 5.00 0.00 43.00 0.00 0.00 9.30 1.00 11.10 1.00 344.00 0.00 6.20 0.00 2.00 1.00 21.51 0.00 3.10 0.00 
26 1.00 8.00 0.00 42.00 0.00 0.00 9.80 1.00 16.00 0.00 351.00 0.00 6.90 0.00 2.20 1.00 22.45 0.00 3.14 0.00 
27 0.00 5.00 0.00 44.00 0.00 0.00 5.70 0.00 15.40 0.00 162.00 0.00 3.60 0.00 1.60 1.00 28.07 0.00 2.25 0.00 
28 0.00 5.00 0.00 39.00 0.00 0.00 8.40 0.00 14.40 0.00 217.00 0.00 5.00 0.00 2.30 1.00 27.38 0.00 2.17 0.00 
29 0.00 5.00 0.00 42.00 0.00 0.00 10.00 1.00 14.10 0.00 244.00 0.00 6.70 0.00 2.60 1.00 26.00 0.00 2.58 0.00 
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Patient crpg5 crpfinal cfinalcd alb albcd gpsfin wcc wcccd hb hbcd plts pltscd neut neutcd lymph lympho lymper lympcd nlr nlrcd 
30 0.00 5.00 0.00 44.00 0.00 0.00 6.70 0.00 12.10 0.00 374.00 0.00 4.40 0.00 1.80 1.00 26.87 0.00 2.44 0.00 
31 0.00 5.00 0.00 43.00 0.00 0.00 8.20 0.00 15.90 0.00 224.00 0.00 5.00 0.00 2.20 1.00 26.83 0.00 2.27 0.00 
32 0.00 5.00 0.00 43.00 0.00 0.00 7.20 0.00 15.10 0.00 151.00 0.00 4.30 0.00 2.30 1.00 31.94 0.00 1.87 0.00 
33 0.00 5.00 0.00 41.00 0.00 0.00 6.10 0.00 15.60 0.00 232.00 0.00 3.60 0.00 2.00 1.00 32.79 0.00 1.80 0.00 
34 1.00 14.00 1.00 45.00 0.00 1.00 7.40 0.00 12.40 0.00 246.00 0.00 4.60 0.00 2.00 1.00 27.03 0.00 2.30 0.00 
35 0.00 5.00 0.00 43.00 0.00 0.00 8.60 1.00 13.30 0.00 416.00 1.00 6.00 0.00 2.00 1.00 23.26 0.00 3.00 0.00 
36 0.00 5.00 0.00 48.00 0.00 0.00 4.10 0.00 8.30 1.00 284.00 0.00 2.50 0.00 1.00 1.00 24.39 0.00 2.50 0.00 
37 0.00 5.00 0.00 42.00 0.00 0.00 5.70 0.00 13.60 0.00 272.00 0.00 3.50 0.00 1.60 1.00 28.07 0.00 2.19 0.00 
38 0.00 5.00 0.00 42.00 0.00 0.00 6.50 0.00 13.80 0.00 239.00 0.00 4.30 0.00 1.40 1.00 21.54 0.00 3.07 0.00 
39 1.00 8.00 0.00 44.00 0.00 0.00 9.00 1.00 7.20 1.00 467.00 1.00 5.80 0.00 2.40 1.00 26.67 0.00 2.42 0.00 
40 0.00 5.00 0.00 39.00 0.00 0.00 9.40 1.00 15.40 0.00 343.00 0.00 5.60 0.00 2.30 1.00 24.47 0.00 2.43 0.00 
41 0.00 5.00 0.00 44.00 0.00 0.00 4.90 0.00 13.00 0.00 196.00 0.00 2.40 0.00 2.00 1.00 40.82 0.00 1.20 0.00 
42 0.00 5.00 0.00 31.00 1.00 1.00 7.00 0.00 12.70 0.00 311.00 0.00 4.50 0.00 2.00 1.00 28.57 0.00 2.25 0.00 
43 0.00 5.00 0.00 39.00 0.00 0.00 6.20 0.00 14.40 0.00 244.00 0.00 4.10 0.00 1.50 1.00 24.19 0.00 2.73 0.00 
44 0.00 5.00 0.00 40.00 0.00 0.00 7.60 0.00 14.60 0.00 306.00 0.00 5.10 0.00 1.40 1.00 18.42 1.00 3.64 0.00 
45 1.00 12.00 1.00 44.00 0.00 1.00 8.00 0.00 15.80 0.00 262.00 0.00 5.20 0.00 2.00 1.00 25.00 0.00 2.60 0.00 
46 0.00 5.00 0.00 49.00 0.00 0.00 9.30 1.00 13.50 0.00 316.00 0.00 5.70 0.00 2.70 1.00 29.03 0.00 2.11 0.00 
47 1.00 7.00 0.00 45.00 0.00 0.00 8.40 0.00 13.00 0.00 300.00 0.00 5.80 0.00 2.00 1.00 23.81 0.00 2.90 0.00 
48 0.00 5.00 0.00 37.00 0.00 0.00 4.90 0.00 10.20 1.00 370.00 0.00 2.60 0.00 1.80 1.00 36.73 0.00 1.44 0.00 
49 0.00 5.00 0.00 43.00 0.00 0.00 8.90 1.00 13.90 0.00 260.00 0.00 5.70 0.00 1.80 1.00 20.22 0.00 3.17 0.00 
50 0.00 5.00 0.00 42.00 0.00 0.00 8.80 1.00 13.80 0.00 299.00 0.00 5.80 0.00 2.40 1.00 27.27 0.00 2.42 0.00 
51 1.00 8.00 0.00 36.00 0.00 0.00 5.60 0.00 9.90 1.00 184.00 0.00 4.70 0.00 0.40 0.00 7.14 2.00 11.75 1.00 
52 0.00 5.00 0.00 42.00 0.00 0.00 7.80 0.00 14.30 0.00 319.00 0.00 3.90 0.00 2.80 1.00 35.90 0.00 1.39 0.00 
53 0.00 5.00 0.00 47.00 0.00 0.00 8.50 1.00 15.40 0.00 229.00 0.00 6.60 0.00 1.10 1.00 12.94 1.00 6.00 1.00 
54 1.00 36.00 1.00 37.00 0.00 1.00 6.70 0.00 10.80 1.00 268.00 0.00 5.20 0.00 0.70 0.00 10.45 2.00 7.43 1.00 
55 0.00 5.00 0.00 37.00 0.00 0.00 10.30 1.00 14.50 0.00   7.90 1.00 1.50 1.00 14.56 1.00 5.27 1.00 
56 1.00 9.00 0.00 43.00 0.00 0.00 14.90 2.00 15.10 0.00 361.00 0.00 12.10 1.00 2.10 1.00 14.09 1.00 5.76 1.00 
57 1.00 7.00 0.00 46.00 0.00 0.00 7.60 0.00 15.00 0.00 352.00 0.00 5.20 0.00 1.60 1.00 21.05 0.00 3.25 0.00 
58 0.00 5.00 0.00 45.00 0.00 0.00 6.20 0.00 16.30 0.00 188.00 0.00 3.90 0.00 1.60 1.00 25.81 0.00 2.44 0.00 
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Patient crpg5 crpfinal cfinalcd alb albcd gpsfin wcc wcccd hb hbcd plts pltscd neut neutcd lymph lympho lymper lympcd nlr nlrcd 
59 1.00 8.00 0.00 46.00 0.00 0.00 6.90 0.00 14.90 0.00 201.00 0.00 4.50 0.00 1.50 1.00 21.74 0.00 3.00 0.00 
60 0.00 5.00 0.00 41.00 0.00 0.00 6.30 0.00 9.00 1.00 241.00 0.00 3.60 0.00 1.90 1.00 30.16 0.00 1.89 0.00 
61 0.00 5.00 0.00   0.00 5.80 0.00 13.20 0.00 229.00 0.00 3.50 0.00 1.80 1.00 31.03 0.00 1.94 0.00 
62 0.00 5.00 0.00 37.00 0.00 0.00 7.80 0.00 15.20 0.00 227.00 0.00 5.10 0.00 1.80 1.00 23.08 0.00 2.83 0.00 
63 1.00 19.00 1.00 44.00 0.00 1.00 8.00 0.00 11.90 1.00 216.00 0.00 6.00 0.00 1.40 1.00 17.50 1.00 4.29 0.00 
64 0.00 5.00 0.00 42.00 0.00 0.00 5.30 0.00 12.20 0.00 274.00 0.00 3.30 0.00 1.30 1.00 24.53 0.00 2.54 0.00 
65 0.00 5.00 0.00 45.00 0.00 0.00               
66 0.00 5.00 0.00 41.00 0.00 0.00 7.80 0.00 14.80 0.00 333.00 0.00 5.40 0.00 1.60 1.00 20.51 0.00 3.38 0.00 
67 0.00 5.00 0.00 40.00 0.00 0.00 6.30 0.00 14.20 0.00 321.00 0.00 4.10 0.00 1.30 1.00 20.63 0.00 3.15 0.00 
68 1.00 14.00 1.00 38.00 0.00 1.00 8.30 0.00 13.50 0.00 327.00 0.00 6.30 0.00 1.50 1.00 18.07 1.00 4.20 0.00 
69 0.00 5.00 0.00 46.00 0.00 0.00 9.30 1.00 15.30 0.00 224.00 0.00 6.30 0.00 2.40 1.00 25.81 0.00 2.63 0.00 
70 0.00 5.00 0.00 34.00 1.00 0.00 5.00 0.00 12.20 0.00 364.00 0.00 3.20 0.00 1.30 1.00 26.00 0.00 2.46 0.00 
71 0.00 5.00 0.00 44.00 0.00 0.00 7.50 0.00 12.80 0.00 195.00 0.00 4.30 0.00 2.30 1.00 30.67 0.00 1.87 0.00 
72 0.00 5.00 0.00 37.00 0.00 0.00 11.60 2.00 10.00 1.00 343.00 0.00 9.80 1.00 0.70 0.00 6.03 2.00 14.00 1.00 
73 0.00 5.00 0.00 43.00 0.00 0.00 7.00 0.00 15.20 0.00 282.00 0.00 4.20 0.00 1.80 1.00 25.71 0.00 2.33 0.00 
74 0.00 5.00 0.00 44.00 0.00 0.00 5.90 0.00 13.30 0.00 410.00 1.00 3.50 0.00 1.80 1.00 30.51 0.00 1.94 0.00 
75 0.00 5.00 0.00 41.00 0.00 0.00 9.00 1.00 15.70 0.00 291.00 0.00 5.20 0.00 2.90 1.00 32.22 0.00 1.79 0.00 
76 0.00 5.00 0.00 41.00 0.00 0.00 5.20 0.00 14.30 0.00 281.00 0.00 2.90 0.00 1.50 1.00 28.85 0.00 1.93 0.00 
77 0.00 5.00 0.00 48.00 0.00 0.00 10.80 1.00 11.00 1.00 233.00 0.00 7.00 0.00 3.20 2.00 29.63 0.00 2.19 0.00 
78 0.00 5.00 0.00 43.00 0.00 0.00 7.00 0.00 14.40 0.00 184.00 0.00 4.80 0.00 1.60 1.00 22.86 0.00 3.00 0.00 
79 0.00 5.00 0.00 39.00 0.00 0.00 6.80 0.00 9.80 1.00 389.00 0.00 4.10 0.00 1.80 1.00 26.47 0.00 2.28 0.00 
80 0.00 5.00 0.00 43.00 0.00 0.00 7.10 0.00 13.10 0.00 234.00 0.00 4.80 0.00 1.80 1.00 25.35 0.00 2.67 0.00 
81 1.00 10.00 0.00 36.00 0.00 0.00 6.00 0.00 11.50 1.00 338.00 0.00 3.90 0.00 1.70 1.00 28.33 0.00 2.29 0.00 
82 0.00 5.00 0.00 41.00 0.00 0.00 9.50 1.00 15.70 0.00 110.00 0.00 5.10 0.00 3.30 2.00 34.74 0.00 1.55 0.00 
83 0.00 5.00 0.00 41.00 0.00 0.00 6.00 0.00 14.70 0.00 318.00 0.00 4.30 0.00 1.00 1.00 16.67 1.00 4.30 0.00 
84 1.00 11.00 1.00 38.00 0.00 1.00 9.70 1.00 10.90 1.00 441.00 1.00 6.70 0.00 2.10 1.00 21.65 0.00 3.19 0.00 
85 0.00 5.00 0.00 44.00 0.00 0.00               
86 0.00 5.00 0.00 41.00 0.00 0.00 8.70 1.00 12.70 0.00 398.00 0.00 5.90 0.00 2.00 1.00 22.99 0.00 2.95 0.00 
87 0.00 5.00 0.00 44.00 0.00 0.00 9.40 1.00 15.30 0.00 308.00 0.00 6.60 0.00 1.90 1.00 20.21 0.00 3.47 0.00 
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Patient crpg5 crpfinal cfinalcd alb albcd gpsfin wcc wcccd hb hbcd plts pltscd neut neutcd lymph lympho lymper lympcd nlr nlrcd 
88 0.00 5.00 0.00 42.00 0.00 0.00 6.60 0.00 13.30 0.00 254.00 0.00 4.50 0.00 1.30 1.00 19.70 1.00 3.46 0.00 
89 1.00 9.00 0.00 38.00 0.00 0.00 11.40 2.00 13.10 0.00 370.00 0.00 7.80 1.00 2.30 1.00 20.18 0.00 3.39 0.00 
90 0.00 5.00 0.00 40.00 0.00 0.00 5.10 0.00 12.60 0.00 359.00 0.00 3.50 0.00 1.20 1.00 23.53 0.00 2.92 0.00 
91 1.00 19.00 1.00 35.00 0.00 1.00 9.90 1.00 9.20 1.00 284.00 0.00 7.20 0.00 2.00 1.00 20.20 0.00 3.60 0.00 
92 1.00 7.00 0.00 44.00 0.00 0.00 8.70 1.00 14.40 0.00 292.00 0.00 6.10 0.00 1.60 1.00 18.39 1.00 3.81 0.00 
93 1.00 7.00 0.00 42.00 0.00 0.00 7.60 0.00 14.30 0.00 182.00 0.00 3.80 0.00 2.90 1.00 38.16 0.00 1.31 0.00 
94 1.00 8.00 0.00 46.00 0.00 0.00 9.00 1.00 15.90 0.00 338.00 0.00 6.30 0.00 1.90 1.00 21.11 0.00 3.32 0.00 
95 1.00 9.00 0.00 45.00 0.00 0.00 5.40 0.00 15.00 0.00 214.00 0.00 3.60 0.00 1.20 1.00 22.22 0.00 3.00 0.00 
96 0.00 5.00 0.00 42.00 0.00 0.00 6.10 0.00 11.80 1.00 251.00 0.00 3.40 0.00 2.30 1.00 37.70 0.00 1.48 0.00 
97 0.00 5.00 0.00 36.00 0.00 0.00 8.70 1.00 15.70 0.00 332.00 0.00 6.00 0.00 2.10 1.00 24.14 0.00 2.86 0.00 
98 1.00 11.00 1.00 37.00 0.00 1.00 8.00 0.00 10.70 1.00 273.00 0.00 4.70 0.00 2.20 1.00 27.50 0.00 2.14 0.00 
99 0.00 5.00 0.00 43.00 0.00 0.00 5.30 0.00 12.10 0.00 290.00 0.00 3.40 0.00 1.50 1.00 28.30 0.00 2.27 0.00 




APPENDIX 3: DATABASE FOR CHAPTER 4: EVALUATION OF 
AN INFLAMMATION BASED PROGNOSTIC SCORE (GPS) IN 





Patient  m0f1 age agecd Site o0g1 histolog typecd date of endo stage treatment treatcd actpall 
1.00 1.00 63.20 0.00 oesoph 0.00 squam 1.00 18-Oct-2004 3.00 CH/DXT  0.00 0.00 
2.00 0.00 71.96 1.00 oesoph 0.00 adeno 0.00 12-Nov-2003 3.00 CH/DXT  0.00 0.00 
3.00 0.00 46.18 0.00 o/g 0.00 adeno 0.00 22-Feb-2002 2.00 Chemo 0.00 0.00 
4.00 0.00 78.81 2.00 oesoph 0.00 squam 1.00 01-Oct-2004 3.00 Chemo 0.00 0.00 
5.00 0.00 72.75 1.00 oesoph 0.00 squam 1.00 01-Sep-2003 4.00 Chemo 0.00 0.00 
6.00 0.00 38.70 0.00 oesoph 0.00 squam 1.00 17-Sep-2004 4.00 Chemo 0.00 0.00 
7.00 0.00 63.83 0.00 oesoph 0.00 squam 1.00 08-Oct-2002 3.00 Chemo 0.00 0.00 
8.00 0.00 66.08 1.00 oesoph 0.00 adeno 0.00 30-Jul-2003 4.00 Chemo 0.00 0.00 
9.00 0.00 62.33 0.00 oesoph 0.00 adeno 0.00 21-Jan-2004 4.00 Chemo 0.00 0.00 
10.00 1.00 70.27 1.00 oesoph 0.00 adeno 0.00 06-Dec-2001 4.00 Chemo 0.00 0.00 
11.00 0.00 54.38 0.00 oesoph 0.00 adeno 0.00 23-Mar-2004 4.00 Chemo 0.00 0.00 
12.00 0.00 76.18 2.00 oesoph 0.00 adeno 0.00 10-Dec-2002 4.00 Chemo 0.00 0.00 
13.00 1.00 66.93 1.00 oesoph 0.00 squam 1.00 14-Nov-2001 2.00 Chemo 0.00 0.00 
14.00 0.00 62.28 0.00 o/g 0.00 adeno 0.00 16-Aug-2004 4.00 Chemo 0.00 0.00 
15.00 0.00 42.72 0.00 oesoph 0.00 adeno 0.00 16-Apr-2002 4.00 Chemo 0.00 0.00 
16.00 0.00 54.67 0.00 oesoph 0.00 squam 1.00 20-Jan-2004 3.00 Chemo 0.00 0.00 
17.00 0.00 66.83 1.00 o/g 0.00 adeno 0.00 14-Dec-2001 2.00 Chemo 0.00 0.00 
18.00 1.00 55.49 0.00 o/g 0.00 adeno 0.00 21-Dec-2004 4.00 Chemo 0.00 0.00 
19.00 1.00 70.85 1.00 oesoph 0.00 adeno 0.00 01-Sep-2004 4.00 Chemo 0.00 0.00 
20.00 0.00 64.68 0.00 o/g 0.00 adeno 0.00 13-Feb-2001 2.00 Chemo 0.00 0.00 
21.00 0.00 60.86 0.00 oesoph 0.00 adeno 0.00 04-Jun-2003 4.00 Chemo 0.00 0.00 
22.00 0.00 55.27 0.00 oesoph 0.00 adeno 0.00 12-Jun-2001 4.00 Chemo 0.00 0.00 
23.00 0.00 49.44 0.00 o/g 0.00 adeno 0.00 23-Jun-2004 4.00 Chemo 0.00 0.00 
24.00 0.00 66.10 1.00 o/g 0.00 adeno 0.00 27-Jul-2004 4.00 Chemo  0.00 0.00 
25.00 0.00 68.98 1.00 oesoph 0.00 adeno 0.00 21-Nov-2001 4.00 Chemo  0.00 0.00 
26.00 0.00 70.14 1.00 o/g 0.00 adeno 0.00 02-May-2001 3.00 Chemo 0.00 0.00 
27.00 0.00 58.80 0.00 oesoph 0.00 adeno 0.00 02-Jan-2001 2.00 Chemo 0.00 0.00 
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28.00 0.00 65.74 0.00 oesoph 0.00 squam 1.00 30-Jan-2001 4.00 Chemo 0.00 0.00 
29.00 1.00 56.33 0.00 oesoph 0.00 adeno 0.00 08-Aug-2002 4.00 Chemo/DXT 0.00 0.00 
30.00 0.00 63.35 0.00 oesoph 0.00 squam 1.00 28-Jul-2000 4.00 Chemo/DXT 0.00 0.00 
31.00 0.00 71.32 1.00 oesoph 0.00 squam 1.00 17-Dec-2002 2.00 Chemo/DXT 0.00 0.00 
32.00 0.00 76.64 2.00 o/g 0.00 adeno 0.00 01-Oct-2001 4.00 Chemo/DXT 0.00 0.00 
33.00 0.00 64.54 0.00 oesoph 0.00 squam 1.00 12-Jun-2001 3.00 Chemo/DXT 0.00 0.00 
34.00 1.00 76.03 2.00 oesoph 0.00 adeno 0.00 14-May-2002 1.00 Chemo/DXT 0.00 0.00 
35.00 0.00 62.65 0.00 oesoph 0.00 squam 1.00 08-Aug-2001 3.00 Chemo/DXT 0.00 0.00 
36.00 0.00 71.68 1.00 oesoph 0.00 squam 1.00 04-Sep-2003 1.00 Chemo/DXT 0.00 0.00 
37.00 0.00 65.47 0.00 oesoph 0.00 squam 1.00 22-May-2003 3.00 Chemo/DXT 0.00 0.00 
38.00 0.00 54.48 0.00 oesoph 0.00 squam 1.00 30-Mar-2000 3.00 Chemo/DXT 0.00 0.00 
39.00 1.00 68.45 1.00 oesoph 0.00 squam 1.00 20-Nov-2003 3.00 Chemo/DXT 0.00 0.00 
40.00 0.00 48.11 0.00 oesoph 0.00 adeno 0.00 27-Feb-2003 4.00 Chemo/DXT 0.00 0.00 
41.00 0.00 75.35 2.00 oesoph 0.00 adeno 0.00 19-Feb-2004 3.00 Chemo/DXT 0.00 0.00 
42.00 0.00 60.92 0.00 oesoph 0.00 adeno 0.00 31-Dec-2002 3.00 Chemo/DXT 0.00 0.00 
43.00 0.00 60.24 0.00 oesoph 0.00 squam 1.00 04-Aug-2003 4.00 Chemo/DXT 0.00 0.00 
44.00 0.00 65.72 0.00 oesoph 0.00 squam 1.00 06-Jan-2004 4.00 Chemo/DXT 0.00 0.00 
45.00 0.00 72.32 1.00 oesoph 0.00 squam 1.00 22-Dec-2003 3.00 Chemo/DXT 0.00 0.00 
46.00 0.00 56.18 0.00 oesoph 0.00 squam 1.00 06-May-2003 3.00 Chemo/DXT 0.00 0.00 
47.00 0.00 60.74 0.00 oesoph 0.00 squam 1.00 15-Mar-2004 4.00 Chemo/DXT 0.00 0.00 
48.00 0.00 76.35 2.00 oesoph 0.00 adeno 0.00 28-Jun-2002 4.00 Chemo/DXT 0.00 0.00 
49.00 1.00 73.96 1.00 oesoph 0.00 squam 1.00 18-Sep-2001 3.00 Chemo/DXT 0.00 0.00 
50.00 0.00 52.72 0.00 oesoph 0.00 squam 1.00 24-Dec-2002 1.00 Chemo/DXT 0.00 0.00 
51.00 1.00 56.62 0.00 oesoph 0.00 squam 1.00 26-Oct-2001 3.00 Chemo/DXT 0.00 0.00 
52.00 0.00 70.35 1.00 oesoph 0.00 squam 1.00 04-Dec-2001 4.00 Chemo/DXT 0.00 0.00 
53.00 0.00 67.88 1.00 oesoph 0.00 squam 1.00 16-Oct-2001 3.00 Chemo/DXT 0.00 0.00 
54.00 0.00 69.23 1.00 oesoph 0.00 squam 1.00 14-Jan-2004 4.00 Chemo/DXT 0.00 0.00 
55.00 0.00 56.48 0.00 oesoph 0.00 adeno 0.00 04-Oct-2001 3.00 Chemo/DXT 0.00 0.00 
56.00 1.00 55.16 0.00 oesoph 0.00 squam 1.00 20-Aug-2003 3.00 Chemo/DXT 0.00 0.00 
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57.00 0.00 62.56 0.00 o/g 0.00 adeno 0.00 05-Mar-2004 4.00 Chemo/DXT 0.00 0.00 
58.00 0.00 72.68 1.00 oesoph 0.00 adeno 0.00 14-Jan-2004 3.00 Chemo/DXT 0.00 0.00 
59.00 1.00 82.11 2.00 oesoph 0.00 squam 1.00 30-Nov-2004 3.00 Chemo/DXT 0.00 0.00 
60.00 0.00 82.31 2.00 oesoph 0.00 adeno 0.00 01-Oct-2002 3.00 Chemo/DXT 0.00 0.00 
61.00 1.00 56.91 0.00 oesoph 0.00 squam 1.00 08-Apr-2004 4.00 Chemo/DXT 0.00 0.00 
62.00 1.00 54.34 0.00 oesoph 0.00 squam 1.00 05-Mar-2002 4.00 Chemo/DXT 0.00 0.00 
63.00 1.00 84.12 2.00 oesoph 0.00 squam 1.00 20-Feb-2001 2.00 DXT 1.00 0.00 
64.00 0.00 80.21 2.00 oesoph 0.00 squam 1.00 04-Apr-2000 1.00 DXT 1.00 0.00 
65.00 0.00 71.91 1.00 oesoph 0.00 squam 1.00 26-Nov-2002 4.00 DXT 1.00 0.00 
66.00 0.00 78.48 2.00 oesoph 0.00 squam 1.00 13-Apr-2004 3.00 DXT 1.00 0.00 
67.00 0.00 76.22 2.00 oesoph 0.00 adeno 0.00 22-Jul-2003 3.00 DXT 1.00 0.00 
68.00 0.00 51.85 0.00 oesoph 0.00 adeno 0.00 10-Dec-2002 4.00 DXT 1.00 0.00 
69.00 0.00 55.67 0.00 oesoph 0.00 adeno 0.00 20-Oct-2003 4.00 DXT 1.00 0.00 
70.00 0.00 73.47 1.00 oesoph 0.00 squam 1.00 26-Oct-2004 3.00 DXT 1.00 0.00 
71.00 1.00 81.79 2.00 oesoph 0.00 squam 1.00 29-Mar-2004 2.00 DXT 1.00 0.00 
72.00 0.00 54.42 0.00 o/g 0.00 adeno 0.00 13-Mar-2000 4.00 DXT 1.00 0.00 
73.00 1.00 75.39 2.00 oesoph 0.00 adeno 0.00 13-Nov-2001 3.00 DXT 1.00 0.00 
74.00 0.00 79.25 2.00 oesoph 0.00 adeno 0.00 30-Aug-2004 2.00 DXT 1.00 0.00 
75.00 1.00 82.43 2.00 oesoph 0.00 squam 1.00 15-Jan-2003 1.00 DXT 1.00 0.00 
76.00 1.00 66.67 1.00 oesoph 0.00 adeno 0.00 26-Nov-2004 4.00 DXT 1.00 0.00 
77.00 0.00 65.16 0.00 oesoph 0.00 squam 1.00 23-Apr-2003 3.00 DXT 1.00 0.00 
78.00 1.00 61.31 0.00 oesoph 0.00 squam 1.00 20-Aug-2002 4.00 DXT 1.00 0.00 
79.00 0.00 80.23 2.00 oesoph 0.00 squam 1.00 25-Jun-2002 4.00 DXT 1.00 0.00 
80.00 0.00 67.02 1.00 oesoph 0.00 squam 1.00 03-Mar-2003 4.00 DXT 1.00 0.00 
81.00 1.00 71.65 1.00 oesoph 0.00 squam 1.00 11-Jun-2003 3.00 DXT & Laser 1.00 0.00 
82.00 1.00 84.17 2.00 oesoph 0.00 adeno 0.00 05-Nov-2004 3.00 DXT & Laser 1.00 0.00 
83.00 0.00 65.40 0.00 oesoph 0.00 squam 1.00 18-Jun-2002 4.00 DXT & Laser 1.00 0.00 
84.00 0.00 81.18 2.00 oesoph 0.00 adeno 0.00 16-Oct-2003 3.00 DXT & Laser 1.00 0.00 
85.00 1.00 76.94 2.00 oesoph 0.00 adeno 0.00 27-Nov-2000 2.00 DXT & Laser 1.00 0.00 
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86.00 1.00 82.10 2.00 oesoph 0.00 squam 1.00 05-Jul-2002 1.00 DXT & Laser 1.00 0.00 
87.00 0.00 86.97 2.00 oesoph 0.00 squam 1.00 08-Aug-2004 3.00 DXT & Laser 1.00 0.00 
88.00 0.00 75.06 2.00 oesoph 0.00 adeno 0.00 31-Jan-2003 3.00 DXT & Laser 1.00 0.00 
89.00 1.00 81.41 2.00 oesoph 0.00 squam 1.00 18-Dec-2001 2.00 DXT& Laser 1.00 0.00 
90.00 0.00 67.91 1.00 oesoph 0.00 squam 1.00 28-Jun-2000 4.00 DXT/Stent 1.00 0.00 
91.00 0.00 88.10 2.00 oesoph 0.00 adeno 0.00 28-May-2002 3.00 Laser 2.00 0.00 
92.00 0.00 75.64 2.00 oesoph 0.00 adeno 0.00 16-Sep-2002 3.00 Laser 2.00 0.00 
93.00 1.00 74.66 1.00 oesoph 0.00 adeno 0.00 22-Jun-2001 1.00 Laser 2.00 0.00 
94.00 1.00 67.09 1.00 oesoph 0.00 adeno 0.00 27-Mar-2000 1.00 Laser 2.00 0.00 
95.00 0.00 75.50 2.00 o/g 0.00 adeno 0.00 30-Jul-2001 3.00 Laser 2.00 0.00 
96.00 0.00 74.82 1.00 oesoph 0.00 adeno 0.00 10-Sep-2002 2.00 Laser 2.00 0.00 
97.00 1.00 81.87 2.00 oesoph 0.00 adeno 0.00 20-Jun-2001 2.00 Laser 2.00 0.00 
98.00 1.00 68.18 1.00 oesoph 0.00 adeno 0.00 24-Mar-2000 4.00 Laser 2.00 0.00 
99.00 0.00 74.00 1.00 oesoph 0.00 adeno 0.00 01-Feb-2000 3.00 Laser 2.00 0.00 
100.00 0.00 81.99 2.00 oesoph 0.00 adeno 0.00 01-Nov-2001 3.00 Laser 2.00 0.00 
101.00 0.00 75.39 2.00 oeosph 0.00 squam 1.00 17-Jun-2002 4.00 Laser 2.00 0.00 
102.00 0.00 72.57 1.00 oesoph 0.00 squam 1.00 29-Feb-2004 3.00 Laser 2.00 0.00 
103.00 1.00 84.39 2.00 oesoph 0.00 adeno 0.00 05-Feb-2002 4.00 Laser 2.00 0.00 
104.00 1.00 86.71 2.00 oesoph 0.00 adeno 0.00 19-Mar-2004 2.00 Laser 2.00 0.00 
105.00 1.00 67.63 1.00 o/g 0.00 adeno 0.00 13-Mar-2000 4.00 Laser 2.00 0.00 
106.00 1.00 81.36 2.00 oesoph 0.00 adeno 0.00 26-Nov-2002 1.00 Laser 2.00 0.00 
107.00 0.00 81.61 2.00 o/g 0.00 adeno 0.00 29-Oct-2002 1.00 Laser 2.00 0.00 
108.00 1.00 82.73 2.00 oesoph 0.00 adeno 0.00 07-May-2003 4.00 Laser 2.00 0.00 
109.00 1.00 78.32 2.00 oesoph 0.00 squam 1.00 28-Mar-2003 3.00 Laser 2.00 0.00 
110.00 0.00 82.98 2.00 oesoph 0.00 adeno 0.00 03-Sep-2004 4.00 Laser 2.00 0.00 
111.00 0.00 79.00 2.00 oesoph 0.00 adeno 0.00 10-Nov-2004 3.00 Laser 2.00 0.00 
112.00 0.00 65.53 0.00 oesoph 0.00 adeno 0.00 23-Apr-2002 2.00 Laser 2.00 0.00 
113.00 1.00 66.59 1.00 oesoph 0.00 squam 1.00 14-Jul-2000 3.00 None 4.00 1.00 
114.00 1.00 70.21 1.00 oesoph 0.00 adeno 0.00 10-Mar-2004 4.00 None 4.00 1.00 
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115.00 0.00 79.52 2.00 oesoph 0.00 squam 1.00 30-Jul-2004 4.00 None 4.00 1.00 
116.00 0.00 82.16 2.00 oesoph 0.00 squam 1.00 27-Sep-2002 4.00 None 4.00 1.00 
117.00 0.00 82.54 2.00 oesoph 0.00 squam 1.00 24-Sep-2004 4.00 None 4.00 1.00 
118.00 0.00 73.97 1.00 oesoph 0.00 adeno 0.00 21-Mar-2000 4.00 None 4.00 1.00 
119.00 0.00 66.57 1.00 oesoph 0.00 squam 1.00 09-Apr-2002 4.00 None 4.00 1.00 
120.00 0.00 69.73 1.00 o/g 0.00 adeno 0.00 14-Mar-2000 4.00 None 4.00 1.00 
121.00 0.00 69.98 1.00 oesoph 0.00 adeno 0.00 10-May2004 3.00 by-pass 3.00 1.00 
122.00 1.00 81.79 2.00 oesoph 0.00 adeno 0.00 26-Mar-2002 2.00 Stent 3.00 1.00 
123.00 0.00 64.80 0.00 oesoph 0.00 adeno 0.00 11-Oct-2002 4.00 Stent 3.00 1.00 
124.00 1.00 82.59 2.00 oesoph 0.00 squam 1.00 17-Dec-2002 3.00 Stent 3.00 1.00 
125.00 0.00 75.17 2.00 oesoph 0.00 squam 1.00 14-Oct-2004 3.00 Stent 3.00 1.00 
126.00 0.00 77.15 2.00 oesoph 0.00 squam 1.00 12-Apr-2002 3.00 Stent 3.00 1.00 
127.00 1.00 81.04 2.00 oesoph 0.00 adeno 0.00 27-Jan-2000 2.00 Stent 3.00 1.00 
128.00 0.00 79.78 2.00 oesoph 0.00 adeno 0.00 28-Jan-2002 3.00 Stent 3.00 1.00 
129.00 0.00 77.69 2.00 oesoph 0.00 squam 1.00 04-Jun-2004 4.00 Stent 3.00 1.00 
130.00 1.00 64.25 0.00 oesoph 0.00 squam 1.00 12-Jan-2000 4.00 Stent 3.00 1.00 
131.00 1.00 94.03 2.00 oesoph 0.00 adeno 0.00 16-Jan-2004 2.00 Stent 3.00 1.00 
132.00 0.00 88.54 2.00 oesoph 0.00 squam 1.00 09-Oct-2002 3.00 Stent 3.00 1.00 
133.00 0.00 74.88 1.00 oesoph 0.00 squam 1.00 15-Feb-2000 3.00 Stent 3.00 1.00 
134.00 0.00 73.52 1.00 oeosph 0.00 squam 1.00 10-Oct-2001 3.00 Stent 3.00 1.00 
135.00 1.00 75.56 2.00 oesoph 0.00 squam 1.00 20-Oct-2004 3.00 Stent 3.00 1.00 
136.00 1.00 94.07 2.00 oesoph 0.00 squam 1.00 11-Sep-2001 4.00 Stent 3.00 1.00 
137.00 1.00 75.61 2.00 oesoph 0.00 squam 1.00 02-Apr-2001 2.00 Stent 3.00 1.00 
138.00 0.00 87.56 2.00 oesoph 0.00 squam 1.00 03-Jul-2001 2.00 Stent 3.00 1.00 
139.00 0.00 61.07 0.00 oesoph 0.00 adeno 0.00 29-Apr-2000 4.00 Stent 3.00 1.00 
140.00 0.00 64.48 0.00 oesoph 0.00 squam 1.00 11-Jan-2000 4.00 Stent 3.00 1.00 
141.00 0.00 70.88 1.00 oesoph 0.00 squam 1.00 27-Oct-2000 3.00 Stent& Chemo 0.00 0.00 
142.00 1.00 68.99 1.00 oesoph 0.00 squam 1.00 23-Apr-2003 3.00 T DXT 1.00 0.00 
143.00 0.00 59.88 0.00 o/g 1.00 adeno 0.00 03-Dec-2004 4.00 CH/DXT 0.00 0.00 
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144.00 1.00 54.36 0.00 gastric 1.00 adeno 0.00 06-Dec-2004 4.00 Chemo 0.00 0.00 
145.00 1.00 61.79 0.00 gastric 1.00 adeno 0.00 08-Oct-2002 4.00 Chemo 0.00 0.00 
146.00 1.00 34.01 0.00 gastric 1.00 adeno 0.00 07-Dec-2001 4.00 Chemo 0.00 0.00 
147.00 1.00 42.09 0.00 gastric 1.00 adeno 0.00 23-Jan-2003 4.00 Chemo 0.00 0.00 
148.00 0.00 67.62 1.00 gastric 1.00 adeno 0.00 10-Jul-2001 4.00 Chemo 0.00 0.00 
149.00 0.00 69.49 1.00 gastric 1.00 adeno 0.00 26-Feb-2002 4.00 Chemo 0.00 0.00 
150.00 1.00 63.99 0.00 gastric 1.00 adeno 0.00 12-Nov-2002 1.00 Chemo 0.00 0.00 
151.00 0.00 73.47 1.00 gastric 1.00 adeno 0.00 16-Jul-2004 4.00 Chemo 0.00 0.00 
152.00 1.00 65.05 0.00 gastric 1.00 adeno 0.00 01-Dec-2003 4.00 Chemo 0.00 0.00 
153.00 0.00 65.38 0.00 gastric 1.00 adeno 0.00 21-Feb-2002 3.00 Chemo 0.00 0.00 
154.00 0.00 43.64 0.00 o/g 1.00 adeno 0.00 29-Jul-2004 4.00 Chemo 0.00 0.00 
155.00 1.00 53.29 0.00 gastric 1.00 adeno 0.00 24-Feb-2004 4.00 Chemo 0.00 0.00 
156.00 0.00 57.72 0.00 gastric 1.00 adeno 0.00 12-Apr-2002 2.00 Chemo 0.00 0.00 
157.00 0.00 54.62 0.00 gastric 1.00 adeno 0.00 19-Jun-2003 4.00 Chemo 0.00 0.00 
158.00 1.00 63.74 0.00 gastric 1.00 adeno 0.00 06-Jul-2004 4.00 Chemo 0.00 0.00 
159.00 0.00 42.48 0.00 o/g 1.00 adeno 0.00 17-Sep-2004 4.00 Chemo 0.00 0.00 
160.00 0.00 46.92 0.00 gastric 1.00 adeno 0.00 02-Mar-2002 4.00 Chemo 0.00 0.00 
161.00 0.00 43.31 0.00 o/g 1.00 adeno 0.00 06-Jan-2003 4.00 Chemo 0.00 0.00 
162.00 0.00 71.71 1.00 gastric 1.00 adeno 0.00 30-Jul-2004 4.00 Chemo 0.00 0.00 
163.00 0.00 44.99 0.00 gastric 1.00 adeno 0.00 01-Mar-2002 4.00 Chemo 0.00 0.00 
164.00 1.00 76.88 2.00 o/g 1.00 adeno 0.00 23-Mar-2004 4.00 Chemo 0.00 0.00 
165.00 1.00 41.38 0.00 gastric 1.00 adeno 0.00 14-Jun-2004 4.00 Chemo  0.00 0.00 
166.00 0.00 52.05 0.00 o/g 1.00 adeno 0.00 05-Jun-2003 4.00 Chemo&Laser 0.00 0.00 
167.00 1.00 76.62 2.00 gastric 1.00 adeno 0.00 19-Dec-2003 3.00 Chemo&Laser 0.00 0.00 
168.00 0.00 76.19 2.00 gastric 1.00 adeno 0.00 30-May-2003 4.00 Chemo&Laser 0.00 0.00 
169.00 1.00 76.56 2.00 gastric 1.00 adeno 0.00 24-Apr-2001 2.00 Chemo/DXT 0.00 0.00 
170.00 0.00 78.84 2.00 o/g 1.00 adeno 0.00 30-Oct-2001 4.00 Chemo/DXT 0.00 0.00 
171.00 0.00 74.54 1.00 gastric 1.00 adeno 0.00 08-Jan-2002 4.00 Chemo/DXT 0.00 0.00 
172.00 0.00 60.26 0.00 gastric 1.00 adeno 0.00 10-Jun-2002 4.00 Chemo/DXT 0.00 0.00 
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173.00 0.00 55.01 0.00 gastric 1.00 adeno 0.00 13-Mar-2002 3.00 Chemo/DXT 0.00 0.00 
174.00 0.00 74.95 1.00 o/g 1.00 adeno 0.00 14-Sep-2004 3.00 Chemo/DXT 0.00 0.00 
175.00 0.00 56.00 0.00 gastric 1.00 adeno 0.00 19-Oct-2001 4.00 Chemo/DXT 0.00 0.00 
176.00 0.00 74.54 1.00 gastric 1.00 adeno 0.00 05-May-2004 4.00 Chemo/DXT 0.00 0.00 
177.00 1.00 33.71 0.00 gastric 1.00 adeno 0.00 06-Dec-2001 4.00 Chemo/DXT 0.00 0.00 
178.00 1.00 46.43 0.00 o/g 1.00 adeno 0.00 20-Jul-2001 4.00 Chemo/DXT 0.00 0.00 
179.00 0.00 69.81 1.00 gastric 1.00 adeno 0.00 30-Nov-2004 3.00 Chemo/DXT 0.00 0.00 
180.00 1.00 47.14 0.00 gastric 1.00 adeno 0.00 09-Sep-2003 4.00 Chemo/DXT 0.00 0.00 
181.00 1.00 73.42 1.00 gastric 1.00 adeno 0.00 23-Oct-2001 4.00 Chemo/DXT 0.00 0.00 
182.00 0.00 62.12 0.00 gastric 1.00 adeno 0.00 30-Dec-2004 4.00 DXT 1.00 0.00 
183.00 0.00 63.53 0.00 gastric 1.00 adeno 0.00 16-Jul-2004 4.00 DXT 1.00 0.00 
184.00 1.00 63.67 0.00 gastric 1.00 adeno 0.00 07-Dec-2004 4.00 DXT 1.00 0.00 
185.00 1.00 68.39 1.00 gastric 1.00 adeno 0.00 22-Jun-2004 2.00 DXT 1.00 0.00 
186.00 0.00 56.78 0.00 gastric 1.00 adeno 0.00 16-Jan-2002 4.00 gastro-jej 3.00 1.00 
187.00 1.00 43.82 0.00 gastric 1.00 adeno 0.00 21-May-2002 3.00 gastro-jej 3.00 1.00 
188.00 0.00 45.28 0.00 gastric 1.00 adeno 0.00 10-Jan-2001 4.00 gastro-jej 3.00 1.00 
189.00 0.00 69.71 1.00 gastric 1.00 adeno 0.00 09-Jun-2000 4.00 gastro-jej 3.00 1.00 
190.00 0.00 64.93 0.00 gastric 1.00 adeno 0.00 30-Apr-2003 4.00 gastro-jej 3.00 1.00 
191.00 1.00 57.48 0.00 gastric 1.00 adeon 0.00 22-Feb-2002 4.00 gastro-jej 3.00 1.00 
192.00 0.00 83.79 2.00 gastric 1.00 adeno 0.00 20-Mar-2000 1.00 Laser 2.00 0.00 
193.00 1.00 72.34 1.00 gastric 1.00 adeno 0.00 25-Jul-2000 3.00 Laser 2.00 0.00 
194.00 0.00 79.99 2.00 o/g 1.00 adeno 0.00 09-Jun-2003 3.00 Laser 2.00 0.00 
195.00 1.00 80.68 2.00 gastric 1.00 adeno 0.00 03-Nov-2003 1.00 Laser 2.00 0.00 
196.00 0.00 75.63 2.00 gastric 1.00 adeno 0.00 25-Jun-2004 2.00 Laser 2.00 0.00 
197.00 0.00 78.31 2.00 gastric 1.00 adeno 0.00 26-Nov-2001 1.00 Laser 2.00 0.00 
198.00 0.00 76.04 2.00 gastric 1.00 adeno 0.00 01-Jul-2003 1.00 Laser 2.00 0.00 
199.00 0.00 63.56 0.00 o/g 1.00 adeno 0.00 23-Aug-2004 4.00 Laser 2.00 0.00 
200.00 1.00 82.97 2.00 gastric 1.00 adeno 0.00 02-Mar-2001 4.00 Laser 2.00 0.00 
201.00 0.00 81.80 2.00 gastric 1.00 adeno 0.00 29-Jan-2003 1.00 Laser 2.00 0.00 
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202.00 1.00 86.61 2.00 o/g 1.00 adeno 0.00 21-Mar-2000 1.00 Laser 2.00 0.00 
203.00 1.00 82.75 2.00 gastric 1.00 adeno 0.00 06-Jan-2004 4.00 Laser 2.00 0.00 
204.00 0.00 83.03 2.00 o/g 1.00 adeno 0.00 27-Feb-2004 4.00 Laser 2.00 0.00 
205.00 0.00 85.40 2.00 gastric 1.00 adeno 0.00 21-Jun-2001 1.00 Laser 2.00 0.00 
206.00 0.00 57.03 0.00 gastric 1.00 adeno 0.00 08-Jun-2000 4.00 Laser 2.00 0.00 
207.00 0.00 81.26 2.00 gastric 1.00 adeno 0.00 22-Jul-2003 1.00 Laser 2.00 0.00 
208.00 0.00 68.48 1.00 gastric 1.00 adeno 0.00 24-Sep-2003 4.00 Laser 2.00 0.00 
209.00 0.00 76.76 2.00 o/g 1.00 adeno 0.00 09-Sep-2003 1.00 Laser 2.00 0.00 
210.00 1.00 78.98 2.00 gastric 1.00 adeno 0.00 26-Apr-2000 4.00 Laser 2.00 0.00 
211.00 0.00 48.56 0.00 gastric 1.00 adeno 0.00 01-May-2002 4.00 Laser 2.00 0.00 
212.00 0.00 84.30 2.00 gastric 1.00 adeno 0.00 06-Nov-2001 4.00 Laser 2.00 0.00 
213.00 0.00 82.93 2.00 o/g 1.00 adeno 0.00 21-Oct-2002 4.00 Laser 2.00 0.00 
214.00 0.00 76.85 2.00 gastric 1.00 adeno 0.00 16-Jun-2000 4.00 Laser 2.00 0.00 
215.00 0.00 89.10 2.00 gastric 1.00 adeno 0.00 05-Jan-2001 1.00 Laser 2.00 0.00 
216.00 0.00 81.08 2.00 gastric 1.00 adeno 0.00 11-Oct-2004 1.00 Laser 2.00 0.00 
217.00 1.00 89.19 2.00 gastric 1.00 adeno 0.00 12-Aug-2002 4.00 Laser 2.00 0.00 
218.00 1.00 71.28 1.00 gastric 1.00 adeno 0.00 05-Jul-2002 4.00 Laser 2.00 0.00 
219.00 1.00 81.07 2.00 gastric 1.00 adeno 0.00 04-May-2004 2.00 Laser 2.00 0.00 
220.00 0.00 79.14 2.00 o/g 1.00 adeno 0.00 01-Apr-2004 4.00 Laser 2.00 0.00 
221.00 1.00 76.32 2.00 gastric 1.00 adeno 0.00 06-Aug-2001 1.00 Laser 2.00 0.00 
222.00 0.00 60.06 0.00 gastric 1.00 adeno 0.00 20-Oct-2004 1.00 Laser 2.00 0.00 
223.00 0.00 84.36 2.00 gastric 1.00 adeno 0.00 22-Oct-2004 1.00 Laser 2.00 0.00 
224.00 1.00 77.57 2.00 o/g 1.00 adeno 0.00 06-Nov-2001 4.00 Laser 2.00 0.00 
225.00 0.00 71.32 1.00 gastric 1.00 adeno 0.00 13-May-2004 1.00 Laser 2.00 0.00 
226.00 0.00 79.90 2.00 gastric 1.00 adeno 0.00 09-Apr-2001 1.00 Laser 2.00 0.00 
227.00 0.00 72.27 1.00 gastric 1.00 adeno 0.00 09-Jul-2003 4.00 Laser 2.00 0.00 
228.00 0.00 76.24 2.00 gastric 1.00 adeno 0.00 05-Oct-2001 3.00 Laser 2.00 0.00 
229.00 1.00 75.35 2.00 gastric 1.00 adeno 0.00 27-Jun-2001 4.00 Laser 2.00 0.00 
230.00 0.00 59.00 0.00 gastric 1.00 adeno 0.00 11-Oct-2000 4.00 None 4.00 1.00 
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231.00 1.00 62.52 0.00 gastric 1.00 adeno 0.00 23-Aug-2002 4.00 None 4.00 1.00 
232.00 1.00 84.38 2.00 gastric 1.00 adeno 0.00 05-Jul-2000 4.00 None 4.00 1.00 
233.00 0.00 81.02 2.00 o/g 1.00 adeno 0.00 02-Sep-2004 4.00 None 4.00 1.00 
234.00 0.00 78.85 2.00 gastric 1.00 adeno 0.00 12-Sep-2003 3.00 None 4.00 1.00 
235.00 1.00 78.92 2.00 gastric 1.00 adeno 0.00 23-Nov-2004 4.00 None 4.00 1.00 
236.00 1.00 46.58 0.00 gastric 1.00 adeno 0.00 07-Dec-2004 4.00 None 4.00 1.00 
237.00 1.00 85.61 2.00 gastric 1.00 adeno 0.00 04-Aug-2003 4.00 None 4.00 1.00 
238.00 0.00 83.97 2.00 gastric 1.00 adeno 0.00 28-Apr-2000 1.00 None 4.00 1.00 
239.00 0.00 70.50 1.00 o/g 1.00 adeno 0.00 27-Jul-2001 4.00 None 4.00 1.00 
240.00 1.00 66.95 1.00 gastric 1.00 adeno 0.00 30-Aug-2002 1.00 None 4.00 1.00 
241.00 1.00 63.49 0.00 gastric 1.00 adeno 0.00 04-May-2001 4.00 None 4.00 1.00 
242.00 1.00 82.80 2.00 gastric 1.00 adeno 0.00 21-Nov-2000 2.00 None 4.00 1.00 
243.00 0.00 30.19 0.00 o/g 1.00 adeno 0.00 16-Oct-2003 4.00 None 4.00 1.00 
244.00 0.00 75.98 2.00 gastric 1.00 adeno 0.00 24-Aug-2004 4.00 None 4.00 1.00 
245.00 0.00 77.28 2.00 gastric 1.00 adeno 0.00 07-Mar-2003 4.00 None 4.00 1.00 
246.00 1.00 78.79 2.00 gastric 1.00 adeno 0.00 10-Jun-2002 4.00 None 4.00 1.00 
247.00 0.00 73.96 1.00 gastric 1.00 adeno 0.00 18-Nov-2003 4.00 None 4.00 1.00 
248.00 0.00 73.94 1.00 gastric 1.00 adeno 0.00 14-Oct-2003 4.00 None 4.00 1.00 
249.00 1.00 74.99 1.00 gastric 1.00 adeno 0.00 04-Dec-2003 4.00 None 4.00 1.00 
250.00 1.00 60.28 0.00 o/g 1.00 adeno 0.00 08-Aug-2000 4.00 None 4.00 1.00 
251.00 0.00 81.02 2.00 o/g 1.00 adeno 0.00 26-Jul-2001 4.00 None 4.00 1.00 
252.00 1.00 79.70 2.00 o/g 1.00 adeno 0.00 18-Apr-2000 4.00 None 4.00 1.00 
253.00 0.00 76.34 2.00 gastric 1.00 adeno 0.00 26-Mar-2004 4.00 None 4.00 1.00 
254.00 1.00 62.27 0.00 gastric 1.00 adeno 0.00 09-May-2003 4.00 None 4.00 1.00 
255.00 0.00 42.06 0.00 gastric 1.00 adeno 0.00 17-Mar-2004 4.00 None 4.00 1.00 
256.00 1.00 77.36 2.00 gastric 1.00 adeno 0.00 07-Dec-2004 3.00 Stent 3.00 1.00 
257.00 0.00 92.45 2.00 gastric 1.00 adeno 0.00 23-Dec-2003 2.00 Stent 3.00 1.00 





Patient  status c of death a0cd1nc2 dofu survmths crp crpcd alb albcd Gps alp alpcd 
1.00 ALIVE  0.00 30-Jun-2005 8.50 56.00 1.00 36.00 0.00 1.00 207.00 0.00 
2.00 DEAD cancer 1.00 18-Apr-2005 17.43 15.00 1.00 39.00 0.00 1.00 162.00 0.00 
3.00 ALIVE  0.00 30-Jun-2005 40.80 1.00 0.00 43.00 0.00 0.00 19.00 0.00 
4.00 ALIVE  0.00 30-Jun-2005 9.07 10.00 0.00 40.00 0.00 0.00 139.00 0.00 
5.00 DEAD cancer 1.00 13-Dec-2003 3.43 22.00 1.00 34.00 1.00 2.00 153.00 0.00 
6.00 ALIVE  0.00 30-Jun-2005 9.53 56.00 1.00 46.00 0.00 1.00 157.00 0.00 
7.00 DEAD renal 2.00 29-Mar-2003 5.73 1.00 0.00 36.00 0.00 0.00 166.00 0.00 
8.00 DEAD cancer 1.00 27-Feb-2005 19.27 9.00 0.00 46.00 0.00 0.00 184.00 0.00 
9.00 DEAD cancer 1.00 30-Apr-2005 15.50 28.00 1.00 47.00 0.00 1.00 189.00 0.00 
10.00 DEAD cancer 1.00 29-Jun-2003 19.00 36.00 1.00 40.00 0.00 1.00 189.00 0.00 
11.00 DEAD cancer 1.00 01-Feb-2005 10.50 1.00 0.00 43.00 0.00 0.00 191.00 0.00 
12.00 DEAD cancer 1.00 23-Sep-2004 21.77 1.00 0.00 43.00 0.00 0.00 191.00 0.00 
13.00 DEAD cancer 1.00 24-Oct-2002 11.47 12.00 1.00 37.00 0.00 1.00 199.00 0.00 
14.00 DEAD cancer 1.00 03-Nov-2004 2.63 36.00 1.00 35.00 0.00 1.00 215.00 0.00 
15.00 DEAD cancer 1.00 30-May-2003 13.63 1.00 0.00 40.00 0.00 0.00 235.00 0.00 
16.00 DEAD cancer 1.00 23-Aug-2004 7.20 27.00 1.00 40.00 0.00 1.00 237.00 0.00 
17.00 DEAD cancer 1.00 20-Nov-2002 11.37 1.00 0.00 44.00 0.00 0.00 258.00 0.00 
18.00 ALIVE  0.00 30-Jun-2005 6.37 8.00 0.00 50.00 0.00 0.00 271.00 0.00 
19.00 ALIVE  0.00 30-Jun-2005 10.07 32.00 1.00 32.00 1.00 2.00 295.00 1.00 
20.00 DEAD cancer 1.00 01-Sep-2002 18.83 12.00 1.00 42.00 0.00 1.00 385.00 1.00 
21.00 DEAD cardiac 2.00 25-May-2004 11.87 42.00 1.00 38.00 0.00 1.00 411.00 1.00 
22.00 DEAD cancer 1.00 11-Dec-2001 6.07 69.00 1.00 41.00 0.00 1.00 630.00 1.00 
23.00 DEAD cancer 1.00 21-Jul-2004 0.93 217.00 1.00 43.00 0.00 1.00 645.00 1.00 
24.00 ALIVE  0.00 30-Jun-2005 11.27 1.00 0.00 40.00 0.00 0.00 148.00 0.00 
25.00 DEAD cancer 1.00 02-Apr-2002 4.40 70.00 1.00 36.00 0.00 1.00 1,479.00 1.00 
26.00 DEAD cancer 1.00 08-Mar-2003 22.50 18.00 1.00 45.00 0.00 1.00 135.00 0.00 
27.00 ALIVE  0.00 30-Jun-2005 54.67 1.00 0.00 39.00 0.00 0.00 135.00 0.00 
28.00 DEAD cancer 1.00 13-Dec-2001 10.57 30.00 1.00 38.00 0.00 1.00 195.00 0.00 
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29.00 DEAD cardiac 2.00 23-Jun-2003 10.63 31.00 1.00 47.00 0.00 1.00 99.00 0.00 
30.00 DEAD cancer 1.00 06-Nov-2000 3.37 23.00 1.00 40.00 0.00 1.00 110.00 0.00 
31.00 DEAD cancer 1.00 23-Jul-2004 19.47 72.00 1.00 39.00 0.00 1.00 118.00 0.00 
32.00 DEAD cancer 1.00 03-Jan-2003 15.30 71.00 1.00 35.00 0.00 1.00 122.00 0.00 
33.00 DEAD cancer 1.00 19-Apr-2002 10.37 28.00 1.00 41.00 0.00 1.00 130.00 0.00 
34.00 DEAD cancer 1.00 28-Nov-2002 6.60 1.00 0.00 44.00 0.00 0.00 132.00 0.00 
35.00 DEAD cancer 1.00 13-Sep-2002 13.37 35.00 1.00 36.00 0.00 1.00 135.00 0.00 
36.00 DEAD cancer 1.00 21-Jan-2004 4.63 1.00 0.00 45.00 0.00 0.00 144.00 0.00 
37.00 ALIVE  0.00 30-Jun-2005 25.67 1.00 0.00 48.00 0.00 0.00 144.00 0.00 
38.00 DEAD cardiac 2.00 05-May-2000 1.20 1.00 0.00 42.00 0.00 0.00 145.00 0.00 
39.00 DEAD cancer 1.00 01-Oct-2004 10.53 38.00 1.00 34.00 1.00 2.00 164.00 0.00 
40.00 DEAD cancer 1.00 27-Dec-2003 10.10 19.00 1.00 34.00 1.00 2.00 164.00 0.00 
41.00 DEAD cancer 1.00 03-Sep-2004 6.57 1.00 0.00 36.00 0.00 0.00 167.00 0.00 
42.00 ALIVE  0.00 30-Jun-2005 30.40 19.00 1.00 41.00 0.00 1.00 168.00 0.00 
43.00 DEAD cancer 1.00 23-Sep-2003 1.67 19.00 1.00 39.00 0.00 1.00 169.00 0.00 
44.00 ALIVE  0.00 30-Jun-2005 18.03 1.00 0.00 44.00 0.00 0.00 170.00 0.00 
45.00 DEAD cancer 1.00 07-Jul-2004 6.60 36.00 1.00 43.00 0.00 1.00 171.00 0.00 
46.00 ALIVE  0.00 30-Jun-2005 26.20 1.00 0.00 38.00 0.00 0.00 183.00 0.00 
47.00 ALIVE  0.00 30-Jun-2005 15.73 1.00 0.00 39.00 0.00 0.00 188.00 0.00 
48.00 DEAD cancer 1.00 08-Mar-2003 8.43 1.00 0.00 42.00 0.00 0.00 192.00 0.00 
49.00 DEAD cancer 1.00 27-Nov-2001 2.33 12.00 1.00 46.00 0.00 1.00 195.00 0.00 
50.00 ALIVE  0.00 30-Jun-2005 30.63 6.00 0.00 46.00 0.00 0.00 197.00 0.00 
51.00 DEAD pneumoni 2.00 17-Jan-2002 2.77 11.00 1.00 36.00 0.00 1.00 197.00 0.00 
52.00 DEAD cancer 1.00 03-May-2002 5.00 10.00 0.00 42.00 0.00 0.00 198.00 0.00 
53.00 DEAD cancer 1.00 14-Feb-2003 16.20 8.00 0.00 46.00 0.00 0.00 204.00 0.00 
54.00 DEAD cancer 1.00 24-Jan-2005 12.53 20.00 1.00 41.00 0.00 1.00 222.00 0.00 
55.00 ALIVE  0.00 30-Jun-2005 45.50 44.00 1.00 42.00 0.00 1.00 222.00 0.00 
56.00 DEAD cancer 1.00 17-Jan-2004 5.00 48.00 1.00 45.00 0.00 1.00 225.00 0.00 
57.00 ALIVE  0.00 30-Jun-2005 16.07 10.00 0.00 45.00 0.00 0.00 235.00 0.00 
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58.00 DEAD cancer 1.00 08-Dec-2004 10.97 1.00 0.00 47.00 0.00 0.00 239.00 0.00 
59.00 ALIVE  0.00 30-Jun-2005 7.07 11.00 1.00 40.00 0.00 1.00 262.00 0.00 
60.00 ALIVE  0.00 30-Jun-2005 33.43 16.00 1.00 40.00 0.00 1.00 322.00 1.00 
61.00 ALIVE  0.00 30-Jun-2005 14.93 8.00 0.00 41.00 0.00 0.00 433.00 1.00 
62.00 DEAD cancer 1.00 05-May-2002 2.03 31.00 1.00 40.00 0.00 1.00 769.00 1.00 
63.00 DEAD cancer 1.00 10-Jun-2005 52.37 9.00 0.00 41.00 0.00 0.00   
64.00 DEAD cancer 1.00 23-Mar-2001 11.77 1.00 0.00 42.00 0.00 0.00 130.00 0.00 
65.00 DEAD cancer 1.00 10-Apr-2003 4.50 50.00 1.00 33.00 1.00 2.00 150.00 0.00 
66.00 DEAD cancer 1.00 10-Apr-2005 12.07 1.00 0.00 43.00 0.00 0.00 160.00 0.00 
67.00 DEAD cancer 1.00 17-Nov-2004 16.13 1.00 0.00 42.00 0.00 0.00 161.00 0.00 
68.00 DEAD cancer 1.00 02-Sep-2003 8.87 12.00 1.00 43.00 0.00 1.00 173.00 0.00 
69.00 DEAD cancer 1.00 12-Oct-2004 11.93 97.00 1.00 43.00 0.00 1.00 176.00 0.00 
70.00 ALIVE  0.00 30-Jun-2005 8.23 62.00 1.00 38.00 0.00 1.00 190.00 0.00 
71.00 ALIVE  0.00 30-Jun-2005 15.27 1.00 0.00 42.00 0.00 0.00 201.00 0.00 
72.00 DEAD cancer 1.00 26-Oct-2000 7.57 37.00 1.00 40.00 0.00 1.00 215.00 0.00 
73.00 DEAD cancer 1.00 09-Aug-2002 8.97 14.00 1.00 44.00 0.00 1.00 219.00 0.00 
74.00 ALIVE  0.00 30-Jun-2005 10.13 1.00 0.00 40.00 0.00 0.00 221.00 0.00 
75.00 ALIVE  0.00 30-Jun-2005 29.90 11.00 1.00 39.00 0.00 1.00 227.00 0.00 
76.00 ALIVE  0.00 30-Jun-2005 7.20 16.00 1.00 44.00 0.00 1.00 231.00 0.00 
77.00 DEAD cancer 1.00 10-Oct-2003 5.67 64.00 1.00 44.00 0.00 1.00 244.00 0.00 
78.00 DEAD cancer 1.00 12-Mar-2003 6.80 6.00 0.00 43.00 0.00 0.00 271.00 0.00 
79.00 DEAD cancer 1.00 03-Feb-2003 7.43 40.00 1.00 38.00 0.00 1.00 366.00 1.00 
80.00 DEAD cancer 1.00 07-Apr-2003 1.17 275.00 1.00 40.00 0.00 1.00 1,055.00 1.00 
81.00 DEAD cancer 1.00 02-Feb-2004 7.87 51.00 1.00 45.00 0.00 1.00 152.00 0.00 
82.00 DEAD cancer 1.00 18-Apr-2005 5.47 7.00 0.00 36.00 0.00 0.00 177.00 0.00 
83.00 DEAD cancer 1.00 23-Dec-2002 6.27 216.00 1.00 27.00 1.00 2.00 191.00 0.00 
84.00 DEAD cancer 1.00 24-Sep-2004 11.47 16.00 1.00 42.00 0.00 1.00 193.00 0.00 
85.00 DEAD cancer 1.00 02-Sep-2001 9.30 19.00 1.00 45.00 0.00 1.00 205.00 0.00 
86.00 DEAD cancer 1.00 11-Mar-2004 20.50 1.00 0.00 35.00 0.00 0.00 216.00 0.00 
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87.00 DEAD cancer 1.00 22-Dec-2004 4.53 12.00 1.00 42.00 0.00 1.00 223.00 0.00 
88.00 DEAD cancer 1.00 17-Apr-2003 2.53 17.00 1.00 36.00 0.00 1.00 443.00 1.00 
89.00 DEAD cancer 1.00 29-Jul-2002 7.43 1.00 0.00 41.00 0.00 0.00   
90.00 DEAD cancer 1.00 27-Jul-2000 0.97 87.00 1.00 34.00 1.00 2.00 240.00 0.00 
91.00 DEAD cancer 1.00 24-Oct-2002 4.97 1.00 0.00 33.00 1.00 1.00 130.00 0.00 
92.00 DEAD cancer 1.00 09-Jun-2003 8.87 25.00 1.00 44.00 0.00 1.00 150.00 0.00 
93.00 DEAD cancer 1.00 02-Mar-2002 8.43 1.00 0.00 40.00 0.00 0.00 155.00 0.00 
94.00 DEAD cancer 1.00 09-May-2004 50.13 1.00 0.00 42.00 0.00 0.00 165.00 0.00 
95.00 DEAD cancer 1.00 21-Jan-2002 5.83 6.00 0.00 42.00 0.00 0.00 175.00 0.00 
96.00 DEAD bleed 2.00 10-May-2003 8.07 1.00 0.00 45.00 0.00 0.00 195.00 0.00 
97.00 DEAD cancer 1.00 07-Jan-2003 18.87 1.00 0.00 43.00 0.00 0.00 195.00 0.00 
98.00 DEAD cancer 1.00 05-Aug-2000 4.47 60.00 1.00 36.00 0.00 1.00 195.00 0.00 
99.00 DEAD cancer 1.00 02-Jun-2001 16.23 1.00 0.00 38.00 0.00 0.00 195.00 0.00 
100.00 DEAD cancer 1.00 27-Jul-2002 8.93 43.00 1.00 43.00 0.00 1.00 198.00 0.00 
101.00 DEAD cancer 1.00 24-Dec-2002 6.33 133.00 1.00 40.00 0.00 1.00 227.00 0.00 
102.00 DEAD cancer 1.00 30-Apr-2004 2.03 39.00 1.00 34.00 1.00 2.00 230.00 0.00 
103.00 DEAD cancer 1.00 28-May-2002 3.73 12.00 1.00 41.00 0.00 1.00 235.00 0.00 
104.00 DEAD cancer 1.00 08-Mar-2005 11.80 17.00 1.00 31.00 1.00 2.00 240.00 0.00 
105.00 DEAD cancer 1.00 31-May-2000 2.63 28.00 1.00 42.00 0.00 1.00 245.00 0.00 
106.00 DEAD cancer 1.00 16-Aug-2004 20.97 1.00 0.00 47.00 0.00 0.00 248.00 0.00 
107.00 DEAD cancer 1.00 03-Sep-2003 10.30 7.00 0.00 43.00 0.00 0.00 324.00 1.00 
108.00 DEAD cancer 1.00 17-Jun-2003 1.37 91.00 1.00 35.00 0.00 1.00 334.00 1.00 
109.00 DEAD cancer 1.00 03-Sep-2004 17.50 122.00 1.00 35.00 0.00 1.00 367.00 1.00 
110.00 DEAD cancer 1.00 05-Nov-2004 2.10 36.00 1.00 33.00 1.00 2.00 424.00 1.00 
111.00 ALIVE  0.00 30-Jun-2005 7.73 1.00 0.00 41.00 0.00 0.00 540.00 1.00 
112.00 DEAD cancer 1.00 15-May-2002 0.73 153.00 1.00 22.00 1.00 2.00 610.00 1.00 
113.00 DEAD cancer 1.00 23-Jun-2001 11.47 31.00 1.00 33.00 1.00 2.00 55.00 0.00 
114.00 DEAD pneumo 1.00 26-Mar-2004 0.53 46.00 1.00 37.00 0.00 1.00 116.00 0.00 
115.00 DEAD cancer 1.00 09-Sep-2004 1.37 173.00 1.00 35.00 0.00 1.00 140.00 0.00 
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116.00 DEAD cancer 1.00 16-Jan-2003 3.70 27.00 1.00 46.00 0.00 1.00 217.00 0.00 
117.00 ALIVE  0.00 30-Jun-2005 9.30 162.00 1.00 26.00 1.00 2.00 270.00 0.00 
118.00 DEAD cancer 1.00 08-Apr-2000 0.60 101.00 1.00 24.00 1.00 2.00 445.00 1.00 
119.00 DEAD cancer 1.00 03-May-2002 0.80 37.00 1.00 40.00 0.00 1.00 741.00 1.00 
120.00 DEAD cancer 1.00 07-May-2000 1.80 87.00 1.00 39.00 0.00 1.00 900.00 1.00 
121.00 DEAD cancer 1.00 14-Mar-2005 10.27 1.00 0.00 38.00 0.00 0.00 138.00 0.00 
122.00 DEAD cancer 1.00 16-May-2002 1.70 23.00 1.00 39.00 0.00 1.00 106.00 0.00 
123.00 DEAD cancer 1.00 09-Dec-2002 1.97 14.00 1.00 36.00 0.00 1.00 118.00 0.00 
124.00 DEAD cancer 1.00 08-Jan-2003 0.73 6.00 0.00 45.00 0.00 0.00 134.00 0.00 
125.00 DEAD cancer 1.00 12-Dec-2004 1.97 70.00 1.00 34.00 1.00 2.00 159.00 0.00 
126.00 DEAD cancer 1.00 29-May-2002 1.57 6.00 0.00 36.00 0.00 0.00 160.00 0.00 
127.00 DEAD cancer 1.00 17-Mar-2002 26.00 26.00 1.00 40.00 0.00 1.00 175.00 0.00 
128.00 DEAD cancer 1.00 24-May-2002 3.87 1.00 0.00 35.00 0.00 0.00 178.00 0.00 
129.00 DEAD cancer 1.00 01-Aug-2004 1.93 44.00 1.00 40.00 0.00 1.00 184.00 0.00 
130.00 DEAD cancer 1.00 14-Jul-2000 6.13 103.00 1.00 35.00 0.00 1.00 190.00 0.00 
131.00 DEAD cancer 1.00 13-Sep-2004 8.03 1.00 0.00 33.00 1.00 1.00 193.00 0.00 
132.00 DEAD cancer 1.00 18-Nov-2002 1.33 66.00 1.00 38.00 0.00 1.00 221.00 0.00 
133.00 DEAD cancer 1.00 26-May-2000 3.37 16.00 1.00 42.00 0.00 1.00 230.00 0.00 
134.00 DEAD cancer 1.00 16-Mar-2002 5.23 1.00 0.00 43.00 0.00 0.00 233.00 0.00 
135.00 DEAD cancer 1.00 22-Mar-2005 5.10 1.00 0.00 44.00 0.00 0.00 292.00 1.00 
136.00 DEAD cancer 1.00 12-Oct-2001 1.03 108.00 1.00 38.00 0.00 1.00 326.00 1.00 
137.00 DEAD cancer 1.00 14-May-2001 1.40 11.00 1.00 41.00 0.00 1.00 420.00 1.00 
138.00 DEAD cancer 1.00 30-Nov-2001 5.00 8.00 0.00 35.00 0.00 0.00 580.00 1.00 
139.00 DEAD cancer 1.00 30-Jun-2000 2.07 216.00 1.00 30.00 1.00 2.00 780.00 1.00 
140.00 DEAD cancer 1.00 20-Jan-2000 0.30 131.00 1.00 39.00 0.00 1.00 2,180.00 1.00 
141.00 DEAD cancer 1.00 24-Dec-2000 1.93 1.00 0.00 44.00 0.00 0.00 155.00 0.00 
142.00 DEAD cancer 1.00 25-Aug-2003 4.13 50.00 1.00 31.00 1.00 2.00 99.00 0.00 
143.00 DEAD bleed 2.00 21-Dec-2004 0.60 171.00 1.00 28.00 1.00 2.00 811.00 1.00 
144.00 ALIVE  0.00 30-Jun-2005 6.87 1.00 0.00 38.00 0.00 0.00 113.00 0.00 
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145.00 DEAD cancer 1.00 05-Jun-2003 8.00 89.00 1.00 38.00 0.00 1.00 138.00 0.00 
146.00 DEAD cancer 1.00 12-Jun-2002 6.23 1.00 0.00 46.00 0.00 0.00 149.00 0.00 
147.00 DEAD cancer 1.00 23-Oct-2003 9.10 1.00 0.00 48.00 0.00 0.00 150.00 0.00 
148.00 DEAD cancer 1.00 13-Apr-2003 21.40 1.00 0.00 46.00 0.00 0.00 155.00 0.00 
149.00 DEAD cancer 1.00 01-Apr-2002 1.13 44.00 1.00 37.00 0.00 1.00 159.00 0.00 
150.00 DEAD cancer 1.00 16-Jan-2004 14.33 18.00 1.00 43.00 0.00 1.00 164.00 0.00 
151.00 ALIVE  0.00 30-Jun-2005 11.63 1.00 0.00 38.00 0.00 0.00 187.00 0.00 
152.00 DEAD cancer 1.00 12-Jan-2004 1.40 53.00 1.00 40.00 0.00 1.00 196.00 0.00 
153.00 DEAD cancer 1.00 29-Apr-2003 14.40 6.00 0.00 42.00 0.00 0.00 198.00 0.00 
154.00 DEAD cancer 1.00 19-Apr-2005 8.80 11.00 1.00 48.00 0.00 1.00 204.00 0.00 
155.00 ALIVE  0.00 30-Jun-2005 16.40 8.00 0.00 38.00 0.00 0.00 212.00 0.00 
156.00 DEAD cancer 1.00 21-Nov-2002 7.43 36.00 1.00 42.00 0.00 1.00 237.00 0.00 
157.00 DEAD cancer 1.00 21-Sep-2003 3.13 26.00 1.00 43.00 0.00 1.00 243.00 0.00 
158.00 ALIVE  0.00 30-Jun-2005 11.97 64.00 1.00 28.00 1.00 2.00 280.00 1.00 
159.00 ALIVE  0.00 30-Jun-2005 9.53 1.00 0.00 44.00 0.00 0.00 290.00 1.00 
160.00 DEAD cancer 1.00 25-May-2002 2.80 57.00 1.00 39.00 0.00 1.00 292.00 1.00 
161.00 DEAD cancer 1.00 28-Aug-2003 7.80 190.00 1.00 38.00 0.00 1.00 303.00 1.00 
162.00 DEAD cancer 1.00 21-Aug-2004 0.73 68.00 1.00 34.00 1.00 2.00 324.00 1.00 
163.00 DEAD cancer 1.00 30-May-2002 3.00 96.00 1.00 43.00 0.00 1.00 500.00 1.00 
164.00 DEAD cancer 1.00 24-Aug-2004 5.13 28.00 1.00 37.00 0.00 1.00 153.00 0.00 
165.00 DEAD cancer 1.00 11-Feb-2005 8.07 88.00 1.00 35.00 0.00 1.00 154.00 0.00 
166.00 ALIVE  0.00 30-Jun-2005 25.20 42.00 1.00 37.00 0.00 1.00 186.00 0.00 
167.00 DEAD cancer 1.00 07-Oct-2004 9.77 15.00 1.00 40.00 0.00 1.00 199.00 0.00 
168.00 DEAD cancer 1.00 04-Aug-2003 2.20 65.00 1.00 35.00 0.00 1.00 244.00 0.00 
169.00 DEAD cancer 1.00 23-Jun-2002 14.17 47.00 1.00 36.00 0.00 1.00 22.00 0.00 
170.00 DEAD cancer 1.00 02-Jul-2003 20.33 1.00 0.00 42.00 0.00 0.00 151.00 0.00 
171.00 DEAD cancer 1.00 11-Feb-2002 1.13 94.00 1.00 32.00 1.00 2.00 159.00 0.00 
172.00 DEAD cancer 1.00 12-Feb-2003 8.23 43.00 1.00 28.00 1.00 2.00 167.00 0.00 
173.00 DEAD cancer 1.00 08-Oct-2002 6.97 6.00 0.00 43.00 0.00 0.00 180.00 0.00 
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174.00 ALIVE  0.00 30-Jun-2005 9.63 10.00 0.00 30.00 1.00 1.00 195.00 0.00 
175.00 DEAD cancer 1.00 27-Dec-2001 2.30 73.00 1.00 35.00 0.00 1.00 217.00 0.00 
176.00 DEAD cancer 1.00 03-Feb-2005 9.13 1.00 0.00 32.00 1.00 1.00 220.00 0.00 
177.00 DEAD cancer 1.00 03-Dec-2002 12.07 11.00 1.00 46.00 0.00 1.00 233.00 0.00 
178.00 DEAD cancer 1.00 13-Jun-2002 10.93 8.00 0.00 44.00 0.00 0.00 285.00 1.00 
179.00 ALIVE  0.00 30-Jun-2005 7.07 1.00 0.00 39.00 0.00 0.00 349.00 1.00 
180.00 DEAD cancer 1.00 13-May-2004 8.23 6.00 0.00 37.00 0.00 0.00 632.00 1.00 
181.00 DEAD cancer 1.00 19-Apr-2002 5.93 23.00 1.00 32.00 1.00 2.00 546.00 1.00 
182.00 DEAD cancer 1.00 08-Feb-2005 1.33 15.00 1.00 39.00 0.00 1.00   
183.00 DEAD cancer 1.00 10-Oct-2004 2.87 11.00 1.00 43.00 0.00 1.00 144.00 0.00 
184.00 ALIVE  0.00 30-Jun-2005 6.83 7.00 0.00 43.00 0.00 0.00 163.00 0.00 
185.00 ALIVE  0.00 30-Jun-2005 12.43 1.00 0.00 43.00 0.00 0.00 279.00 0.00 
186.00 DEAD cancer 1.00 21-Sep-2002 8.27 1.00 0.00 42.00 0.00 0.00 138.00 0.00 
187.00 DEAD cancer 1.00 10-Aug-2002 2.70 45.00 1.00 44.00 0.00 1.00 143.00 0.00 
188.00 DEAD cancer 1.00 15-Aug-2001 7.23 41.00 1.00 30.00 1.00 2.00 145.00 0.00 
189.00 DEAD cancer 1.00 02-Sep-2000 2.83 14.00 1.00 35.00 0.00 1.00 205.00 0.00 
190.00 DEAD sepsis 1.00 23-May-2003 0.77 1.00 0.00 43.00 0.00 0.00 208.00 0.00 
191.00 DEAD cancer 1.00 16-Mar-2002 0.73 28.00 1.00 36.00 0.00 1.00 229.00 0.00 
192.00 DEAD PE 2.00 23-Oct-2002 31.57 1.00 0.00 38.00 0.00 0.00   
193.00 DEAD cancer 1.00 23-Jun-2001 11.10 13.00 1.00 37.00 0.00 1.00 85.00 0.00 
194.00 DEAD cancer 1.00 16-Oct-2004 16.50 24.00 1.00 40.00 0.00 1.00 99.00 0.00 
195.00 ALIVE  0.00 30-Jun-2005 20.17 1.00 0.00 42.00 0.00 0.00 103.00 0.00 
196.00 DEAD cancer 1.00 10-Jul-2004 0.50 20.00 1.00 24.00 1.00 2.00 120.00 0.00 
197.00 DEAD cancer 1.00 16-Sep-2002 9.80 1.00 0.00 38.00 0.00 0.00 127.00 0.00 
198.00 DEAD cancer 1.00 08-Oct-2004 15.50 10.00 0.00 34.00 1.00 1.00 128.00 0.00 
199.00 DEAD cancer 1.00 04-Nov-2004 2.43 19.00 1.00 34.00 1.00 2.00 130.00 0.00 
200.00 DEAD cancer 1.00 18-Sep-2001 6.67 7.00 0.00 34.00 1.00 1.00 135.00 0.00 
201.00 DEAD cancer 1.00 03-Jun-2003 4.17 15.00 1.00 35.00 0.00 1.00 136.00 0.00 
202.00 DEAD cancer 1.00 27-Feb-2001 11.43 1.00 0.00 35.00 0.00 0.00 145.00 0.00 
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203.00 DEAD cancer 1.00 10-Jun-2004 5.20 8.00 0.00 42.00 0.00 0.00 162.00 0.00 
204.00 DEAD cancer 1.00 03-May-2004 2.20 96.00 1.00 30.00 1.00 2.00 173.00 0.00 
205.00 DEAD cancer 1.00 10-Jul-2001 0.63 6.00 0.00 44.00 0.00 0.00 180.00 0.00 
206.00 DEAD cancer 1.00 04-Aug-2000 1.90 96.00 1.00 38.00 0.00 1.00 180.00 0.00 
207.00 ALIVE  0.00 30-Jun-2005 23.63 1.00 0.00 42.00 0.00 0.00 192.00 0.00 
208.00 DEAD cancer 1.00 31-Dec-2003 3.27 1.00 0.00 38.00 0.00 0.00 193.00 0.00 
209.00 ALIVE  0.00 30-Jun-2005 22.00 9.00 0.00 46.00 0.00 0.00 193.00 0.00 
210.00 DEAD cancer 1.00 13-Jun-2000 1.60 24.00 1.00 33.00 1.00 2.00 195.00 0.00 
211.00 DEAD cancer 1.00 27-May-2002 0.87 39.00 1.00 37.00 0.00 1.00 199.00 0.00 
212.00 DEAD cancer 1.00 26-Mar-2002 4.67 82.00 1.00 34.00 1.00 2.00 200.00 0.00 
213.00 DEAD cancer 1.00 16-Aug-2003 9.97 43.00 1.00 39.00 0.00 1.00 207.00 0.00 
214.00 DEAD cancer 1.00 27-Jul-2000 1.37 1.00 0.00 37.00 0.00 0.00 215.00 0.00 
215.00 DEAD cancer 1.00 29-Nov-2002 23.10 8.00 0.00 37.00 0.00 0.00 225.00 0.00 
216.00 ALIVE  0.00 30-Jun-2005 8.73 60.00 1.00 25.00 1.00 2.00 231.00 0.00 
217.00 DEAD cancer 1.00 04-Nov-2002 2.80 8.00 0.00 40.00 0.00 0.00 246.00 0.00 
218.00 DEAD cancer 1.00 27-Aug-2002 1.77 120.00 1.00 32.00 1.00 2.00 251.00 0.00 
219.00 DEAD cancer 1.00 09-May-2005 12.33 1.00 0.00 39.00 0.00 0.00 253.00 0.00 
220.00 ALIVE  0.00 30-Jun-2005 15.17 1.00 0.00 39.00 0.00 0.00 256.00 0.00 
221.00 DEAD  1.00 16-Feb-2003 18.63 6.00 0.00 36.00 0.00 0.00 260.00 0.00 
222.00 ALIVE  0.00 30-Jun-2005 8.43 29.00 1.00 31.00 1.00 2.00 264.00 0.00 
223.00 ALIVE  0.00 30-Jun-2005 8.37 58.00 1.00 27.00 1.00 2.00 265.00 0.00 
224.00 DEAD cancer 1.00 04-Dec-2001 0.93 52.00 1.00 39.00 0.00 1.00 309.00 1.00 
225.00 ALIVE  0.00 30-Jun-2005 13.77 1.00 0.00 45.00 0.00 0.00 320.00 1.00 
226.00 DEAD cancer 1.00 25-Dec-2002 20.83 1.00 0.00 44.00 0.00 0.00 380.00 1.00 
227.00 DEAD pneumoni 2.00 07-Jul-2004 12.13 157.00 1.00 32.00 1.00 2.00 431.00 1.00 
228.00 DEAD cancer 1.00 18-Nov-2001 1.47 22.00 1.00 41.00 0.00 1.00 479.00 1.00 
229.00 DEAD cancer 1.00 13-Sep-2001 2.60 42.00 1.00 49.00 0.00 1.00 570.00 1.00 
230.00 DEAD cancer 1.00 20-May-2001 7.37 17.00 1.00 48.00 0.00 1.00 135.00 0.00 
231.00 DEAD cancer 1.00 04-Oct-2002 1.40 171.00 1.00 42.00 0.00 1.00 140.00 0.00 
 228 
 
Patient  status c of death a0cd1nc2 dofu survmths crp crpcd alb albcd Gps alp alpcd 
232.00 DEAD cancer 1.00 09-Jul-2000 0.13 99.00 1.00 29.00 1.00 2.00 150.00 0.00 
233.00 DEAD cancer 1.00 21-Oct-2004 1.63 23.00 1.00 28.00 1.00 2.00 167.00 0.00 
234.00 DEAD cancer 1.00 01-Oct-2004 12.83 12.00 1.00 37.00 0.00 1.00 176.00 0.00 
235.00 ALIVE  0.00 30-Jun-2005 7.30 1.00 0.00 42.00 0.00 0.00 197.00 0.00 
236.00 DEAD cancer 1.00 26-Dec-2004 0.63 79.00 1.00 40.00 0.00 1.00 205.00 0.00 
237.00 DEAD cancer 1.00 04-Sep-2003 1.03 38.00 1.00 28.00 1.00 2.00 209.00 0.00 
238.00 DEAD cancer 1.00 06-Dec-2000 7.40 18.00 1.00 38.00 0.00 1.00 210.00 0.00 
239.00 DEAD cancer 1.00 11-Feb-2002 6.63 11.00 1.00 34.00 1.00 2.00 215.00 0.00 
240.00 ALIVE  0.00 30-Jun-2005 34.50 8.00 0.00 44.00 0.00 0.00 222.00 0.00 
241.00 DEAD cancer 1.00 30-May-2001 0.87 89.00 1.00 40.00 0.00 1.00 230.00 0.00 
242.00 DEAD cancer 1.00 14-Jan-2001 1.80 8.00 0.00 38.00 0.00 0.00 260.00 0.00 
243.00 DEAD cancer 1.00 13-Jan-2004 2.97 8.00 0.00 40.00 0.00 0.00 270.00 0.00 
244.00 DEAD cancer 1.00 05-Oct-2004 1.40 38.00 1.00 37.00 0.00 1.00 293.00 1.00 
245.00 DEAD cancer 1.00 17-Apr-2003 1.37 31.00 1.00 28.00 1.00 2.00 309.00 1.00 
246.00 DEAD cancer 1.00 24-Jul-2002 1.47 74.00 1.00 33.00 1.00 2.00 401.00 1.00 
247.00 DEAD cancer 1.00 01-Feb-2004 2.50 171.00 1.00 36.00 0.00 1.00 414.00 1.00 
248.00 DEAD cancer 1.00 04-Nov-2003 0.70 109.00 1.00 35.00 0.00 1.00 490.00 1.00 
249.00 DEAD cancer 1.00 27-May-2004 5.83 253.00 1.00 29.00 1.00 2.00 530.00 1.00 
250.00 DEAD cancer 1.00 01-Sep-2000 0.80 117.00 1.00 33.00 1.00 2.00 640.00 1.00 
251.00 DEAD cancer 1.00 26-Sep-2001 2.07 16.00 1.00 33.00 1.00 2.00 930.00 1.00 
252.00 DEAD cancer 1.00 29-Jul-2000 3.40 30.00 1.00 40.00 0.00 1.00 1,110.00 1.00 
253.00 DEAD cancer 1.00 03-Jun-2004 2.30 89.00 1.00 36.00 0.00 1.00 1,346.00 1.00 
254.00 DEAD cancer 1.00 23-May-2003 0.47 29.00 1.00 28.00 1.00 2.00 1,635.00 1.00 
255.00 DEAD cancer 1.00 24-Apr-2004 1.27 30.00 1.00 22.00 1.00 2.00 2,396.00 1.00 
256.00 ALIVE  0.00 30-Jun-2005 6.83 1.00 0.00 31.00 1.00 1.00 132.00 0.00 
257.00 DEAD cancer 1.00 01-May-2004 4.33 64.00 1.00 38.00 0.00 1.00 185.00 0.00 




APPENDIX 4: DATABASE FOR CHAPTER 5:    
COMPARISON OF AN INFLAMMATION BASED PROGNOSTIC 
SCORE (GPS) WITH PERFORMANCE STATUS (ECOG-PS), IN 
PATIENTS RECEIVING PALLIATIVE CHEMOTHERAPY FOR 




Patient  m0f1 age agecd site o0g1 histology typecd date of endo stage stagecd status dofu 
1 0.00 65.47 1.00 oesoph 0.00 squam 1.00 22-May-2003 3.00 1.00 ALIVE 31-Jan-2007 
2 0.00 66.10 1.00 o/g 0.00 adeno 0.00 27-Jul-2004 4.00 1.00 ALIVE 31-Jan-2007 
3 1.00 73.71 1.00 G 1.00 A 0.00 13-Jun-2005 4.00 1.00 ALIVE 31-Jan-2007 
4 0.00 74.72 1.00 O 0.00 A 0.00 25-May-2005 4.00 1.00 ALIVE 31-Jan-2007 
5 0.00 69.81 1.00 gastric 1.00 adeno 0.00 30-Nov-2004 3.00 1.00 DEAD 19-Jun-2005 
6 0.00 65.38 1.00 gastric 1.00 adeno 0.00 21-Feb-2002 3.00 1.00 DEAD 29-Apr-2003 
7 1.00 64.50 0.00 g 1.00 a 0.00 06-Oct-1999 3.00 1.00 DEAD 03-Dec-2001 
8 0.00 75.35 2.00 oesoph 0.00 adeno 0.00 19-Feb-2004 3.00 1.00 DEAD 03-Sep-2004 
9 0.00 72.68 1.00 oesoph 0.00 adeno 0.00 14-Jan-2004 3.00 1.00 DEAD 08-Dec-2004 
10 0.00 56.85 0.00 0 0.00 s 1.00 21-Sep-1999 3.00 1.00 DEAD 17-Sep-2000 
11 1.00 55.49 0.00 o/g 0.00 adeno 0.00 21-Dec-2004 4.00 1.00 DEAD 03-Sep-2005 
12 0.00 42.48 0.00 gast 1.00 adeno 0.00 17-Sep-2004 4.00 1.00 DEAD 10-Sep-2005 
13 1.00 54.36 0.00 gastric 1.00 adeno 0.00 06-Dec-2004 4.00 1.00 DEAD 06-Nov-2005 
14 0.00 44.14 0.00 OES 0.00 A 0.00 26-Jul-2005 4.00 1.00 DEAD 02-Jun-2006 
15 1.00 42.09 0.00 gastric 1.00 adeno 0.00 23-Jan-2003 4.00 1.00 DEAD 23-Oct-2003 
16 0.00 56.46 0.00 G 1.00 A 0.00 08-Apr-2005 4.00 1.00 DEAD 20-Sep-2005 
17 0.00 62.56 0.00 o/g 0.00 adeno 0.00 05-Mar-2004 4.00 1.00 DEAD 11-Aug-2005 
18 0.00 70.35 1.00 oesoph 0.00 squam 1.00 04-Dec-2001 4.00 1.00 DEAD 03-May-2002 
19 0.00 73.47 1.00 gastric 1.00 adeno 0.00 16-Jul-2004 4.00 1.00 DEAD 30-Sep-2005 
20 0.00 76.35 2.00 oesoph 0.00 adeno 0.00 28-Jun-2002 4.00 1.00 DEAD 08-Mar-2003 
21 1.00 46.43 0.00 o/g 1.00 adeno 0.00 20-Jul-2001 4.00 1.00 DEAD 13-Jun-2002 
22 0.00 67.62 1.00 gastric 1.00 adeno 0.00 10-Jul-2001 4.00 1.00 DEAD 13-Apr-2003 
23 0.00 42.72 0.00 oesoph 0.00 adeno 0.00 16-Apr-2002 4.00 1.00 DEAD 30-May-2003 
24 0.00 54.38 0.00 oesoph 0.00 adeno 0.00 23-Mar-2004 4.00 1.00 DEAD 01-Feb-2005 
25 0.00 66.08 1.00 oesoph 0.00 adeno 0.00 30-Jul-2003 4.00 1.00 DEAD 27-Feb-2005 
26 0.00 63.83 0.00 oesoph 0.00 squam 1.00 08-Oct-2002 3.00 1.00 DEAD 29-Mar-2003 
27 0.00 52.80 0.00 G 1.00 A 0.00 08-Apr-2005 4.00 1.00 ALIVE 31-Jan-2007 
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28 0.00 74.95 1.00 gas 1.00 adeno 0.00 14-Sep-2004 3.00 1.00 DEAD 04-Nov-2005 
29 0.00 68.34 1.00 g 1.00 a 0.00 01-Jul-1999 3.00 1.00 DEAD 23-Jun-2000 
30 0.00 55.01 0.00 gastric 1.00 adeno 0.00 13-Mar-2002 3.00 1.00 DEAD 08-Oct-2002 
31 0.00 54.67 0.00 oesoph 0.00 squam 1.00 20-Jan-2004 3.00 1.00 DEAD 23-Aug-2004 
32 0.00 70.14 1.00 o/g 0.00 adeno 0.00 02-May-2001 3.00 1.00 DEAD 08-Mar-2003 
33 0.00 60.86 0.00 oesoph 0.00 adeno 0.00 04-Jun-2003 3.00 1.00 DEAD 25-May-2004 
34 0.00 71.96 1.00 oesoph 0.00 adeno 0.00 12-Nov-2003 3.00 1.00 DEAD 18-Apr-2005 
35 0.00 75.18 2.00 OE 0.00 A 1.00 18-Mar-2005 3.00 1.00 DEAD 15-Jan-2006 
36 0.00 46.92 0.00 gastric 1.00 adeno 0.00 02-Mar-2002 4.00 1.00 DEAD 25-May-2002 
37 0.00 52.05 0.00 o/g 1.00 adeno 0.00 05-Jun-2003 4.00 1.00 DEAD 01-Sep-2004 
38 0.00 43.64 0.00 gas 1.00 adeno 0.00 29-Jul-2004 4.00 1.00 DEAD 19-Apr-2005 
39 1.00 65.08 1.00 G 1.00 A 0.00 16-Aug-2005 4.00 1.00 ALIVE 21-Aug-2006 
40 0.00 49.76 0.00 gastric 1.00 adeno 0.00 10-Oct-2000 4.00 1.00 DEAD 17-Jan-2001 
41 0.00 56.00 0.00 gastric 1.00 adeno 0.00 19-Oct-2001 4.00 1.00 DEAD 27-Dec-2001 
42 0.00 68.98 1.00 oesoph 0.00 adeno 0.00 21-Nov-2001 4.00 1.00 DEAD 02-Apr-2002 
43 0.00 44.99 0.00 gastric 1.00 adeno 0.00 01-Mar-2002 4.00 1.00 DEAD 30-May-2002 
44 1.00 61.79 0.00 gastric 1.00 adeno 0.00 08-Oct-2002 4.00 1.00 DEAD 05-Jun-2003 
45 1.00 70.27 1.00 oesoph 0.00 adeno 0.00 06-Dec-2001 4.00 1.00 DEAD 29-Jun-2003 
46 0.00 76.19 2.00 gastric 1.00 adeno 0.00 30-May-2003 4.00 1.00 DEAD 04-Aug-2003 
47 1.00 41.38 0.00 gastric 1.00 adeno 0.00 14-Jun-2004 4.00 1.00 DEAD 11-Feb-2005 
48 0.00 62.28 0.00 o/g 0.00 adeno 0.00 16-Aug-2004 4.00 1.00 DEAD 03-Nov-2004 
49 0.00 62.33 0.00 oesoph 0.00 adeno 0.00 21-Jan-2004 4.00 1.00 DEAD 30-Apr-2005 
50 0.00 55.27 0.00 oesoph 0.00 adeno 0.00 12-Jun-2001 4.00 1.00 DEAD 11-Dec-2001 
51 0.00 43.31 0.00 gast 1.00 adeno 0.00 06-Jan-2003 4.00 1.00 DEAD 28-Aug-2003 
52 1.00 63.20 0.00 oesoph 0.00 squam 1.00 18-Oct-2004 4.00 1.00 DEAD 03-Dec-2005 
53 0.00 69.23 1.00 oesoph 0.00 squam 1.00 14-Jan-2004 4.00 1.00 DEAD 24-Jan-2005 
54 0.00 65.74 1.00 oesoph 0.00 squam 1.00 30-Jan-2001 4.00 1.00 DEAD 13-Dec-2001 
55 0.00 76.64 2.00 o/g 0.00 adeno 0.00 01-Oct-2001 4.00 1.00 DEAD 03-Jan-2003 
56 0.00 65.65 1.00 o 0.00 s 1.00 05-Jan-1999 4.00 1.00 DEAD 01-Mar-2000 
 232 
 
Patient  m0f1 age agecd site o0g1 histology typecd date of endo stage stagecd Status dofu 
57 0.00 63.35 0.00 oesoph 0.00 squam 1.00 28-Jul-2000 4.00 1.00 DEAD 06-Nov-2000 
58 0.00 70.31 1.00 OES 0.00 S 1.00 30-Nov-2005 4.00 1.00 ALIVE 31-Jan-2007 
59 0.00 60.29 0.00 0 0.00 a 0.00 14-Sep-1999 3.00 1.00 DEAD 25-May-2000 
60 1.00 68.45 1.00 oesoph 0.00 squam 1.00 20-Nov-2003 3.00 1.00 DEAD 01-Sep-2004 
61 1.00 70.85 1.00 oesoph 0.00 adeno 0.00 01-Sep-2004 4.00 1.00 DEAD 26-Feb-2005 
62 1.00 74.82 1.00 OES 0.00 A 0.00 01-Sep-2005 4.00 1.00 DEAD 15-Jun-2006 
63 0.00 60.26 0.00 gastric 1.00 adeno 0.00 10-Jun-2002 4.00 1.00 DEAD 12-Feb-2003 
64 1.00 73.42 1.00 gastric 1.00 adeno 0.00 23-Oct-2001 4.00 1.00 DEAD 19-Apr-2002 




              
              
Patient  cofdeath a0cd1nc2 crp crpcd alb albcd hb hbcd wcc wcccd lymph lymphper Lymphcd 
1  0.00 1.00 0.00 48.00 0.00 14.90 0.00 7.40 0.00 0.80 10.81 2.00 
2  0.00 1.00 0.00 40.00 0.00 14.10 0.00 9.40 1.00 2.50 26.60 0.00 
3  0.00 6.00 0.00 42.00 0.00 12.20 0.00 7.90 0.00 2.70 34.18 0.00 
4  0.00 6.00 0.00 43.00 0.00 15.40 0.00 8.10 0.00 2.20 27.16 0.00 
5 cancer 1.00 1.00 0.00 39.00 0.00 14.30 0.00 7.70 0.00 1.30 16.88 1.00 
6 cancer 1.00 6.00 0.00 42.00 0.00 14.40 0.00 9.10 1.00 2.60 28.57 0.00 
7 cancer 1.00 6.00 0.00 39.00 0.00 11.70 1.00 7.40 0.00 1.60 21.62 0.00 
8 cancer 1.00 1.00 0.00 36.00 0.00 13.60 0.00 6.90 0.00 2.60 37.68 0.00 
9 cancer 1.00 1.00 0.00 47.00 0.00 10.60 1.00 6.30 0.00 0.90 14.29 1.00 
10 cancer 1.00 6.00 0.00 40.00 0.00        
11 cancer 1.00 8.00 0.00 50.00 0.00 15.40 0.00 8.30 0.00 2.60 31.33 0.00 
12 cancer 1.00 1.00 0.00 44.00 0.00 14.60 0.00 9.90 1.00 2.00 20.20 0.00 
13 cancer 1.00 1.00 0.00 38.00 0.00 14.90 0.00 6.50 0.00 1.50 23.08 0.00 
14 cancer 1.00 6.00 0.00 44.00 0.00 11.90 1.00 2.90 0.00 1.10 37.93 0.00 
15 cancer 1.00 1.00 0.00 48.00 0.00 10.20 1.00 6.40 0.00 0.50 7.81 2.00 
16 cancer 1.00 6.00 0.00 45.00 0.00 17.30 0.00 17.70 2.00 3.90 22.03 0.00 
17 cancer 1.00 10.00 0.00 45.00 0.00 14.00 0.00 9.10 1.00 1.80 19.78 1.00 
18 cancer 1.00 10.00 0.00 42.00 0.00 15.10 0.00 8.20 0.00 2.60 31.71 0.00 
19 cancer 1.00 1.00 0.00 38.00 0.00 12.30 0.00 9.40 1.00 1.70 18.09 1.00 
20 cancer 1.00 1.00 0.00 42.00 0.00 13.20 0.00 6.10 0.00 1.00 16.39 1.00 
21 cancer 1.00 8.00 0.00 44.00 0.00 13.60 0.00 7.30 0.00 2.40 32.88 0.00 
22 cancer 1.00 1.00 0.00 46.00 0.00 16.00 0.00 10.40 1.00 3.20 30.77 0.00 
23 cancer 1.00 1.00 0.00 40.00 0.00 15.00 0.00 5.60 0.00 1.90 33.93 0.00 
24 cancer 1.00 1.00 0.00 43.00 0.00 15.30 0.00 7.60 0.00 0.90 11.84 2.00 
25 cancer 1.00 9.00 0.00 46.00 0.00 14.00 0.00 12.70 2.00 1.60 12.60 1.00 
26 renal 2.00 1.00 0.00 36.00 0.00 14.20 0.00 7.10 0.00 1.80 25.35 0.00 
27  0.00 27.00 1.00 41.00 0.00 15.70 0.00 7.60 0.00 2.70 35.53 0.00 
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Patient  cofdeath a0cd1nc2 crp crpcd alb albcd hb hbcd wcc wcccd lymph lymphper Lymphcd 
28 cancer 1.00 10.00 0.00 30.00 1.00 13.20 0.00 8.50 1.00 2.80 32.94 0.00 
29 cancer 1.00 39.00 1.00 43.00 0.00 12.10 0.00 4.70 0.00 0.70 14.89 1.00 
30 cancer 1.00 14.00 1.00 43.00 0.00 15.90 0.00 8.50 1.00 2.40 28.24 0.00 
31 cancer 1.00 27.00 1.00 40.00 0.00 13.50 0.00 9.20 1.00 1.90 20.65 0.00 
32 cancer 1.00 18.00 1.00 45.00 0.00 10.70 1.00 12.70 2.00 1.50 11.81 2.00 
33 cancer 1.00 42.00 1.00 38.00 0.00 14.60 0.00 7.40 0.00 1.60 21.62 0.00 
34 cancer 1.00 15.00 1.00 39.00 0.00 14.70 0.00 9.40 1.00 2.80 29.79 0.00 
35 cancer 1.00 22.00 1.00 35.00 0.00 13.50 0.00 7.80 0.00 1.20 15.38 1.00 
36 cancer 1.00 57.00 1.00 39.00 0.00 12.20 0.00 10.50 1.00 1.40 13.33 1.00 
37 cancer 1.00 42.00 1.00 37.00 0.00 13.60 0.00 6.70 0.00 1.10 16.42 1.00 
38 cancer 1.00 11.00 1.00 48.00 0.00 13.40 0.00 11.80 2.00 2.30 19.49 1.00 
39 cancer 1.00 12.00 1.00 39.00 0.00 15.60 0.00 7.30 0.00 1.30 17.81 1.00 
40 cancer 1.00 37.00 1.00 0.00 0.00 14.50 0.00 8.90 1.00 1.30 14.61 1.00 
41 cancer 1.00 73.00 1.00 35.00 0.00 12.90 0.00 17.20 2.00 2.50 14.53 1.00 
42 cancer 1.00 70.00 1.00 36.00 0.00 10.70 1.00 12.10 2.00 0.60 4.96 2.00 
43 cancer 1.00 96.00 1.00 43.00 0.00 14.10 0.00 9.80 1.00 1.60 16.33 1.00 
44 cancer 1.00 89.00 1.00 38.00 0.00 11.40 1.00 3.90 0.00 0.60 15.38 1.00 
45 cancer 1.00 36.00 1.00 40.00 0.00 12.00 0.00 6.40 0.00 1.20 18.75 1.00 
46 cancer 1.00 65.00 1.00 35.00 0.00 8.80 1.00 5.60 0.00 0.70 12.50 1.00 
47 cancer 1.00 88.00 1.00 35.00 0.00 10.50 1.00 14.50 2.00 1.10 7.59 2.00 
48 cancer 1.00 36.00 1.00 35.00 0.00 15.40 0.00 7.90 0.00 1.80 22.78 0.00 
49 cancer 1.00 28.00 1.00 47.00 0.00 16.10 0.00 15.00 2.00 2.00 13.33 1.00 
50 cancer 1.00 69.00 1.00 41.00 0.00 13.30 0.00 7.60 0.00 2.00 26.32 0.00 
51 cancer 1.00 190.00 1.00 38.00 0.00 9.30 1.00 10.70 1.00 1.70 15.89 1.00 
52 cancer 1.00 56.00 1.00 36.00 0.00 13.60 0.00 14.00 2.00 1.80 12.86 1.00 
53 cancer 1.00 20.00 1.00 41.00 0.00 15.00 0.00 8.00 0.00 1.10 13.75 1.00 
54 cancer 1.00 30.00 1.00 38.00 0.00 16.20 0.00 10.60 1.00 1.70 16.04 1.00 
55 cancer 1.00 71.00 1.00 35.00 0.00 12.20 0.00 9.10 1.00 1.80 19.78 1.00 
56 cancer 1.00 38.00 1.00   12.00 0.00 4.50 0.00 1.30 28.89 0.00 
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Patient  cofdeath a0cd1nc2 crp crpcd alb albcd hb hbcd wcc wcccd lymph lymphper lymphcd 
57 cancer 1.00 23.00 1.00 40.00 0.00 14.80 0.00 14.70 2.00 1.80 12.24 1.00 
58  0.00 20.00 1.00 32.00 1.00 14.00 0.00 6.00 0.00 1.50 25.00 0.00 
59 cancer 1.00 295.00 1.00 34.00 1.00 9.60 1.00 14.50 2.00 1.30 8.97 2.00 
60 cancer 1.00 38.00 1.00 34.00 1.00 12.00 0.00 7.90 0.00 1.40 17.72 1.00 
61 cancer 1.00 32.00 1.00 32.00 1.00 11.20 1.00 11.40 2.00 1.00 8.77 2.00 
62 cancer 1.00 18.00 1.00 28.00 1.00 13.00 0.00 5.90 0.00 1.60 27.12 0.00 
63 cancer 1.00 43.00 1.00 28.00 1.00 11.60 1.00 12.40 2.00 0.80 6.45 2.00 
64 cancer 1.00 23.00 1.00 32.00 1.00 6.10 1.00 8.70 1.00 1.70 19.54 1.00 





              
              
patient  gps survmths ps radia chemtype chemtyp numcycle chemred toxicity Clinires clinrecd ctrespon Ctrescd 
1 0.00 45.00 0.00 30.00 cisp 5fu 1.00 3.00 0.00 2.00 Good 0.00 partial 0.00 
2 0.00 30.60 2.00 0.00 ecf 0.00 1.00 1.00  Poor 1.00   
3 0.00 19.90 1.00 0.00 ecf 0.00 6.00 0.00 3.00 Good 0.00 partial 0.00 
4 0.00 20.53 0.00 0.00 ecf 0.00 6.00 0.00 2.00 Good 0.00 partial 0.00 
5 0.00 6.70 1.00 0.00 epiru/oxali/capci 3.00 4.00 1.00 2.00 Good 0.00 partial 0.00 
6 0.00 14.40 1.00 0.00 ecf 0.00 6.00 0.00 1.00 Good 0.00 partial 0.00 
7 0.00 26.30 1.00 0.00 mcf 2.00 6.00 1.00 2.00 Good 0.00 partial 0.00 
8 0.00 6.57 0.00 0.00 5fu/ cispla 1.00 1.00 1.00 2.00 Poor 1.00 progress 2.00 
9 0.00 10.97 1.00 20.00 ecf 0.00 6.00 0.00 1.00 Static 1.00 static 1.00 
10 0.00 12.07  36.00 ecf 0.00 4.00 0.00 2.00 Good 0.00 partial 0.00 
11 0.00 8.53 1.00 0.00 epiru/oxal/5fu 3.00 6.00 1.00 3.00 Poor 1.00 partial 0.00 
12 0.00 11.93 0.00 0.00 ecf 0.00 7.00 0.00 2.00 Stati 1.00 static 1.00 
13 0.00 11.17 0.00 0.00 ecf 0.00 6.00 0.00 1.00 Partial 0.00 progress 2.00 
14 0.00 10.37 1.00 0.00 ecf 0.00 6.00 0.00 3.00 Poor 1.00 static 1.00 
15 0.00 9.10 0.00 0.00 ecf 0.00 6.00 0.00 2.00 Good 0.00 partial 0.00 
16 0.00 5.50 0.00 0.00 ecf 0.00 2.00 1.00 ! Poor 1.00 progress 2.00 
17 0.00 17.47 0.00 0.00 epirub, oxalaplatin 3.00 6.00 0.00 1.00 Good 0.00 partial 0.00 
18 0.00 5.00 1.00 0.00 cisp 5fu 1.00 4.00 0.00 3.00 Poor 1.00 static 1.00 
19 0.00 14.70 0.00 0.00 cisp 5fu 1.00 6.00 0.00 3.00 Good 0.00 partial 0.00 
20 0.00 8.43 1.00 20.00 ecf 0.00 6.00 0.00 1.00 Poor 1.00 static 1.00 
21 0.00 10.93 0.00 30.00 ecf 0.00 6.00 0.00 2.00 Good 0.00 partial 0.00 
22 0.00 21.40 1.00 30.00 ecf 0.00 6.00 0.00 0.00 Good 0.00 static 1.00 
23 0.00 13.63 0.00 30.00 ecf 0.00 6.00 0.00 3.00 Good 0.00 static 1.00 
24 0.00 10.50 0.00 30.00 ecf 0.00 6.00 0.00 1.00 Good 0.00 static 1.00 
25 0.00 19.27 0.00 30.00 ecf 0.00 6.00 0.00 2.00 Good 0.00 partial 0.00 
26 0.00 5.73 1.00 0.00 cis 5fu 1.00 3.00 1.00 4.00 Good 0.00 partial 0.00 
27 1.00 22.10 0.00 0.00 ecf 0.00 6.00 0.00 2.00 Static 1.00 static 1.00 
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patient  gps survmths ps radia chemtype chemtyp numcycle chemred toxicity Clinires clinrecd ctrespon Ctrescd 
28 1.00 13.87 1.00 0.00 e 5fu carboplat 3.00 6.00 0.00 3.00 Partia 0.00 partial 0.00 
29 1.00 11.93 1.00 0.00 epir cisp capcit 3.00 6.00 0.00 2.00 Poor 1.00 partia 0.00 
30 1.00 6.97 1.00 0.00 mcf 2.00 3.00 1.00 2.00 Poor 1.00 static 1.00 
31 1.00 7.20 0.00 20.00 cisp 5fu 1.00 4.00 0.00 2.00 Poor 1.00 progress 2.00 
32 1.00 22.50 1.00 30.00 ecf 0.00 6.00 0.00 1.00 Good 0.00 partial 0.00 
33 1.00 11.87 0.00 30.00 ecf 0.00 6.00 0.00 1.00 Good 0.00 static 1.00 
34 1.00 17.43 1.00 30.00 cisp 5fu 1.00 4.00 0.00 3.00 Good 0.00 static 1.00 
35 1.00 10.10 1.00 30.00 cisp 5fu 1.00 3.00 0.00 1.00 Good 0.00 static 1.00 
36 1.00 2.80 0.00 0.00 ecf 0.00 2.00 1.00 3.00 Poor 1.00 progress 2.00 
37 1.00 15.13 0.00 0.00 ecf 0.00 6.00 1.00 3.00 Good 0.00 partial 0.00 
38 1.00 8.80 0.00 0.00 ecf 0.00 6.00 0.00 2.00 Parti 0.00 partial 0.00 
39 1.00 12.33 0.00 0.00 ecf 0.00 6.00 0.00 4.00 Poor 1.00 static 1.00 
40 1.00 3.30 2.00 0.00 ecf 0.00 1.00 1.00 2.00 Poor 1.00   
41 1.00 2.30 1.00 0.00 ecf 0.00 1.00 1.00 3.00 Poor 1.00   
42 1.00 4.40 1.00 0.00 ecf 0.00 1.00 1.00 3.00 Poor 1.00   
43 1.00 3.00 2.00 0.00 ecf 0.00 2.00 1.00 3.00 Poor 1.00   
44 1.00 8.00 0.00 0.00 ecf 0.00 6.00 0.00 3.00 Good 0.00 partial 0.00 
45 1.00 19.00 2.00 0.00 ecf 0.00 6.00 1.00 3.00 Good 0.00 partial 0.00 
46 1.00 2.20 0.00 0.00 ecf 0.00 1.00 1.00 3.00 Poor 1.00   
47 1.00 8.07 1.00 0.00 ecf 0.00 6.00 0.00 2.00 Partial 0.00 partial 0.00 
48 1.00 2.63 0.00 0.00 ecf 0.00 2.00 1.00 2.00 Poor 1.00 static 1.00 
49 1.00 15.50 0.00 20.00 ecf 0.00 3.00 1.00 4.00 Poor 1.00 progress 2.00 
50 1.00 6.07 1.00 30.00 ecf 0.00 4.00 0.00 2.00 Static 1.00 static 1.00 
51 1.00 7.80 0.00 30.00 ecf 0.00 6.00 0.00 3.00 Good 0.00 static 1.00 
52 1.00 13.70 1.00 30.00 cis 5fu 1.00 3.00 1.00 2.00 Poor 1.00 static 1.00 
53 1.00 12.53 0.00 30.00 cisp 5fu 1.00 3.00 0.00 3.00 Poor 1.00   
54 1.00 10.57 1.00 30.00 cispl, 5fu 1.00 4.00 0.00 1.00 Poor 1.00   
55 1.00 15.30 2.00 30.00 cispl,5fu 1.00 4.00 0.00 0.00 Poor 1.00 partial 0.00 
56 1.00 14.03 1.00 35.00 cisp 5fu mitomy 2.00 6.00 0.00 0.00 Good 0.00 partial 0.00 
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patient  gps survmths ps radia chemtype chemtyp numcycle chemred toxicity Clinires clinrecd ctrespon ctrescd 
57 1.00 3.37 1.00 45.00 cisp 5fu 1.00 3.00 1.00 1.00 Poor 1.00   
58 2.00 14.23 1.00 30.00 cisp 5fu 1.00 2.00 0.00 0.00 Poor 1.00   
59 2.00 8.47 0.00 20.00 mcf 2.00 6.00 0.00 1.00 Good 0.00 partial 0.00 
60 2.00 9.53 0.00 30.00 cisp 5fu 1.00 3.00 0.00 1.00 Poor 1.00   
61 2.00 5.93 1.00 0.00 5fu pic 3.00 2.00 1.00 4.00 Poor 1.00   
62 2.00 9.57 0.00 0.00 ecf 0.00 3.00 0.00 2.00 Poor 1.00 partia 0.00 
63 2.00 8.23 1.00 0.00 ecf 0.00 5.00 1.00 3.00 Good 0.00 partial 0.00 
64 2.00 5.93 1.00 0.00 mcf 2.00 2.00 1.00 2.00 Poor 1.00   





APPENDIX 5:  DATABASE FOR CHAPTER 6: 
IS HYPOALBUMINAEMIA AND INDEPENDENT PROGNOSTIC 
FACTOR IN PATIENTS WITH GASTRIC CANCER? 
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Patient m0f1 age agecd dateendo positcd tnmstcd a0c1n2 doffu survmths treatment 
1 0.00 70 1.00 16-Jun-2005 1.00 4.00 1.00 12-Aug-2005 1.90 surgery 
2 0.00 83 2.00 27-Feb-2004 1.00 4.00 1.00 03-May-2004 2.20 Laser 
3 1.00 81 2.00 06-Dec-2005 1.00 4.00 0.00 30-Apr-2007 17.00 DXT 
4 0.00 81 2.00 26-Jul-2001 1.00 4.00 1.00 26-Sep-2001 2.07 None 
5 1.00 60 0.00 08-Aug-2000 1.00 4.00 1.00 01-Sep-2000 0.80 None 
6 0.00 70 1.00 27-Jul-2001 1.00 4.00 1.00 11-Feb-2002 6.63 None 
7 1.00 87 2.00 21-Mar-2000 1.00 1.00 1.00 27-Feb-2001 11.43 Laser 
8 0.00 75 2.00 01-Feb-2005 1.00 2.00 1.00 13-Jun-2006 16.57 LASER 
9 1.00 77 2.00 23-Mar-2004 1.00 4.00 1.00 24-Aug-2004 5.13 Chemo & 
10 0.00 52 0.00 05-Jun-2003 1.00 4.00 1.00 01-Sep-2004 15.13 Chemo & 
11 0.00 79 2.00 01-Apr-2004 1.00 4.00 1.00 01-May-2005 13.17 Laser 
12 0.00 83 2.00 21-Oct-2002 1.00 4.00 1.00 16-Aug-2003 9.97 Laser 
13 1.00 78 2.00 06-Nov-2001 1.00 4.00 1.00 04-Dec-2001 0.93 Laser 
14 0.00 53 0.00 03-Jun-2005 1.00 2.00 1.00 22-Sep-2006 15.87 LASER 
15 0.00 79 2.00 30-Oct-2001 1.00 4.00 1.00 02-Jul-2003 20.33 Chemo/DX 
16 0.00 42 0.00 17-Sep-2004 1.00 4.00 1.00 10-Sep-2005 11.93 Chemo 
17 0.00 44 0.00 26-Jul-2005 1.00 4.00 1.00 02-Jun-2006 10.37 CHEMO 
18 0.00 77 2.00 09-Sep-2003 1.00 1.00 1.00 30-Nov-2005 27.10 Laser 
19 0.00 44 0.00 29-Jul-2004 1.00 4.00 1.00 19-Apr-2005 8.80 Chemo 
20 0.00 61 0.00 18-Nov-2005 1.00 4.00 1.00 11-Dec-2005 0.77 ONCOL 
21 0.00 76 2.00 26-Aug-2005 1.00 4.00 1.00 07-Jul-2006 10.50 NO TRT 
22 1.00 41 0.00 14-Jun-2004 1.00 4.00 1.00 11-Feb-2005 8.07 Chemo & 
23 0.00 74 1.00 14-Oct-2003 1.00 4.00 1.00 04-Nov-2003 0.70 None 
24 0.00 53 0.00 12-Apr-2005 1.00 4.00 0.00 30-Apr-2007 24.93 CHEMO 
25 0.00 81 2.00 22-Jul-2003 1.00 1.00 0.00 30-Apr-2007 45.93 Laser 
26 1.00 67 1.00 30-Aug-2002 1.00 1.00 0.00 30-Apr-2007 56.80 None 
27 0.00 68 1.00 10-Jul-2001 1.00 4.00 1.00 13-Apr-2003 21.40 Chemo 
28 0.00 84 2.00 22-Oct-2004 2.00 1.00 1.00 15-Oct-2005 11.93 Laser 
29 1.00 64 0.00 06-Jul-2004 2.00 4.00 1.00 10-Sep-2004 2.20 Chemo 
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Patient m0f1 age agecd dateendo positcd tnmstcd a0c1n2 doffu survmths treatment 
30 0.00 60 0.00 20-Oct-2004 2.00 1.00 0.00 30-Apr-2007 30.73 Laser 
31 0.00 72 1.00 09-Jul-2003 2.00 4.00 2.00 07-Jul-2004 12.13 Laser 
32 1.00 79 2.00 26-Apr-2000 2.00 4.00 1.00 13-Jun-2000 1.60 Laser 
33 1.00 79 2.00 15-Jul-2005 2.00 2.00 0.00 30-Apr-2007 21.80 LASER 
34 0.00 76 2.00 01-Jul-2003 2.00 1.00 1.00 08-Oct-2004 15.50 Laser 
35 1.00 77 2.00 25-Apr-2005 2.00 3.00 1.00 24-Sep-2005 5.07 LASER 
36 0.00 72 1.00 30-Jul-2004 2.00 4.00 1.00 21-Aug-2004 0.73 Chemo 
37 0.00 82 2.00 29-Jan-2003 2.00 1.00 1.00 03-Jun-2003 4.17 Laser 
38 0.00 91 2.00 06-Jul-2005 2.00 4.00 1.00 30-Jul-2005 0.80 NO TRT 
39 1.00 47 0.00 09-Sep-2003 2.00 4.00 1.00 13-May-2004 8.23 Chemo/DX 
40 0.00 77 2.00 16-Jun-2000 2.00 4.00 1.00 27-Jul-2000 1.37 Laser 
41 0.00 89 2.00 05-Jan-2001 2.00 1.00 1.00 29-Nov-2002 23.10 Laser 
42 1.00 72 1.00 25-Jul-2000 2.00 3.00 1.00 23-Jun-2001 11.10 Laser 
43 0.00 75 2.00 17-Dec-2004 2.00 4.00 0.00 30-Apr-2007 28.80 NO TRT 
44 1.00 54 0.00 06-Dec-2004 2.00 4.00 1.00 06-Nov-2005 11.17 Chemo 
45 0.00 78 2.00 26-Nov-2001 2.00 1.00 1.00 16-Sep-2002 9.80 Laser 
46 1.00 62 0.00 08-Oct-2002 2.00 4.00 1.00 05-Jun-2003 8.00 Chemo 
47 0.00 57 0.00 08-Jun-2000 2.00 4.00 1.00 04-Aug-2000 1.90 Laser 
48 1.00 65 1.00 01-Dec-2003 2.00 4.00 1.00 12-Jan-2004 1.40 Chemo 
49 1.00 47 0.00 07-Dec-2004 2.00 4.00 1.00 26-Dec-2004 0.63 None 
50 1.00 63 0.00 04-May-2001 2.00 4.00 1.00 30-May-2001 0.87 None 
51 1.00 64 0.00 10-Oct-2005 2.00 4.00 1.00 29-Oct-2006 12.80 CHEMO 
52 0.00 65 1.00 29-Jun-2005 2.00 2.00 0.00 30-Apr-2007 22.33 LASER 
53 1.00 74 1.00 13-Jun-2005 2.00 3.00 0.00 30-Apr-2007 22.87 ONCOL 
54 1.00 25 0.00 10-Oct-2005 2.00 4.00 1.00 07-Sep-2006 11.07 CHEMO 
55 0.00 55 0.00 13-Mar-2002 2.00 3.00 1.00 08-Oct-2002 6.97 Chemo/DX 
56 1.00 68 1.00 22-Jun-2004 2.00 2.00 0.00 30-Apr-2007 34.73 DXT 
57 1.00 81 2.00 09-Nov-2005 2.00 2.00 0.00 30-Apr-2007 17.90 LASER 
58 1.00 64 0.00 07-Dec-2004 2.00 4.00 1.00 10-Oct-2005 10.23 DXT 
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Patient m0f1 age agecd dateendo positcd tnmstcd a0c1n2 doffu survmths treatment 
59 0.00 64 0.00 16-Jul-2004 2.00 4.00 1.00 10-Oct-2004 2.87 DXT 
60 1.00 64 0.00 12-Nov-2002 2.00 1.00 1.00 16-Jan-2004 14.33 Chemo 
61 0.00 55 0.00 19-Jun-2003 2.00 4.00 1.00 21-Sep-2003 3.13 Chemo 
62 1.00 42 0.00 23-Jan-2003 2.00 4.00 1.00 23-Oct-2003 9.10 Chemo 
63 0.00 59 0.00 11-Oct-2000 2.00 4.00 1.00 20-May-2001 7.37 None 
64 1.00 75 2.00 27-Jun-2001 2.00 4.00 1.00 13-Sep-2001 2.60 Laser 
65 1.00 81 2.00 07-Jul-2005 3.00 4.00 1.00 31-Dec-2005 5.90 Laser 
66 0.00 76 2.00 25-Jun-2004 3.00 2.00 1.00 10-Jul-2004 0.50 Laser 
67 1.00 62 0.00 09-May-2003 3.00 4.00 1.00 23-May-2003 0.47 None 
68 0.00 77 2.00 07-Mar-2003 3.00 4.00 1.00 17-Apr-2003 1.37 None 
69 1.00 86 2.00 04-Aug-2003 3.00 4.00 1.00 04-Sep-2003 1.03 None 
70 0.00 76 2.00 23-Jun-2005 3.00 2.00 1.00 02-Oct-2006 15.53 GASTRO-J 
71 1.00 77 2.00 07-Dec-2004 3.00 3.00 0.00 30-Apr-2007 29.13 Stent 
72 0.00 85 2.00 24-Oct-2005 3.00 3.00 1.00 09-Feb-2006 3.60 LASER 
73 0.00 84 2.00 06-Nov-2001 3.00 4.00 1.00 26-Mar-2002 4.67 Laser 
74 0.00 70 1.00 09-Jun-2000 3.00 4.00 1.00 02-Sep-2000 2.83 gastro-j 
75 0.00 76 2.00 30-May-2003 3.00 4.00 1.00 04-Aug-2003 2.20 Chemo & 
76 1.00 77 2.00 12-Dec-2005 3.00 4.00 1.00 24-Dec-2005 0.40 LASER 
77 1.00 57 0.00 22-Feb-2002 3.00 4.00 1.00 16-Mar-2002 0.73 gastro-j 
78 1.00 77 2.00 24-Apr-2001 3.00 2.00 1.00 23-Jun-2002 14.17 Chemo/DX 
79 0.00 76 2.00 26-Mar-2004 3.00 4.00 1.00 03-Jun-2004 2.30 None 
80 0.00 74 1.00 18-Nov-2003 3.00 4.00 1.00 01-Feb-2004 2.50 None 
81 0.00 69 1.00 26-Feb-2002 3.00 4.00 1.00 01-Apr-2002 1.13 Chemo 
82 1.00 83 2.00 21-Nov-2000 3.00 2.00 1.00 14-Jan-2001 1.80 None 
83 0.00 84 2.00 28-Apr-2000 3.00 1.00 1.00 06-Dec-2000 7.40 None 
84 0.00 92 2.00 23-Dec-2003 3.00 2.00 1.00 01-May-2004 4.33 Stent 
85 1.00 81 2.00 04-May-2004 3.00 2.00 1.00 09-May-2005 12.33 Laser 
86 0.00 82 2.00 14-Oct-2005 3.00 4.00 1.00 10-Jan-2006 2.93 LASER 
87 0.00 84 2.00 18-Aug-2005 3.00 2.00 0.00 30-Apr-2007 20.67 Laser 
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Patient m0f1 age agecd dateendo positcd tnmstcd a0c1n2 doffu survmths treatment 
88 0.00 62 0.00 30-Dec-2004 3.00 4.00 1.00 08-Feb-2005 1.33 DXT 
89 0.00 52 0.00 05-Jul-2005 3.00 4.00 1.00 22-Aug-2005 1.60 STENT 
90 0.00 76 2.00 05-Oct-2001 3.00 3.00 1.00 18-Nov-2001 1.47 Laser 
91 0.00 57 0.00 16-Jan-2002 3.00 4.00 1.00 21-Sep-2002 8.27 gastro-j 
92 1.00 81 2.00 03-Nov-2003 3.00 1.00 1.00 20-Oct-2005 23.90 Laser 
93 0.00 65 1.00 30-Apr-2003 3.00 4.00 1.00 23-May-2003 0.77 gastro-j 
94 0.00 56 0.00 07-Mar-2005 3.00 4.00 1.00 20-Sep-2005 6.57 CHEMO 
95 0.00 85 2.00 21-Jun-2001 3.00 1.00 1.00 10-Jul-2001 0.63 Laser 
96 1.00 44 0.00 21-May-2002 3.00 3.00 1.00 10-Aug-2002 2.70 gastro-j 
97 0.00 81 2.00 02-Sep-2004 4.00 4.00 1.00 21-Oct-2004 1.63 None 
98 0.00 60 0.00 10-Jun-2002 4.00 4.00 1.00 12-Feb-2003 8.23 Chemo/DX 
99 0.00 60 0.00 03-Dec-2004 4.00 4.00 2.00 21-Dec-2004 0.60 CH/DXT & 
100 1.00 84 2.00 05-Jul-2000 4.00 4.00 1.00 09-Jul-2000 0.13 None 
101 1.00 75 2.00 04-Dec-2003 4.00 4.00 1.00 27-May-2004 5.83 None 
102 0.00 75 2.00 14-Sep-2004 4.00 3.00 1.00 03-Nov-2005 13.83 Chemo/DX 
103 0.00 45 0.00 10-Jan-2001 4.00 4.00 1.00 15-Aug-2001 7.23 gastro-j 
104 1.00 73 1.00 23-Oct-2001 4.00 4.00 1.00 19-Apr-2002 5.93 Chemo/DX 
105 0.00 75 2.00 08-Jan-2002 4.00 4.00 1.00 11-Feb-2002 1.13 Chemo/DX 
106 1.00 71 1.00 05-Jul-2002 4.00 4.00 1.00 27-Aug-2002 1.77 Laser 
107 1.00 79 2.00 10-Jun-2002 4.00 4.00 1.00 24-Jul-2002 1.47 None 
108 1.00 83 2.00 02-Mar-2001 4.00 4.00 1.00 18-Sep-2001 6.67 Laser 
109 0.00 74 1.00 05-Sep-2005 4.00 3.00 1.00 15-Jun-2006 9.43 ONCOL 
110 0.00 64 0.00 23-Aug-2004 4.00 4.00 1.00 04-Nov-2004 2.43 Laser 
111 0.00 56 0.00 19-Oct-2001 4.00 4.00 1.00 27-Dec-2001 2.30 Chemo/DX 
112 0.00 79 2.00 12-Sep-2003 4.00 3.00 1.00 01-Oct-2004 12.83 None 
113 1.00 67 1.00 14-Sep-2005 4.00 4.00 1.00 01-Mar-2006 5.60 ONCOL 
114 0.00 76 2.00 24-Aug-2004 4.00 4.00 1.00 05-Oct-2004 1.40 None 
115 0.00 49 0.00 01-May-2002 4.00 4.00 1.00 27-May-2002 0.87 Laser 
116 0.00 68 1.00 24-Sep-2003 4.00 4.00 1.00 31-Dec-2003 3.27 Laser 
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Patient m0f1 age agecd dateendo positcd tnmstcd a0c1n2 doffu survmths treatment 
117 0.00 73 1.00 16-Jul-2004 4.00 4.00 1.00 30-Sep-2005 14.70 Chemo 
118 0.00 84 2.00 20-Mar-2000 4.00 1.00 2.00 23-Oct-2002 31.57 Laser 
119 1.00 53 0.00 24-Feb-2004 4.00 4.00 0.00 30-Apr-2007 38.70 Chemo 
120 0.00 43 0.00 06-Jan-2003 4.00 4.00 1.00 28-Aug-2003 7.80 Chemo 
121 0.00 70 1.00 30-Nov-2004 4.00 3.00 1.00 19-Jun-2005 6.70 Chemo/DX 
122 1.00 65 1.00 16-Aug-2005 4.00 4.00 1.00 21-Aug-2006 12.33 ONCOL 
123 0.00 47 0.00 02-Mar-2002 4.00 4.00 1.00 25-May-2002 2.80 Chemo 
124 0.00 30 0.00 16-Oct-2003 4.00 4.00 1.00 13-Jan-2004 2.97 None 
125 1.00 89 2.00 12-Aug-2002 4.00 4.00 1.00 04-Nov-2002 2.80 Laser 
126 0.00 80 2.00 09-Jun-2003 4.00 3.00 1.00 16-Oct-2004 16.50 Laser 
127 1.00 80 2.00 18-Apr-2000 4.00 4.00 1.00 29-Jul-2000 3.40 None 
128 0.00 65 1.00 21-Feb-2002 4.00 3.00 1.00 29-Apr-2003 14.40 Chemo 
129 1.00 79 2.00 23-Nov-2004 4.00 4.00 1.00 04-May-2005 5.40 None 
130 1.00 83 2.00 06-Jan-2004 4.00 4.00 1.00 10-Jun-2004 5.20 Laser 
131 0.00 58 0.00 12-Apr-2002 4.00 2.00 1.00 21-Nov-2002 7.43 Chemo 
132 1.00 63 0.00 23-Aug-2002 4.00 4.00 1.00 04-Oct-2002 1.40 None 
133 0.00 45 0.00 01-Mar-2002 4.00 4.00 1.00 30-May-2002 3.00 Chemo 
134 1.00 66 1.00 14-Jul-2005 4.00 4.00 0.00 30-Apr-2007 21.83 ONCOL 
135 1.00 46 0.00 20-Jul-2001 4.00 4.00 1.00 13-Jun-2002 10.93 Chemo/DX 
136 0.00 70 1.00 09-Oct-2001 4.00 4.00 1.00 18-Jan-2002 3.37 Stent 
137 1.00 34 0.00 07-Dec-2001 4.00 4.00 1.00 12-Jun-2002 6.23 Chemo 
138 1.00 34 0.00 06-Dec-2001 4.00 4.00 1.00 03-Dec-2002 12.07 Chemo/DX 
139 0.00 42 0.00 17-Mar-2004 5.00 4.00 1.00 24-Apr-2004 1.27 None 
140 0.00 81 2.00 11-Oct-2004 5.00 1.00 1.00 01-Dec-2005 13.87 Laser 
141 0.00 75 2.00 05-May-2004 5.00 4.00 1.00 03-Feb-2005 9.13 Chemo/DX 
142 0.00 78 2.00 03-Jun-2005 5.00 2.00 0.00 30-Apr-2007 23.20 LASER 
143 1.00 76 2.00 06-Aug-2001 5.00 1.00 1.00 16-Feb-2003 18.63 Laser 
144 1.00 77 2.00 19-Dec-2003 5.00 3.00 1.00 07-Oct-2004 9.77 Chemo & 
145 0.00 69 1.00 15-Feb-2005 5.00 4.00 1.00 18-Apr-2005 2.07 LASER 
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Patient m0f1 age agecd dateendo positcd tnmstcd a0c1n2 doffu survmths treatment 
146 0.00 80 2.00 09-Apr-2001 5.00 1.00 1.00 25-Dec-2002 20.83 Laser 
147 0.00 71 1.00 13-May-2004 5.00 1.00 1.00 09-Jan-2007 32.37 Laser 
148 0.00 52 0.00 11-Jul-2001 1.00 1.00 1.00 31-Mar-2002 8.77 surgery 
149 1.00 74 1.00 02-Mar-2005 2.00 1.00 2.00 24-Jun-2005 3.80 surgery 
150 0.00 52 0.00 10-May-2004 2.00 1.00 1.00 25-Nov-2004 6.63 surgery 
151 0.00 61 0.00 22-May-2000 2.00 1.00 0.00 28-Feb-2007 82.43 surgery 
152 0.00 68 1.00 30-Jun-2004 2.00 1.00 0.00 28-Feb-2007 32.43 surgery 
153 0.00 42 0.00 18-Aug-2004 2.00 1.00 0.00 28-Feb-2007 30.80 surgery 
154 0.00 71 1.00 16-May-2001 3.00 1.00 0.00 28-Feb-2007 70.47 surgery 
155 0.00 36 0.00 04-May-2005 3.00 1.00 0.00 28-Feb-2007 22.17 surgery 
156 0.00 76 2.00 11-Jun-2003 3.00 1.00 0.00 28-Feb-2007 45.27 surgery 
157 1.00 47 0.00 18-Aug-2005 3.00 1.00 0.00 28-Feb-2007 18.63 surgery 
158 0.00 59 0.00 29-Mar-1999 3.00 1.00 0.00 28-Feb-2007 96.43 surgery 
159 0.00 61 0.00 20-Dec-2000 5.00 1.00 1.00 16-Dec-2003 36.37 surgery 
160 0.00 64 0.00 10-Jan-2001 5.00 1.00 0.00 28-Feb-2007 74.67 surgery 
161 0.00 64 0.00 05-Sep-2002 1.00 2.00 1.00 18-Jun-2003 9.53 surgery 
162 0.00 66 1.00 11-Jun-2001 1.00 2.00 1.00 18-Aug-2002 14.43 surgery 
163 0.00 75 2.00 08-Nov-2000 1.00 1.00 0.00 28-Feb-2007 76.77 surgery 
164 1.00 72 1.00 11-Apr-2001 1.00 1.00 0.00 28-Feb-2007 71.63 surgery 
165 1.00 48 0.00 03-Jul-2002 1.00 2.00 0.00 28-Feb-2007 56.70 surgery 
166 0.00 67 1.00 12-Jan-2005 2.00 1.00 0.00 28-Feb-2007 25.90 surgery 
167 1.00 59 0.00 29-May-2000 2.00 1.00 0.00 28-Feb-2007 82.20 surgery 
168 0.00 68 1.00 24-Jun-2002 2.00 2.00 0.00 28-Feb-2007 57.00 surgery 
169 1.00 88 2.00 12-Aug-1999 3.00 4.00 1.00 05-Aug-2000 11.97 surgery 
170 1.00 63 0.00 06-May-1999 3.00 2.00 0.00 28-Feb-2007 95.17 surgery 
171 0.00 50 0.00 23-Feb-2005 3.00 2.00 0.00 28-Feb-2007 24.50 surgery 
172 0.00 48 0.00 01-Dec-1999 3.00 1.00 0.00 28-Feb-2007 88.20 surgery 
173 0.00 67 1.00 24-Jan-2001 3.00 2.00 0.00 28-Feb-2007 74.20 surgery 
174 0.00 70 1.00 17-Apr-2002 3.00 1.00 0.00 28-Feb-2007 59.27 surgery 
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Patient m0f1 age agecd dateendo positcd tnmstcd a0c1n2 doffu survmths treatment 
175 1.00 76 2.00 15-Dec-2005 3.00 1.00 0.00 28-Feb-2007 14.67 surgery 
176 0.00 60 0.00 06-Nov-2000 4.00 1.00 1.00 22-Sep-2001 10.67 surgery 
177 0.00 71 1.00 16-Nov-2000 4.00 3.00 1.00 27-Oct-2001 11.50 surgery 
178 0.00 69 1.00 30-Mar-2005 5.00 1.00 0.00 28-Feb-2007 23.33 surgery 
179 0.00 64 0.00 07-Sep-2005 5.00 1.00 0.00 28-Feb-2007 17.97 surgery 
180 0.00 59 0.00 29-May-2002 5.00 1.00 0.00 28-Feb-2007 57.87 surgery 
181 1.00 73 1.00 26-Mar-2001 1.00 4.00 1.00 26-Aug-2001 5.10 surgery 
182 0.00 68 1.00 31-Dec-1997 1.00 3.00 1.00 26-Mar-2000 27.20 surgery 
183 1.00 77 2.00 24-Mar-2003 1.00 3.00 1.00 01-Sep-2003 5.37 surgery 
184 0.00 34 0.00 22-Mar-2000 1.00 3.00 1.00 04-Aug-2001 16.67 surgery 
185 0.00 41 0.00 17-Aug-2000 1.00 3.00 0.00 28-Feb-2007 79.53 surgery 
186 0.00 59 0.00 05-Dec-2001 1.00 3.00 0.00 28-Feb-2007 63.70 surgery 
187 1.00 58 0.00 09-Jun-2005 1.00 3.00 1.00 31-May-2006 11.87 surgery 
188 0.00 74 1.00 13-Oct-2005 1.00 4.00 0.00 28-Feb-2007 16.77 surgery 
189 0.00 51 0.00 16-Sep-1998 1.00 3.00 0.00 28-Feb-2007 102.90 surgery 
190 0.00 68 1.00 20-Mar-2002 1.00 3.00 1.00 22-Mar-2003 12.23 surgery 
191 1.00 74 1.00 28-Apr-1997 2.00 3.00 1.00 08-Oct-1999 29.77 surgery 
192 0.00 76 2.00 03-May-2000 2.00 3.00 1.00 30-Apr-2001 12.07 surgery 
193 0.00 65 1.00 04-Aug-2005 2.00 3.00 0.00 28-Feb-2007 19.10 surgery 
194 0.00 51 0.00 24-Nov-2005 2.00 2.00 0.00 28-Feb-2007 15.37 surgery 
195 0.00 64 0.00 01-Sep-2005 2.00 3.00 0.00 28-Feb-2007 18.17 surgery 
196 0.00 73 1.00 13-Oct-1999 2.00 3.00 1.00 14-Dec-2003 50.77 surgery 
197 1.00 75 2.00 31-May-2001 3.00 3.00 1.00 23-May-2002 11.90 surgery 
198 1.00 77 2.00 17-May-2004 3.00 3.00 0.00 28-Feb-2007 33.90 Surgery 
199 0.00 56 0.00 21-Jun-2000 3.00 3.00 1.00 01-Jan-2005 55.17 Surgery 
200 1.00 68 1.00 16-Jun-1997 3.00 3.00 1.00 08-Dec-1999 30.17 Surgery 
201 1.00 67 1.00 01-Jun-2000 3.00 3.00 1.00 08-Feb-2001 8.40 Surgery 
202 0.00 70 1.00 01-Nov-2002 3.00 2.00 1.00 13-Jul-2005 32.83 Surgery 
203 0.00 75 2.00 03-Sep-2002 3.00 3.00 1.00 30-Jan-2004 17.13 Surgery 
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Patient m0f1 age agecd dateendo positcd tnmstcd a0c1n2 doffu survmths treatment 
204 0.00 67 1.00 24-Aug-2005 3.00 3.00 0.00 28-Feb-2007 18.43 Surgery 
205 0.00 66 1.00 05-Jul-1999 3.00 2.00 1.00 14-Feb-2003 44.00 Surgery 
206 1.00 34 0.00 16-Jul-1997 3.00 3.00 1.00 30-Jul-1998 12.63 Surgery 
207 1.00 41 0.00 14-Nov-2001 3.00 2.00 1.00 08-Oct-2002 10.93 Surgery 
208 0.00 60 0.00 30-Jun-1997 3.00 3.00 0.00 28-Feb-2007 117.67 Surgery 
209 0.00 72 1.00 21-Oct-1998 3.00 2.00 1.00 29-Nov-2004 74.37 Surgery 
210 1.00 31 0.00 16-Feb-2005 3.00 2.00 0.00 28-Feb-2007 24.73 Surgery 
211 1.00 83 2.00 08-Dec-2005 4.00 3.00 0.00 28-Feb-2007 14.90 Surgery 
212 0.00 70 1.00 20-Aug-2003 4.00 3.00 1.00 25-Mar-2004 7.27 Surgery 
213 0.00 56 0.00 07-Jan-1998 4.00 3.00 2.00 12-Feb-1998 1.20 Surgery 
214 0.00 74 1.00 10-Sep-2003 5.00 3.00 1.00 15-Dec-2005 27.57 Surgery 
215 0.00 60 0.00 06-Oct-2004 5.00 3.00 0.00 28-Feb-2007 29.17 Surgery 
216 0.00 72 1.00 09-Jan-2002 5.00 2.00 0.00 28-Feb-2007 62.53 Surgery 





Patient treatcd3 crpfinal logcrp cfinalcd albfinal Albfincd gps Mgps 
1 0.00 6.00 0.78 0.00 41.00 0.00 0.00 0.00 
2 1.00 96.00 1.98 1.00 30.00 1.00 2.00 2.00 
3 1.00 23.00 1.36 1.00 32.00 1.00 2.00 2.00 
4 2.00 16.00 1.20 1.00 33.00 1.00 2.00 2.00 
5 2.00 117.00 2.07 1.00 33.00 1.00 2.00 2.00 
6 2.00 11.00 1.04 1.00 34.00 1.00 2.00 2.00 
7 1.00 6.00 0.78 0.00 35.00 0.00 0.00 0.00 
8 1.00 6.00 0.78 0.00 37.00 0.00 0.00 0.00 
9 1.00 28.00 1.45 1.00 37.00 0.00 1.00 1.00 
10 1.00 42.00 1.62 1.00 37.00 0.00 1.00 1.00 
11 1.00 6.00 0.78 0.00 39.00 0.00 0.00 0.00 
12 1.00 43.00 1.63 1.00 39.00 0.00 1.00 1.00 
13 1.00 52.00 1.72 1.00 39.00 0.00 1.00 1.00 
14 1.00 21.00 1.32 1.00 40.00 0.00 1.00 1.00 
15 1.00 6.00 0.78 0.00 42.00 0.00 0.00 0.00 
16 1.00 6.00 0.78 0.00 44.00 0.00 0.00 0.00 
17 1.00 6.00 0.78 0.00 44.00 0.00 0.00 0.00 
18 1.00 9.00 0.95 0.00 46.00 0.00 0.00 0.00 
19 1.00 11.00 1.04 1.00 48.00 0.00 1.00 1.00 
20 1.00 217.00 2.34 1.00 28.00 1.00 2.00 2.00 
21 2.00 10.00 1.00 0.00 33.00 1.00 1.00 0.00 
22 1.00 88.00 1.94 1.00 35.00 0.00 1.00 1.00 
23 2.00 109.00 2.04 1.00 35.00 0.00 1.00 1.00 
24 1.00 38.00 1.58 1.00 39.00 0.00 1.00 1.00 
25 1.00 6.00 0.78 0.00 42.00 0.00 0.00 0.00 
26 2.00 8.00 0.90 0.00 44.00 0.00 0.00 0.00 
27 1.00 6.00 0.78 0.00 46.00 0.00 0.00 0.00 
28 1.00 58.00 1.76 1.00 27.00 1.00 2.00 2.00 
29 1.00 64.00 1.81 1.00 28.00 1.00 2.00 2.00 
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Patient treatcd3 crpfinal logcrp cfinalcd albfinal Albfincd gps Mgps 
30 1.00 29.00 1.46 1.00 31.00 1.00 2.00 2.00 
31 1.00 157.00 2.20 1.00 32.00 1.00 2.00 2.00 
32 1.00 24.00 1.38 1.00 33.00 1.00 2.00 2.00 
33 1.00 6.00 0.78 0.00 34.00 1.00 1.00 0.00 
34 1.00 10.00 1.00 0.00 34.00 1.00 1.00 0.00 
35 1.00 19.00 1.28 1.00 34.00 1.00 2.00 2.00 
36 1.00 68.00 1.83 1.00 34.00 1.00 2.00 2.00 
37 1.00 15.00 1.18 1.00 35.00 0.00 1.00 1.00 
38 2.00 10.00 1.00 0.00 36.00 0.00 0.00 0.00 
39 1.00 6.00 0.78 0.00 37.00 0.00 0.00 0.00 
40 1.00 6.00 0.78 0.00 37.00 0.00 0.00 0.00 
41 1.00 8.00 0.90 0.00 37.00 0.00 0.00 0.00 
42 1.00 13.00 1.11 1.00 37.00 0.00 1.00 1.00 
43 2.00 17.00 1.23 1.00 37.00 0.00 1.00 1.00 
44 1.00 6.00 0.78 0.00 38.00 0.00 0.00 0.00 
45 1.00 6.00 0.78 0.00 38.00 0.00 0.00 0.00 
46 1.00 89.00 1.95 1.00 38.00 0.00 1.00 1.00 
47 1.00 96.00 1.98 1.00 38.00 0.00 1.00 1.00 
48 1.00 53.00 1.72 1.00 40.00 0.00 1.00 1.00 
49 2.00 79.00 1.90 1.00 40.00 0.00 1.00 1.00 
50 2.00 89.00 1.95 1.00 40.00 0.00 1.00 1.00 
51 1.00 6.00 0.78 0.00 41.00 0.00 0.00 0.00 
52 1.00 6.00 0.78 0.00 42.00 0.00 0.00 0.00 
53 1.00 6.00 0.78 0.00 42.00 0.00 0.00 0.00 
54 1.00 6.00 0.78 0.00 43.00 0.00 0.00 0.00 
55 1.00 6.00 0.78 0.00 43.00 0.00 0.00 0.00 
56 1.00 6.00 0.78 0.00 43.00 0.00 0.00 0.00 
57 1.00 6.00 0.78 0.00 43.00 0.00 0.00 0.00 
58 1.00 7.00 0.85 0.00 43.00 0.00 0.00 0.00 
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Patient treatcd3 crpfinal logcrp cfinalcd albfinal Albfincd gps Mgps 
59 1.00 11.00 1.04 1.00 43.00 0.00 1.00 1.00 
60 1.00 18.00 1.26 1.00 43.00 0.00 1.00 1.00 
61 1.00 26.00 1.41 1.00 43.00 0.00 1.00 1.00 
62 1.00 6.00 0.78 0.00 48.00 0.00 0.00 0.00 
63 2.00 17.00 1.23 1.00 48.00 0.00 1.00 1.00 
64 1.00 42.00 1.62 1.00 49.00 0.00 1.00 1.00 
65 1.00 26.00 1.41 1.00 7.00 1.00 2.00 2.00 
66 1.00 20.00 1.30 1.00 24.00 1.00 2.00 2.00 
67 2.00 29.00 1.46 1.00 28.00 1.00 2.00 2.00 
68 2.00 31.00 1.49 1.00 28.00 1.00 2.00 2.00 
69 2.00 38.00 1.58 1.00 28.00 1.00 2.00 2.00 
70 1.00 8.00 0.90 0.00 30.00 1.00 1.00 0.00 
71 2.00 6.00 0.78 0.00 31.00 1.00 1.00 0.00 
72 1.00 21.00 1.32 1.00 32.00 1.00 2.00 2.00 
73 1.00 82.00 1.91 1.00 34.00 1.00 2.00 2.00 
74 1.00 14.00 1.15 1.00 35.00 0.00 1.00 1.00 
75 1.00 65.00 1.81 1.00 35.00 0.00 1.00 1.00 
76 1.00 16.00 1.20 1.00 36.00 0.00 1.00 1.00 
77 1.00 28.00 1.45 1.00 36.00 0.00 1.00 1.00 
78 1.00 47.00 1.67 1.00 36.00 0.00 1.00 1.00 
79 2.00 89.00 1.95 1.00 36.00 0.00 1.00 1.00 
80 2.00 171.00 2.23 1.00 36.00 0.00 1.00 1.00 
81 1.00 44.00 1.64 1.00 37.00 0.00 1.00 1.00 
82 2.00 8.00 0.90 0.00 38.00 0.00 0.00 0.00 
83 2.00 18.00 1.26 1.00 38.00 0.00 1.00 1.00 
84 2.00 64.00 1.81 1.00 38.00 0.00 1.00 1.00 
85 1.00 6.00 0.78 0.00 39.00 0.00 0.00 0.00 
86 1.00 6.00 0.78 0.00 39.00 0.00 0.00 0.00 
87 1.00 6.00 0.78 0.00 39.00 0.00 0.00 0.00 
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Patient treatcd3 crpfinal logcrp cfinalcd albfinal Albfincd gps Mgps 
88 1.00 15.00 1.18 1.00 39.00 0.00 1.00 1.00 
89 2.00 11.00 1.04 1.00 40.00 0.00 1.00 1.00 
90 1.00 22.00 1.34 1.00 41.00 0.00 1.00 1.00 
91 1.00 6.00 0.78 0.00 42.00 0.00 0.00 0.00 
92 1.00 6.00 0.78 0.00 42.00 0.00 0.00 0.00 
93 1.00 6.00 0.78 0.00 43.00 0.00 0.00 0.00 
94 1.00 6.00 0.78 0.00 44.00 0.00 0.00 0.00 
95 1.00 6.00 0.78 0.00 44.00 0.00 0.00 0.00 
96 1.00 45.00 1.65 1.00 44.00 0.00 1.00 1.00 
97 2.00 23.00 1.36 1.00 28.00 1.00 2.00 2.00 
98 1.00 43.00 1.63 1.00 28.00 1.00 2.00 2.00 
99 1.00 171.00 2.23 1.00 28.00 1.00 2.00 2.00 
100 2.00 99.00 2.00 1.00 29.00 1.00 2.00 2.00 
101 2.00 253.00 2.40 1.00 29.00 1.00 2.00 2.00 
102 1.00 10.00 1.00 0.00 30.00 1.00 1.00 0.00 
103 1.00 41.00 1.61 1.00 30.00 1.00 2.00 2.00 
104 1.00 23.00 1.36 1.00 32.00 1.00 2.00 2.00 
105 1.00 94.00 1.97 1.00 32.00 1.00 2.00 2.00 
106 1.00 120.00 2.08 1.00 32.00 1.00 2.00 2.00 
107 2.00 74.00 1.87 1.00 33.00 1.00 2.00 2.00 
108 1.00 7.00 0.85 0.00 34.00 1.00 1.00 0.00 
109 1.00 10.00 1.00 0.00 34.00 1.00 1.00 0.00 
110 1.00 19.00 1.28 1.00 34.00 1.00 2.00 2.00 
111 1.00 73.00 1.86 1.00 35.00 0.00 1.00 1.00 
112 2.00 12.00 1.08 1.00 37.00 0.00 1.00 1.00 
113 1.00 35.00 1.54 1.00 37.00 0.00 1.00 1.00 
114 2.00 38.00 1.58 1.00 37.00 0.00 1.00 1.00 
115 1.00 39.00 1.59 1.00 37.00 0.00 1.00 1.00 
116 1.00 6.00 0.78 0.00 38.00 0.00 0.00 0.00 
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Patient treatcd3 crpfinal logcrp cfinalcd albfinal Albfincd gps Mgps 
117 1.00 6.00 0.78 0.00 38.00 0.00 0.00 0.00 
118 1.00 6.00 0.78 0.00 38.00 0.00 0.00 0.00 
119 1.00 8.00 0.90 0.00 38.00 0.00 0.00 0.00 
120 1.00 190.00 2.28 1.00 38.00 0.00 1.00 1.00 
121 1.00 6.00 0.78 0.00 39.00 0.00 0.00 0.00 
122 1.00 12.00 1.08 1.00 39.00 0.00 1.00 1.00 
123 1.00 57.00 1.76 1.00 39.00 0.00 1.00 1.00 
124 2.00 8.00 0.90 0.00 40.00 0.00 0.00 0.00 
125 1.00 8.00 0.90 0.00 40.00 0.00 0.00 0.00 
126 1.00 24.00 1.38 1.00 40.00 0.00 1.00 1.00 
127 2.00 30.00 1.48 1.00 40.00 0.00 1.00 1.00 
128 1.00 6.00 0.78 0.00 42.00 0.00 0.00 0.00 
129 2.00 6.00 0.78 0.00 42.00 0.00 0.00 0.00 
130 1.00 8.00 0.90 0.00 42.00 0.00 0.00 0.00 
131 1.00 36.00 1.56 1.00 42.00 0.00 1.00 1.00 
132 2.00 171.00 2.23 1.00 42.00 0.00 1.00 1.00 
133 1.00 96.00 1.98 1.00 43.00 0.00 1.00 1.00 
134 1.00 6.00 0.78 0.00 44.00 0.00 0.00 0.00 
135 1.00 8.00 0.90 0.00 44.00 0.00 0.00 0.00 
136 2.00 8.00 0.90 0.00 44.00 0.00 0.00 0.00 
137 1.00 6.00 0.78 0.00 46.00 0.00 0.00 0.00 
138 1.00 11.00 1.04 1.00 46.00 0.00 1.00 1.00 
139 2.00 30.00 1.48 1.00 22.00 1.00 2.00 2.00 
140 1.00 60.00 1.78 1.00 25.00 1.00 2.00 2.00 
141 1.00 6.00 0.78 0.00 32.00 1.00 1.00 0.00 
142 1.00 8.00 0.90 0.00 34.00 1.00 1.00 0.00 
143 1.00 6.00 0.78 0.00 36.00 0.00 0.00 0.00 
144 1.00 15.00 1.18 1.00 40.00 0.00 1.00 1.00 
145 1.00 26.00 1.41 1.00 40.00 0.00 1.00 1.00 
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Patient treatcd3 crpfinal logcrp cfinalcd albfinal Albfincd gps Mgps 
146 1.00 6.00 0.78 0.00 44.00 0.00 0.00 0.00 
147 1.00 6.00 0.78 0.00 45.00 0.00 0.00 0.00 
148 0.00 6.00 0.78 0.00 42.00 0.00 0.00 0.00 
149 0.00 33.00 1.52 1.00 32.00 1.00 2.00 2.00 
150 0.00 6.00 0.78 0.00 42.00 0.00 0.00 0.00 
151 0.00 6.00 0.78 0.00 43.00 0.00 0.00 0.00 
152 0.00 6.00 0.78 0.00 45.00 0.00 0.00 0.00 
153 0.00 6.00 0.78 0.00 46.00 0.00 0.00 0.00 
154 0.00 6.00 0.78 0.00 37.00 0.00 0.00 0.00 
155 0.00 6.00 0.78 0.00 40.00 0.00 0.00 0.00 
156 0.00 6.00 0.78 0.00 41.00 0.00 0.00 0.00 
157 0.00 6.00 0.78 0.00 44.00 0.00 0.00 0.00 
158 0.00 6.00 0.78 0.00 45.00 0.00 0.00 0.00 
159 0.00 9.00 0.95 0.00 40.00 0.00 0.00 0.00 
160 0.00 7.00 0.85 0.00 42.00 0.00 0.00 0.00 
161 0.00 19.00 1.28 1.00 35.00 0.00 1.00 1.00 
162 0.00 6.00 0.78 0.00 43.00 0.00 0.00 0.00 
163 0.00 6.00 0.78 0.00 44.00 0.00 0.00 0.00 
164 0.00 8.00 0.90 0.00 44.00 0.00 0.00 0.00 
165 0.00 6.00 0.78 0.00 45.00 0.00 0.00 0.00 
166 0.00 10.00 1.00 0.00 40.00 0.00 0.00 0.00 
167 0.00 6.00 0.78 0.00 42.00 0.00 0.00 0.00 
168 0.00 7.00 0.85 0.00 44.00 0.00 0.00 0.00 
169 0.00 6.00 0.78 0.00 36.00 0.00 0.00 0.00 
170 0.00 6.00 0.78 0.00 37.00 0.00 0.00 0.00 
171 0.00 6.00 0.78 0.00 40.00 0.00 0.00 0.00 
172 0.00 6.00 0.78 0.00 41.00 0.00 0.00 0.00 
173 0.00 6.00 0.78 0.00 41.00 0.00 0.00 0.00 
174 0.00 6.00 0.78 0.00 43.00 0.00 0.00 0.00 
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Patient treatcd3 crpfinal logcrp cfinalcd albfinal Albfincd gps Mgps 
175 0.00 6.00 0.78 0.00 43.00 0.00 0.00 0.00 
176 0.00 36.00 1.56 1.00 37.00 0.00 1.00 1.00 
177 0.00 17.00 1.23 1.00 38.00 0.00 1.00 1.00 
178 0.00 6.00 0.78 0.00 38.00 0.00 0.00 0.00 
179 0.00 6.00 0.78 0.00 39.00 0.00 0.00 0.00 
180 0.00 6.00 0.78 0.00 42.00 0.00 0.00 0.00 
181 0.00 8.00 0.90 0.00 35.00 0.00 0.00 0.00 
182 0.00 15.00 1.18 1.00 40.00 0.00 1.00 1.00 
183 0.00 6.00 0.78 0.00 41.00 0.00 0.00 0.00 
184 0.00 12.00 1.08 1.00 44.00 0.00 1.00 1.00 
185 0.00 6.00 0.78 0.00 46.00 0.00 0.00 0.00 
186 0.00 8.00 0.90 0.00 46.00 0.00 0.00 0.00 
187 0.00 6.00 0.78 0.00 31.00 1.00 1.00 0.00 
188 0.00 41.00 1.61 1.00 40.00 0.00 1.00 1.00 
189 0.00 6.00 0.78 0.00 44.00 0.00 0.00 0.00 
190 0.00 9.00 0.95 0.00 45.00 0.00 0.00 0.00 
191 0.00 21.00 1.32 1.00 36.00 0.00 1.00 1.00 
192 0.00 6.00 0.78 0.00 40.00 0.00 0.00 0.00 
193 0.00 6.00 0.78 0.00 42.00 0.00 0.00 0.00 
194 0.00 6.00 0.78 0.00 43.00 0.00 0.00 0.00 
195 0.00 6.00 0.78 0.00 43.00 0.00 0.00 0.00 
196 0.00 6.00 0.78 0.00 44.00 0.00 0.00 0.00 
197 0.00 6.00 0.78 0.00 34.00 1.00 1.00 0.00 
198 0.00 6.00 0.78 0.00 37.00 0.00 0.00 0.00 
199 0.00 9.00 0.95 0.00 38.00 0.00 0.00 0.00 
200 0.00 11.00 1.04 1.00 38.00 0.00 1.00 1.00 
201 0.00 6.00 0.78 0.00 39.00 0.00 0.00 0.00 
202 0.00 6.00 0.78 0.00 39.00 0.00 0.00 0.00 
203 0.00 6.00 0.78 0.00 41.00 0.00 0.00 0.00 
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Patient treatcd3 crpfinal logcrp cfinalcd albfinal Albfincd gps Mgps 
204 0.00 34.00 1.53 1.00 41.00 0.00 1.00 1.00 
205 0.00 6.00 0.78 0.00 42.00 0.00 0.00 0.00 
206 0.00 6.00 0.78 0.00 43.00 0.00 0.00 0.00 
207 0.00 6.00 0.78 0.00 43.00 0.00 0.00 0.00 
208 0.00 6.00 0.78 0.00 43.00 0.00 0.00 0.00 
209 0.00 6.00 0.78 0.00 46.00 0.00 0.00 0.00 
210 0.00 6.00 0.78 0.00 47.00 0.00 0.00 0.00 
211 0.00 6.00 0.78 0.00 36.00 0.00 0.00 0.00 
212 0.00 9.00 0.95 0.00 37.00 0.00 0.00 0.00 
213 0.00 6.00 0.78 0.00 38.00 0.00 0.00 0.00 
214 0.00 6.00 0.78 0.00 39.00 0.00 0.00 0.00 
215 0.00 6.00 0.78 0.00 41.00 0.00 0.00 0.00 
216 0.00 6.00 0.78 0.00 41.00 0.00 0.00 0.00 




APPENDIX 6: DATABASE FOR CHAPTER 7:   
COMPARISON OF PRE-TREATMENT CLINICAL PROGNOSTIC 
FACTORS IN PATIENTS WITH GASTRO-OESOPHAGEAL 
CANCER AND PROPOSAL OF A NEW STAGING SYSTEM. 
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Patient m0f1 age agecd weight karnofer clinstag clinstge dateop site positcd histolog typecd a0c1n2 
1 1.00 53 0 1.00 0.00 4.00 94.00 24-Feb-2004 gastric 1.00 adeno 0.00 0.00 
2 1.00 82 2 0.00 0.00 1.00 0.00 15-Jan-2003 oesoph 0.00 squam 1.00 0.00 
3 0.00 82 2 0.00 0.00 3.00 46.00 01-Oct-2002 Oesoph 0.00 adeno 0.00 0.00 
4 0.00 65 0 1.00 0.00 3.00 46.00 22-May-2003 Oesoph 0.00 squam 1.00 0.00 
5 0.00 79 2 0.00 32.00 2.00 30.00 30-Aug-2004 Oesoph 0.00 adeno 0.00 0.00 
6 0.00 73 1 1.00 0.00 3.00 46.00 26-Oct-2004 Oesoph 0.00 squam 1.00 0.00 
7 0.00 53 0 1.00 0.00 1.00 30.00 24-Dec-2002 Oesoph 0.00 squam 1.00 0.00 
8 1.00 67 1 1.00 0.00 1.00 0.00 30-Aug-2002 Gastric 1.00 adeno 0.00 0.00 
9 1.00 57 0 0.00 0.00 4.00 94.00 08-Apr-2004 Oesoph 0.00 squam 1.00 0.00 
10 0.00 81 2 0.00 0.00 1.00 0.00 22-Jul-2003 Gastric 1.00 adeno 0.00 0.00 
11 0.00 42 0 0.00 0.00 2.00 30.00 18-Aug-2004 G 1.00 adeno 0.00 0.00 
12 0.00 68 1 0.00 0.00 1.00 0.00 30-Jun-2004 G 1.00 adeno 0.00 0.00 
13 0.00 72 1 0.00 0.00 1.00 0.00 09-Jan-2002 G 1.00 adeno 0.00 0.00 
14 0.00 76 2 0.00 0.00 1.00 0.00 11-Jun-2003 G 1.00 adeno 0.00 0.00 
15 0.00 59 0 0.00 0.00 1.00 0.00 29-May-2002 G 1.00 adeno 0.00 0.00 
16 0.00 58 0 1.00 0.00 3.00 46.00 25-Jul-2002 O 0.00 adeno 0.00 0.00 
17 0.00 64 0 0.00 0.00 3.00 46.00 06-Mar-2002 O 0.00 adeno 0.00 0.00 
18 0.00 59 0 1.00 0.00 2.00 30.00 17-Mar-2003 O 0.00 squam 1.00 0.00 
19 1.00 71 1 0.00 0.00 2.00 30.00 12-May-2004 O 0.00 squam 1.00 0.00 
20 0.00 70 1 0.00 0.00 1.00 0.00 17-Apr-2002 G 1.00 adeno 0.00 0.00 
21 0.00 68 1 1.00 0.00 1.00 0.00 02-Oct-2002 O 0.00 adeno 0.00 0.00 
22 1.00 73 1 0.00 0.00 2.00 30.00 24-Apr-2002 O 0.00 adeno 0.00 0.00 
23 1.00 71 1 0.00 0.00 1.00 0.00 25-Jun-2003 O 0.00 squam 1.00 0.00 
24 0.00 68 1 1.00 0.00 2.00 30.00 24-Jun-2002 G 1.00 adeno 0.00 0.00 
25 0.00 55 0 1.00 0.00 3.00 46.00 10-Sep-2003 O 0.00 adeno 0.00 0.00 
26 0.00 46 0 0.00 0.00 2.00 30.00 26-Jun-2003 O 0.00 adeno 0.00 0.00 
27 1.00 48 0 0.00 0.00 3.00 46.00 03-Jul-2002 G 1.00 adeno 0.00 0.00 
28 0.00 60 0 0.00 0.00 1.00 0.00 06-Oct-2004 G 1.00 adeno 0.00 0.00 
29 0.00 56 0 1.00 0.00 2.00 30.00 15-Jan-2003 O 0.00 adeno 0.00 0.00 




Patient m0f1 age agecd weight karnofer clinstag clinstge dateop Site positcd histolog typecd a0c1n2 
31 1.00 54 0 1.00 0.00 4.00 94.00 05-Mar-2002 Oesoph 0.00 squam 1.00 1.00 
32 0.00 76 2 0.00 0.00 1.00 0.00 01-Jul-2003 Gastric 1.00 adeno 0.00 1.00 
33 0.00 78 2 0.00 0.00 3.00 46.00 13-Apr-2004 Oesoph 0.00 squam 1.00 1.00 
34 0.00 62 0 1.00 0.00 4.00 94.00 30-Dec-2004 Gastric 1.00 adeno 0.00 1.00 
35 1.00 89 2 0.00 0.00 4.00 94.00 12-Aug-2002 Gastric 1.00 adeno 0.00 1.00 
36 0.00 80 2 1.00 0.00 3.00 46.00 28-Jan-2002 Oesoph 0.00 adeno 0.00 1.00 
37 0.00 60 0 0.00 32.00 1.00 0.00 20-Oct-2004 Gastric 1.00 adeno 0.00 1.00 
38 0.00 49 0 1.00 0.00 4.00 94.00 23-Jun-2004 o/g 0.00 adeno 0.00 1.00 
39 0.00 76 2 1.00 0.00 3.00 46.00 22-Jul-2003 Oesoph 0.00 adeno 0.00 1.00 
40 1.00 78 2 1.00 0.00 3.00 46.00 28-Mar-2003 Oesoph 0.00 squam 1.00 1.00 
41 0.00 64 0 0.00 0.00 4.00 94.00 16-Jul-2004 Gastric 1.00 adeno 0.00 1.00 
42 1.00 62 0 1.00 0.00 4.00 94.00 08-Oct-2002 Gastric 1.00 adeno 0.00 1.00 
43 1.00 64 0 1.00 0.00 4.00 94.00 06-Jul-2004 Gastric 1.00 adeno 0.00 1.00 
44 0.00 88 2 1.00 0.00 3.00 46.00 28-May-2002 Oesoph 0.00 adeno 0.00 1.00 
45 1.00 47 0 0.00 0.00 4.00 94.00 07-Dec-2004 Gastric 1.00 adeno 0.00 1.00 
46 0.00 48 0 1.00 0.00 4.00 94.00 27-Feb-2003 Oesoph 0.00 adeno 0.00 1.00 
47 0.00 70 1 1.00 0.00 3.00 46.00 30-Nov-2004 Gastric 1.00 adeno 0.00 1.00 
48 0.00 73 1 0.00 0.00 4.00 94.00 01-Sep-2003 Oesoph 0.00 squam 1.00 1.00 
49 1.00 76 2 1.00 0.00 1.00 0.00 14-May-2002 Oesoph 0.00 adeno 0.00 1.00 
50 1.00 65 0 1.00 0.00 4.00 94.00 01-Dec-2003 Gastric 1.00 adeno 0.00 1.00 
51 0.00 56 0 1.00 0.00 4.00 94.00 20-Oct-2003 Oesoph 0.00 adeno 0.00 1.00 
52 1.00 55 0 0.00 0.00 4.00 94.00 21-Dec-2004 o/g 0.00 adeno 0.00 1.00 
53 0.00 75 2 1.00 0.00 4.00 94.00 05-May-2004 Gastric 1.00 adeno 0.00 1.00 
54 0.00 82 2 1.00 0.00 1.00 0.00 29-Jan-2003 Gastric 1.00 adeno 0.00 1.00 
55 1.00 79 2 0.00 0.00 4.00 94.00 23-Nov-2004 Gastric 1.00 adeno 0.00 1.00 
56 0.00 66 1 1.00 0.00 4.00 94.00 27-Jul-2004 o/g 0.00 adeno 0.00 1.00 
57 0.00 79 2 1.00 68.00 4.00 94.00 01-Apr-2004 o/g 1.00 adeno 0.00 1.00 
58 0.00 47 0 1.00 0.00 4.00 94.00 02-Mar-2002 Gastric 1.00 adeno 0.00 1.00 
59 0.00 58 0 0.00 0.00 2.00 30.00 12-Apr-2002 Gastric 1.00 adeno 0.00 1.00 





Patient m0f1 age agecd weight karnofer clinstag clinstge dateop Site positcd histolog typecd a0c1n2 
61 0.00 64 0 1.00 0.00 3.00 46.00 01-Mar-2004 Oesoph 0.00 squam 1.00 1.00 
62 1.00 79 2 1.00 0.00 4.00 94.00 10-Jun-2002 Gastric 1.00 adeno 0.00 1.00 
63 0.00 63 0 0.00 0.00 4.00 94.00 05-Mar-2004 o/g 0.00 adeno 0.00 1.00 
64 1.00 69 1 0.00 0.00 3.00 46.00 23-Apr-2003 Oesoph 0.00 squam 1.00 1.00 
65 1.00 81 2 1.00 32.00 2.00 30.00 04-May-2004 Gastric 1.00 adeno 0.00 1.00 
66 1.00 84 2 0.00 0.00 3.00 46.00 05-Nov-2004 Oesoph 0.00 adeno 0.00 1.00 
67 0.00 76 2 1.00 0.00 4.00 94.00 24-Aug-2004 Gastric 1.00 adeno 0.00 1.00 
68 0.00 64 0 0.00 0.00 4.00 94.00 23-Aug-2004 o/g 1.00 adeno 0.00 1.00 
69 0.00 73 1 1.00 0.00 3.00 46.00 14-Jan-2004 Oesoph 0.00 adeno 0.00 1.00 
70 0.00 73 1 1.00 0.00 4.00 94.00 16-Jul-2004 Gastric 1.00 adeno 0.00 1.00 
71 0.00 92 2 0.00 0.00 2.00 30.00 23-Dec-2003 Gastric 1.00 adeno 0.00 1.00 
72 0.00 60 0 0.00 0.00 4.00 94.00 04-Aug-2003 Oesoph 0.00 squam 1.00 1.00 
73 1.00 64 0 0.00 0.00 4.00 94.00 07-Dec-2004 Gastric 1.00 adeno 0.00 1.00 
74 0.00 52 0 1.00 0.00 4.00 94.00 05-Jun-2003 o/g 1.00 adeno 0.00 1.00 
75 0.00 83 2 1.00 0.00 4.00 94.00 03-Sep-2004 Oesoph 0.00 adeno 0.00 1.00 
76 0.00 81 2 0.00 0.00 1.00 0.00 11-Oct-2004 Gastric 1.00 adeno 0.00 1.00 
77 0.00 43 0 1.00 0.00 4.00 94.00 06-Jan-2003 o/g 1.00 adeno 0.00 1.00 
78 0.00 42 0 1.00 0.00 4.00 94.00 17-Mar-2004 Gastric 1.00 adeno 0.00 1.00 
79 1.00 57 0 1.00 0.00 4.00 94.00 22-Feb-2002 Gastric 1.00 adeon 0.00 1.00 
80 0.00 74 1 1.00 0.00 4.00 94.00 14-Oct-2003 Gastric 1.00 adeno 0.00 1.00 
81 0.00 61 0 1.00 0.00 3.00 46.00 31-Dec-2002 Oesoph 0.00 adeno 0.00 1.00 
82 0.00 49 0 1.00 0.00 4.00 94.00 01-May-2002 Gastric 1.00 adeno 0.00 1.00 
83 0.00 80 2 0.00 32.00 3.00 46.00 09-Jun-2003 o/g 1.00 adeno 0.00 1.00 
84 0.00 65 0 0.00 0.00 4.00 94.00 18-Jun-2002 Oesoph 0.00 squam 1.00 1.00 
85 1.00 76 2 1.00 0.00 3.00 46.00 20-Oct-2004 Oesoph 0.00 squam 1.00 1.00 
86 0.00 62 0 1.00 0.00 4.00 94.00 16-Aug-2004 o/g 0.00 adeno 0.00 1.00 
87 1.00 83 2 1.00 0.00 4.00 94.00 06-Jan-2004 Gastric 1.00 adeno 0.00 1.00 
88 0.00 72 1 0.00 0.00 4.00 94.00 30-Jul-2004 Gastric 1.00 adeno 0.00 1.00 
89 1.00 82 2 1.00 0.00 2.00 30.00 26-Mar-2002 Oesoph 0.00 adeno 0.00 1.00 
90 1.00 94 2 0.00 0.00 2.00 30.00 16-Jan-2004 Oesoph 0.00 adeno 0.00 1.00 
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Patient m0f1 age agecd weight karnofer clinstag clinstge dateop Site positcd histolog typecd a0c1n2 
91 0.00 68 1 0.00 0.00 4.00 94.00 24-Sep-2003 Gastric 1.00 adeno 0.00 1.00 
92 0.00 75 2 1.00 0.00 4.00 94.00 17-Jun-2002 Oeosph 0.00 squam 1.00 1.00 
93 0.00 76 2 1.00 0.00 3.00 46.00 16-Sep-2002 Oesoph 0.00 adeno 0.00 1.00 
94 0.00 75 2 1.00 0.00 3.00 46.00 14-Oct-2004 Oesoph 0.00 squam 1.00 1.00 
95 0.00 54 0 1.00 0.00 4.00 94.00 23-Mar-2004 Oesoph 0.00 adeno 0.00 1.00 
96 1.00 55 0 0.00 0.00 3.00 46.00 20-Aug-2003 Oesoph 0.00 squam 1.00 1.00 
97 0.00 72 1 1.00 0.00 3.00 46.00 12-Nov-2003 Oesoph 0.00 adeno 0.00 1.00 
98 1.00 72 1 1.00 0.00 3.00 46.00 11-Jun-2003 Oesoph 0.00 squam 1.00 1.00 
99 0.00 83 2 0.00 0.00 4.00 94.00 27-Feb-2004 o/g 1.00 adeno 0.00 1.00 
100 0.00 69 1 1.00 0.00 4.00 94.00 14-Jan-2004 Oesoph 0.00 squam 1.00 1.00 
101 1.00 77 2 1.00 0.00 3.00 46.00 07-Dec-2004 Gastric 1.00 adeno 0.00 1.00 
102 1.00 64 0 1.00 0.00 1.00 0.00 12-Nov-2002 Gastric 1.00 adeno 0.00 1.00 
103 0.00 79 2 0.00 0.00 3.00 46.00 10-Nov-2004 Oesoph 0.00 adeno 0.00 1.00 
104 0.00 82 2 1.00 0.00 4.00 94.00 27-Sep-2002 Oesoph 0.00 squam 1.00 1.00 
105 1.00 61 0 0.00 0.00 4.00 94.00 20-Aug-2002 Oesoph 0.00 squam 1.00 1.00 
106 0.00 66 1 0.00 0.00 4.00 94.00 06-Jan-2004 Oesoph 0.00 squam 1.00 1.00 
107 1.00 84 2 1.00 0.00 4.00 94.00 05-Feb-2002 Oesoph 0.00 adeno 0.00 1.00 
108 1.00 47 0 0.00 0.00 4.00 94.00 09-Sep-2003 Gastric 1.00 adeno 0.00 1.00 
109 0.00 75 2 1.00 0.00 3.00 46.00 14-Sep-2004 o/g 1.00 adeno 0.00 1.00 
110 0.00 65 0 1.00 0.00 4.00 94.00 11-Oct-2002 Oesoph 0.00 adeno 0.00 1.00 
111 1.00 67 1 1.00 0.00 4.00 94.00 26-Nov-2004 Oesoph 0.00 adeno 0.00 1.00 
112 1.00 66 1 0.00 0.00 2.00 30.00 19-Sep-2003 Oesoph 0.00 adeno 0.00 1.00 
113 1.00 54 0 0.00 0.00 4.00 94.00 06-Dec-2004 Gastric 1.00 adeno 0.00 1.00 
114 0.00 72 1 1.00 0.00 3.00 46.00 22-Dec-2003 Oesoph 0.00 squam 1.00 1.00 
115 0.00 69 1 1.00 0.00 4.00 94.00 26-Feb-2002 Gastric 1.00 adeno 0.00 1.00 
116 0.00 80 2 0.00 0.00 4.00 94.00 30-Jul-2004 Oesoph 0.00 squam 1.00 1.00 
117 1.00 41 0 1.00 0.00 4.00 94.00 14-Jun-2004 Gastric 1.00 adeno 0.00 1.00 
118 0.00 81 2 1.00 0.00 4.00 94.00 02-Sep-2004 o/g 1.00 adeno 0.00 1.00 
119 1.00 82 2 0.00 0.00 1.00 0.00 05-Jul-2002 Oesoph 0.00 squam 1.00 1.00 





Patient m0f1 age agecd weight karnofer clinstag clinstge dateop Site positcd histolog typecd a0c1n2 
121 0.00 77 2 1.00 0.00 4.00 94.00 07-Mar-2003 Gastric 1.00 adeno 0.00 1.00 
122 1.00 81 2 0.00 32.00 1.00 0.00 03-Nov-2003 Gastric 1.00 adeno 0.00 1.00 
123 0.00 75 2 1.00 0.00 4.00 94.00 08-Jan-2002 Gastric 1.00 adeno 0.00 1.00 
124 0.00 77 2 1.00 0.00 3.00 46.00 12-Apr-2002 Oesoph 0.00 squam 1.00 1.00 
125 0.00 81 2 1.00 0.00 3.00 46.00 16-Oct-2003 Oesoph 0.00 adeno 0.00 1.00 
126 0.00 79 2 0.00 0.00 3.00 46.00 01-Oct-2004 Oesoph 0.00 squam 1.00 1.00 
127 0.00 70 1 0.00 0.00 3.00 46.00 10-May-2004 Oesoph 0.00 adeno 0.00 1.00 
128 0.00 76 2 1.00 0.00 4.00 94.00 26-Mar-2004 Gastric 1.00 adeno 0.00 1.00 
129 0.00 45 0 1.00 0.00 4.00 94.00 01-Mar-2002 Gastric 1.00 adeno 0.00 1.00 
130 1.00 86 2 1.00 0.00 4.00 94.00 04-Aug-2003 Gastric 1.00 adeno 0.00 1.00 
131 0.00 46 0 1.00 0.00 2.00 30.00 22-Feb-2002 o/g 0.00 adeno 0.00 1.00 
132 0.00 46 0 1.00 0.00 2.00 30.00 22-Feb-2002 Oesoph 0.00 adeno 0.00 1.00 
133 0.00 72 1 1.00 0.00 1.00 0.00 04-Sep-2003 Oesoph 0.00 squam 1.00 1.00 
134 0.00 55 0 1.00 0.00 3.00 46.00 20-Jan-2004 Oesoph 0.00 squam 1.00 1.00 
135 0.00 65 0 1.00 0.00 3.00 46.00 21-Feb-2002 Gastric 1.00 adeno 0.00 1.00 
136 0.00 75 2 1.00 0.00 3.00 46.00 19-Feb-2004 Oesoph 0.00 adeno 0.00 1.00 
137 0.00 65 0 0.00 0.00 3.00 46.00 23-Apr-2003 Oesoph 0.00 squam 1.00 1.00 
138 1.00 75 2 1.00 0.00 4.00 94.00 04-Dec-2003 Gastric 1.00 adeno 0.00 1.00 
139 0.00 76 2 1.00 0.00 4.00 94.00 28-Jun-2002 Oesoph 0.00 adeno 0.00 1.00 
140 0.00 76 2 1.00 0.00 4.00 94.00 30-May-2003 Gastric 1.00 adeno 0.00 1.00 
141 0.00 66 1 1.00 0.00 4.00 94.00 30-Jul-2003 Oesoph 0.00 adeno 0.00 1.00 
142 0.00 61 0 1.00 0.00 4.00 94.00 15-Mar-2004 Oesoph 0.00 squam 1.00 1.00 
143 1.00 56 0 1.00 0.00 4.00 94.00 08-Aug-2002 Oesoph 0.00 adeno 0.00 1.00 
144 0.00 72 1 1.00 0.00 4.00 94.00 26-Nov-2002 Oesoph 0.00 squam 1.00 1.00 
145 1.00 83 2 1.00 0.00 4.00 94.00 07-May-2003 Oesoph 0.00 adeno 0.00 1.00 
146 1.00 63 0 0.00 0.00 4.00 94.00 23-Aug-2002 Gastric 1.00 adeno 0.00 1.00 
147 0.00 84 2 0.00 32.00 1.00 0.00 22-Oct-2004 Gastric 1.00 adeno 0.00 1.00 
148 0.00 43 0 1.00 0.00 4.00 94.00 16-Apr-2002 Oesoph 0.00 adeno 0.00 1.00 
149 0.00 57 0 1.00 0.00 4.00 94.00 16-Jan-2002 Gastric 1.00 adeno 0.00 1.00 
150 1.00 68 1 0.00 0.00 2.00 30.00 22-Jun-2004 Gastric 1.00 adeno 0.00 1.00 
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Patient m0f1 age agecd weight karnofer clinstag clinstge dateop Site positcd histolog typecd a0c1n2 
151 1.00 62 0 0.00 0.00 4.00 94.00 09-May-2003 Gastric 1.00 adeno 0.00 1.00 
152 0.00 80 2 1.00 0.00 4.00 94.00 25-Jun-2002 Oesoph 0.00 squam 1.00 1.00 
153 0.00 83 2 0.00 0.00 4.00 94.00 21-Oct-2002 o/g 1.00 adeno 0.00 1.00 
154 0.00 42 0 1.00 0.00 4.00 94.00 17-Sep-2004 o/g 1.00 adeno 0.00 1.00 
155 0.00 75 2 1.00 0.00 3.00 46.00 31-Jan-2003 Oesoph 0.00 adeno 0.00 1.00 
156 0.00 76 2 0.00 0.00 4.00 94.00 10-Dec-2002 Oesoph 0.00 adeno 0.00 1.00 
157 0.00 56 0 0.00 0.00 3.00 46.00 06-May-2003 Oesoph 0.00 squam 1.00 1.00 
158 1.00 82 2 1.00 0.00 3.00 46.00 30-Nov-2004 Oesoph 0.00 squam 1.00 1.00 
159 0.00 87 2 1.00 32.00 3.00 46.00 08-Aug-2004 Oesoph 0.00 squam 1.00 1.00 
160 0.00 79 2 1.00 32.00 3.00 46.00 12-Sep-2003 Gastric 1.00 adeno 0.00 1.00 
161 0.00 74 1 0.00 0.00 4.00 94.00 18-Nov-2003 Gastric 1.00 adeno 0.00 1.00 
162 1.00 77 2 1.00 0.00 3.00 46.00 19-Dec-2003 Gastric 1.00 adeno 0.00 1.00 
163 1.00 87 2 0.00 68.00 2.00 30.00 19-Mar-2004 Oesoph 0.00 adeno 0.00 1.00 
164 0.00 55 0 1.00 0.00 4.00 94.00 19-Jun-2003 Gastric 1.00 adeno 0.00 1.00 
165 0.00 52 0 1.00 0.00 4.00 94.00 10-Dec-2002 Oesoph 0.00 adeno 0.00 1.00 
166 0.00 78 2 1.00 32.00 4.00 94.00 04-Jun-2004 Oesoph 0.00 squam 1.00 1.00 
167 0.00 39 0 0.00 0.00 4.00 94.00 17-Sep-2004 Oesoph 0.00 squam 1.00 1.00 
168 1.00 82 2 0.00 0.00 2.00 30.00 29-Mar-2004 Oesoph 0.00 squam 1.00 1.00 
169 0.00 89 2 1.00 0.00 3.00 46.00 09-Oct-2002 Oesoph 0.00 squam 1.00 1.00 
170 0.00 44 0 0.00 0.00 4.00 94.00 29-Jul-2004 o/g 1.00 adeno 0.00 1.00 
171 0.00 55 0 1.00 0.00 3.00 46.00 13-Mar-2002 Gastric 1.00 adeno 0.00 1.00 
172 0.00 82 2 1.00 0.00 1.00 0.00 29-Oct-2002 o/g 0.00 adeno 0.00 1.00 
173 0.00 60 0 1.00 0.00 4.00 94.00 10-Jun-2002 Gastric 1.00 adeno 0.00 1.00 
174 1.00 71 1 1.00 0.00 4.00 94.00 05-Jul-2002 Gastric 1.00 adeno 0.00 1.00 
175 0.00 67 1 0.00 0.00 4.00 94.00 09-Apr-2002 Oesoph 0.00 squam 1.00 1.00 
176 1.00 70 1 1.00 0.00 4.00 94.00 10-Mar-2004 Oesoph 0.00 adeno 0.00 1.00 
177 1.00 68 1 1.00 0.00 3.00 46.00 20-Nov-2003 Oesoph 0.00 squam 1.00 1.00 
178 0.00 73 1 1.00 0.00 3.00 46.00 29-Feb-2004 Oesoph 0.00 squam 1.00 1.00 
179 1.00 63 0 0.00 0.00 3.00 46.00 18-Oct-2004 Oesoph 0.00 squam 1.00 1.00 





Patient m0f1 age agecd weight karnofer clinstag clinstge dateop Site positcd histolog typecd a0c1n2 
181 1.00 77 2 1.00 0.00 4.00 94.00 23-Mar-2004 o/g 1.00 adeno 0.00 1.00 
182 0.00 76 2 1.00 32.00 2.00 30.00 25-Jun-2004 Gastric 1.00 adeno 0.00 1.00 
183 0.00 71 1 1.00 0.00 2.00 30.00 17-Dec-2002 Oesoph 0.00 squam 1.00 1.00 
184 0.00 71 1 1.00 0.00 1.00 0.00 13-May-2004 Gastric 1.00 adeno 0.00 1.00 
185 1.00 81 2 0.00 0.00 1.00 0.00 26-Nov-2002 Oesoph 0.00 adeno 0.00 1.00 
186 0.00 83 2 0.00 32.00 4.00 94.00 24-Sep-2004 Oesoph 0.00 squam 1.00 1.00 
187 0.00 62 0 1.00 0.00 4.00 94.00 21-Jan-2004 Oesoph 0.00 adeno 0.00 1.00 
188 0.00 65 0 0.00 0.00 4.00 94.00 30-Apr-2003 Gastric 1.00 adeno 0.00 1.00 
189 1.00 42 0 0.00 0.00 4.00 94.00 23-Jan-2003 Gastric 1.00 adeno 0.00 1.00 
190 1.00 83 2 1.00 0.00 3.00 46.00 17-Dec-2002 Oesoph 0.00 squam 1.00 1.00 
191 0.00 30 0 1.00 0.00 4.00 94.00 16-Oct-2003 o/g 1.00 adeno 0.00 1.00 
192 0.00 66 1 1.00 0.00 2.00 30.00 23-Apr-2002 Oesoph 0.00 adeno 0.00 1.00 
193 0.00 77 2 0.00 0.00 1.00 0.00 09-Sep-2003 o/g 1.00 adeno 0.00 1.00 
194 1.00 70 1 0.00 0.00 2.00 30.00 25-Mar-2003 O 0.00 adeno 0.00 1.00 
195 0.00 52 0 1.00 0.00 2.00 30.00 10-May-2004 G 1.00 adeno 0.00 1.00 
196 0.00 70 1 1.00 0.00 3.00 46.00 01-Nov-2002 G 1.00 adeno 0.00 1.00 
197 0.00 70 1 1.00 0.00 3.00 46.00 20-Aug-2003 G 1.00 adeno 0.00 1.00 
198 1.00 46 0 1.00 0.00 2.00 30.00 17-Jun-2004 O 0.00 squam 1.00 1.00 
199 0.00 58 0 1.00 0.00 2.00 30.00 28-Apr-2004 O 0.00 squam 1.00 1.00 
200 0.00 64 0 0.00 0.00 1.00 0.00 05-Sep-2002 G 1.00 adeno 0.00 1.00 
201 0.00 69 1 0.00 0.00 1.00 0.00 04-Feb-2004 O 0.00 adeno 0.00 1.00 
202 0.00 75 2 1.00 0.00 2.00 30.00 03-Sep-2002 G 1.00 adeno 0.00 1.00 
203 0.00 68 1 1.00 0.00 3.00 46.00 20-Mar-2002 G 1.00 adeno 0.00 1.00 
204 0.00 59 0 1.00 0.00 3.00 46.00 27-Aug-2003 O 0.00 adeno 0.00 1.00 
205 0.00 68 1 0.00 0.00 3.00 46.00 03-Jun-2002 O 0.00 adeno 0.00 1.00 
206 0.00 51 0 1.00 0.00 3.00 46.00 22-Dec-2004 O 0.00 squam 1.00 1.00 
207 0.00 74 1 0.00 0.00 3.00 46.00 10-Sep-2003 G 1.00 adeno 0.00 1.00 
208 0.00 61 0 1.00 0.00 4.00 94.00 04-Jun-2003 Oesoph 0.00 adeno 0.00 2.00 
209 0.00 72 1 0.00 32.00 4.00 94.00 09-Jul-2003 Gastric 1.00 adeno 0.00 2.00 
210 0.00 64 0 1.00 0.00 3.00 46.00 08-Oct-2002 Oesoph 0.00 squam 1.00 2.00 
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Patient m0f1 age agecd weight karnofer clinstag clinstge dateop Site positcd histolog typecd a0c1n2 
211 0.00 60 0 1.00 0.00 4.00 94.00 03-Dec-2004 o/g 1.00 adeno 0.00 2.00 
212 0.00 75 2 1.00 0.00 2.00 30.00 10-Sep-2002 Oesoph 0.00 adeno 0.00 2.00 
213 1.00 58 0 0.00 0.00 1.00 0.00 21-Apr-2004 O 0.00 squam 1.00 2.00 
214 1.00 80 2 1.00 0.00 2.00 30.00 11-Feb-2004 O 0.00 adeno 0.00 2.00 
215 0.00 62 0 1.00 0.00 3.00 46.00 21-May-2003 O 0.00 adeno 0.00 2.00 
216 0.00 68 1 0.00 0.00 2.00 30.00 03-Mar-2003 O 0.00 adeno 0.00 2.00 





Patient doffu survmths crpgre5 crpfinal cfinalcd albfinal albfincd mgps ers erscd treatment treatcd 
1 31-Jul-2008 53.97 1.00 8.00 0.00 38.00 0.00 0.00 134.00 2.00 Chemo 2.00 
2 31-Jul-2008 67.47 1.00 11.00 1.00 39.00 0.00 1.00 20.00 0.00 DXT 2.00 
3 31-Jul-2008 71.00 1.00 16.00 1.00 40.00 0.00 1.00 66.00 1.00 rad chem/rad 1.00 
4 31-Jul-2008 63.23 0.00 5.00 0.00 48.00 0.00 0.00 66.00 1.00 Chemo/DXT 2.00 
5 31-Jul-2008 47.70 0.00 5.00 0.00 40.00 0.00 0.00 62.00 1.00 DXT 2.00 
6 31-Jul-2008 45.80 1.00 62.00 1.00 38.00 0.00 1.00 86.00 1.00 DXT 2.00 
7 31-Jul-2008 68.20 0.00 5.00 0.00 46.00 0.00 0.00 50.00 0.00 rad chem/rad 1.00 
8 31-Jul-2008 72.07 1.00 8.00 0.00 44.00 0.00 0.00 40.00 0.00 None 3.00 
9 31-Jul-2008 52.50 1.00 8.00 0.00 41.00 0.00 0.00 114.00 1.00 rad chem/rad 1.00 
10 31-Jul-2008 61.20 0.00 5.00 0.00 42.00 0.00 0.00 0.00 0.00 Laser 3.00 
11 31-Jul-2008 48.10 0.00 5.00 0.00 46.00 0.00 0.00 30.00 0.00 Surg 0.00 
12 31-Jul-2008 49.73 0.00 5.00 0.00 45.00 0.00 0.00 0.00 0.00 Surg 0.00 
13 31-Jul-2008 79.83 0.00 5.00 0.00 41.00 0.00 0.00 0.00 0.00 Surg 0.00 
14 31-Jul-2008 62.57 0.00 5.00 0.00 41.00 0.00 0.00 0.00 0.00 Surg 0.00 
15 31-Jul-2008 75.17 0.00 5.00 0.00 42.00 0.00 0.00 0.00 0.00 Surg 0.00 
16 31-Jul-2008 73.27 0.00 5.00 0.00 47.00 0.00 0.00 66.00 1.00 Surg 0.00 
17 31-Jul-2008 77.97 0.00 5.00 0.00 39.00 0.00 0.00 46.00 0.00 Surg 0.00 
18 31-Jul-2008 65.43 0.00 5.00 0.00 45.00 0.00 0.00 50.00 0.00 Surg 0.00 
19 31-Jul-2008 51.37 0.00 5.00 0.00 44.00 0.00 0.00 30.00 0.00 Surg 0.00 
20 31-Jul-2008 76.57 0.00 5.00 0.00 43.00 0.00 0.00 0.00 0.00 Surg 0.00 
21 31-Jul-2008 70.97 0.00 5.00 0.00 42.00 0.00 0.00 20.00 0.00 Surg 0.00 
22 31-Jul-2008 76.33 0.00 5.00 0.00 43.00 0.00 0.00 30.00 0.00 Surg 0.00 
23 31-Jul-2008 62.10 0.00 5.00 0.00 40.00 0.00 0.00 0.00 0.00 Surg 0.00 
24 31-Jul-2008 74.30 1.00 7.00 0.00 44.00 0.00 0.00 70.00 1.00 Surg 0.00 
25 31-Jul-2008 59.53 0.00 5.00 0.00 37.00 0.00 0.00 66.00 1.00 Surg 0.00 
26 31-Jul-2008 62.07 0.00 5.00 0.00 48.00 0.00 0.00 30.00 0.00 Surg 0.00 
27 31-Jul-2008 74.00 0.00 5.00 0.00 45.00 0.00 0.00 46.00 0.00 Surg 0.00 
28 31-Jul-2008 46.47 0.00 5.00 0.00 41.00 0.00 0.00 0.00 0.00 Surg 0.00 
29 31-Jul-2008 67.47 0.00 5.00 0.00 47.00 0.00 0.00 50.00 0.00 Surg 0.00 





Patient doffu survmths crpgre5 crpfinal cfinalcd albfinal albfincd mgps ers erscd treatment treatcd 
31 05-May-2002 2.03 1.00 31.00 1.00 40.00 0.00 1.00 134.00 2.00 Chemo/DXT 2.00 
32 08-Oct-2004 15.50 1.00 10.00 0.00 34.00 1.00 0.00 20.00 0.00 Laser 3.00 
33 10-Apr-2005 12.07 0.00 5.00 0.00 43.00 0.00 0.00 46.00 0.00 DXT 2.00 
34 08-Feb-2005 1.33 1.00 15.00 1.00 39.00 0.00 1.00 134.00 2.00 DXT 2.00 
35 04-Nov-2002 2.80 1.00 8.00 0.00 40.00 0.00 0.00 114.00 1.00 Laser 3.00 
36 24-May-2002 3.87 0.00 5.00 0.00 35.00 0.00 0.00 66.00 1.00 Stent 3.00 
37 13-Feb-2008 40.37 1.00 29.00 1.00 31.00 1.00 2.00 52.00 0.00 Laser 3.00 
38 21-Jul-2004 0.93 1.00 217.00 1.00 43.00 0.00 1.00 134.00 2.00 Chemo 2.00 
39 17-Nov-2004 16.13 0.00 5.00 0.00 42.00 0.00 0.00 66.00 1.00 DXT 2.00 
40 03-Sep-2004 17.50 1.00 122.00 1.00 35.00 0.00 1.00 86.00 1.00 Laser 3.00 
41 10-Oct-2004 2.87 1.00 11.00 1.00 43.00 0.00 1.00 114.00 1.00 DXT 2.00 
42 05-Jun-2003 8.00 1.00 89.00 1.00 38.00 0.00 1.00 134.00 2.00 Chemo 2.00 
43 10-Sep-2004 2.20 1.00 64.00 1.00 41.00 0.00 1.00 134.00 2.00 Chemo 2.00 
44 24-Oct-2002 4.97 0.00 5.00 0.00 33.00 1.00 0.00 66.00 1.00 Laser 3.00 
45 26-Dec-2004 0.63 1.00 79.00 1.00 40.00 0.00 1.00 114.00 1.00 None 3.00 
46 27-Dec-2003 10.10 1.00 19.00 1.00 34.00 1.00 2.00 134.00 2.00 Chemo/DXT 2.00 
47 19-Jun-2005 6.70 0.00 5.00 0.00 39.00 0.00 0.00 66.00 1.00 Chemo/DXT 2.00 
48 13-Dec-2003 3.43 1.00 22.00 1.00 34.00 1.00 2.00 114.00 1.00 Chemo 2.00 
49 28-Nov-2002 6.60 0.00 1.00 0.00 44.00 0.00 0.00 20.00 0.00 rad chem/rad 1.00 
50 12-Jan-2004 1.40 1.00 53.00 1.00 40.00 0.00 1.00 134.00 2.00 Chemo 2.00 
51 12-Oct-2004 11.93 1.00 97.00 1.00 43.00 0.00 1.00 134.00 2.00 DXT 2.00 
52 26-Aug-2005 8.27 1.00 8.00 0.00 50.00 0.00 0.00 114.00 1.00 Chemo 2.00 
53 03-Feb-2005 9.13 0.00 5.00 0.00 32.00 1.00 0.00 114.00 1.00 Chemo/DXT 2.00 
54 03-Jun-2003 4.17 1.00 15.00 1.00 35.00 0.00 1.00 40.00 0.00 Laser 3.00 
55 04-May-2005 5.40 0.00 5.00 0.00 42.00 0.00 0.00 94.00 1.00 None 3.00 
56 04-Feb-2005 6.40 0.00 5.00 0.00 40.00 0.00 0.00 114.00 1.00 Chemo & Laser 2.00 
57 01-May-2005 13.17 0.00 5.00 0.00 39.00 0.00 0.00 182.00 2.00 Laser 3.00 
58 25-May-2002 2.80 1.00 57.00 1.00 39.00 0.00 1.00 134.00 2.00 Chemo 2.00 
59 21-Nov-2002 7.43 1.00 36.00 1.00 42.00 0.00 1.00 50.00 0.00 Chemo 2.00 
60 07-Apr-2003 1.17 1.00 275.00 1.00 40.00 0.00 1.00 114.00 1.00 DXT 2.00 
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Patient doffu survmths crpgre5 crpfinal cfinalcd albfinal albfincd mgps ers erscd treatment treatcd 
61 26-Jan-2005 11.03 1.00 10.00 0.00 44.00 0.00 0.00 86.00 1.00 rad chem/rad 1.00 
62 24-Jul-2002 1.47 1.00 74.00 1.00 33.00 1.00 2.00 134.00 2.00 None 3.00 
63 11-Aug-2005 17.47 1.00 10.00 0.00 45.00 0.00 0.00 114.00 1.00 Chemo/DXT 2.00 
64 25-Aug-2003 4.13 1.00 50.00 1.00 31.00 1.00 2.00 66.00 1.00 Trachy & DXT 2.00 
65 09-May-2005 12.33 0.00 5.00 0.00 39.00 0.00 0.00 82.00 1.00 Laser 3.00 
66 18-Apr-2005 5.47 1.00 7.00 0.00 36.00 0.00 0.00 66.00 1.00 DXT & Laser 2.00 
67 05-Oct-2004 1.40 1.00 38.00 1.00 37.00 0.00 1.00 134.00 2.00 None 3.00 
68 04-Nov-2004 2.43 1.00 19.00 1.00 34.00 1.00 2.00 114.00 1.00 Laser 3.00 
69 08-Dec-2004 10.97 0.00 6.00 0.00 47.00 0.00 0.00 66.00 1.00 Chemo/DXT 2.00 
70 30-Sep-2005 14.70 0.00 6.00 0.00 38.00 0.00 0.00 114.00 1.00 Chemo 2.00 
71 01-May-2004 4.33 1.00 64.00 1.00 38.00 0.00 1.00 50.00 0.00 Stent 3.00 
72 23-Sep-2003 1.67 1.00 19.00 1.00 39.00 0.00 1.00 114.00 1.00 Chemo/DXT 2.00 
73 10-Oct-2005 10.23 1.00 7.00 0.00 43.00 0.00 0.00 114.00 1.00 DXT 2.00 
74 01-Sep-2004 15.13 1.00 42.00 1.00 37.00 0.00 1.00 134.00 2.00 Chemo & Laser 2.00 
75 05-Nov-2004 2.10 1.00 36.00 1.00 33.00 1.00 2.00 134.00 2.00 Laser 3.00 
76 01-Dec-2005 13.87 1.00 60.00 1.00 25.00 1.00 2.00 20.00 0.00 Laser 3.00 
77 28-Aug-2003 7.80 1.00 190.00 1.00 38.00 0.00 1.00 134.00 2.00 Chemo 2.00 
78 24-Apr-2004 1.27 1.00 30.00 1.00 22.00 1.00 2.00 134.00 2.00 None 3.00 
79 16-Mar-2002 0.73 1.00 28.00 1.00 36.00 0.00 1.00 134.00 2.00 gastro-jej 3.00 
80 04-Nov-2003 0.70 1.00 109.00 1.00 35.00 0.00 1.00 134.00 2.00 None 3.00 
81 26-Jul-2005 31.27 1.00 19.00 1.00 41.00 0.00 1.00 86.00 1.00 rad chem/rad 1.00 
82 27-May-2002 0.87 1.00 39.00 1.00 37.00 0.00 1.00 134.00 2.00 Laser 3.00 
83 16-Oct-2004 16.50 1.00 24.00 1.00 40.00 0.00 1.00 98.00 1.00 Laser 3.00 
84 23-Dec-2002 6.27 1.00 216.00 1.00 27.00 1.00 2.00 114.00 1.00 DXT & Laser 2.00 
85 22-Mar-2005 5.10 0.00 5.00 0.00 44.00 0.00 0.00 66.00 1.00 Stent 3.00 
86 03-Nov-2004 2.63 1.00 36.00 1.00 35.00 0.00 1.00 134.00 2.00 Chemo 2.00 
87 10-Jun-2004 5.20 1.00 8.00 0.00 42.00 0.00 0.00 134.00 2.00 Laser 3.00 
88 21-Aug-2004 0.73 1.00 68.00 1.00 34.00 1.00 2.00 114.00 1.00 Chemo 2.00 
89 16-May-2002 1.70 1.00 23.00 1.00 39.00 0.00 1.00 70.00 1.00 Stent 3.00 





Patient doffu survmths crpgre5 crpfinal cfinalcd albfinal albfincd mgps ers erscd treatment treatcd 
91 31-Dec-2003 3.27 0.00 5.00 0.00 38.00 0.00 0.00 94.00 1.00 Laser 3.00 
92 24-Dec-2002 6.33 1.00 133.00 1.00 40.00 0.00 1.00 134.00 2.00 Laser 3.00 
93 09-Jun-2003 8.87 1.00 25.00 1.00 44.00 0.00 1.00 86.00 1.00 Laser 3.00 
94 12-Dec-2004 1.97 1.00 70.00 1.00 34.00 1.00 2.00 86.00 1.00 Stent 3.00 
95 01-Feb-2005 10.50 0.00 5.00 0.00 43.00 0.00 0.00 114.00 1.00 Chemo 2.00 
96 17-Jan-2004 5.00 1.00 48.00 1.00 45.00 0.00 1.00 66.00 1.00 rad chem/rad 1.00 
97 18-Apr-2005 17.43 1.00 15.00 1.00 39.00 0.00 1.00 86.00 1.00 CH/DXT &Laser 2.00 
98 02-Feb-2004 7.87 1.00 51.00 1.00 45.00 0.00 1.00 86.00 1.00 DXT & Laser 2.00 
99 03-May-2004 2.20 1.00 96.00 1.00 30.00 1.00 2.00 114.00 1.00 Laser 3.00 
100 24-Jan-2005 12.53 1.00 20.00 1.00 41.00 0.00 1.00 134.00 2.00 Chemo/DXT 2.00 
101 20-Mar-2005 3.43 0.00 5.00 0.00 31.00 1.00 0.00 66.00 1.00 Stent 3.00 
102 16-Jan-2004 14.33 1.00 18.00 1.00 43.00 0.00 1.00 40.00 0.00 Chemo 2.00 
103 30-Jan-2006 14.87 0.00 5.00 0.00 41.00 0.00 0.00 46.00 0.00 Laser 3.00 
104 16-Jan-2003 3.70 1.00 27.00 1.00 46.00 0.00 1.00 134.00 2.00 None 3.00 
105 12-Mar-2003 6.80 0.00 5.00 0.00 43.00 0.00 0.00 94.00 1.00 DXT 2.00 
106 19-Apr-2005 15.63 0.00 1.00 0.00 44.00 0.00 0.00 94.00 1.00 rad chem/rad 1.00 
107 28-May-2002 3.73 1.00 12.00 1.00 41.00 0.00 1.00 134.00 2.00 Laser 3.00 
108 13-May-2004 8.23 0.00 5.00 0.00 37.00 0.00 0.00 94.00 1.00 Chemo/DXT 2.00 
109 03-Nov-2005 13.83 1.00 10.00 0.00 30.00 1.00 0.00 86.00 1.00 Chemo/DXT 2.00 
110 09-Dec-2002 1.97 1.00 14.00 1.00 36.00 0.00 1.00 134.00 2.00 Stent 3.00 
111 23-Mar-2006 16.07 1.00 16.00 1.00 44.00 0.00 1.00 134.00 2.00 DXT 2.00 
112 08-Sep-2005 24.00 0.00 1.00 0.00 43.00 0.00 0.00 30.00 0.00 rad chem/rad 1.00 
113 06-Nov-2005 11.17 0.00 5.00 0.00 38.00 0.00 0.00 94.00 1.00 Chemo 2.00 
114 07-Jul-2004 6.60 1.00 36.00 1.00 43.00 0.00 1.00 86.00 1.00 Chemo/DXT 2.00 
115 01-Apr-2002 1.13 1.00 44.00 1.00 37.00 0.00 1.00 134.00 2.00 Chemo 2.00 
116 09-Sep-2004 1.37 1.00 173.00 1.00 35.00 0.00 1.00 114.00 1.00 None 3.00 
117 11-Feb-2005 8.07 1.00 88.00 1.00 35.00 0.00 1.00 134.00 2.00 Chemo & Laser 2.00 
118 21-Oct-2004 1.63 1.00 23.00 1.00 28.00 1.00 2.00 134.00 2.00 None 3.00 
119 11-Mar-2004 20.50 0.00 5.00 0.00 35.00 0.00 0.00 0.00 0.00 DXT & Laser 2.00 
120 10-Aug-2002 2.70 1.00 45.00 1.00 44.00 0.00 1.00 86.00 1.00 gastro-jej 3.00 
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121 17-Apr-2003 1.37 1.00 31.00 1.00 28.00 1.00 2.00 134.00 2.00 None 3.00 
122 20-Oct-2005 23.90 0.00 5.00 0.00 42.00 0.00 0.00 32.00 0.00 Laser 3.00 
123 11-Feb-2002 1.13 1.00 94.00 1.00 32.00 1.00 2.00 134.00 2.00 Chemo/DXT 2.00 
124 29-May-2002 1.57 0.00 5.00 0.00 36.00 0.00 0.00 66.00 1.00 Stent 3.00 
125 24-Sep-2004 11.47 1.00 16.00 1.00 42.00 0.00 1.00 86.00 1.00 DXT & Laser 2.00 
126 25-Mar-2007 30.17 1.00 10.00 0.00 40.00 0.00 0.00 66.00 1.00 Chemo 2.00 
127 14-Mar-2005 10.27 0.00 5.00 0.00 38.00 0.00 0.00 46.00 0.00 oesoph-jej 3.00 
128 03-Jun-2004 2.30 1.00 89.00 1.00 36.00 0.00 1.00 134.00 2.00 None 3.00 
129 30-May-2002 3.00 1.00 96.00 1.00 43.00 0.00 1.00 134.00 2.00 Chemo 2.00 
130 04-Sep-2003 1.03 1.00 38.00 1.00 28.00 1.00 2.00 134.00 2.00 None 3.00 
131 12-Jul-2005 41.20 0.00 5.00 0.00 43.00 0.00 0.00 50.00 0.00 Chemo 2.00 
132 20-Jul-2005 41.47 0.00 5.00 0.00 43.00 0.00 0.00 50.00 0.00 rad chem/rad 1.00 
133 21-Jan-2004 4.63 0.00 5.00 0.00 45.00 0.00 0.00 20.00 0.00 Chemo/DXT 2.00 
134 23-Aug-2004 7.20 1.00 27.00 1.00 40.00 0.00 1.00 86.00 1.00 Chemo 2.00 
135 29-Apr-2003 14.40 0.00 5.00 0.00 42.00 0.00 0.00 66.00 1.00 Chemo 2.00 
136 03-Sep-2004 6.57 0.00 5.00 0.00 36.00 0.00 0.00 66.00 1.00 Chemo/DXT 2.00 
137 10-Oct-2003 5.67 1.00 64.00 1.00 44.00 0.00 1.00 66.00 1.00 DXT 2.00 
138 27-May-2004 5.83 1.00 253.00 1.00 29.00 1.00 2.00 134.00 2.00 None 3.00 
139 08-Mar-2003 8.43 0.00 5.00 0.00 42.00 0.00 0.00 114.00 1.00 Chemo/DXT 2.00 
140 04-Aug-2003 2.20 1.00 65.00 1.00 35.00 0.00 1.00 134.00 2.00 Chemo & Laser 2.00 
141 27-Feb-2005 19.27 1.00 9.00 0.00 46.00 0.00 0.00 134.00 2.00 Chemo 2.00 
142 30-Jul-2005 16.73 0.00 5.00 0.00 39.00 0.00 0.00 114.00 1.00 Chemo/DXT 2.00 
143 23-Jun-2003 10.63 1.00 31.00 1.00 47.00 0.00 1.00 134.00 2.00 rad chem/rad 1.00 
144 10-Apr-2003 4.50 1.00 50.00 1.00 33.00 1.00 2.00 134.00 2.00 DXT 2.00 
145 17-Jun-2003 1.37 1.00 91.00 1.00 35.00 0.00 1.00 134.00 2.00 Laser 3.00 
146 04-Oct-2002 1.40 1.00 171.00 1.00 42.00 0.00 1.00 114.00 1.00 None 3.00 
147 15-Oct-2005 11.93 1.00 58.00 1.00 27.00 1.00 2.00 52.00 0.00 Laser 3.00 
148 30-May-2003 13.63 0.00 5.00 0.00 40.00 0.00 0.00 114.00 1.00 Chemo 2.00 
149 21-Sep-2002 8.27 0.00 5.00 0.00 42.00 0.00 0.00 114.00 1.00 gastro-jej 3.00 





Patient doffu survmths crpgre5 crpfinal cfinalcd albfinal albfincd mgps ers erscd treatment treatcd 
151 23-May-2003 0.47 1.00 29.00 1.00 28.00 1.00 2.00 114.00 1.00 None 3.00 
152 03-Feb-2003 7.43 1.00 40.00 1.00 38.00 0.00 1.00 134.00 2.00 DXT 2.00 
153 16-Aug-2003 9.97 1.00 43.00 1.00 39.00 0.00 1.00 114.00 1.00 Laser 3.00 
154 10-Sep-2005 11.93 0.00 5.00 0.00 44.00 0.00 0.00 114.00 1.00 Chemo 2.00 
155 17-Apr-2003 2.53 1.00 17.00 1.00 36.00 0.00 1.00 86.00 1.00 DXT & Laser 2.00 
156 23-Sep-2004 21.77 0.00 5.00 0.00 43.00 0.00 0.00 94.00 1.00 rad chem/rad 1.00 
157 23-Aug-2005 28.00 0.00 5.00 0.00 38.00 0.00 0.00 46.00 0.00 rad chem/rad 1.00 
158 27-Jul-2005 7.97 1.00 11.00 1.00 40.00 0.00 1.00 86.00 1.00 Chemo/DXT 2.00 
159 22-Dec-2004 4.53 1.00 12.00 1.00 42.00 0.00 1.00 118.00 1.00 DXT & Laser 2.00 
160 01-Oct-2004 12.83 1.00 12.00 1.00 37.00 0.00 1.00 118.00 1.00 None 3.00 
161 01-Feb-2004 2.50 1.00 171.00 1.00 36.00 0.00 1.00 114.00 1.00 None 3.00 
162 07-Oct-2004 9.77 1.00 15.00 1.00 40.00 0.00 1.00 86.00 1.00 Chemo & Laser 2.00 
163 08-Mar-2005 11.80 1.00 17.00 1.00 31.00 1.00 2.00 118.00 1.00 Laser 3.00 
164 21-Sep-2003 3.13 1.00 26.00 1.00 43.00 0.00 1.00 134.00 2.00 Chemo 2.00 
165 02-Sep-2003 8.87 1.00 12.00 1.00 43.00 0.00 1.00 134.00 2.00 DXT 2.00 
166 01-Aug-2004 1.93 1.00 44.00 1.00 40.00 0.00 1.00 166.00 2.00 Stent 3.00 
167 18-Jan-2005 4.10 1.00 56.00 1.00 46.00 0.00 1.00 114.00 1.00 Chemo 2.00 
168 14-May-2006 25.87 0.00 5.00 0.00 42.00 0.00 0.00 30.00 0.00 DXT 2.00 
169 18-Nov-2002 1.33 1.00 66.00 1.00 38.00 0.00 1.00 86.00 1.00 Stent 3.00 
170 19-Apr-2005 8.80 1.00 11.00 1.00 48.00 0.00 1.00 114.00 1.00 Chemo 2.00 
171 08-Oct-2002 6.97 0.00 5.00 0.00 43.00 0.00 0.00 66.00 1.00 Chemo/DXT 2.00 
172 03-Sep-2003 10.30 1.00 7.00 0.00 43.00 0.00 0.00 40.00 0.00 Laser 3.00 
173 12-Feb-2003 8.23 1.00 43.00 1.00 28.00 1.00 2.00 134.00 2.00 Chemo/DXT 2.00 
174 27-Aug-2002 1.77 1.00 120.00 1.00 32.00 1.00 2.00 134.00 2.00 Laser 3.00 
175 03-May-2002 0.80 1.00 37.00 1.00 40.00 0.00 1.00 114.00 1.00 None 3.00 
176 26-Mar-2004 0.53 1.00 46.00 1.00 37.00 0.00 1.00 134.00 2.00 None 3.00 
177 01-Oct-2004 10.53 1.00 38.00 1.00 34.00 1.00 2.00 86.00 1.00 Chemo/DXT 2.00 
178 30-Apr-2004 2.03 1.00 39.00 1.00 34.00 1.00 2.00 86.00 1.00 Laser 3.00 
179 03-Dec-2005 13.70 1.00 56.00 1.00 36.00 0.00 1.00 66.00 1.00 CH/DXT & Laser 2.00 
180 26-Feb-2005 5.93 1.00 32.00 1.00 32.00 1.00 2.00 134.00 2.00 Chemo 2.00 
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181 24-Aug-2004 5.13 1.00 28.00 1.00 37.00 0.00 1.00 134.00 2.00 Chemo & Laser 2.00 
182 10-Jul-2004 0.50 1.00 20.00 1.00 24.00 1.00 2.00 102.00 1.00 Laser 3.00 
183 23-Jul-2004 19.47 1.00 72.00 1.00 39.00 0.00 1.00 70.00 1.00 Chemo/DXT 2.00 
184 09-Jan-2007 32.37 0.00 5.00 0.00 45.00 0.00 0.00 20.00 0.00 Laser 3.00 
185 16-Aug-2004 20.97 0.00 5.00 0.00 47.00 0.00 0.00 0.00 0.00 Laser 3.00 
186 14-Nov-2004 1.70 1.00 162.00 1.00 26.00 1.00 2.00 146.00 2.00 None 3.00 
187 30-Apr-2005 15.50 1.00 28.00 1.00 47.00 0.00 1.00 134.00 2.00 Chemo 2.00 
188 23-May-2003 0.77 0.00 5.00 0.00 43.00 0.00 0.00 94.00 1.00 gastro-jej 3.00 
189 23-Oct-2003 9.10 0.00 5.00 0.00 48.00 0.00 0.00 94.00 1.00 Chemo 2.00 
190 08-Jan-2003 0.73 0.00 5.00 0.00 45.00 0.00 0.00 66.00 1.00 Stent 3.00 
191 13-Jan-2004 2.97 1.00 8.00 0.00 40.00 0.00 0.00 134.00 2.00 None 3.00 
192 15-May-2002 0.73 1.00 153.00 1.00 22.00 1.00 2.00 70.00 1.00 Laser 3.00 
193 30-Nov-2005 27.10 1.00 9.00 0.00 46.00 0.00 0.00 20.00 0.00 Laser 3.00 
194 26-Oct-2004 19.37 1.00 19.00 1.00 44.00 0.00 1.00 50.00 0.00 Surg 0.00 
195 25-Nov-2004 6.63 0.00 5.00 0.00 42.00 0.00 0.00 50.00 0.00 Surg 0.00 
196 13-Jul-2005 32.83 0.00 5.00 0.00 39.00 0.00 0.00 66.00 1.00 Surg 0.00 
197 25-Mar-2004 7.27 1.00 9.00 0.00 37.00 0.00 0.00 86.00 1.00 Surg 0.00 
198 11-Jun-2008 48.50 1.00 8.00 0.00 36.00 0.00 0.00 70.00 1.00 Surg 0.00 
199 16-Oct-2007 42.20 0.00 5.00 0.00 39.00 0.00 0.00 50.00 0.00 Surg 0.00 
200 18-Jun-2003 9.53 1.00 19.00 1.00 35.00 0.00 1.00 20.00 0.00 Surg 0.00 
201 10-Aug-2004 6.27 0.00 5.00 0.00 41.00 0.00 0.00 0.00 0.00 Surg 0.00 
202 30-Jan-2004 17.13 0.00 5.00 0.00 41.00 0.00 0.00 50.00 0.00 Surg 0.00 
203 22-Mar-2003 12.23 1.00 9.00 0.00 45.00 0.00 0.00 86.00 1.00 Surg 0.00 
204 18-Apr-2005 20.00 0.00 5.00 0.00 43.00 0.00 0.00 66.00 1.00 Surg 0.00 
205 13-Nov-2003 17.60 0.00 5.00 0.00 41.00 0.00 0.00 46.00 0.00 Surg 0.00 
206 10-Dec-2005 11.77 0.00 5.00 0.00 49.00 0.00 0.00 66.00 1.00 Surg 0.00 
207 15-Dec-2005 27.57 0.00 5.00 0.00 39.00 0.00 0.00 46.00 0.00 Surg 0.00 
208 25-May-2004 11.87 1.00 42.00 1.00 38.00 0.00 1.00 134.00 2.00 Chemo 2.00 
209 07-Jul-2004 12.13 1.00 157.00 1.00 32.00 1.00 2.00 146.00 2.00 chemo/Laser 2.00 
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211 21-Dec-2004 0.60 1.00 171.00 1.00 28.00 1.00 2.00 134.00 2.00 CH/DXT & Laser 2.00 
212 10-May-2003 8.07 0.00 5.00 0.00 45.00 0.00 0.00 50.00 0.00 Laser 3.00 
213 13-Sep-2004 4.83 0.00 5.00 0.00 42.00 0.00 0.00 0.00 0.00 Surg 0.00 
214 30-Jul-2006 30.00 0.00 5.00 0.00 42.00 0.00 0.00 50.00 0.00 Surg 0.00 
215 26-Nov-2007 55.00 0.00 5.00 0.00 40.00 0.00 0.00 66.00 1.00 Surg 0.00 
216 26-Mar-2006 37.30 0.00 5.00 0.00 43.00 0.00 0.00 30.00 0.00 Surg 0.00 
217 19-Jul-2005 23.53 0.00 5.00 0.00 38.00 0.00 0.00 66.00 1.00 Surg 0.00 
 
 
